CN107670054A - 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体 - Google Patents
用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体 Download PDFInfo
- Publication number
- CN107670054A CN107670054A CN201710800310.5A CN201710800310A CN107670054A CN 107670054 A CN107670054 A CN 107670054A CN 201710800310 A CN201710800310 A CN 201710800310A CN 107670054 A CN107670054 A CN 107670054A
- Authority
- CN
- China
- Prior art keywords
- carrier
- nano
- antigen
- human cytokines
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002539 nanocarrier Substances 0.000 title claims abstract description 307
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 185
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 185
- 230000028993 immune response Effects 0.000 title abstract description 137
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 261
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 260
- 102000036639 antigens Human genes 0.000 claims abstract description 212
- 239000000427 antigen Substances 0.000 claims abstract description 211
- 108091007433 antigens Proteins 0.000 claims abstract description 211
- 239000003018 immunosuppressive agent Substances 0.000 claims abstract description 93
- 239000000203 mixture Substances 0.000 claims description 181
- 210000004027 cell Anatomy 0.000 claims description 102
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 68
- 102000004190 Enzymes Human genes 0.000 claims description 55
- 108090000790 Enzymes Proteins 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 230000008878 coupling Effects 0.000 claims description 49
- 238000010168 coupling process Methods 0.000 claims description 49
- 238000005859 coupling reaction Methods 0.000 claims description 49
- 102000004169 proteins and genes Human genes 0.000 claims description 48
- 239000003112 inhibitor Substances 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- 230000001225 therapeutic effect Effects 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 13
- 229940088597 hormone Drugs 0.000 claims description 11
- 239000005556 hormone Substances 0.000 claims description 11
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 10
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 239000000893 inhibin Substances 0.000 claims description 9
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 9
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 8
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 239000003114 blood coagulation factor Substances 0.000 claims description 8
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 8
- 229960002986 dinoprostone Drugs 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 8
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 8
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 8
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 8
- 235000021075 protein intake Nutrition 0.000 claims description 7
- 229940122614 Adenosine receptor agonist Drugs 0.000 claims description 6
- 239000012826 P38 inhibitor Substances 0.000 claims description 6
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 230000004898 mitochondrial function Effects 0.000 claims description 6
- 239000003207 proteasome inhibitor Substances 0.000 claims description 6
- 239000003379 purinergic P1 receptor agonist Substances 0.000 claims description 6
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 5
- 108010000912 Egg Proteins Proteins 0.000 claims description 5
- 102000002322 Egg Proteins Human genes 0.000 claims description 5
- 235000014103 egg white Nutrition 0.000 claims description 5
- 210000000969 egg white Anatomy 0.000 claims description 5
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 5
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 137
- 230000002829 reductive effect Effects 0.000 abstract description 8
- 229920000642 polymer Polymers 0.000 description 139
- 239000000243 solution Substances 0.000 description 64
- -1 albumen Z Proteins 0.000 description 59
- 229940088598 enzyme Drugs 0.000 description 53
- 108090000765 processed proteins & peptides Proteins 0.000 description 53
- 239000011049 pearl Substances 0.000 description 52
- 210000000612 antigen-presenting cell Anatomy 0.000 description 49
- 239000000463 material Substances 0.000 description 48
- 239000002105 nanoparticle Substances 0.000 description 46
- 235000018102 proteins Nutrition 0.000 description 45
- 230000000694 effects Effects 0.000 description 43
- 239000002245 particle Substances 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 210000001744 T-lymphocyte Anatomy 0.000 description 39
- 229960002930 sirolimus Drugs 0.000 description 37
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 36
- 230000004044 response Effects 0.000 description 34
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 32
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 32
- 238000009472 formulation Methods 0.000 description 30
- 239000002253 acid Substances 0.000 description 28
- 230000003993 interaction Effects 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 229920001223 polyethylene glycol Polymers 0.000 description 26
- 210000003289 regulatory T cell Anatomy 0.000 description 25
- 229920001577 copolymer Polymers 0.000 description 24
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 23
- 239000002953 phosphate buffered saline Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 238000011282 treatment Methods 0.000 description 22
- 239000003814 drug Substances 0.000 description 21
- 239000010410 layer Substances 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 18
- 229920000728 polyester Polymers 0.000 description 18
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 17
- 229910052737 gold Inorganic materials 0.000 description 17
- 150000002632 lipids Chemical class 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 17
- 150000007523 nucleic acids Chemical class 0.000 description 17
- 238000001556 precipitation Methods 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- 239000010931 gold Substances 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 108010058846 Ovalbumin Proteins 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000002502 liposome Substances 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 239000000839 emulsion Substances 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 13
- 229940092253 ovalbumin Drugs 0.000 description 13
- 230000006399 behavior Effects 0.000 description 12
- 150000001720 carbohydrates Chemical class 0.000 description 12
- 235000014633 carbohydrates Nutrition 0.000 description 12
- 239000005482 chemotactic factor Substances 0.000 description 12
- 230000006698 induction Effects 0.000 description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 12
- 229920000570 polyether Polymers 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 108010014172 Factor V Proteins 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 239000008187 granular material Substances 0.000 description 11
- 238000012423 maintenance Methods 0.000 description 11
- 229920001983 poloxamer Polymers 0.000 description 11
- 229920000307 polymer substrate Polymers 0.000 description 11
- 239000002023 wood Substances 0.000 description 11
- 108010074864 Factor XI Proteins 0.000 description 10
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 10
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 9
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 125000003368 amide group Chemical group 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 238000009739 binding Methods 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 238000000527 sonication Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 9
- 229960000187 tissue plasminogen activator Drugs 0.000 description 9
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 8
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 8
- 102000018942 N-acetylgalactosamine-4-sulfatase activity proteins Human genes 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 150000001412 amines Chemical group 0.000 description 8
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 8
- 108010089934 carbohydrase Proteins 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 229960000575 trastuzumab Drugs 0.000 description 8
- 102100022641 Coagulation factor IX Human genes 0.000 description 7
- 229930105110 Cyclosporin A Natural products 0.000 description 7
- 108010076282 Factor IX Proteins 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 101150113720 aunc gene Proteins 0.000 description 7
- 235000013339 cereals Nutrition 0.000 description 7
- 230000024203 complement activation Effects 0.000 description 7
- QBEPNUQJQWDYKU-BMGKTWPMSA-N egrifta Chemical compound C([C@H](NC(=O)C/C=C/CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O)C1=CC=C(O)C=C1 QBEPNUQJQWDYKU-BMGKTWPMSA-N 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000002082 metal nanoparticle Substances 0.000 description 7
- 210000004681 ovum Anatomy 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000004417 polycarbonate Substances 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 230000002194 synthesizing effect Effects 0.000 description 7
- 108700002800 tesamorelin Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102000004411 Antithrombin III Human genes 0.000 description 6
- 108090000935 Antithrombin III Proteins 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 6
- 108010074604 Epoetin Alfa Proteins 0.000 description 6
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 6
- 102000015696 Interleukins Human genes 0.000 description 6
- 108010063738 Interleukins Proteins 0.000 description 6
- 102100035792 Kininogen-1 Human genes 0.000 description 6
- 208000015439 Lysosomal storage disease Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102100038124 Plasminogen Human genes 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 6
- 150000001345 alkine derivatives Chemical class 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 229960005348 antithrombin iii Drugs 0.000 description 6
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000000562 conjugate Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 108010072166 idursulfase Proteins 0.000 description 6
- 229940047122 interleukins Drugs 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 210000002824 peroxisome Anatomy 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 229920000747 poly(lactic acid) Polymers 0.000 description 6
- 229920001610 polycaprolactone Polymers 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 6
- 229960001874 tesamorelin Drugs 0.000 description 6
- 229960003989 tocilizumab Drugs 0.000 description 6
- 108010047303 von Willebrand Factor Proteins 0.000 description 6
- 102100036537 von Willebrand factor Human genes 0.000 description 6
- 101710153593 Albumin A Proteins 0.000 description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 102100030563 Coagulation factor XI Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108010014173 Factor X Proteins 0.000 description 5
- 102100037362 Fibronectin Human genes 0.000 description 5
- 102000004366 Glucosidases Human genes 0.000 description 5
- 108010056771 Glucosidases Proteins 0.000 description 5
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 240000000233 Melia azedarach Species 0.000 description 5
- 108010051456 Plasminogen Proteins 0.000 description 5
- 239000005864 Sulphur Substances 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000012620 biological material Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 229910052681 coesite Inorganic materials 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 229910052906 cristobalite Inorganic materials 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000002296 dynamic light scattering Methods 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 229940012882 elaprase Drugs 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 5
- 229960004222 factor ix Drugs 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 150000002338 glycosides Chemical class 0.000 description 5
- 102000045921 human GAA Human genes 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229960005027 natalizumab Drugs 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 229920001451 polypropylene glycol Polymers 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 229910052682 stishovite Inorganic materials 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 150000003568 thioethers Chemical class 0.000 description 5
- 229910052905 tridymite Inorganic materials 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 101710158075 Bucky ball Proteins 0.000 description 4
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108010074860 Factor Xa Proteins 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 102100040018 Interferon alpha-2 Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 102000004195 Isomerases Human genes 0.000 description 4
- 108090000769 Isomerases Proteins 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 102000004317 Lyases Human genes 0.000 description 4
- 108090000856 Lyases Proteins 0.000 description 4
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010068701 Pegloticase Proteins 0.000 description 4
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 4
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108090000113 Plasma Kallikrein Proteins 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 229940096437 Protein S Drugs 0.000 description 4
- 108010066124 Protein S Proteins 0.000 description 4
- 102000029301 Protein S Human genes 0.000 description 4
- 108010094028 Prothrombin Proteins 0.000 description 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 4
- 108010000499 Thromboplastin Proteins 0.000 description 4
- 102000002262 Thromboplastin Human genes 0.000 description 4
- 102000036693 Thrombopoietin Human genes 0.000 description 4
- 108010041111 Thrombopoietin Proteins 0.000 description 4
- 102000004357 Transferases Human genes 0.000 description 4
- 108090000992 Transferases Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 4
- 108010004977 Vasopressins Proteins 0.000 description 4
- 102000002852 Vasopressins Human genes 0.000 description 4
- NJSVDVPGINTNGX-UHFFFAOYSA-N [dimethoxy(propyl)silyl]oxymethanamine Chemical compound CCC[Si](OC)(OC)OCN NJSVDVPGINTNGX-UHFFFAOYSA-N 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 108010062065 albumin interferon Proteins 0.000 description 4
- 229960000548 alemtuzumab Drugs 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 230000001475 anti-trypsic effect Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000005784 autoimmunity Effects 0.000 description 4
- 229960000397 bevacizumab Drugs 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 150000001768 cations Chemical group 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 239000011258 core-shell material Substances 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 238000006352 cycloaddition reaction Methods 0.000 description 4
- 108010057085 cytokine receptors Proteins 0.000 description 4
- 102000003675 cytokine receptors Human genes 0.000 description 4
- 229960002806 daclizumab Drugs 0.000 description 4
- 239000000412 dendrimer Substances 0.000 description 4
- 229920000736 dendritic polymer Polymers 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000002532 enzyme inhibitor Substances 0.000 description 4
- 229940125532 enzyme inhibitor Drugs 0.000 description 4
- 229960003388 epoetin alfa Drugs 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 108010039650 imiglucerase Proteins 0.000 description 4
- 229960002127 imiglucerase Drugs 0.000 description 4
- 238000000760 immunoelectrophoresis Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000013554 lipid monolayer Substances 0.000 description 4
- 229940091827 lumizyme Drugs 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 229940103023 myozyme Drugs 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229960001376 pegloticase Drugs 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 229920001432 poly(L-lactide) Polymers 0.000 description 4
- 108700022290 poly(gamma-glutamic acid) Proteins 0.000 description 4
- 229920000515 polycarbonate Polymers 0.000 description 4
- 229920006324 polyoxymethylene Polymers 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229960002855 simvastatin Drugs 0.000 description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 229960001967 tacrolimus Drugs 0.000 description 4
- AKXUUJCMWZFYMV-UHFFFAOYSA-M tetrakis(hydroxymethyl)phosphanium;chloride Chemical compound [Cl-].OC[P+](CO)(CO)CO AKXUUJCMWZFYMV-UHFFFAOYSA-M 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- 230000003614 tolerogenic effect Effects 0.000 description 4
- 229960005356 urokinase Drugs 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 102100026277 Alpha-galactosidase A Human genes 0.000 description 3
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 3
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 102400000739 Corticotropin Human genes 0.000 description 3
- 101800000414 Corticotropin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 3
- 108010017544 Glucosylceramidase Proteins 0.000 description 3
- 102000004547 Glucosylceramidase Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 102000004157 Hydrolases Human genes 0.000 description 3
- 108090000604 Hydrolases Proteins 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 239000004425 Makrolon Substances 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 108010019759 OVA 323-339 Proteins 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 3
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 229940022705 aldurazyme Drugs 0.000 description 3
- 108010030291 alpha-Galactosidase Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000001736 anti-fibrinolysin Effects 0.000 description 3
- 229960003270 belimumab Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 108090001015 cancer procoagulant Proteins 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 108700005721 conestat alfa Proteins 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical group C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 229960001348 estriol Drugs 0.000 description 3
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 3
- CJGXMNONHNZEQQ-UHFFFAOYSA-N ethyl 2-amino-3-phenylpropanoate Chemical group CCOC(=O)C(N)CC1=CC=CC=C1 CJGXMNONHNZEQQ-UHFFFAOYSA-N 0.000 description 3
- 229960005167 everolimus Drugs 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 108010089296 galsulfase Proteins 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 108010013846 hematide Proteins 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000008629 immune suppression Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002998 immunogenetic effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000001524 infective effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 239000013528 metallic particle Substances 0.000 description 3
- 229940068704 naglazyme Drugs 0.000 description 3
- 239000002070 nanowire Substances 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 229950005751 ocrelizumab Drugs 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 3
- 229960005184 panobinostat Drugs 0.000 description 3
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 229920001308 poly(aminoacid) Polymers 0.000 description 3
- 229920002643 polyglutamic acid Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 229920000193 polymethacrylate Polymers 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 229940127293 prostanoid Drugs 0.000 description 3
- 239000002096 quantum dot Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229960003876 ranibizumab Drugs 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 238000009256 replacement therapy Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 229960001302 ridaforolimus Drugs 0.000 description 3
- 229940080817 rotenone Drugs 0.000 description 3
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 235000015170 shellfish Nutrition 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Chemical compound [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 3
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 3
- 229960003726 vasopressin Drugs 0.000 description 3
- 239000007762 w/o emulsion Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 2
- ZMEWRPBAQVSBBB-GOTSBHOMSA-N (2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[[2-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetyl]amino]hexanoic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 ZMEWRPBAQVSBBB-GOTSBHOMSA-N 0.000 description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- ONJZYZYZIKTIEG-CFBQITSMSA-N (3s,6s,9r,10r,11s,12s,13e,15e,18s,21s)-18-[(2e,4e,8s,9s)-10-[(2s,3r,4s,5s,6r,9s,11s)-9-ethyl-4-hydroxy-3,5,11-trimethyl-8-oxo-1-oxa-7-azaspiro[5.5]undecan-2-yl]-9-hydroxy-8-methyldeca-2,4-dien-2-yl]-10,12-dihydroxy-3-[(3-hydroxyphenyl)methyl]-11-methyl-9- Chemical compound N1C(=O)[C@@H](CC)C[C@H](C)[C@]21[C@@H](C)[C@@H](O)[C@@H](C)[C@H](C[C@H](O)[C@@H](C)CC\C=C\C=C(/C)[C@H]1OC(=O)[C@@H]3CCCN(N3)C(=O)[C@H](CC=3C=C(O)C=CC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(C)=O)[C@H](O)[C@@H](C)[C@@H](O)/C=C/C=C/C1)O2 ONJZYZYZIKTIEG-CFBQITSMSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- 150000000177 1,2,3-triazoles Chemical class 0.000 description 2
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- QUNWUDVFRNGTCO-UHFFFAOYSA-N 1,7-dimethylxanthine Chemical compound N1C(=O)N(C)C(=O)C2=C1N=CN2C QUNWUDVFRNGTCO-UHFFFAOYSA-N 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 2
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 108010013043 Acetylesterase Proteins 0.000 description 2
- 102100031786 Adiponectin Human genes 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102400000059 Arg-vasopressin Human genes 0.000 description 2
- 101800001144 Arg-vasopressin Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 2
- 102000004631 Calcineurin Human genes 0.000 description 2
- 108010042955 Calcineurin Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102100029117 Coagulation factor X Human genes 0.000 description 2
- 102100030556 Coagulation factor XII Human genes 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 239000005946 Cypermethrin Substances 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 102100031939 Erythropoietin Human genes 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 108010080865 Factor XII Proteins 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 229940080349 GPR agonist Drugs 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 102000004858 Growth differentiation factor-9 Human genes 0.000 description 2
- 108090001086 Growth differentiation factor-9 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 2
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 2
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102100039897 Interleukin-5 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- DAHIQPJTGIHDGO-IRXDYDNUSA-N Mesembrine Chemical compound C1=C(OC)C(OC)=CC=C1[C@@]1(CCC(=O)C2)[C@H]2N(C)CC1 DAHIQPJTGIHDGO-IRXDYDNUSA-N 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 2
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 108010082093 Placenta Growth Factor Proteins 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920001273 Polyhydroxy acid Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- ONJZYZYZIKTIEG-UHFFFAOYSA-N Sanglifehrin A Natural products N1C(=O)C(CC)CC(C)C21C(C)C(O)C(C)C(CC(O)C(C)CCC=CC=C(C)C1OC(=O)C3CCCN(N3)C(=O)C(CC=3C=C(O)C=CC=3)NC(=O)C(C(C)C)NC(=O)C(CCC(C)=O)C(O)C(C)C(O)C=CC=CC1)O2 ONJZYZYZIKTIEG-UHFFFAOYSA-N 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100040613 Uromodulin Human genes 0.000 description 2
- 108010027007 Uromodulin Proteins 0.000 description 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- FKAWLXNLHHIHLA-YCBIHMBMSA-N [(2r,3r,5r,7r,8s,9s)-2-[(1s,3s,4s,5r,6r,7e,9e,11e,13z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(e)-3-[2-[(2s)-4-[[(2s,3s,4s)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4 Chemical compound O1C([C@@H](C)CCNC(=O)[C@@H](O)[C@@H](O)[C@H](COC)N(C)C)=NC(\C=C\C[C@H]2[C@H]([C@H](O)C[C@]3(O2)C([C@@H](OP(O)(O)=O)[C@@H]([C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C(\C)=C\C=C\C(\C)=C/C#N)OC)O3)(C)C)C)=C1 FKAWLXNLHHIHLA-YCBIHMBMSA-N 0.000 description 2
- XYVNHPYNSPGYLI-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O XYVNHPYNSPGYLI-UUOKFMHZSA-N 0.000 description 2
- 229960000446 abciximab Drugs 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960005339 acitretin Drugs 0.000 description 2
- 229960002916 adapalene Drugs 0.000 description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 2
- 229960003227 afelimomab Drugs 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 229950009106 altumomab Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 229960001694 anagrelide Drugs 0.000 description 2
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 229950006061 anatumomab mafenatox Drugs 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 229950005725 arcitumomab Drugs 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229950000103 atorolimumab Drugs 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960004669 basiliximab Drugs 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 229950003269 bectumomab Drugs 0.000 description 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 2
- 229960003094 belinostat Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940054066 benzamide antipsychotics Drugs 0.000 description 2
- 150000003936 benzamides Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 229950001303 biciromab Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 description 2
- 229940046731 calcineurin inhibitors Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229930008399 cantharidic acid Natural products 0.000 description 2
- 229940095758 cantharidin Drugs 0.000 description 2
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 2
- 229930008397 cantharidin Natural products 0.000 description 2
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 2
- 229940034605 capromab pendetide Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
- 229960000419 catumaxomab Drugs 0.000 description 2
- 229950006754 cedelizumab Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229930183167 cerebroside Natural products 0.000 description 2
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 2
- 229960005110 cerivastatin Drugs 0.000 description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 2
- 229950009226 ciglitazone Drugs 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 229960005424 cypermethrin Drugs 0.000 description 2
- KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 description 2
- 229950007409 dacetuzumab Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 238000002242 deionisation method Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229950008962 detumomab Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229960002563 disulfiram Drugs 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- OMFNSKIUKYOYRG-MOSHPQCFSA-N drotaverine Chemical compound C1=C(OCC)C(OCC)=CC=C1\C=C/1C2=CC(OCC)=C(OCC)C=C2CCN\1 OMFNSKIUKYOYRG-MOSHPQCFSA-N 0.000 description 2
- 229960002065 drotaverine Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229950011109 edobacomab Drugs 0.000 description 2
- 229960001776 edrecolomab Drugs 0.000 description 2
- 229960000284 efalizumab Drugs 0.000 description 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 2
- 229950009760 epratuzumab Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 2
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 2
- 229960002199 etretinate Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229950001488 faralimomab Drugs 0.000 description 2
- 125000005313 fatty acid group Chemical group 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 229950010404 fostriecin Drugs 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229950001109 galiximab Drugs 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 150000001261 hydroxy acids Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
- 229960002491 ibudilast Drugs 0.000 description 2
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 2
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 229950002200 igovomab Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229940073062 imuran Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229950007937 inolimomab Drugs 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229950010828 keliximab Drugs 0.000 description 2
- DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- 229960002486 laronidase Drugs 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 229950002950 lintuzumab Drugs 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229950008083 maslimomab Drugs 0.000 description 2
- 229950008001 matuzumab Drugs 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 229960005108 mepolizumab Drugs 0.000 description 2
- ZZDBMDNRQQDSKG-UHFFFAOYSA-N methyl 5-bromo-1-benzofuran-2-carboxylate Chemical compound BrC1=CC=C2OC(C(=O)OC)=CC2=C1 ZZDBMDNRQQDSKG-UHFFFAOYSA-N 0.000 description 2
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 229960003574 milrinone Drugs 0.000 description 2
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 2
- 229950002142 minretumomab Drugs 0.000 description 2
- 229960005249 misoprostol Drugs 0.000 description 2
- 229950003063 mitumomab Drugs 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229950008897 morolimumab Drugs 0.000 description 2
- 229960003816 muromonab-cd3 Drugs 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 229960002915 nebacumab Drugs 0.000 description 2
- 229950009675 nerelimomab Drugs 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 229960000916 niflumic acid Drugs 0.000 description 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 2
- 229960001346 nilotinib Drugs 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229960000470 omalizumab Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 2
- YOURXVGYNVXQKT-UHFFFAOYSA-N oxacycloundecane-2,11-dione Chemical compound O=C1CCCCCCCCC(=O)O1 YOURXVGYNVXQKT-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 229960000402 palivizumab Drugs 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- CWODDUGJZSCNGB-HQNRRURTSA-N palytoxin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CCCCC[C@H](C)C[C@@H]2[C@@]3(C)C[C@H](C)C[C@@](O3)(CCCCCCC[C@H](O)C[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@](O)(C[C@H](O)[C@@H](C)\C=C\[C@@H](O)CC[C@@H](O)[C@@H](O)[C@H]4O[C@H](C[C@@H](O)[C@H](O)C[C@@H]5[C@H]([C@H](O)[C@@H](O)[C@H](C[C@H](O)\C=C/C=C/C[C@@H](O)[C@H](O)[C@H](O)C\C=C/C(=C)CC[C@H](O)[C@@H](O)[C@H](O)[C@H](C)C[C@@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](\C=C/[C@@H](O)[C@H](O)C[C@H]7O[C@H]8C[C@H](O[C@@H]8CC[C@@H]8[C@@H](C[C@@H](CN)O8)O)C7)O6)O)O5)O)[C@@H](O)[C@H](O)C4)O3)O)O2)[C@H](C[C@H](O)[C@H](O)C(\C)=C\[C@H](O)C[C@@H](C)[C@H](O)C(=O)N\C=C\C(=O)NCCCO)[C@H](O)[C@@H](O)[C@@H]1O CWODDUGJZSCNGB-HQNRRURTSA-N 0.000 description 2
- 229960005548 palytoxin Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229960000639 pazopanib Drugs 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 229950011098 pendetide Drugs 0.000 description 2
- IEKVHGDUBCZHRB-UHFFFAOYSA-N phenylarsenic Chemical compound [As]C1=CC=CC=C1 IEKVHGDUBCZHRB-UHFFFAOYSA-N 0.000 description 2
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 2
- RRRUXBQSQLKHEL-UHFFFAOYSA-N piclamilast Chemical compound COC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OC1CCCC1 RRRUXBQSQLKHEL-UHFFFAOYSA-N 0.000 description 2
- 229950005184 piclamilast Drugs 0.000 description 2
- KASDHRXLYQOAKZ-XDSKOBMDSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 229960002797 pitavastatin Drugs 0.000 description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920001855 polyketal Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229950003700 priliximab Drugs 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 235000012950 rattan cane Nutrition 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229920013730 reactive polymer Polymers 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229950005854 regavirumab Drugs 0.000 description 2
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical compound C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- DAPAQENNNINUPW-IDAMAFBJSA-N rocaglamide Chemical compound C1=CC(OC)=CC=C1[C@]1([C@@H]([C@H]([C@H]2O)C(=O)N(C)C)C=3C=CC=CC=3)[C@]2(O)C2=C(OC)C=C(OC)C=C2O1 DAPAQENNNINUPW-IDAMAFBJSA-N 0.000 description 2
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 2
- 229960002586 roflumilast Drugs 0.000 description 2
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 2
- 229950005741 rolipram Drugs 0.000 description 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 2
- 229960000672 rosuvastatin Drugs 0.000 description 2
- 229960004017 salmeterol Drugs 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229950004951 sevirumab Drugs 0.000 description 2
- 229950008684 sibrotuzumab Drugs 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- XBUIKNRVGYFSHL-IAVQPKKASA-M sodium;[(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2r)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] hydrogen phosphate Chemical compound [Na+].OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)([O-])=O)[C@@](O)(C)\C=C\[C@H]1CC=CC(=O)O1 XBUIKNRVGYFSHL-IAVQPKKASA-M 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000003980 solgel method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000012128 staining reagent Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 229950010708 sulesomab Drugs 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960000565 tazarotene Drugs 0.000 description 2
- 229950008300 telimomab aritox Drugs 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000006177 thiolation reaction Methods 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 229950007217 tremelimumab Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- 229950005082 tuvirumab Drugs 0.000 description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 2
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 description 2
- 229960000438 udenafil Drugs 0.000 description 2
- 229960000241 vandetanib Drugs 0.000 description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
- 229960002381 vardenafil Drugs 0.000 description 2
- 229950005208 vepalimomab Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- 229950003511 votumumab Drugs 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- 229950001346 zolimomab aritox Drugs 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 description 1
- DFBIRQPKNDILPW-LKUXBXJISA-N (1S,2S,4S,5R,7S,8R,9S,11R,13R)-8-hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one Chemical compound CC(C)[C@@]12O[C@@H]1[C@@H]1O[C@]11[C@]3(O[C@@H]3C[C@@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O DFBIRQPKNDILPW-LKUXBXJISA-N 0.000 description 1
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 1
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 1
- MFZSNESUTRVBQX-XEURHVNRSA-N (2S)-2-amino-6-[4-[[3-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-3-oxopropyl]disulfanyl]pentanoylamino]hexanoic acid Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCSSC(C)CCC(=O)NCCCC[C@H](N)C(O)=O)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 MFZSNESUTRVBQX-XEURHVNRSA-N 0.000 description 1
- FOIAQXXUVRINCI-LBAQZLPGSA-N (2S)-2-amino-6-[[4-[2-[bis(carboxymethyl)amino]-3-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]propyl]phenyl]carbamothioylamino]hexanoic acid Chemical compound N[C@@H](CCCCNC(=S)Nc1ccc(CC(CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)cc1)C(O)=O FOIAQXXUVRINCI-LBAQZLPGSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- LLOKIGWPNVSDGJ-AFBVCZJXSA-N (3s,6s,9s,12r)-3,6-dibenzyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 LLOKIGWPNVSDGJ-AFBVCZJXSA-N 0.000 description 1
- VFCXONOPGCDDBQ-AQTBWJFISA-N (3z)-3-[[4-(dimethylamino)naphthalen-1-yl]methylidene]-1h-indol-2-one Chemical compound C12=CC=CC=C2C(N(C)C)=CC=C1\C=C/1C2=CC=CC=C2NC\1=O VFCXONOPGCDDBQ-AQTBWJFISA-N 0.000 description 1
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 1
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 1
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical compound CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical class OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 150000005058 1,8-naphthyridines Chemical class 0.000 description 1
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical class CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical class C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- MAASHDQFQDDECQ-UHFFFAOYSA-N 2,3-bis(2-hydroxyethylthio)naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(SCCO)=C(SCCO)C(=O)C2=C1 MAASHDQFQDDECQ-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- NYEZZYQZRQDLEH-UHFFFAOYSA-N 2-ethyl-4,5-dihydro-1,3-oxazole Chemical compound CCC1=NCCO1 NYEZZYQZRQDLEH-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical compound OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical class OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 description 1
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- VMUXSMXIQBNMGZ-UHFFFAOYSA-N 3,4-dihydrocoumarin Chemical compound C1=CC=C2OC(=O)CCC2=C1 VMUXSMXIQBNMGZ-UHFFFAOYSA-N 0.000 description 1
- IOSAAWHGJUZBOG-UHFFFAOYSA-N 3-(6-amino-9h-purin-9-yl)nonan-2-ol Chemical compound N1=CN=C2N(C(C(C)O)CCCCCC)C=NC2=C1N IOSAAWHGJUZBOG-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- IMXHGCRIEAKIBU-UHFFFAOYSA-N 4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=NC(N2CCOCC2)=C(C=NN2C3CCN(CC3)C(=O)OC)C2=N1 IMXHGCRIEAKIBU-UHFFFAOYSA-N 0.000 description 1
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- IFGWYHGYNVGVRB-UHFFFAOYSA-N 5-(2,4-difluorophenoxy)-n-[2-(dimethylamino)ethyl]-1-(2-methylpropyl)indazole-6-carboxamide Chemical compound CN(C)CCNC(=O)C=1C=C2N(CC(C)C)N=CC2=CC=1OC1=CC=C(F)C=C1F IFGWYHGYNVGVRB-UHFFFAOYSA-N 0.000 description 1
- HINJNZFCMLSBCI-PKOBYXMFSA-N 5-chloro-n-[(2s,3r)-4-(dimethylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl]-1h-indole-2-carboxamide Chemical compound C([C@@H]([C@@H](O)C(=O)N(C)C)NC(=O)C=1NC2=CC=C(Cl)C=C2C=1)C1=CC=CC=C1 HINJNZFCMLSBCI-PKOBYXMFSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- KQEPIRKXSUIUTH-UHFFFAOYSA-N 7-chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepin-2-one Chemical compound C12=CC(Cl)=CC=C2NC(=O)CSC1C1=CC=CC=C1Cl KQEPIRKXSUIUTH-UHFFFAOYSA-N 0.000 description 1
- CPRAGQJXBLMUEL-UHFFFAOYSA-N 9-(1-anilinoethyl)-7-methyl-2-(4-morpholinyl)-4-pyrido[1,2-a]pyrimidinone Chemical compound C=1C(C)=CN(C(C=C(N=2)N3CCOCC3)=O)C=2C=1C(C)NC1=CC=CC=C1 CPRAGQJXBLMUEL-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- KVLFRAWTRWDEDF-IRXDYDNUSA-N AZD-8055 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3[C@H](COCC3)C)N3[C@H](COCC3)C)C2=N1 KVLFRAWTRWDEDF-IRXDYDNUSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100034134 Activin receptor type-1B Human genes 0.000 description 1
- 102100034135 Activin receptor type-1C Human genes 0.000 description 1
- 102100021886 Activin receptor type-2A Human genes 0.000 description 1
- 102100027647 Activin receptor type-2B Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- DTDADHMBRZKXSC-GKASHWOUSA-N Aricine Chemical compound C1=C(OC)C=C2C(CCN3C[C@H]4[C@H](C)OC=C([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 DTDADHMBRZKXSC-GKASHWOUSA-N 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- IUCNQFHEWLYECJ-FNAJZLPOSA-L Atractyloside Chemical compound [K+].[K+].O1[C@H](CO)[C@@H](OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@@H](OC(=O)CC(C)C)[C@@H]1O[C@H]1C[C@@]2(C)[C@@H]3CC[C@@H](C(=C)[C@@H]4O)C[C@]34CC[C@@H]2[C@H](C(O)=O)C1 IUCNQFHEWLYECJ-FNAJZLPOSA-L 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- VHKZGNPOHPFPER-ONNFQVAWSA-N BAY11-7085 Chemical compound CC(C)(C)C1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 VHKZGNPOHPFPER-ONNFQVAWSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KLYCPFXDDDMZNQ-UHFFFAOYSA-N Benzyne Chemical compound C1=CC#CC=C1 KLYCPFXDDDMZNQ-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 1
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 description 1
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 description 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241001282763 Carlina gummifera Species 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 102100037529 Coagulation factor V Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 108700040183 Complement C1 Inhibitor Proteins 0.000 description 1
- 102000055157 Complement C1 Inhibitor Human genes 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000230452 Cyclothone braueri Species 0.000 description 1
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- TZYWCYJVHRLUCT-ZRBLBEILSA-N D-leucinamide, n-[(phenylmethoxy)carbonyl]-l-leucyl-n-[(1s)-1-formyl-3-methylbutyl]- Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-ZRBLBEILSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- IEPRKVQEAMIZSS-UHFFFAOYSA-N Di-Et ester-Fumaric acid Natural products CCOC(=O)C=CC(=O)OCC IEPRKVQEAMIZSS-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- IEPRKVQEAMIZSS-WAYWQWQTSA-N Diethyl maleate Chemical compound CCOC(=O)\C=C/C(=O)OCC IEPRKVQEAMIZSS-WAYWQWQTSA-N 0.000 description 1
- 230000010777 Disulfide Reduction Effects 0.000 description 1
- 102100031788 E3 ubiquitin-protein ligase MYLIP Human genes 0.000 description 1
- 101710190174 E3 ubiquitin-protein ligase MYLIP Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101710134985 Esterase-4 Proteins 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- LQYJRWROYVBAKF-UHFFFAOYSA-N Ferrugin Natural products COc1ccc(cc1)C2CC3Oc4cc(OC)cc(OC)c4C2(O)C3(O)c5ccccc5 LQYJRWROYVBAKF-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- 229910004042 HAuCl4 Inorganic materials 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 1
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 description 1
- 101000970954 Homo sapiens Activin receptor type-2A Proteins 0.000 description 1
- 101000937269 Homo sapiens Activin receptor type-2B Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 description 1
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 description 1
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 description 1
- 101100222381 Homo sapiens CXCL11 gene Proteins 0.000 description 1
- 101001027836 Homo sapiens Coagulation factor V Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000893552 Homo sapiens Embryonic growth/differentiation factor 1 Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101001054659 Homo sapiens Latent-transforming growth factor beta-binding protein 1 Proteins 0.000 description 1
- 101000602237 Homo sapiens Neuroblastoma suppressor of tumorigenicity 1 Proteins 0.000 description 1
- 101001113490 Homo sapiens Poly(A)-specific ribonuclease PARN Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 101000642464 Homo sapiens Spermatogenesis-associated protein 2-like protein Proteins 0.000 description 1
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- YMFNPBSZFWXMAD-UHFFFAOYSA-N JSH-23 Chemical compound NC1=CC(C)=CC=C1NCCCC1=CC=CC=C1 YMFNPBSZFWXMAD-UHFFFAOYSA-N 0.000 description 1
- 108010025252 Kassinin Proteins 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 102100027000 Latent-transforming growth factor beta-binding protein 1 Human genes 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000918728 Monotes Species 0.000 description 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 description 1
- 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 description 1
- 102100030607 Mothers against decapentaplegic homolog 9 Human genes 0.000 description 1
- 239000005462 Mubritinib Substances 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 241000531313 Mundulea sericea Species 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 101100288960 Mus musculus Lefty1 gene Proteins 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- ZTXUSFPBLYQDDN-UHFFFAOYSA-N N-(3,4-dihydroxyphenyl)-N-ethylnitrous amide Chemical compound OC=1C=C(N(CC)N=O)C=CC1O ZTXUSFPBLYQDDN-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- CHILCFMQWMQVAL-UHFFFAOYSA-N N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CHILCFMQWMQVAL-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical class NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 101800003845 Neuropeptide Y Proteins 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 101000840556 Oryza sativa subsp. japonica Hexokinase-4, chloroplastic Proteins 0.000 description 1
- 101710129178 Outer plastidial membrane protein porin Proteins 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- BIVQBWSIGJFXLF-UHFFFAOYSA-N PPM-18 Chemical compound C=1C(=O)C2=CC=CC=C2C(=O)C=1NC(=O)C1=CC=CC=C1 BIVQBWSIGJFXLF-UHFFFAOYSA-N 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 102100034869 Plasma kallikrein Human genes 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- 229920002396 Polyurea Polymers 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 108010087786 Prolactin-Releasing Hormone Proteins 0.000 description 1
- 102100028850 Prolactin-releasing peptide Human genes 0.000 description 1
- 241001250496 Prorocentrum concavum Species 0.000 description 1
- 241000200247 Prorocentrum micans Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000006478 Protein Phosphatase 2 Human genes 0.000 description 1
- 108010058956 Protein Phosphatase 2 Proteins 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 102000002294 Purinergic P2X Receptors Human genes 0.000 description 1
- 108010000836 Purinergic P2X Receptors Proteins 0.000 description 1
- 241000274582 Pycnanthus angolensis Species 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- ZQUSFAUAYSEREK-WKILWMFISA-N SB-239063 Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)[C@@H]2CC[C@@H](O)CC2)=N1 ZQUSFAUAYSEREK-WKILWMFISA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 101700031501 SMAD9 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 102100030254 Spermatogenesis-associated protein 2 Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000971004 Streptomyces fulvissimus Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 229940126624 Tacatuzumab tetraxetan Drugs 0.000 description 1
- 241001441723 Takifugu Species 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- 102400001005 Teneurin C-terminal-associated peptide Human genes 0.000 description 1
- 101800002375 Teneurin C-terminal-associated peptide Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- LLOKIGWPNVSDGJ-UHFFFAOYSA-N Trapoxin B Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCN2C(=O)C1CC1=CC=CC=C1 LLOKIGWPNVSDGJ-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 1
- 235000021322 Vaccenic acid Nutrition 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 102100037820 Voltage-dependent anion-selective channel protein 1 Human genes 0.000 description 1
- 244000067645 Wedelia chinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 description 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 1
- GJEAMHAFPYZYDE-UHFFFAOYSA-N [C].[S] Chemical compound [C].[S] GJEAMHAFPYZYDE-UHFFFAOYSA-N 0.000 description 1
- 229950005186 abagovomab Drugs 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- HVYLDJKDVOOTHV-UHFFFAOYSA-N acetic acid;2-iminoethanethiol Chemical compound CC(O)=O.CC(O)=O.SCC=N HVYLDJKDVOOTHV-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229960001239 agalsidase alfa Drugs 0.000 description 1
- 108010049936 agalsidase alfa Proteins 0.000 description 1
- 229950008459 alacizumab pegol Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BVCZEBOGSOYJJT-UHFFFAOYSA-N ammonium carbamate Chemical compound [NH4+].NC([O-])=O BVCZEBOGSOYJJT-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 239000002416 angiotensin derivative Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229950005794 anrukinzumab Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000603 anti-haemophilic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- UHDJCSZGZJGMDR-UHFFFAOYSA-N aricine Natural products COC(=O)C1=COC(C)C2(C)CN3CCc4c([nH]c5ccc(OC)cc45)C3(C)CC12C UHDJCSZGZJGMDR-UHFFFAOYSA-N 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229950002882 aselizumab Drugs 0.000 description 1
- FYQXODZRNSCOTR-UHFFFAOYSA-N atractyloside Natural products O1C(CO)C(OS(O)(=O)=O)C(OS(O)(=O)=O)C(OC(=O)CC(C)C)C1OC1CC2(C)C3CCC(C(=C)C4O)CC34CCC2C(C(O)=O)C1 FYQXODZRNSCOTR-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 description 1
- 229960000307 avanafil Drugs 0.000 description 1
- ZBOMSHVRJSJGNR-JBNKPAQWSA-N azanium;(2r)-3-[(2s,6r,8s,11r)-2-[(e,2r)-4-[(2s,2'r,4r,4as,6r)-4-hydroxy-2-[(1s,3s)-1-hydroxy-3-[(3r,6s)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4h-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-11-hy Chemical compound [NH4+].C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CCC4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)C3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C([O-])=O)CC[C@H]2O ZBOMSHVRJSJGNR-JBNKPAQWSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229950001863 bapineuzumab Drugs 0.000 description 1
- 229950007843 bavituximab Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229950000321 benralizumab Drugs 0.000 description 1
- JEUUNKOFKDUVMN-UHFFFAOYSA-N benzo[f]chromen-1-one Chemical compound C1=CC=CC2=C3C(=O)C=COC3=CC=C21 JEUUNKOFKDUVMN-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 108010034937 benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal Proteins 0.000 description 1
- 229950010015 bertilimumab Drugs 0.000 description 1
- 229950010559 besilesomab Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 108010042362 beta-Lipotropin Proteins 0.000 description 1
- JWAZRIHNYRIHIV-UHFFFAOYSA-N beta-hydroxynaphthyl Natural products C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960005522 bivatuzumab mertansine Drugs 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229960002874 briakinumab Drugs 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
- 229960004361 calcifediol Drugs 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 229950007296 cantuzumab mertansine Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- CBPNZQVSJQDFBE-HXVVJGEPSA-N ccl-779 Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HXVVJGEPSA-N 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- XAKAQCMEMMZUEO-UHFFFAOYSA-N chembl1256623 Chemical compound O=NN(C)C1=CC=C(O)C(O)=C1 XAKAQCMEMMZUEO-UHFFFAOYSA-N 0.000 description 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Substances ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 229950010905 citatuzumab bogatox Drugs 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 229950002334 clenoliximab Drugs 0.000 description 1
- 238000012650 click reaction Methods 0.000 description 1
- 229950002595 clivatuzumab tetraxetan Drugs 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920000891 common polymer Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000000431 corpus luteum hormone Substances 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- URYYYIJUCLTKBY-UHFFFAOYSA-N cyclohexylmethyl 4-(n'-octylcarbamimidoyl)benzoate;hydrochloride Chemical compound Cl.C1=CC(C(N)=NCCCCCCCC)=CC=C1C(=O)OCC1CCCCC1 URYYYIJUCLTKBY-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- SEGLCEQVOFDUPX-UHFFFAOYSA-N di-(2-ethylhexyl)phosphoric acid Chemical compound CCCCC(CC)COP(O)(=O)OCC(CC)CCCC SEGLCEQVOFDUPX-UHFFFAOYSA-N 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- DMSHWWDRAYHEBS-UHFFFAOYSA-N dihydrocoumarin Natural products C1CC(=O)OC2=C1C=C(OC)C(OC)=C2 DMSHWWDRAYHEBS-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229950005168 dorlimomab aritox Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229950000006 ecromeximab Drugs 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229950002209 efungumab Drugs 0.000 description 1
- 229940102510 egrifta Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 description 1
- 229940108623 eicosenoic acid Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 229940020485 elidel Drugs 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 229950002507 elsilimomab Drugs 0.000 description 1
- 238000004836 empirical method Methods 0.000 description 1
- DAPAQENNNINUPW-UHFFFAOYSA-N endo rocaglamide Natural products C1=CC(OC)=CC=C1C1(C(C(C2O)C(=O)N(C)C)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 DAPAQENNNINUPW-UHFFFAOYSA-N 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 229950002798 enlimomab Drugs 0.000 description 1
- 229950000565 enlimomab pegol Drugs 0.000 description 1
- ZJKNESGOIKRXQY-UHFFFAOYSA-N enoximone Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(C)NC(=O)N1 ZJKNESGOIKRXQY-UHFFFAOYSA-N 0.000 description 1
- 229960000972 enoximone Drugs 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229950006414 epitumomab cituxetan Drugs 0.000 description 1
- 229940089118 epogen Drugs 0.000 description 1
- 229950004292 erlizumab Drugs 0.000 description 1
- 229950008579 ertumaxomab Drugs 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229950009569 etaracizumab Drugs 0.000 description 1
- JCEGKJFZOJBPOL-UHFFFAOYSA-N ethanol;2-hydroxypropanoic acid Chemical compound CCO.CC(O)C(O)=O JCEGKJFZOJBPOL-UHFFFAOYSA-N 0.000 description 1
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical group Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229950005562 exbivirumab Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940093443 fanolesomab Drugs 0.000 description 1
- 229950009929 farletuzumab Drugs 0.000 description 1
- 229950001563 felvizumab Drugs 0.000 description 1
- 229950010512 fezakinumab Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 229950008085 figitumumab Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 229950004923 fontolizumab Drugs 0.000 description 1
- 229950011078 foravirumab Drugs 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229950004003 fresolimumab Drugs 0.000 description 1
- 238000011207 functional examination Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 229950002508 gantenerumab Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229950004792 gavilimomab Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229950002026 girentuximab Drugs 0.000 description 1
- 229950009672 glembatumumab vedotin Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229940126613 gomiliximab Drugs 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 108010052188 hepatoma-derived growth factor Proteins 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- FVMMOSQBOWPRQW-UHFFFAOYSA-N heterophylline Natural products CC(=O)OC1C2(C)C(OC(=O)C=3C=CC=CC=3)CC(C(O3)(C)C)C(OC(=O)C=4C=NC=CC=4)C32C(C)CC1OC(=O)C1=CC=CN=C1 FVMMOSQBOWPRQW-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical class CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000000864 hyperglycemic agent Substances 0.000 description 1
- 229950010245 ibalizumab Drugs 0.000 description 1
- 229960002396 idursulfase Drugs 0.000 description 1
- 229950007354 imciromab Drugs 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 229950001014 intetumumab Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229950010939 iratumumab Drugs 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- 229950002183 lebrikizumab Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229950001275 lemalesomab Drugs 0.000 description 1
- 229950010470 lerdelimumab Drugs 0.000 description 1
- 229950002884 lexatumumab Drugs 0.000 description 1
- 229950005173 libivirumab Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 229950003526 lorvotuzumab mertansine Drugs 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- 229950000128 lumiliximab Drugs 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- 229950002736 marizomib Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- DAHIQPJTGIHDGO-UHFFFAOYSA-N mesembrine Natural products C1=C(OC)C(OC)=CC=C1C1(CCC(=O)C2)C2N(C)CC1 DAHIQPJTGIHDGO-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229950005555 metelimumab Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- FLEVIENZILQUKB-DMJMAAGCSA-N methyl 4-[3-[6-amino-9-[(2r,3r,4s,5s)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]purin-2-yl]prop-2-ynyl]cyclohexane-1-carboxylate Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(C#CCC3CCC(CC3)C(=O)OC)=NC(N)=C2N=C1 FLEVIENZILQUKB-DMJMAAGCSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229950003734 milatuzumab Drugs 0.000 description 1
- 229950007812 mocetinostat Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960001521 motavizumab Drugs 0.000 description 1
- ZTFBIUXIQYRUNT-MDWZMJQESA-N mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 description 1
- 229950002212 mubritinib Drugs 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- GTDHYNXLIKNVTJ-UHFFFAOYSA-N n-(1-hydroxy-2-methylpropan-2-yl)octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NC(C)(C)CO GTDHYNXLIKNVTJ-UHFFFAOYSA-N 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- 229950003027 nacolomab tafenatox Drugs 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 229950009793 naptumomab estafenatox Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical class CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229950010465 odulimomab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229930191479 oligomycin Natural products 0.000 description 1
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 1
- 229950009057 oportuzumab monatox Drugs 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 229950002610 otelixizumab Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229950010626 pagibaximab Drugs 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 229950003570 panobacumab Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 1
- 229940069510 parthenolide Drugs 0.000 description 1
- 229950011485 pascolizumab Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229960005570 pemtumomab Drugs 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229940067082 pentetate Drugs 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 238000001259 photo etching Methods 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 229940126620 pintumomab Drugs 0.000 description 1
- 229940072644 pitressin Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Chemical class 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Chemical class 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 229950009904 pritumumab Drugs 0.000 description 1
- 229940029359 procrit Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000002877 prolactin releasing hormone Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229950002786 rafivirumab Drugs 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- ZLQMRLSBXKQKMG-UHFFFAOYSA-N rauniticine Natural products COC(=O)C1=CC2CC3N(CCc4c3[nH]c5ccccc45)CC2C(C)O1 ZLQMRLSBXKQKMG-UHFFFAOYSA-N 0.000 description 1
- 229960004910 raxibacumab Drugs 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 210000002707 regulatory b cell Anatomy 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950001808 robatumumab Drugs 0.000 description 1
- RRVZOJQBRVGMMK-HCBGRYSISA-N rocaglaol Chemical compound C1=CC(OC)=CC=C1[C@]1([C@@H](C[C@H]2O)C=3C=CC=CC=3)[C@]2(O)C2=C(OC)C=C(OC)C=C2O1 RRVZOJQBRVGMMK-HCBGRYSISA-N 0.000 description 1
- RRVZOJQBRVGMMK-UHFFFAOYSA-N rocaglaol Natural products C1=CC(OC)=CC=C1C1(C(CC2O)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 RRVZOJQBRVGMMK-UHFFFAOYSA-N 0.000 description 1
- 229950010316 rontalizumab Drugs 0.000 description 1
- 229950009092 rovelizumab Drugs 0.000 description 1
- 229950005374 ruplizumab Drugs 0.000 description 1
- 229930189723 salinosporamide Natural products 0.000 description 1
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 1
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229950007308 satumomab Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 101150011068 sfk1 gene Proteins 0.000 description 1
- 229960003466 sibutramine hydrochloride Drugs 0.000 description 1
- 229950010077 sifalimumab Drugs 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 229950003804 siplizumab Drugs 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- BYHIFOCTDVNQQT-GHIYGBLASA-M sodium;(2r)-3-[(2s,6r,8s,11r)-2-[(e,2r)-4-[(2s,2'r,4r,4as,6r,8ar)-4-hydroxy-2-[(1s,3s)-1-hydroxy-3-[(2s,3r,6s)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4h-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl] Chemical compound [Na+].C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C([O-])=O)CC[C@H]2O BYHIFOCTDVNQQT-GHIYGBLASA-M 0.000 description 1
- PTTPUWGBPLLBKW-UHFFFAOYSA-M sodium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound [Na+].CC(C)CC1=CC=C(C(C)C([O-])=O)C=C1 PTTPUWGBPLLBKW-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 229950007874 solanezumab Drugs 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 229950006551 sontuzumab Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229950002549 stamulumab Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 description 1
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229950001072 tadocizumab Drugs 0.000 description 1
- 229960001832 taliglucerase alfa Drugs 0.000 description 1
- 108010072309 taliglucerase alfa Proteins 0.000 description 1
- 229950004218 talizumab Drugs 0.000 description 1
- 229950008160 tanezumab Drugs 0.000 description 1
- 229950001603 taplitumomab paptox Drugs 0.000 description 1
- 229950000864 technetium (99mtc) nofetumomab merpentan Drugs 0.000 description 1
- 229950001788 tefibazumab Drugs 0.000 description 1
- CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 229950001289 tenatumomab Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229950000301 teneliximab Drugs 0.000 description 1
- 229950010127 teplizumab Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- QZZGJDVWLFXDLK-UHFFFAOYSA-N tetracosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(O)=O QZZGJDVWLFXDLK-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- 108010050939 thrombocytin Proteins 0.000 description 1
- 230000001646 thyrotropic effect Effects 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 229950004742 tigatuzumab Drugs 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical class N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229950001802 toralizumab Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 108010060596 trapoxin B Proteins 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 229950003364 tucotuzumab celmoleukin Drugs 0.000 description 1
- 108700008509 tucotuzumab celmoleukin Proteins 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229950004362 urtoxazumab Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229950000386 vapaliximab Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 229960004406 velaglucerase alfa Drugs 0.000 description 1
- 229950000815 veltuzumab Drugs 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 229960005289 voclosporin Drugs 0.000 description 1
- BICRTLVBTLFLRD-PTWUADNWSA-N voclosporin Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O BICRTLVBTLFLRD-PTWUADNWSA-N 0.000 description 1
- 108010057559 voclosporin Proteins 0.000 description 1
- 229950001212 volociximab Drugs 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- XQDCKJKKMFWXGB-UHFFFAOYSA-N wedelolactone Chemical compound O1C2=CC(O)=C(O)C=C2C2=C1C1=C(O)C=C(OC)C=C1OC2=O XQDCKJKKMFWXGB-UHFFFAOYSA-N 0.000 description 1
- RFQPHWCAHNTCDX-UHFFFAOYSA-N wedelolactone Natural products COc1cc(O)cc2OC(=O)c3c(oc4cc(O)c(O)cc34)c12 RFQPHWCAHNTCDX-UHFFFAOYSA-N 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
- 229950009083 ziralimumab Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
Abstract
本申请涉及用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体。在此披露了包含治疗性蛋白APC可呈递抗原和免疫抑制剂的合成纳米载体组合物、以及相关的方法,这些治疗性蛋白APC可呈递抗原和免疫抑制剂提供了对治疗性蛋白特异的致耐受性免疫应答。
Description
本申请是申请日为2012年4月27日、申请号为“201280020302.4”、发明名称为“用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体”的中国专利申请的分案申请,原申请是国际申请PCT/US2012/035366的中国国家阶段申请。
相关申请
本申请根据美国法典第35篇第119条要求2011年4月29日提交的美国临时申请61/480,946、2011年7月29日提交的美国临时申请61/513,514、2011年9月6日提交的美国临时申请61/531,147、2011年9月6日提交的美国临时申请61/531,153、2011年9月6日提交的美国临时申请61/531,164、2011年9月6日提交的美国临时申请61/531,168、2011年9月6日提交的美国临时申请61/531,175、2011年9月6日提交的美国临时申请61/531,180、2011年9月6日提交的美国临时申请61/531,194、20111年9月6日提交的美国临时申请61/531,204、2011年9月6日提交的美国临时申请61/531,209、2011年9月6日提交的美国临时申请61/531,215的权益,这些临时申请各自的全部内容通过引用结合在此。
技术领域
本发明涉及具有治疗性蛋白抗原呈递细胞(APC)可呈递抗原和免疫抑制剂的多种合成纳米载体组合物、以及相关的方法。这些组合物和方法允许通过APC有效摄取来使免疫应答向有利于发展对治疗性蛋白特异的致耐受性免疫应答的方向转变。提供的这些组合物和方法因此可以用来在受试者中产生一种致耐受性免疫应答,在该受试者中给予了一种治疗性蛋白或预期会产生所不希望的免疫应答。
背景技术
治疗性处理(如蛋白质或酶替代疗法)常常对特定的治疗剂产生所不希望的免疫应答。在此类情况下,免疫系统的细胞将这种治疗剂识别为外来的并且试图破坏它,正如这些细胞试图破坏时感染生物(如细菌和病毒)一样。可以通过使用免疫抑制剂药物来降低这样的所不希望的免疫应答。然而,常规的免疫抑制剂药物是广泛作用的(broad-acting)。另外,为了维持免疫抑制,免疫抑制剂药物疗法通常是一个终生的命题。令人遗憾的是,使用广泛作用的免疫抑制剂与严重副作用(如肿瘤、感染、肾毒性以及代谢紊乱)的风险相关联。因此,新的免疫抑制剂疗法将是有益的。
发明内容
在一方面,提供了一种组合物,该组合物包含(i)第一群体的合成纳米载体和(ii)第二群体的合成纳米载体,这些第一群体的合成纳米载体与免疫抑制剂偶联,这些第二群体的合成纳米载体与治疗性蛋白APC可呈递抗原偶联。在一个实施例中,该第一群体和第二群体是相同的群体。在另一个实施例中,该第一群体和第二群体是不同的群体。
在又另一个实施例中,这些免疫抑制剂包含一种抑制素、一种mTOR抑制剂、一种TGF-β信号剂、一种皮质类固醇、一种线粒体功能抑制剂、一种P38抑制剂、一种NF-κβ抑制剂、一种腺苷受体激动剂、一种前列腺素E2激动剂、一种磷酸二酯酶4抑制剂、一种HDAC抑制剂或一种蛋白酶体抑制剂。在再另一个实施例中,该mTOR抑制剂是雷帕霉素或一种雷帕霉素类似物。
在一些实施例中,通过使该治疗性蛋白与这些合成纳米载体偶联来提供这些治疗性蛋白APC可呈递抗原。在其他实施例中,通过偶联从该治疗性蛋白获得或衍生的一种多肽或肽来提供这些治疗性蛋白APC可呈递抗原。在一个另外的实施例中,这些治疗性蛋白APC可呈递抗原包含一种治疗性蛋白的MHC I类限制性表位和/或MHC II类限制性表位和/或B细胞表位。在另一个实施例中,这些治疗性蛋白APC可呈递抗原包含一种治疗性蛋白的MHCII类限制性表位。在另一个实施例中,这些治疗性蛋白APC可呈递抗原基本上不包含治疗性蛋白的B细胞表位。在另一个实施例中,这些治疗性蛋白APC可呈递抗原包含一种治疗性蛋白的MHCII类限制性表位并且基本上不包含治疗性蛋白的B细胞表位。
在一个实施例中,这些治疗性蛋白APC可呈递抗原包含一种用于蛋白质替代或蛋白质补充疗法的治疗性蛋白、或其片段或衍生物。在另一个实施例中,这些治疗性蛋白APC可呈递抗原包含一种可输注或可注射的治疗性蛋白、酶、酶辅助因子、激素、血液或凝血因子、细胞因子、干扰素、生长因子、单克隆抗体、多克隆抗体或与庞贝氏病相关的蛋白质、或任何上述物质的片段或衍生物。在另一个实施例中,该可输注或可注射的治疗性蛋白包含托珠单抗(Tocilizumab)、α-1抗胰蛋白酶、Hematide、白蛋白干扰素α-2b、Rhucin、替莫瑞林(tesamorelin)、奥瑞珠单抗(ocrelizumab)、贝利木单抗(belimumab)、聚乙二醇重组尿酸酶(pegloticase)、α-他利苷酶(taliglucerase alfa)、阿加糖酶α(agalsidase alfa)或葡糖脑苷脂酶α(velaglucerase alfa)。在另一个实施例中,该酶包括氧化还原酶、转移酶、水解酶、裂解酶、异构酶或连接酶。在另一个实施例中,该酶包括用于针对溶酶体贮积症的酶替代疗法的酶。在另一个实施例中,用于针对溶酶体贮积症的酶替代疗法的酶包括伊米苷酶(imiglucerase)、a-半乳糖苷酶A(a-gal A)、阿加糖酶β、酸性a-葡萄糖苷酶(GAA)、阿葡糖苷酶α、LUMIZYME、MYOZYME、芳基硫酸酯酶B、拉罗尼酶(laronidase)、ALDURAZYME、艾度硫酸酯酶(idursulfase)、ELAPRASE、芳基硫酸酯酶B或NAGLAZYME。在另一个实施例中,细胞因子包括淋巴因子、白细胞介素、趋化因子、1型细胞因子或一种2型细胞因子。在另一个实施例中,血液和凝血因子包括因子I、因子II、组织因子、因子V、因子VII、因子VIII、因子IX、因子X、因子Xa、因子XII、因子XIII、血管性血友病因子(von Willebrand factor)、前激肽释放酶、高分子量激肽原、纤连蛋白、抗凝血酶III、肝素辅助因子II、蛋白C、蛋白S、蛋白Z、蛋白Z相关蛋白酶抑制剂(ZPI)、纤溶酶原、α2-抗纤维蛋白溶酶、组织型纤溶酶原激活物(tPA)、尿激酶、纤溶酶原激活物抑制剂-1(PAI1)、纤溶酶原激活物抑制剂-2(PAI2)、癌性促凝物质或阿法依伯汀。在再另一个实施例中,该治疗性蛋白质在基于细胞的疗法的细胞中表达、通过这些细胞来表达或在这些细胞上表达。
在一个实施例中,该组合物处于有效产生针对治疗性蛋白APC可呈递抗原或从其获得或衍生这些抗原的治疗性蛋白的致耐受性免疫应答的量。在另一个实施例中,当向受试者给予时,该组合物处于有效降低治疗性蛋白特异性抗体的产生的量。
在另一个实施例中,平均在这些第一和/或第二群体的合成纳米载体上的免疫抑制剂和/或抗原的负载是在0.0001%与50%之间。在再另一个实施例中,平均在这些第一和/或第二群体的合成纳米载体上的免疫抑制剂和/或抗原的负载是在0.1%与10%之间。
在一个实施例中,该第一群体和/或第二群体的合成纳米载体包括脂质纳米颗粒、聚合物纳米颗粒、金属纳米颗粒、基于表面活性剂的乳液、树枝状化合物、巴基球(buckyball)、纳米线、病毒样颗粒、或肽或蛋白质颗粒。在另一个实施例中,该第一和/或第二群体的合成纳米载体包括脂质纳米颗粒。在又一个实施例中,该第一和/或第二群体的合成纳米载体包括脂质体。在再另一个实施例中,该第一和/或第二群体的合成纳米载体包括金属纳米颗粒。在一个另外的实施例中,这些金属纳米颗粒包含金纳米颗粒。在又一个另外的实施例中,该第一和/或第二群体的合成纳米载体包括聚合物纳米颗粒。在另一个实施例中,这些聚合物纳米颗粒包含聚合物,这些聚合物是非甲氧基封端的普朗尼克聚合物。在再一个另外的实施例中,这些聚合物纳米颗粒包含聚酯、与聚醚偶联的聚酯、聚氨基酸、聚碳酸酯、聚缩醛、聚缩酮、多糖、聚乙基噁唑啉或聚乙烯亚胺。在另一个实施例中,聚酯包含一种聚(乳酸)、聚(乙醇酸)、聚(乳酸-乙醇酸)共聚物或聚己酸内酯。在又一个实施例中,这些聚合物纳米颗粒包含聚酯以及与聚醚偶联的聚酯。在另一个实施例中,该聚醚包含聚乙二醇或聚丙二醇。
在另一个实施例中,使用对该第一和/或第二群体的合成纳米载体进行的动态光散射而获得的粒度分布的平均值大于100nm的直径。在另一个实施例中,该直径大于150nm。在另一个实施例中,该直径大于200nm。在另一个实施例中,该直径大于250nm。在另一个实施例中,该直径大于300nm。
在一个另外的实施例中,该第一群体和/或第二群体的合成纳米载体的长宽比是大于1∶1、1∶1.2、1∶1.5、1∶2、1∶3、1∶5、1∶7或1∶10。
在又一个实施例中,该组合物进一步包含一种药学上可接受的赋形剂。
在另一方面,提供了一种包含在此提供的任何这些组合物的剂型。
在另一方面,提供了一种包括向正被给予或将被给予一种治疗性蛋白的受试者给予在此提供的任何这些组合物或剂型的方法。在一个实施例中,该方法进一步包括向该受试者给予该治疗性蛋白。在另一个实施例中,在给予该组合物或剂型之前、与此同时或在此之后给予该治疗性蛋白。在又一个实施例中,向该受试者给予一个或多个维持剂量的该组合物或剂型。
在又另一个实施例中,该方法进一步包括在给予该组合物或剂型和/或该治疗性蛋白之前和/或之后评定该受试者中的所不希望的免疫应答的产生。在一个实施例中,该所不希望的免疫应答是产生治疗性蛋白特异性抗体。在另一个实施例中,该所不希望的免疫应答是对该治疗性蛋白特异的CD4+ T细胞增殖和/或活性。在又另一个实施例中,该所不希望的免疫应答是对该治疗性蛋白特异的B细胞增殖和/或活性。
在一个实施例中,该治疗性蛋白包含一种用于蛋白质替代或蛋白质补充疗法的治疗性蛋白。在另一个实施例中,该治疗性蛋白包含一种可输注或可注射的治疗性蛋白、酶、酶辅助因子、激素、血液或凝血因子、细胞因子、干扰素、生长因子、单克隆抗体、多克隆抗体或与庞贝氏病相关的蛋白质。在另一个实施例中,该可输注或可注射的治疗性蛋白包含托珠单抗、α-1抗胰蛋白酶、Hematide、白蛋白干扰素α-2b、Rhucin、替莫瑞林、奥瑞珠单抗、贝利木单抗、聚乙二醇重组尿酸酶、α-他利苷酶、阿加糖酶α或葡糖脑苷脂酶α。在另一个实施例中,酶包括氧化还原酶、转移酶、水解酶、裂解酶、异构酶或连接酶。在另一个实施例中,酶包括一种用于针对溶酶体贮积症的酶替代疗法的酶。在另一个实施例中,用于针对溶酶体贮积症的酶替代疗法的酶包括伊米苷酶、a-半乳糖苷酶A(a-gal A)、阿加糖酶β、酸性a-葡萄糖苷酶(GAA)、阿葡糖苷酶α、LUMIZYME、MYOZYME、芳基硫酸酯酶B、拉罗尼酶、ALDURAZYME、艾度硫酸酯酶、ELAPRASE、芳基硫酸酯酶B或NAGLAZYME。在另一个实施例中,细胞因子包括淋巴因子、白细胞介素、趋化因子、1型细胞因子或2型细胞因子。在另一个实施例中,血液和凝血因子包括因子I、因子II、组织因子、因子V、因子VII、因子VIII、因子IX、因子X、因子Xa、因子XII、因子XIII、血管性血友病因子、前激肽释放酶、高分子量激肽原、纤连蛋白、抗凝血酶III、肝素辅助因子II、蛋白C、蛋白S、蛋白Z、蛋白Z相关蛋白酶抑制剂(ZPI)、纤溶酶原、α2-抗纤维蛋白溶酶、组织型纤溶酶原激活物(tPA)、尿激酶、纤溶酶原激活物抑制剂-1(PAI1)、纤溶酶原激活物抑制剂-2(PAI2)、癌性促凝物质或阿法依伯汀。在再另一个实施例中,治疗性蛋白质在基于细胞的疗法的细胞中表达、通过这些细胞来表达或在这些细胞上表达。
在一个实施例中,通过静脉内、腹膜内、透粘膜、经口、皮下、肺部、鼻内、皮内或肌肉内给予来进行这些第一和/或第二群体的合成纳米载体和/或治疗性蛋白的给予。在另一个实施例中,通过吸入或静脉内、皮下或透粘膜给予来进行这些第一和/或第二群体的合成纳米载体和/或治疗性蛋白的给予。
在再另一个方面,提供了一种包括向受试者给予一种组合物的方法,该组合物包含(i)第一群体的合成纳米载体和(ii)第二群体的合成纳米载体,这些第一群体的合成纳米载体与免疫抑制剂偶联,这些第二群体的合成纳米载体与治疗性蛋白APC可呈递抗原偶联,其中该组合物处于有效降低针对这些治疗性蛋白APC可呈递抗原的所不希望的免疫应答的产生的量。在又另一个方面,提供了一种包括通过给予一种组合物而降低在受试者中所不希望的免疫应答的产生的方法,该组合物包含(i)第一群体的合成纳米载体和(ii)第二群体的合成纳米载体,这些第一群体的合成纳米载体与免疫抑制剂偶联,这些第二群体的合成纳米载体与治疗性蛋白APC可呈递抗原偶联。在一个另外的方面,提供了一种包括根据一种治疗方案(protocol)向受试者给予一种组合物的方法,该治疗方案先前已显示可降低一个或多个测试受试者中针对治疗性蛋白APC可呈递抗原的所不希望的免疫应答的产生;其中该组合物包含(i)第一群体的合成纳米载体和(ii)第二群体的合成纳米载体,这些第一群体的合成纳米载体与免疫抑制剂偶联,这些第二群体的合成纳米载体与治疗性蛋白APC可呈递抗原偶联。在一个实施例中,该第一群体和第二群体是相同的群体。在另一个实施例中,该第一群体和第二群体是不同的群体。
在又一个实施例中,该方法进一步包括提供或鉴定该受试者。在再另一个实施例中,该方法进一步包括在给予该组合物之前和/或之后评定该受试者中的所不希望的免疫应答的产生。在一个实施例中,所不希望的免疫应答是产生治疗性蛋白特异性抗体和/或对该治疗性蛋白特异的CD4+ T细胞增殖和/或活性和/或对该治疗性蛋白特异的B细胞增殖和/或活性。
在另一个实施例中,这些免疫抑制剂包括一种抑制素、一种mTOR抑制剂、一种TGF-β信号剂、一种皮质类固醇、一种线粒体功能抑制剂、一种P38抑制剂、一种NF-κβ抑制剂、一种腺苷受体激动剂、一种前列腺素E2激动剂、一种磷酸二酯酶4抑制剂、一种HDAC抑制剂或一种蛋白酶体抑制剂。在又一个实施例中,该mTOR抑制剂是雷帕霉素或一种雷帕霉素类似物。
在一些实施例中,通过使该治疗性蛋白与这些合成纳米载体偶联来提供这些治疗性蛋白APC可呈递抗原。在其他实施例中,通过偶联从该治疗性蛋白获得或衍生的一种多肽或肽来提供这些治疗性蛋白APC可呈递抗原。在一个另外的实施例中,这些治疗性蛋白APC可呈递抗原包含治疗性蛋白的MHC I类限制性表位和/或MHC II类限制性表位和/或B细胞表位。在另一个实施例中,这些治疗性蛋白APC可呈递抗原包含治疗性蛋白的MHC II类限制性表位。在另一个实施例中,这些治疗性蛋白APC可呈递抗原基本上不包含治疗性蛋白的B细胞表位。在另一个实施例中,这些治疗性蛋白APC可呈递抗原包含治疗性蛋白的MHC II类限制性表位并且基本上不包含治疗性蛋白的B细胞表位。
在一个实施例中,该治疗性蛋白包括用于蛋白质替代或蛋白质补充疗法的治疗性蛋白。在另一个实施例中,该治疗性蛋白包括一种可输注或可注射的治疗性蛋白、酶、酶辅助因子、激素、血液或凝血因子、细胞因子、干扰素、生长因子、单克隆抗体、多克隆抗体或与庞贝氏病相关的蛋白质。在另一个实施例中,该可输注或可注射的治疗性蛋白包括托珠单抗、α-1抗胰蛋白酶、Hematide、白蛋白干扰素α-2b、Rhucin、替莫瑞林、奥瑞珠单抗、贝利木单抗、聚乙二醇重组尿酸酶、α-他利苷酶、阿加糖酶α或葡糖脑苷脂酶α。在另一个实施例中,酶包括氧化还原酶、转移酶、水解酶、裂解酶、异构酶或连接酶。在另一个实施例中,酶包括用于针对溶酶体贮积症的酶替代疗法的酶。在另一个实施例中,用于针对溶酶体贮积症的酶替代疗法的酶包括伊米苷酶、a-半乳糖苷酶A(a-gal A)、阿加糖酶β、酸性a-葡萄糖苷酶(GAA)、阿葡糖苷酶α、LUMIZYME、MYOZYME、芳基硫酸酯酶B、拉罗尼酶、ALDURAZYME、艾度硫酸酯酶、ELAPRASE、芳基硫酸酯酶B或NAGLAZYME。在另一个实施例中,细胞因子包括淋巴因子、白细胞介素、趋化因子、1型细胞因子或2型细胞因子。在另一个实施例中,血液和凝血因子包括因子I、因子II、组织因子、因子V、因子VII、因子VHI、因子IX、因子X、因子Xa、因子XII、因子XIII、血管性血友病因子、前激肽释放酶、高分子量激肽原、纤连蛋白、抗凝血酶III、肝素辅助因子II、蛋白C、蛋白S、蛋白Z、蛋白Z相关蛋白酶抑制剂(ZPI)、纤溶酶原、α2-抗纤维蛋白溶酶、组织型纤溶酶原激活物(tPA)、尿激酶、纤溶酶原激活物抑制剂-1(PAI1)、纤溶酶原激活物抑制剂-2(PAI2)、癌性促凝物质或阿法依伯汀。在再另一个实施例中,该治疗性蛋白质在基于细胞的疗法的细胞中表达、通过这些细胞来表达或在这些细胞上表达。
在一个实施例中,该组合物处于有效降低治疗性蛋白特异性抗体的产生和/或对该治疗性蛋白特异的CD4+ T细胞增殖和/或活性和/或对该治疗性蛋白特异的B细胞增殖和/或活性的量。
在另一个实施例中,平均在这些第一和/或第二群体的合成纳米载体上的免疫抑制剂和/或抗原的负载是在0.0001%与50%之间。在再另一个实施例中,平均在这些第一和/或第二群体的合成纳米载体上的免疫抑制剂和/或抗原的负载是在0.1%与10%之间。
在一个实施例中,该第一群体和/或第二群体的合成纳米载体包括脂质纳米颗粒、聚合物纳米颗粒、金属纳米颗粒、基于表面活性剂的乳液、树枝状化合物、巴基球、纳米线、病毒样颗粒或肽或蛋白质颗粒。在另一个实施例中,该第一和/或第二群体的合成纳米载体包括脂质纳米颗粒。在又另一个实施例中,该第一和/或第二群体的合成纳米载体包括脂质体。在再另一个实施例中,该第一和/或第二群体的合成纳米载体包括金属纳米颗粒。在一个另外的实施例中,这些金属纳米颗粒包括金纳米颗粒。在又一个另外的实施例中,该第一和/或第二群体的合成纳米载体包括聚合物纳米颗粒。在另一个实施例中,这些聚合物纳米颗粒包括聚合物,聚合物是非甲氧基封端的普朗尼克聚合物。在再一个另外的实施例中,聚合物纳米颗粒包含聚酯、与聚醚偶联的聚酯、聚氨基酸、聚碳酸酯、聚缩醛、聚缩酮、多糖、聚乙基噁唑啉或聚乙烯亚胺。在另一个实施例中,聚酯包括聚(乳酸)、聚(乙醇酸)、聚(乳酸-乙醇酸)共聚物或聚己酸内酯。在又一个实施例中,聚合物纳米颗粒包括聚酯以及与聚醚偶联的聚酯。在再另一个实施例中,该聚醚包括聚乙二醇或聚丙二醇。
在另一个实施例中,使用对该第一和/或第二群体的合成纳米载体进行的动态光散射而获得的粒度分布的平均值是大于100nm的直径。在另一个实施例中,该直径大于150nm。在另一个实施例中,该直径大于200nm。在另一个实施例中,该直径大于250nm。在另一个实施例中,该直径大于300nm。
在一个另外的实施例中,该第一群体和/或第二群体的合成纳米载体的长宽比大于1∶1、1∶1.2、1∶1.5、1∶2、1∶3、1∶5、1∶7或1∶10。
在再一个另外的实施例中,该组合物进一步包含一种药学上可接受的赋形剂。
在又一个另外的实施例中,该方法进一步包括向该受试者给予该治疗性蛋白。在一个实施例中,在给予该组合物之前、与此同时或在此之后给予该治疗性蛋白。
在另一个实施例中,向该受试者给予一个或多个维持剂量的该组合物。
在再另一个实施例中,该方法进一步包括在给予该组合物和/或治疗性蛋白之前和/或之后评定该受试者中的所不希望的免疫应答的产生。在另一个实施例中,该所不希望的免疫应答是产生治疗性蛋白特异性抗体和/或对该治疗性蛋白特异的CD4+ T细胞增殖和/或活性和/或对该治疗性蛋白特异的B细胞增殖和/或活性。
在一个实施例中,通过静脉内、腹膜内、透粘膜、经口、皮下、肺部、鼻内、皮内或肌肉内给予来进行这些第一和/或第二群体的合成纳米载体和/或治疗性蛋白的给予。在另一个实施例中,通过吸入或静脉内、皮下或透粘膜给予来进行这些第一和/或第二群体的合成纳米载体和/或治疗性蛋白的给予。
在一个另外的方面,提供了一种方法,该方法包括(i)产生与免疫抑制剂偶联的第一群体的合成纳米载体,和(ii)产生与治疗性蛋白APC可呈递抗原偶联的第二群体的合成纳米载体。在一个实施例中,该第一群体和第二群体是相同的群体。在另一个实施例中,该第一群体和第二群体是不同的群体。在又一个实施例中,产生的这些第一和第二群体的合成纳米载体是如在此任何地方所提供的来定义的。
在一个实施例中,该方法进一步包括产生一种组合物的剂型,该组合物包含产生的这些第一和第二群体的合成纳米载体。在再另一个实施例中,该方法进一步包括制造一种包含这些第一群体和第二群体的合成纳米载体的组合物、或可供受试者给予的剂型。在一个另外的实施例中,该方法进一步包括评定使用一种包含这些第一群体和第二群体的合成纳米载体的组合物时的所不希望的免疫应答的降低。在一个实施例中,该所不希望的免疫应答是产生治疗性蛋白特异性抗体和/或对该治疗性蛋白特异的CD4+ T细胞增殖和/或活性和/或对该治疗性蛋白特异的B细胞增殖和/或活性。
在又一个另外的方面,提供了一种用于生产一种组合物或剂型的工艺,该组合物或剂型包含(i)第一群体的合成纳米载体,这些第一群体的合成纳米载体与免疫抑制剂偶联,和(ii)第二群体的合成纳米载体,这些第二群体的合成纳米载体与治疗性蛋白APC可呈递抗原偶联,该工艺包括如在此提供的任何方法中所定义的步骤。
在另一方面,提供了一种通过在此提供的任何方法或工艺可获得的组合物或剂型。
在又一个方面,在此提供的任何这些组合物或剂型可以用于治疗或预防。
在再另一个方面,在此提供的任何这些组合物或剂型可以在诱导针对治疗性蛋白抗原的致耐受性免疫应答的方法、基于细胞的疗法、蛋白质替代疗法、蛋白质补充疗法或在此提供的任何方法中使用。
在一个另外的方面,提供了在此提供的任何这些组合物或剂型用于制造一种药剂的用途,该药剂用于诱导针对治疗性蛋白抗原的致耐受性免疫应答的方法、基于细胞的疗法、蛋白质替代疗法、蛋白质补充疗法或在此提供的任何方法中。
在再另一个方面,提供了一种包含在此提供的任何这些组合物的剂型。
在提供的任何这些组合物和方法的一些实施例中,预防性地、在免疫应答早期(例如,在IgM阶段过程中)和/或在建立成熟记忆应答和/或IgG抗体应答之前给予在此提供的这些组合物。在此提供的任何这些组合物和方法的实施例中,这些组合物和方法可以降低效应T细胞与抗原反应的频率和/或这些效应T细胞产生促炎细胞因子的能力。在此提供的任何这些组合物和方法的其他实施例中,这些组合物和方法增加了抑制性调节性T细胞或B细胞的频率,这些抑制性调节性T细胞或B细胞减少了所不希望的治疗性蛋白免疫应答的发生。
在此提供的任何这些组合物和方法的一个实施例中,作为包含以上提到的这些表位的蛋白质的抗原可以与这些合成纳米载体偶联。在另一个实施例中,包含以上提到的这些表位、但包含位于这一个或多个表位的一端或两端侧面的另外氨基酸的多肽或肽可以与这些合成纳米载体偶联。在另一个实施例中,这些表位本身与这些合成纳米载体偶联。
附图说明
图1显示了来自Treg的流式细胞检测分析的结果。
图2显示了使用包含免疫抑制剂(雷帕霉素或辛伐他汀)的本发明的合成纳米载体对抗原特异性的效应T细胞的数目的影响(在单次注射之后)。
图3显示了使用包含免疫抑制剂(雷帕霉素或辛伐他汀)的本发明的合成纳米载体使腘淋巴结细胞的数目减少(在多次注射之后)。
图4证明了使用包含免疫抑制剂雷帕霉素和ova抗原的合成纳米载体使抗OVA IgG抗体减少。
图5证明了在对照组和被动组中,使用包含免疫抑制剂雷帕霉素和OVA抗原的合成纳米载体使抗OVA IgG抗体减少。
图6显示了使用包含ova肽和免疫抑制剂雷帕霉素的合成纳米载体的给予使抗原特异性IgG水平降低。
图7证明使用包含ova肽和免疫抑制剂雷帕霉素的合成纳米载体使抗原特异性的B细胞的数目减少。
图8证明了来自用包含ova肽和免疫抑制剂的合成纳米载体治疗的哮喘模型动物受试者的灌洗样品中CD4+ T细胞的数目减少。
图9证明了在哮喘模型动物受试者中用包含ova肽和免疫抑制剂雷帕霉素的合成纳米载体进行处理所引起的分裂CD4+ T细胞的百分数降低。
具体实施方式
在详细描述本发明之前,应当理解本发明不局限于具体举例说明的材料或工艺参数,因为这些当然可以变化。还应当理解在此使用的术语只是为了描述本发明的具体实施例的目的,并不旨在限制使用可替代的术语来描述本发明。
无论在前或在后,在此引用的所有公开物、专利以及专利申请,出于所有目的特此通过引用以其全文结合在此。
如在本说明书和所附权利要求中所使用,单数形式“一个(种)(a,an)”和“该(the)”包括复数指代物,除非内容另外明确表明。例如,提及的“一种聚合物”包括两种或更多种此类分子的混合物或不同分子量的单个聚合物种类的混合物;提及的“一种合成纳米载体”包括两种或更多种此类合成载体的混合物或多个此类合成纳米载体;提及的“一种DNA分子”包括两种或更多种此类DNA分子的混合物或多个此类DNA分子;提及的“一种免疫抑制剂”包括两种或更多种此类物质的混合物或多个免疫抑制剂分子;诸如此类。
如在此所使用,术语“包括(comprise)”或其变体,如“包括(comprises)”或“包括(comprising)”意在表明包括任何列举的整体(例如,一个特点、要素、特征、特性、方法/工艺步骤或限制)或整体的组(例如,多个特点、多个要素、多个特征、多个特性、多种方法/多个工艺步骤或多个限制),但是不排除任何其他整体或整体的组。因此,如在此所使用,术语“包括”是包含性的但是不排除另外的、未列举的整体或方法/工艺步骤。
在此处提供的任何这些组合物和方法的多个实施例中,“包括”可用“基本上由......组成(consisting essentially of)”或“由......组成(consisting of)”来替代。短语“基本上由......组成”在此用来要求限定的一个或多个整体或步骤以及不实质上影响所要求的发明的特征或功能的那些。如在此所使用,术语“组成(consisting)”用来表明仅存在所列举的整体(例如,一个特点、要素、特征、特性、方法/工艺步骤或限制)或整体的组(例如,多个特点、多个要素、多个特征、多个特性、多种方法/多个工艺步骤或多个限制)。
A.前言
如先前所提到的,目前常规的免疫抑制剂是广泛作用的并且通常导致免疫系统的总体系统性下调。在此提供的这些组合物和方法通过例如允许靶向递送至感兴趣的免疫细胞而允许更具针对性的免疫作用。因此,这些组合物和方法可以以一种更有方向性的方式实现免疫抑制。已经发现,包含MHC II类限制性表位的递送免疫抑制剂和抗原可以有效地降低抗原特异性抗体的产生以及降低抗原特异性CD4+ T细胞和B细胞的产生。因为此类免疫应答可以有益于抵消在用治疗性蛋白进行治疗性处理的过程中产生的所不希望的免疫应答,本发明在促进受试者中的致耐受性免疫应答中是有用的,这些受试者已经接受、正在接受或将要接受针对其产生或预期会针对其产生所不希望的免疫应答的治疗性蛋白。在一些实施例中,本发明防止或抑制了所不希望的免疫应答,这些所不希望的免疫应答可以中和某些治疗性处理的有益作用。
本发明的诸位发明人已经意外地并且令人惊讶地发现,通过实践在此披露的本发明,可以克服以上指出的问题和限制。具体地说,诸位发明人已经意外地发现,提供诱导针对治疗性蛋白的致耐受性免疫应答的合成纳米载体组合物和相关方法是有可能的。在此描述的这些组合物包括了包含(i)第一群体的合成纳米载体和(ii)第二群体的合成纳米载体的组合物,这些第一群体的合成纳米载体与免疫抑制剂偶联,这些第二群体的合成纳米载体与治疗性蛋白APC可呈递抗原偶联。
在另一方面,提供了在此的任何这些组合物的多种剂型。可以将此类剂型给予一位受试者,如对其有需要(例如,对治疗性蛋白特异的致耐受性免疫应答有需要)的受试者。在一个实施例中,该受试者是已经、正在或将要用针对其产生或预期会针对其产生所不希望的免疫应答的治疗性蛋白进行治疗的受试者。
在另一方面,向受试者给予在此提供的任何这些组合物。可以按有效降低针对一种或多种治疗性蛋白的所不希望的免疫应答的产生的量给予该组合物。在一个实施例中,根据一种治疗方案向受试者给予一种组合物,该治疗方案先前已显示可以降低一个或多个受试者中针对多种治疗性蛋白的所不希望的免疫应答的产生。该所不希望的免疫应答可以是产生治疗性蛋白特异性抗体、CD4+ T细胞增殖和/或活性、或B细胞增殖和/或活性、或其组合。这些所不希望的免疫应答还可以是产生来自上述所不希望的免疫应答下游的其他免疫应答。在多个实施例中,有效的量或治疗方案产生或已经显示可产生所希望的免疫应答。此类免疫应答包括降低上述任何所不希望的免疫应答或其组合。此类免疫应答包括任何致耐受性免疫应答,如在此描述的那些。
可以在向受试者给予一种治疗性蛋白之前、与此同时或在此之后向该受试者给予这些组合物。在一些实施例中,在该受试者中建立成熟记忆应答之前给予这些合成纳米载体组合物。在一些实施例中,提供的这些方法可以进一步包括给予该治疗性蛋白。在多个实施例中,还可以作为一个或多个维持剂量向已经接受、正在接受或将要接受治疗性蛋白的受试者给予所提供的这些组合物。在此类实施例中,给予所提供的这些组合物,使得所不希望的免疫应答的产生被降低持续一定长度的时间。在此在其他地方提供了此类长度的时间的例子。
在又一个方面,提供了一种(i)产生第一群体的合成纳米载体和(ii)产生第二群体的合成纳米载体的方法,这些第一群体的合成纳米载体与免疫抑制剂偶联,这些第二群体的合成纳米载体与治疗性蛋白APC可呈递抗原偶联。在一个实施例中,该方法进一步包括产生一种剂型,该剂型包含这些第一和第二群体的合成纳米载体。
现在,在以下将更详细地描述本发明。
B.定义
“给予(Administering)”或“给予(administration)”意指以药理学上有用的方式向受试者提供一种物质。
在用于向受试者给予的一种组合物或剂型的背景下的“有效的量”是指在该受试者中产生一种或多种希望的免疫应答(例如,产生致耐受性免疫应答(例如,减少抗原特异性CD4+ T细胞或抗原特异性B细胞的增殖、激活、诱导、募集、或减少抗原特异性抗体的产生))的该组合物或剂型的量。因此,在一些实施例中,有效的量是产生一种或多种这些希望的免疫应答的在此提供的一种组合物的任何量。这个量可以出于体外或体内目的。对于体内目的而言,该量可以是临床医师将认为对有抗原特异性耐受需要的受试者可以具有临床益处的量。
有效的量可以仅涉及降低所不希望的免疫应答的水平,虽然在一些实施例中,它涉及完全防止所不希望的免疫应答。有效的量还可以涉及延迟所不希望的免疫应答的发生。有效的量还可以是产生所希望的治疗终点或所希望的治疗结果的在此提供的一种组合物的量。有效的量优选在受试者中导致针对抗原的致耐受性免疫应答。可以通过常规方法来监测任何上述免疫应答的实现。
在提供的任何这些组合物和方法的一些实施例中,该有效的量是其中使所希望的免疫应答在该受试者中持续至少1周、至少2周、至少1个月、至少2个月、至少3个月、至少4个月、至少5个月、至少6个月、至少9个月、至少1年、至少2年、至少5年、或更长时间的量。在提供的任何这些组合物和方法的其他实施例中,该有效的量是产生一种可测量的所希望的免疫应答(例如,可测量的免疫应答(例如,针对一种特异性抗原)降低)持续至少1周、至少2周、至少1个月、至少2个月、至少3个月、至少4个月、至少5个月、至少6个月、至少9个月、至少1年、至少2年、至少5年、或更长时间的量。
当然,有效的量将取决于正被治疗的具体受试者;病症、疾病或紊乱的严重性;个体患者的参数,包括年龄、身体状况、体型以及体重;治疗持续时间;同步疗法(如果有)的性质;特定的给药途径、以及健康执业医师的知识和专业技能内的类似因素。这些因素为本领域普通技术人员所熟知,并且可以仅用常规实验方法解决。通常优选的是使用最大剂量,即根据正确医学判断的最高安全剂量。然而,本领域普通技术人员应当理解,出于医学原因、心理原因或几乎任何其他原因,患者可以坚持较低剂量或耐受剂量。
通常,本发明的组合物中的这些免疫抑制剂和/或抗原的剂量可以在从约10μg/kg至约100,000μg/kg的范围内。在一些实施例中,这些剂量可以在从约0.1mg/kg至约100mg/kg的范围内。在再其他的实施例中,这些剂量可以在从约0.1mg/kg至约25mg/kg、约25mg/kg至约50mg/kg、约50mg/kg至约75mg/kg、或约75mg/kg至约100mg/kg的范围内。可替代地,可以基于提供希望的量的免疫抑制剂和/或抗原的合成纳米载体的数目给予该剂量。例如,有用的剂量包括每剂量大于106个、107个、108个、109个或1010个合成纳米载体。有用的剂量的其他例子包括每剂量从约1×106至约1×1010个、约1×107至约1×109个、或约1×108至约1×109个合成纳米载体。
“抗原”意指B细胞抗原或T细胞抗原。“抗原的一种或多种类型”意指共享相同的、或基本上相同的抗原特性的分子。在一些实施例中,抗原可以是蛋白质类、多肽类、肽类、脂蛋白类、糖脂类、多核苷酸类、多糖类,或被包含或表达在细胞中。在一些实施例中,例如当没有很好定义或表征这些抗原时,这些抗原可以被包含在细胞或组织制品、细胞碎片、细胞外来体、条件培养基等等之内。可以与受试者暴露于引起所不希望的免疫应答者相同的形式将一种抗原与这些合成纳米载体组合,但该抗原还可以是其片段或衍生物。然而,当为一个片段或衍生物时,针对由这样的受试者遇到的形式的所希望的免疫应答是使用所提供的这些组合物和方法的优选结果。
“抗原特异性”是指由该抗原或其部分的存在引起的、或产生特异性地识别或结合该抗原的多种分子的任何免疫应答。例如,在该免疫应答是抗原特异性抗体产生的情况下,产生了特异性地结合该抗原的多种抗体。作为另一个例子,在该免疫应答是抗原特异性B细胞或CD4+ T细胞增殖和/或活性的情况下,该增殖和/或活性由单独地或与MHC分子复合的该抗原或其部分、B细胞等等的识别引起。
“评定一种免疫应答”是指对体外或体内免疫应答的水平、存在或不存在、降低、增加等等进行的任何测量或测定。可以在从受试者中获得的一个或多个样品上进行此类测量或测定。可以用在此提供的任何方法或本领域中已知的其他方法来进行此类评定。
“处于风险中”的受试者是健康执业医师认为其具有患上在此所提供的疾病、紊乱或病症的机会的受试者、或健康执业医师认为其具有经历在此所提供的所不希望的免疫应答的机会的受试者。
如在此所使用的“平均值”是指算术平均值,除非另外指出。
“B细胞抗原”意指由B细胞识别并且触发B细胞中的免疫应答的任何抗原(例如由B细胞或其上的受体特异性地识别的抗原)。在一些实施例中,作为一种T细胞抗原的抗原也是一种B细胞抗原。在其他实施例中,该T细胞抗原并不也是一种B细胞抗原。B细胞抗原包括但不限于蛋白质类、肽类等等。在一些实施例中,B细胞抗原包括非蛋白抗原(即,不是一种蛋白质或肽抗原)。
“同时”意指以时间相关的、优选地时间充分相关的方式向受试者给予两种或更多种物质,以便提供对免疫应答的调节。在多个实施例中,可以通过以相同剂型给予两种或更多种物质而发生同时给予。在其他实施例中,同时给予可以涵盖以不同剂型、但在指定时间段内、优选在1个月内、更优选在1周内、再更优选在1天内并且甚至更优选在1小时内给予两种或更多种物质。
“偶联(Couple)”或“偶联(Coupled)”或“偶联(Couples)”(诸如此类)意指使一个实体(例如一个部分)与另一个实体在化学上结合。在一些实施例中,偶联是共价的,这意味着该偶联是在两个实体之间在存在共价键的背景下发生的。在非共价的实施例中,通过非共价相互作用介导非共价偶联,这些非共价相互作用包括但不限于:电荷相互作用、亲和相互作用、金属配位、物理吸附、主-客体相互作用、疏水相互作用、TT堆积相互作用、氢键相互作用、范德华相互作用、磁相互作用、静电相互作用、偶极-偶极相互作用、和/或其组合。在多个实施例中,封装是偶联的一种形式。
“衍生的”意指由一种材料或与一种材料相关的信息制备的,而不是从该材料“获得的”。此类材料可以是直接取自一种生物材料的材料的实质性地改变或加工的形式。此类材料还包括从与一种生物材料相关的信息所产生的材料。
“剂型”意指在一种适用于向受试者给予的介质、载体、媒介物或装置中的药理学和/或免疫学活性材料。
“封装”意指将物质的至少一个部分封闭在合成纳米载体内。在一些实施例中,一种物质被完全封闭在合成纳米载体内。在其他实施例中,被封装的物质的大部分或全部不暴露于该合成纳米载体外的局部环境。在其他实施例中,不超过50%、40%、30%、20%、10%或5%(重量/重量)暴露于局部环境。封装不同于吸附,吸附是将物质的大部分或全部置于合成纳米载体的表面上,并且使得该物质暴露于该合成纳米载体外的局部环境。
“表位”,又称为抗原决定簇,是由免疫系统,确切地由例如抗体、B细胞、或T细胞识别的抗原部分。如在此所使用,“MHC I类限制性表位”是通过在有核细胞上发现的MHC I类分子呈递给免疫细胞的表位。“MHC II类限制性的表位”是通过在抗原呈递细胞(APC)上(例如,在专门的抗原呈递免疫细胞上,如在巨噬细胞、B细胞以及树突状细胞上,或在非造血细胞如肝细胞上)发现的MHC II类分子呈递给免疫细胞的表位。“B细胞表位”是由抗体或B细胞识别的分子结构。在一些实施例中,该表位本身是一种抗原。
许多表位是本领域普通技术人员已知的,并且根据本发明的一些方面适合的示例性表位包括但不限于列在免疫表位数据库(www.immuneepitope.org,维塔·R(Vita R)、札瑞布斯基·L(Zarebski L)、格林鲍姆·JA(Greenbaum JA)、埃马米·H(Emami H)、霍夫·I(Hoof I)、萨利姆·N(Salimi N)、达美乐·R(Damle R)、赛特·A(Sette A)、彼得斯·B(Peters B),免疫表位数据库2.0(The immune epitope database 2.0).核酸研究(Nucleic Acids Res),2010年1月;38(数据库发行号):D854-62;该免疫表位数据库的全部内容以及2011年8月的IEDB 2.4版本的所有数据库条目,并且具体地说在其中披露的所有表位通过引用结合在此)中的那些。还可以使用公开可获得的算法来鉴定表位,这些算法例如在以下文献中描述的算法:王平(Wang P)、西德尼·J(Sidney J)、金姆·Y(Kim Y)、赛特·A(Sette A)、伦德·O(Lund O)、尼耳森·M(Nielsen M)、彼得斯·B(Peters B),2010,用于HLA DR、DP以及DQ分子的肽结合预测(peptide binding predictions for HLA DR,DPand DQ molecules),BMC生物信息学(BMC Bioinformatics)2010,11:568;王平(Wang P)、西德尼·J(Sidney J)、道·C(Dow C)、莫斯·B(Mothé B)、赛特·A(Sette A)、彼得斯·B(Peters B),2008,MHC II类肽结合预测的系统性评定和一致方法的评估(A systematicassessment of MHC class II peptide binding predictions and evaluation of aconsensus approach),PLoS计算生物学(PLoS Comput Biol.)4(4):e1000048;尼耳森·M(Nielsen M)、伦德·O(Lund O),2009,NN-比对,用于MHC II类肽结合预测的基于人工神经网络的比对算法(NN-align.An artificial neural network-based alignmentalgorithm for MHC class II peptide binding prediction),BMC生物信息学(BMCBioinformatics),10:296;尼耳森·M(Nielsen M)、伦德高·C(Lundegaard C)、伦德·O(Lund O),2007,使用新颖的稳定化矩阵比对方法SMM-比对预测MHC II类结合亲和性(Prediction of MHC class II binding affinity using SMM-align,a novelstabilization matrix alignment method),BMC生物信息学(BMC Bioinformatics),8:238;裴·HH(Bui HH)、西德尼·J(Sidney J)、彼得斯·B(Peters B)、萨塞默塞·M(Sathiamurthy M)、真一·A(Sinichi A)、潘顿·KA(Purton KA)、莫斯·BR(Mothé BR)、奇萨利·FV(Chisari FV)、沃特金斯·DI(Watkins DI)、赛特·A(Sette A),2005,免疫遗传学(Immunogenetics),57:304-314;斯图尔尼奥洛·T(Sturniolo T)、博诺·E(Bono E)、丁·J(Ding J)、拉德里查尼·L(Raddrizzani L)、图雷西·O(Tuereci O)、萨因·U(SahinU)、布雷桑勒·M(Braxenthaler M)、加利亚西·F(Gallazzi F)、普罗狄·MP(Protti MP)、西尼加利亚·F(Sinigaglia F)、汉姆莫·J(Hammer J),1999,使用DNA微阵列和虚拟的HLAII类矩阵产生组织特异性的和混杂的HLA配体数据库(Generation of tissue-specificand promiscuous HLA ligand databases using DNA microarrays and virtual HLAclass II matrices).自然生物技术(Nat Biotechnol),17(6):555-561;尼耳森·M(Nielsen M)、伦德高·C(Lundegaard C)、沃林·P(Worning P)、拉尔莫勒·SL(Lauemoller SL)、拉姆博特·K(Lamberth K)、布斯·S(Buus S)、布鲁纳克·S(BrunakS)、伦德·O(Lund O),2003,使用具有新颖序列表示的神经网络可靠预测T细胞表位(Reliable prediction of T-cell epitopes using neural networks with novelsequence representations),蛋白质科学(Protein Sci)12:1007-1017;裴·HH(Bui HH)、西德尼·J(Sidney J)、彼得斯·B(Peters B)、萨塞默塞·M(Sathiamurthy M)、真一·A(Sinichi A)、潘顿·KA(Purton KA)、莫斯·BR(Mothe BR)、奇萨利·FV(Chisari FV)、沃特金斯·DI(Watkins DI)、赛特·A(Sette A),2005,特异性MHC结合预测工具的自动产生和评估:ARB矩阵应用(Automated generation and evaIuation of specific MHCbinding predictive tools:ARB matrix applications),免疫遗传学(Immunogenetics)57:304-314;彼得斯·B(Peters B)、赛特·A(Sette A),2005,使用稳定化的矩阵方法产生描述生物过程的序列特异性的定量模型(Generating quantitative models describingthe sequence specificity of biological processes with the stabilized matrixmethod),BMC生物信息学(BMC Bioinformatics)6:132;周·PY(Chou PY)、法斯曼·GD(Fasman GD),1978,由氨基酸序列预测蛋白质的二级结构(Prediction of the secondarystructure of proteins from their amino acid sequence),酶学相关领域分子生物学进展(Adv Enzymol Relat Areas Mol Biol)47:45-148;伊米妮·EA(Emini EA)、休斯·JV(Hughes JV)、珀洛·DS(Perlow DS)、博格·J(Boger J),1985,由病毒特异性合成肽诱导中和甲型肝炎病毒的抗体(Induction of hepatitis A virus-neutralizing antibodyby a virus-specific synthetic peptide),病毒学期刊(J Virol)55:836-839;卡普拉斯·PA(Karplus PA)、舒尔兹·GE(Schulz GE),1985,预测蛋白质中的链柔性(Predictionof chain flexibility in proteins),自然科学(Naturwissenschaften)72:212-213;科拉斯卡·AS(Kolaskar AS)、顿考恩卡·PC(Tongaonkar PC),1990,用于预测蛋白质抗原上的抗原决定簇的半经验方法(A semi-empirical method for prediction of antigenicdeterminants on protein antigens),FEBS快报(FEBS Lett)276:172-174;帕克·JM(Parker JM)、郭·D(Guo D)、霍奇斯·RS(Hodges RS),1986,来源于高效液相色谱法肽保留数据的新型亲水性标度:预测的表面残基与抗原性和源自X射线的可接近位点的相关性(New hydrophilicity scale derived from high-performance liquid chromatographypeptide retention data:correlation of predicted surface residues withantigenicity and X-ray-derived accessible sites),生物化学(Biochemistry)25:5425-5432;拉森·JE(Larsen JE)、伦德·O(Lund O)、尼耳森·M(Nielsen M),2006,用于预测线性B细胞表位的改进方法(Improved method for predicting linear B-cellepitopes),免疫研究(Immunome Res)2:2;波诺马连科·JV(Ponomarenko JV)、伯恩·PE(Bourne PE),2007,抗体-蛋白质相互作用:基准数据集和预测工具评估(Antibody-protein interactions:benchmark datasets and prediction tools evaluation),BMC结构生物学(BMC Struct Biol)7:64;哈斯特安德森·P(Haste Andersen P)、尼耳森·M(Nielsen M)、伦德·O(Lund O),2006,使用蛋白质3D结构预测不连续B细胞表位中的残基(Prediction of residues in discontinuous B-cell epitopes using protein 3Dstructures),蛋白质科学(Protein Sci)15:2558-2567;波诺马连科·JV(PonomarenkoJV)、裴·H(Bui H)、李·W(Li W)、福斯德·N(Fusseder N)、伯恩·PE(Bourne PE)、赛特Sette A、彼得斯·B(Peters B),2008,ElliPro:用于预测抗体表位的新型基于结构的工具(ElliPro:a new structure-based tool for the prediction of antibody epitopes),BMC生物信息学(BMC Bioinformatics)9:514;尼耳森·M(Nielsen M)、伦德高·C(Lundegaard C)、布里加·T(Blicher T)、彼得斯·B(Peters B)、赛特·A(Sette A)、贾斯特逊·S(Justesen S)、布斯·S(Buus S)以及伦德·O(Lund O),2008,PLoS计算生物学(PLoS Comput Biol.)4(7)e1000107,肽结合具有已知序列的任何HLA-DR分子的定量预测:NetMHCIIpan(Quantitative predictions of peptide binding to any HLA-DRmolecule of known sequence:NetMHCIIpan);这些文献各自的全部内容通过引用结合在此以用于披露用于鉴定表位的方法和算法。
“产生”意指本身直接地或间接地(如但不限于,通过依赖某人的语言或行为采取行动的不相关的第三方)引起一种行为(如一种免疫应答(例如,致耐受性免疫应答))发生。
“鉴定”是允许临床医师将受试者识别为可能从在此提供的这些方法和组合物中获益者的任何行为或一系列行为。优选地,鉴定的受试者是对如在此所提供的致耐受性免疫应答有需要者。该行为或一系列行为可以是本身直接地或间接地,如但不限于,通过依赖某人的语言或行为采取行动的不相关的第三方。
“免疫抑制剂”意指引起APC具有免疫抑制性(例如,致耐受性作用)的一种化合物。免疫抑制作用通常是指由APC产生或表达细胞因子或其他因子,该产生或表达降低、抑制或防止所不希望的免疫应答、或促进所希望的免疫应答。当该APC对识别由该APC呈递的抗原的免疫细胞产生一种免疫抑制作用时,该免疫抑制作用被称为是对呈递的抗原特异的。此种作用在此还称为致耐受性作用。不受任何具体理论束缚,认为该免疫抑制或致耐受作用是该免疫抑制剂被递送至该APC上的结果,优选在一种抗原(例如,一种给予的抗原或已经存在于体内的抗原)存在的情况下。因此,该免疫抑制剂包括提供针对一种抗原的致耐受性免疫应答的化合物,这些化合物可以被或可以不被提供在相同的组合物或不同的组合物中。在一个实施例中,该免疫抑制剂是引起APC促进一个或多个免疫效应细胞中的调节表型的免疫抑制剂。例如,可以通过抑制抗原特异性CD4+ T细胞或B细胞的产生、诱导、刺激或募集;抑制抗原特异性抗体的产生、Treg细胞(例如,CD4+ CD25highFoxP3+ Treg细胞)的产生、诱导、刺激或募集等等,对该调节表型进行表征。这可以是CD4+ T细胞或B细胞转化为调节表型的结果。这还可以是在其他免疫细胞(如CD8+ T细胞、巨噬细胞以及iNKT细胞)中诱导FoxP3的结果。在一个实施例中,该免疫抑制剂是在APC加工抗原之后影响该APC的应答的免疫抑制剂。在另一个实施例中,该免疫抑制剂不是干扰抗原加工的免疫抑制剂。在一个另外的实施例中,该免疫抑制剂不是一种细胞凋亡信号分子。在另一个实施例中,该免疫抑制剂不是一种磷脂。
免疫抑制剂包括但不限于:抑制素;mTOR抑制剂,如雷帕霉素或一种雷帕霉素类似物;TGF-β信号剂;TGF-β受体激动剂;组蛋白去乙酰化酶抑制剂,如曲古抑菌素A(Trichostatin A);皮质类固醇类;线粒体功能抑制剂,如鱼藤酮(rotenone);P38抑制剂;NF-κβ抑制剂,如6Bio、地塞米松、TCPA-1、IKK VII;腺苷受体激动剂;前列腺素E2激动剂(PGE2),如米索前列醇(Misoprostol);磷酸二酯酶抑制剂,如磷酸二酯酶4抑制剂(PDE4),如咯利普兰(Rolipram);蛋白酶体抑制剂;激酶抑制剂;G-蛋白偶联受体激动剂;G-蛋白偶联受体拮抗剂;糖皮质激素类;类视黄醇类;细胞因子抑制剂;细胞因子受体抑制剂;细胞因子受体激活剂;过氧化物酶体增殖物激活受体拮抗剂;过氧化物酶体增殖物激活受体激动剂;组蛋白去乙酰化酶抑制剂;钙调磷酸酶(calcineurin)抑制剂;磷酸酶抑制剂;PI3KB抑制剂,如TGX-221;自噬(autophagy)抑制剂,如3-甲基腺嘌呤;芳香烃受体抑制剂;蛋白酶体抑制剂I(PSI);以及氧化的ATP,如P2X受体阻断剂。免疫抑制剂还包括IDO、维生素D3、环孢霉素类(如环孢霉素A)、芳香烃受体抑制剂、白藜芦醇、硫唑嘌呤(Aza)、6-巯基嘌呤(6-MP)、6-硫鸟嘌呤(6-TG)、FK506、萨菲菌素A(sanglifehrin A)、沙美特罗(salmeterol)、吗替麦考酚酯(mycophenolate mofetil)(MMF)、阿司匹林以及其他COX抑制剂、尼氟酸、雌三醇以及雷公藤甲素(triptolide)。在多个实施例中,免疫抑制剂可以包含在此提供的任何药剂(agent)。
免疫抑制剂可以是对APC直接提供免疫抑制(例如,致耐受)作用的一种化合物,或该免疫抑制剂可以是间接(即,在给予之后以某种方式被加工之后)提供免疫抑制(例如,致耐受)作用的一种化合物。因此,免疫抑制剂包括在此提供的任何化合物的前药形式。
免疫抑制剂还可以包括编码在此提供的产生免疫抑制(例如,致耐受)免疫应答的肽、多肽或蛋白质的核酸。因此,在多个实施例中,免疫抑制剂是编码一种产生免疫抑制(例如,致耐受)免疫应答的肽、多肽或蛋白质的核酸,并且该免疫抑制剂是与合成纳米载体偶联的核酸。
该核酸可以是DNA或RNA,如mRNA。在多个实施例中,这些发明的组合物包含一种互补物,如一种全长互补物,或在此提供的任何这些核酸的一种简并物(由于遗传密码的简并性)。在多个实施例中,核酸是一种表达载体,当转染至细胞系中时,该表达载体可以被转录。在多个实施例中,该表达载体可以包含除其他之外的质粒、逆转录病毒、或腺病毒。可以使用标准的分子生物学方法来分离或合成核酸,例如通过使用聚合酶链反应来产生核酸片段,然后对该核酸片段进行纯化并且克隆至表达载体中。对本发明的实践有用的另外技术可以在2007年约翰威立国际出版公司(John Wiley and Sons,Inc.)的现代分子生物学实验方案(Current Protocols in Molecular Biology);分子克隆:实验室手册(第三版)萨姆布鲁克(Molecular Cloning:A Laboratory Manual(Third Edition)JosephSambrook),彼得麦卡勒姆癌症研究所(Peter MacCallum Cancer Institute),墨尔本(Melbourne),澳大利亚(Australia);大卫罗素(David Russell),德克萨斯大学西南医学中心(University of Texas Southwestern Medical Center),达拉斯(Dallas),冷泉港(Cold Spring Harbor)中找到。
在多个实施例中,在此提供的这些免疫抑制剂与合成纳米载体偶联。在多个优选的实施例中,免疫抑制剂是除了构成该合成纳米载体的结构的材料之外的一个成分。例如,在一个实施例中,在合成纳米载体由一种或多种聚合物构成的情况下,该免疫抑制剂是除了这一种或多种聚合物之外的并且与其偶联的一种化合物。作为另一个实例,在一个实施例中,在该合成纳米载体由一种或多种脂质构成的情况下,该免疫抑制剂又是除了这一种或多种脂质之外的并且与其偶联的。在多个实施例中,例如在该合成纳米载体的材料也产生一种免疫抑制(例如,致耐受)作用的情况下,该免疫抑制剂是产生一种免疫抑制(例如,致耐受)作用的、除了该合成纳米载体材料之外而存在的一种成分。
其他示例性的免疫抑制剂包括但不限于:小分子药物、天然产物、抗体(例如,对抗CD20、CD3、CD4的抗体)、基于生物制剂的药物、基于碳水化合物的药物、纳米颗粒、脂质体、RNAi、反义核酸、适体、氨甲蝶呤、NSAID;芬戈莫德(fingolimod);那他珠单抗(natalizumab);阿仑单抗(alemtuzumab);抗CD3;他克莫司(tacrolimus)(FK506)等等。另外的免疫抑制剂对于本领域的技术人员是已知的,并且本发明在此方面不受限制。
免疫抑制剂或治疗性蛋白APC可呈递抗原的“负载”是基于整个合成纳米载体中的材料的总重量,与合成纳米载体偶联的免疫抑制剂或治疗性蛋白APC可呈递抗原的量(重量/重量)。通常,该负载被计算为在一个群体的合成纳米载体上的平均值。在一个实施例中,平均在这些第一群体的合成纳米载体上的免疫抑制剂的负载是在0.0001%与50%之间。在另一个实施例中,平均在这些第一群体和/或第二群体的合成纳米载体上的该治疗性蛋白APC可呈递抗原的负载是在0.0001%与50%之间。在又另一个实施例中,该免疫抑制剂和/或治疗性蛋白APC可呈递抗原的负载是在0.01%与20%之间。在一个另外的实施例中,该免疫抑制剂和/或治疗性蛋白APC可呈递抗原的负载是在0.1%与10%之间。在再一个另外的实施例中,该免疫抑制剂和/或治疗性蛋白APC可呈递抗原的负载是在1%与10%之间。在又另一个实施例中,平均在该群体的合成纳米载体上的免疫抑制剂和/或治疗性蛋白APC可呈递抗原的负载是至少0.1%、至少0.2%、至少0.3%、至少0.4%、至少0.5%、至少0.6%、至少0.7%、至少0.8%、至少0.9%、至少1%、至少2%、至少3%、至少4%、至少5%、至少6%、至少7%、至少8%、至少9%、至少10%、至少11%、至少12%、至少13%、至少14%、至少15%、至少16%、至少17%、至少18%、至少19%或至少20%。在又一个另外的实施例中,平均在该群体的合成纳米载体上的免疫抑制剂和/或治疗性蛋白APC可呈递抗原的负载是0.1%、0.2%、0.3%、0.4%、0.5%、0.6%、0.7%、0.8%、0.9%、1%、2%、3%、4%、5%、6%、7%、8%、9%、10%、11%、12%、13%、14%、15%、16%、17%、18%、19%或20%。在以上实施例中的一些实施例中,平均在一个群体的合成纳米载体上的免疫抑制剂和/或治疗性蛋白APC可呈递抗原的负载是不大于25%。在多个实施例中,如实例中所描述对该负载进行计算。
在提供的任何这些组合物和方法的多个实施例中,如下计算该负载:收集近似3mg的合成纳米载体,并且离心以使上清液与合成纳米载体沉淀物分离。向该沉淀物添加乙腈,并且对样品进行超声处理并离心以去除任何不溶的材料。在RP-HPLC上注射该上清液和沉淀物,并且在278nm处读取吸光度。该沉淀物中的μg用来计算%包载(负载),在上清液和沉淀物中的μg用来计算回收的总μg。
“维持剂量”是指在初始剂量已经在受试者中产生免疫抑制(例如,致耐受)应答之后,为了持续所希望的免疫抑制(例如,致耐受)应答而向受试者给予的剂量。维持剂量例如可以是维持在该初始剂量之后所实现的致耐受作用、防止该受试者中的所不希望的免疫应答、或防止该受试者变为处于经历所不希望的免疫应答(包括所不希望的水平的免疫应答)风险的受试者的剂量。在一些实施例中,该维持剂量是足以持续适当水平的所希望的免疫应答的剂量。
“合成纳米载体的最大尺寸”意指沿着该合成纳米载体的任何轴线测量的纳米载体的最大尺寸。“合成纳米载体的最小尺寸”意指沿着该合成纳米载体的任何轴线测量的合成纳米载体的最小尺寸。例如,对于球形合成纳米载体而言,合成纳米载体的最大和最小尺寸将是基本上相同的,并且将是该合成纳米载体的直径的大小。类似地,针对立方形合成纳米载体,合成纳米载体的最小尺寸将是它的高度、宽度或长度中最小的,而合成纳米载体的最大尺寸将是它的高度、宽度或长度中最大的。在一个实施例中,基于样品中的合成纳米载体的总数,样品中至少75%、优选地至少80%、更优选地至少90%的这些合成纳米载体的最小尺寸等于或大于100nm。在一个实施例中,基于样品中的合成纳米载体的总数,样品中至少75%、优选地至少80%、更优选地至少90%的这些合成纳米载体的最小尺寸等于或小于5μm。优选地,基于样品中的合成纳米载体的总数,样品中至少75%、优选地至少80%、更优选地至少90%的这些合成纳米载体的最小尺寸大于110nm、更优选地大于120nm、更优选地大于130nm、并且还更优选地大于150nm。发明的合成纳米载体的最大尺寸与最小尺寸的长宽比可以取决于实施例而变化。例如,这些合成纳米载体的最大尺寸与最小尺寸的长宽比可以从1∶1至1,000,000∶1、优选地从1∶1至100,000∶1、更优选地从1∶1至10,000∶1、更优选地从1∶1至1000∶1、再更优选地从1∶1至100∶1、并且又更优选地从1∶1至10∶1变化。优选地,基于样品中的合成纳米载体的总数,样品中至少75%、优选地至少80%、更优选地至少90%的这些合成纳米载体的最大尺寸等于或小于3μm、更优选地等于或小于2μm、更优选地等于或小于1μm、更优选地等于或小于800nm、更优选地等于或小于600nm、并且还更优选地等于或小于500nm。在多个优选的实施例中,基于样品中的合成纳米载体的总数,样品中至少75%、优选地至少80%、更优选地至少90%的这些合成纳米载体的最小尺寸等于或大于100nm、更优选地等于或大于120nm、更优选地等于或大于130nm、更优选地等于或大于140nm、并且还更优选地等于或大于150nm。通过将这些合成纳米载体悬浮在一种液体(通常是水性)介质中,并且使用动态光散射(DLS)(例如使用一台Brookhaven ZetaPALS仪器),获得合成纳米载体尺寸(例如,直径)的测量值。例如,可以将具有合成纳米载体的悬浮液从水性缓冲剂中稀释到纯化水中以达到近似0.01至0.1mg/mL的最终的合成纳米载体悬浮液浓度。可以在一个适合的比色皿中直接制备稀释的悬浮液,或转移至该比色皿中以用于DLS分析。然后可以将该比色皿置于DLS中,允许其平衡至受控的温度,并且然后扫描充分的时间以在介质的粘度和样品的折射率的适当输入的基础上获得稳定且可再现的分布。然后报告有效直径,或该分布的平均值。合成纳米载体的“尺寸”或“大小”或“直径”意指使用动态光散射获得的粒度分布的平均值。
“MHC”是指主要组织相容性复合体,即在大多数脊椎动物中发现的编码MHC分子的一个大的基因组区或基因家族,这些MHC分子将被加工的蛋白质的片段或表位展示在细胞表面上。细胞表面上的MHC:肽的呈递允许通过免疫细胞(通常是T细胞)来监视。存在两大类MHC分子:I类和II类。通常,I类MHC分子被发现在有核细胞上并且将肽呈递给细胞毒性T细胞。II类MHC分子被发现在某些免疫细胞(主要是巨噬细胞、B细胞以及树突状细胞)上,这些免疫细胞共同称为专职性APC。MHC区中最有名的基因是编码细胞表面上的抗原呈递蛋白的亚型。在人类中,这些基因被称为人白细胞抗原(HLA)基因。
“非甲氧基封端的聚合物”意指具有以除了甲氧基之外的部分结束的至少一个末端的聚合物。在一些实施例中,该聚合物具有以除了甲氧基之外的部分结束的至少两个末端。在其他实施例中,该聚合物不具有以甲氧基结束的末端。“非甲氧基封端的普朗尼克聚合物”意指除了在两个末端处具有甲氧基的线性普朗尼克聚合物之外的一种聚合物。如在此所提供的聚合物纳米颗粒可以包含非甲氧基封端的聚合物或非甲氧基封端的普朗尼克聚合物。
“获得”意指直接从一种材料中取得并且基本上不用改变和/或加工而使用。
“药学上可接受的赋形剂”意指与列举的这些合成纳米载体一起使用以配制本发明的组合物的药理学上非活性的材料。药物学上可接受的赋形剂包含本领域中已知的各种材料,包括但不限于糖类(如葡萄糖、乳糖,等等)、防腐剂(如抗微生物剂)、复原助剂、着色剂、盐水(如磷酸盐缓冲盐水)、以及缓冲剂。
“治疗方案(Protocol)”是指针对受试者的一种或多种物质的任何给药方案。给药方案可以包括给药的量、频率和/或方式。在一些实施例中,此种治疗方案可以用来向一个或多个测试受试者给予本发明的一种或多种组合物。然后可以对这些测试受试者中的免疫应答进行评定,以便确定该治疗方案是否对降低所不希望的免疫应答或产生所希望的免疫应答(例如,促进致耐受性作用)有效。还可以代替或除了前面提到的这些免疫应答之外,对任何其他治疗性和/或预防性作用进行评定。可以使用在此提供的任何方法或本领域中已知的其他方法确定一个治疗方案是否具有所希望的作用。例如,可以从已经根据一个具体的治疗方案而被给予了在此提供的一种组合物的受试者中获得一群细胞,以便确定特异性免疫细胞、细胞因子、抗体等等是否被减少、产生、激活等等。用于检测免疫细胞的存在和/或数目的有用方法包括但不限于流式细胞检测方法(例如,FACS)和免疫组织化学方法。用于免疫细胞标记物的特异性染色的抗体和其他结合剂是商业上可获得的。此类试剂盒典型地包括用于多种抗原的染色试剂,这些染色试剂允许来自异质细胞群体的所希望的细胞群的基于FACS的检测、分离和/或定量。
“提供受试者”是引起临床医师与受试者接触并且向其给予在此提供的一种组合物或在其上进行在此提供的一种方法的任何行为或一系列行为。优选地,该受试者是对如在此所提供的一种致耐受性免疫应答有需要者。该行为或一系列行为可以是本身直接地或间接地,如但不限于,通过依赖某人的语言或行为采取行动的不相关的第三方。
“受试者”意指动物,包括温血哺乳动物,如人类和灵长类;鸟类;家庭饲养动物或农场动物,如猫、狗、绵羊、山羊、牛、马以及猪;实验动物,如小鼠、大鼠以及豚鼠;鱼类;爬行动物;动物园和野生动物;等等。
“基本上无B细胞表位”是指不存在处于刺激B细胞应答的基本上激活的量的B细胞表位(在抗原的背景下是其本身、与一种载体结合、或与一种发明的组合物结合)。在多个实施例中,基本上无B细胞表位的一种组合物不合可测量的量的抗原的B细胞表位。在其他实施例中,此种组合物可以包含可测量的量的抗原的B细胞表位,但所述量并不有效于产生一种可测量的B细胞免疫应答(在抗原的背景下是其本身、与一种载体结合、或与一种发明的组合物结合),如抗原特异性抗体产生或抗原特异性B细胞增殖和/或活性,或并不有效于产生一种显著可测量的B细胞免疫应答(在抗原的背景下是其本身、与一种载体结合、或与一种发明的组合物结合)。在一些实施例中,一种显著可测量的B细胞免疫应答是在受试者中产生或将预期会产生不利的临床结果的B细胞免疫应答。在其他实施例中,一种显著可测量的B细胞免疫应答是大于由对照抗原(例如,已知不包含该抗原的B细胞表位或不刺激B细胞免疫应答的抗原)产生的相同类型免疫应答(例如,抗原特异性抗体产生或抗原特异性B细胞增殖和/或活性)的水平的B细胞免疫应答。在一些实施例中,一种显著可测量的B细胞免疫应答(如抗体滴度的测量值(例如,通过ELISA))比由一种对照物(例如,对照抗原)产生的相同类型应答大2倍、3倍、4倍、5倍、6倍、7倍、8倍、9倍、10倍、15倍、20倍或更多倍。在其他实施例中,基本上无B细胞表位的一种组合物是产生很少至不产生抗原特异性抗体滴度的组合物(在抗原的背景下是其本身、与一种载体结合、或与一种发明的组合物结合)的组合物。此类组合物包括产生的抗体滴度(如EC50值)为小于500、400、300、200、100、50、40、30、20或10的那些。在一些实施例中,一种显著可测量的B细胞免疫应答是比由一种对照物产生的相同类型应答大10%、25%、50%、100%、2倍、3倍、4倍、5倍、6倍、7倍、8倍、9倍、10倍、15倍、20倍或更多倍的B细胞数目或增殖的测量值。用于测量B细胞应答的其他方法是本领域普通技术人员已知的。
在多个实施例中,为了确保一种组合物基本上不包含B细胞表位,对抗原进行选择,使得这些抗原不包含用于与如在此所提供的与合成纳米载体偶联的B细胞表位。在其他实施例中,为了确保一种组合物基本上不包含抗原的B细胞表位,产生与该抗原偶联的合成纳米载体并且测试其B细胞免疫应答(例如,抗原特异性抗体产生、B细胞增殖和/或活性)。然后可以选择展现出希望的特性的多种组合物。
“一种或多种合成纳米载体”意指在自然中未发现的、并且在大小上具有小于或等于5微米的至少一个尺寸的离散物体。白蛋白纳米颗粒通常被包括为合成纳米载体,然而在某些实施例中,这些合成纳米载体并不包含白蛋白纳米颗粒。在多个实施例中,发明的合成纳米载体不包含壳聚糖。在其他实施例中,发明的合成纳米载体不是基于脂质的纳米颗粒。在另外多个实施方案中,发明的合成纳米载体不包含磷脂。
一种合成纳米载体可以是但不限于以下各项中的一种或多种:基于脂质的纳米颗粒(在此又称为脂质纳米颗粒,即构成它们结构的大多数材料是脂质的纳米颗粒)、聚合物纳米颗粒、金属纳米颗粒、基于表面活性剂的乳液、树枝状化合物、巴基球、纳米线、病毒样颗粒(即,主要由病毒结构蛋白构成、但不是感染性的或具有低感染性的颗粒)、基于肽或蛋白质的颗粒(在此又称为蛋白质颗粒,即构成它们结构的大多数材料是肽或蛋白质的颗粒)(如白蛋白纳米颗粒)、和/或使用纳米材料的组合而发展的纳米颗粒(如脂质-聚合物纳米颗粒)。合成纳米载体可以具有各种不同的形状,包括但不局限于:球形、立方形、锥形、长方形、圆柱形、螺旋管形,等等。根据本发明的合成纳米载体包含一个或多个表面。可以适合用于实践本发明的示例性的合成纳米载体包含:(1)披露在格列夫(Gref)等人的美国专利5,543,158中的可生物降解的纳米颗粒、(2)萨尔兹曼(Saltzman)等人的公开美国专利申请20060002852的聚合物纳米颗粒、(3)戴斯蒙(DeSimone)等人的公开美国专利申请20090028910的光刻构建(lithographically constructed)的纳米颗粒、(4)冯·艾德里安(von Andrian)等人的WO 2009/051837的披露内容、或(5)披露在佩纳德斯(Penades)等人的公开美国专利申请2008/0145441中的纳米颗粒、(6)披露在德洛斯里奥斯(de los Rios)等人的公开美国专利申请20090226525中的蛋白质纳米颗粒、(7)披露在西贝尔(Sebbel)等人的公开美国专利申请20060222652中的病毒样颗粒、(8)披露在巴赫曼(Bachmann)等人的公开美国专利申请20060251677中的与核酸偶联的病毒样颗粒、(9)披露在WO 2010047839A1或WO 2009106999 A2中的病毒样颗粒、(10)披露在P·保利赛利(P.Paolicelli)等人的“可以高效结合并递送病毒样颗粒的表面修饰的基于PLGA的纳米颗粒(Surface-modifiedPLGA-based Nanoparticles that can Efficiently Associate and Deliver Virus-like Particles)”纳米医学(Nanomedicine),5(6):843-853(2010)中的纳米沉淀的纳米颗粒、或(11)披露在美国公开号2002/0086049中的凋亡细胞、凋亡小体、或合成或半合成的模拟物。在多个实施例中,合成纳米载体可以具有大于1∶1、1∶1.2、1∶1.5、1∶2、1∶3、1∶5、1∶7、或大于1∶10的长宽比。
具有等于或小于约100nm、优选地等于或小于100nm的最小尺寸的根据本发明的合成纳米载体不包含具有使补体活化的羟基的表面,或可替代地包含主要由不是使补体活化的羟基的部分组成的表面。在一个优选的实施例中,具有等于或小于约100nm、优选地等于或小于100nm的最小尺寸的根据本发明的合成纳米载体不包含基本上使补体活化的表面,或可替代地包含主要由不是基本上使活化补体的部分组成的表面。在一个更优选的实施例中,具有等于或小于约100nm、优选地等于或小于100nm的最小尺寸的根据本发明的合成纳米载体不包含使补体活化的表面,或可替代地包含主要由不使补体活化的部分组成的表面。在多个实施例中,合成纳米载体排除病毒样颗粒。在多个实施例中,合成纳米载体可以具有大于1∶1、1∶1.2、1∶1.5、1∶2、1∶3、1∶5、1∶7、或大于1∶10的长宽比。
“T细胞抗原”意指CD4+ T细胞抗原或CD8+细胞抗原。“CD4+ T细胞抗原”意指由CD4+ T细胞识别并且触发CD4+ T细胞中的免疫应答的任何抗原,例如经由结合到II类主要组织相容性复合体分子(MHC)上的抗原或其一部分的呈递而被CD4+ T细胞上的T细胞受体特异性地识别的抗原。“CD8+ T细胞抗原”意指由CD8+ T细胞识别并且触发CD8+ T细胞中的免疫应答的任何抗原,例如经由结合到I类主要组织相容性复合体分子(MHC)上的抗原或其一部分的呈递而被CD8+ T细胞上的T细胞受体特异性地识别的抗原。在一些实施例中,作为T细胞抗原的抗原也是一种B细胞抗原。在其他实施例中,该T细胞抗原并不也是一种B细胞抗原。T细胞抗原通常是蛋白类或肽类。
“治疗性蛋白”是指可以向受试者给予并且具有一种治疗性作用的任何蛋白质或基于蛋白质的疗法。此类疗法包括蛋白质替代和蛋白质补充疗法。此类疗法还包括给予外源或外来的蛋白质、抗体疗法、以及细胞或基于细胞的疗法。治疗性蛋白包括酶、酶辅助因子、激素、凝血因子、细胞因子、生长因子、单克隆抗体、以及多克隆抗体。在此在其他地方提供了其他治疗性蛋白的实例。可以在细胞之中、之上或由细胞产生治疗性蛋白,并且可以从此类细胞中获得治疗性蛋白、或以此类细胞的形式给予这些治疗性蛋白。在多个实施例中,在以下细胞之中、之上或由以下细胞产生该治疗性蛋白:哺乳动物细胞、昆虫细胞、酵母细胞、细菌细胞、植物细胞、转基因动物细胞、转基因植物细胞等等。可以在此类细胞中重组地产生该治疗性蛋白。可以在病毒转化的细胞之中、之上或由病毒转化的细胞产生该治疗性蛋白。还可以在自体细胞之中、之上或由自体细胞产生该治疗性蛋白,这些自体细胞已经被转染、转导或以另外的方式操纵以表达该治疗性蛋白。可替代地,可以作为一种核酸或通过将一种核酸引入到病毒、VLP、脂质体等等中来给予该治疗性蛋白。可替代地,可以从此类形式中获得该治疗性蛋白并且作为该治疗性蛋白本身而给予。因此,受试者包括已经接受、正接受或将要接受上述任何物质的任何受试者。此类受试者包括已经接受、正接受或将要接受以下各项的受试者:基因治疗;已经被转染、转导或以另外的方式操纵以表达一种治疗性蛋白、多肽或肽的自体细胞;或表达一种治疗性蛋白、多肽或肽的细胞。
“治疗性蛋白APC可呈递抗原”意指与一种治疗性蛋白结合的抗原(即,该治疗性蛋白或其片段可以产生针对该治疗性蛋白的免疫应答(例如,产生治疗性蛋白特异性抗体))。通常,治疗性蛋白APC可呈递抗原可以通过免疫系统(例如,免疫系统的细胞,如通过包括但不限于树突状细胞、B细胞或巨噬细胞的抗原呈递细胞而呈递)被呈递用于识别。该治疗性蛋白APC可呈递抗原可以通过例如T细胞被呈递用于识别。此类抗原可以经由结合到I类或II类主要组织相容性复合体分子(MHC)上的抗原的表位的呈递而被T细胞识别并且触发T细胞中的免疫应答。治疗性蛋白APC可呈递抗原通常包括蛋白质类、多肽类、肽类、脂蛋白类,或被包含在或表达在细胞之中、之上或由细胞表达。在一些实施例中,这些治疗性蛋白抗原与合成纳米载体偶联,并且包含MHC I类限制性表位和/或MHC II类限制性表位和/或B细胞表位。在其他实施例中,这些抗原不包含B细胞表位,如当包括这些B细胞表位将使所不希望的免疫免疫加剧时。在其他实施例中,这些抗原包含MHC II类限制性表位并且基本上不包含B细胞表位。优选地,对该治疗性蛋白特异的一种或多种致耐受性免疫应答由在此提供的这些组合物产生。
“致耐受免疫应答”意指可以导致对一种抗原或表达此种抗原的一种细胞、组织、器官等等特异的免疫抑制的任何免疫应答。此类免疫应答包括对该抗原或表达此抗原的细胞、组织、器官等等特异的所不希望的免疫应答的任何降低、延迟或抑制。此类免疫应答还包括对该抗原或表达此抗原的细胞、组织、器官等等特异的所希望的免疫应答的任何刺激、产生、诱导、促进或募集。因此,致耐受性免疫应答包括不存在或降低针对抗原的所不希望的免疫应答,这可以通过抗原反应性细胞以及存在或促进抑制性细胞来介导。在此所提供的致耐受性免疫应答包括免疫耐受性。“产生致耐受性免疫应答”意指产生对一种抗原或表达此抗原的细胞、组织、器官等等特异的任何上述免疫应答。该致耐受性免疫应答可以是MHC I类限制性呈递和/或MHC II类限制性呈递和/或B细胞呈递和/或由CD1d进行的呈递等等的结果。
致耐受性免疫应答包括CD4+ T细胞、CD8+ T细胞或B细胞增殖和/或活性的任何降低、延迟或抑制。致耐受性免疫应答还包括抗原特异性抗体产生的降低。致耐受性免疫应答还可以包括导致调节性细胞的刺激、诱导、产生或募集的任何应答,这些调节性细胞如CD4+Treg细胞、CD8+ Treg细胞、Breg细胞等等。在一些实施例中,该致耐受性免疫应答是导致转变为一种调节性表型的致耐受性免疫应答,该调节性表型的特征在于产生、诱导、刺激或募集调节性细胞。
致耐受性免疫应答还包括导致CD4+ Treg细胞和/或CD8+ Treg细胞的刺激、产生或募集的任何应答。CD4+ Treg细胞可以表达转录因子FoxP3并且抑制炎症应答和自身免疫性炎性疾病(自身免疫性疾病中的人调节性T细胞(Human regulatory T cells inautoimmune diseases),科夫塔诺维奇·GL(Cvetanovich GL)、哈弗·DA(Hafler DA),免疫学当前观点(Curr Opin Immunol.)2010年12月;22(6):753-60,调节性T细胞和自身免疫性(Regulatory T cells and autoimmunity),维拉·J(Vila J)、艾萨克·JD(IsaacsJD)、安德森·AE(Anderson AE),血液学当前观点(Curr Opin Hematol.)2009年7月;16(4):274-9)。此类细胞还抑制T细胞对B细胞的帮助并且诱导对自身和外来抗原的耐受性(基于FoxP3+ 调节性T细胞活化和扩增的过敏和自身免疫性的治疗性方法(Therapeuticapproaches to allergy and autoimmunity based on FoxP3+regulatory T-cellactivation and expansion),宫良·M(Miyara M)、永·K(Wing K)、板口·(SakaguchiS),过敏临床免疫学期刊(J Allergy Clin Immunol),2009年4月;123(4):749-55)。当抗原由APC上的II类蛋白质呈递时,CD4+ Treg细胞识别这种抗原。识别由I类(和Qa-1)呈递的抗原的CD8+ Treg细胞还可以抑制T细胞对B细胞的帮助,并且导致诱导对自身和外来抗原二者的耐受性的抗原特异性抑制的活化。已经显示,Qa-1与CD8+ Treg细胞的相互作用的破坏可使免疫应答失调,并且导致自身抗体形成和自身免疫性致命性系统性红斑狼疮的产生(金(Kim)等人,自然(Nature),2010年9月16日,467(7313):328-32)。还已经显示,CD8+Treg细胞可抑制包括类风湿性关节炎和结肠炎的自身免疫性炎性疾病的模型(自身免疫性关节炎中的CD4+ CD25+ 调节性T细胞(CD4+ CD25+ regulatory T cells in autoimmunearthritis),欧·S(Oh S)、兰金·AL(Rankin AL)、卡顿·AJ(Caton AJ),免疫性评论(Immunol Rev),2010年1月;233(1):97-111,炎性肠病中的调节性T细胞(Regulatory Tcells in inflammatory bowel disease).博登·EK(Boden EK)、斯奈普·SB(SnapperSB),肠胃病学当前观点(Curr Opin Gastroenterol),2008年11月;24(6):733-41)。在一些实施例中,提供的这些组合物可以有效地产生两种类型的应答(CD4+ Treg和CD8+ Treg)。在其他实施例中,可以在其他免疫细胞(如巨噬细胞、iNKT细胞等等)中诱导FoxP3,并且在此提供的这些组合物同样可以产生这些应答中的一种或多种。
致耐受性免疫应答还包括但不限于:诱导调节性细胞因子,如Treg细胞因子;诱导抑制性细胞因子;抑制炎性细胞因子(例如,IL-4、IL-1b、IL-5、TNF-α、IL-6、GM-CSF、IFN-γ、IL-2、IL-9、IL-12、IL-17、IL-18、IL-21、IL-22、IL-23、M-CSF、C反应性蛋白、急性期蛋白、趋化因子(例如,MCP-1、RANTES、MIP-1α、MIP-1β、MIG、ITAC或IP-10);产生抗炎性细胞因子(例如,IL-4、IL-13、IL-10等等)、趋化因子(例如,CCL-2、CXCL8)、蛋白酶(例如,MMP-3、MMP-9)、白三烯(例如,CysLT-1、CysLT-2)、前列腺素(例如,PGE2)或组胺;抑制向Th17、Th1或Th2免疫应答的极化;抑制效应细胞特异性细胞因子:Th17(例如,IL-17、IL-25)、Th1(IFN-γ)、Th2(例如,IL-4、IL-13);抑制Th1特异性、Th2特异性或TH17特异性的转录因子;抑制效应T细胞的增殖;诱导效应T细胞的凋亡;诱导致耐受性的树突状细胞特异性的基因;诱导FoxP3表达;抑制IgE诱导或IgE介导的免疫应答;抑制抗体应答(例如,抗原特异性抗体的产生);抑制T辅助细胞应答;产生TGF-β和/或IL-10;抑制自身抗体的效应子功能(例如,细胞耗尽、细胞或组织损伤、或补体活化的抑制);等等。
任何上述的免疫应答可以在一个或多个动物模型中体内测量或可以在体外测量。本领域普通技术人员熟悉此类体内或体外测量。所不希望的免疫应答或致耐受性免疫应答可以使用例如评定免疫细胞数目和/或功能的方法、四聚物分析、ELISPOT、基于流式细胞检测的细胞因子表达、细胞因子分泌的分析、细胞因子表达谱绘制、基因表达谱绘制、蛋白质表达谱绘制、细胞表面标记分析、基于PCR的免疫细胞受体基因用法的检测(参见T·克雷(T.Clay)等人,“用于监测针对癌症的主动免疫治疗的细胞免疫应答的测定(Assays forMonitoring Cellular Immune Response to Active Immunotherapy of Cancer)”临床癌症研究(Clinical Cancer Research)7:1127-1135(2001))等等来监测。所不希望的免疫应答或致耐受性免疫应答还可以使用例如评定血浆或血清中的蛋白质水平的方法、免疫细胞增殖和/或功能测定等等来监测。在一些实施例中,致耐受性免疫应答可以通过评定FoxP3的诱导来监测。另外,在实例中更详细地描述了具体方法。
优选地,致耐受性免疫应答导致对在此描述的疾病、紊乱或病症的发展、进展或病理的抑制。可以用具有此类疾病、紊乱或病症的动物模型来测量这些发明的组合物是否可以导致对在此描述的疾病、紊乱或病症的发展、进展或病理的抑制。在一些实施例中,可以通过确定临床终点、临床功效、临床症状、疾病生物标记和/或临床得分来评定所不希望的免疫应答的降低或致耐受性免疫应答的产生。还可以用诊断试验评定所不希望的免疫应答或致耐受性免疫应答,以便评定在此所提供的疾病、紊乱或病症的存在或不存在。可以进一步通过测量受试者中的治疗性蛋白水平和/或功能的方法来评定所不希望的免疫应答。
在一些实施例中,可以在给予在此提供的合成纳米载体的一种组合物之前和/或在给予一种治疗性蛋白之前监测或评定受试者中的所不希望的免疫应答或致耐受性免疫应答的产生。在其他实施例中,可以在给予在此提供的合成纳米载体的一种组合物之后和/或在给予一种治疗性蛋白之后评定所不希望的免疫应答或致耐受性免疫应答的产生。在一些实施例中,在给予合成纳米载体的该组合物之后、但在给予该治疗性蛋白之前完成该评定。在其他实施例中,在给予该治疗性蛋白之后、但在给予该组合物之前完成该评定。在再其他的实施例中,在给予这些合成纳米载体和该治疗性蛋白二者之前进行该评定,而在又其他的实施例中,在给予这些合成纳米载体和该治疗性蛋白二者之后进行该评定。在另外的多个实施例中,在给予这些合成纳米载体和/或该治疗性蛋白之前和之后都进行该评定。在再其他的实施例中,在受试者上进行多于一次的该评定,以便确定令人希望的免疫状态被维持在该受试者中,该受试者例如为已经被给予、正被给予或将要被给予一种治疗性蛋白的受试者。
可以通过测定一个或多个抗体滴度来评定抗体应答。“抗体滴度”意指抗体产生的可测量水平。用于测量抗体滴度的方法是本领域中已知的并且包括酶联免疫吸附测定(ELISA)。在多个实施例中,该抗体应答可以被定量为例如抗体的数目、抗体的浓度、或滴度。这些值可以是绝对的或它们可以是相对的。用于定量抗体应答的测定包括抗体捕获测定、酶联免疫吸附测定(ELISA)、抑制液相吸附测定(inhibition liquid phaseabsorption assay,ILPAA)、火箭免疫电泳(rocket immunoelectrophoresis,RIE)测定、以及线状免疫电泳(line immunoelectrophoresis,LIE)测定。当比较一种抗体应答与另一种抗体应答时,优选地使用相同类型的定量值(例如,滴度)和测量方法(例如,ELISA)进行该比较。
用于测量抗体滴度的ELISA方法(例如,一种典型的夹心ELISA)可以由以下步骤组成:(i)制备一种ELISA-板包被材料,使得感兴趣的抗体靶标与一种底物聚合物或其他适合的材料偶联;(ii)在一种水溶液(如PBS)中制备该包被材料,并且将该包被材料溶液递送至一个多孔板的孔中用于使该包被层过夜沉积在该多孔板上;(iii)用洗涤缓冲液(如含0.05%吐温-20的PBS)彻底洗涤该多孔板以去除过量的包被材料;(iv)通过施加一种稀释剂溶液(如含10%胎牛血清的PBS)来封闭该板的非特异性结合;(v)用洗涤缓冲液将该封闭/稀释剂溶液从该板上洗涤下来;(vi)根据需要用稀释剂对含有抗体和适当标准品(阳性对照)的一种或多种血清样品进行稀释,以获得适当地使ELISA应答饱和的浓度;(vii)在该多孔板上对这些血浆样品进行连续稀释,这样以涵盖适用于产生ELISA应答曲线的浓度范围;(viii)孵育该板以提供抗体-靶标结合;(ix)用洗涤缓冲液洗涤该板以去除未结合抗原的抗体;(x)添加适当浓度的处于相同稀释剂中的一种第二检测抗体,如能够结合第一抗体的一种生物素偶联的检测抗体;(xi)用所施加的该检测抗体孵育该板,随后用洗涤缓冲液进行洗涤;(xii)添加将与生物素化的抗体上发现的生物素结合的酶(如链霉亲和素-HRP(辣根过氧化物酶))并且进行孵育;(xiii)洗涤该多孔板;(xiv)将一种或多种底物(如TMB溶液)添加至该板上;(xv)当显色完全时施加一种终止溶液(如2N硫酸);(xvi)在针对该底物的特定波长下读取这些板孔的光密度(450nm减去570nm处的读数);(xvi)对数据应用一个适合的多参数曲线拟合,并且将半最大有效浓度(EC50)定义为达到这些板标准品的半最大值OD值时的曲线上的浓度。
“所不希望的免疫应答”是指由暴露于抗原而引起的、促进或加剧在此提供的疾病、紊乱或病症(或其症状)的,或是在此提供的疾病、紊乱或病症的症状的任何所不希望的免疫应答。此类免疫应答通常对受试者的健康具有负面影响或表明对受试者的健康的负面影响。所不希望的免疫应答包括抗原特异性抗体产生、抗原特异性B细胞增殖和/或活性、或抗原特异性CD4+ T细胞增殖和/或活性。
C.发明组合物
在此提供了多种致耐受性的合成纳米载体组合物和相关的方法,这些致耐受性的合成纳米载体组合物包含免疫抑制剂和治疗性蛋白APC可呈递抗原。此类组合物和方法是对降低所不希望的免疫应答的产生和促进对治疗性蛋白特异的致耐受性免疫应答的产生有用的。可以向希望有针对治疗性蛋白的致耐受性免疫应答的受试者给予这些组合物。此类受试者包括已经被、正在被或将要被给予一种治疗性蛋白的那些。在多个实施例中,对受试者给予在此提供的这些合成纳米载体,并且然后给予一种或多种治疗性蛋白。在其他实施例中,对受试者给予一种治疗性蛋白并且然后是所提供的这些合成纳米载体。在再其他的实施例中,同时给予这些合成纳米载体和这一种或多种治疗性蛋白。
如上所提到的,这些合成纳米载体被设计成包含免疫抑制剂和(在一些实施例中)抗原,针对该抗原的致耐受性作用是所希望的。在多个实施例中,这些抗原包含MHC II类限制性表位,当与免疫抑制剂结合呈递时,这些表位可以导致致耐受性作用,如抗原特异性CD4+ T细胞增殖和/或活性的降低。所得到的这些致耐受性作用还包括抗原特异性B细胞增殖和/或活性的降低、和/或抗原特异性抗体产生的降低。根据本发明,可以使用各种各样的合成纳米载体。在一些实施例中,合成纳米载体是球体或球状体。在一些实施例中,合成纳米载体是扁平的或盘状的。在一些实施例中,合成纳米载体是立方体或立方形的。在一些实施例中,合成纳米载体是卵形或椭圆形的。在一些实施例中,合成纳米载体是圆柱体、锥体、或锥形。
在一些实施例中,希望使用在大小、形状、和/或构成方面较一致的一个群体的合成纳米载体,使得每一合成纳米载体具有相似特性。例如,基于合成纳米载体的总数,至少80%、至少90%、或至少95%的这些合成纳米载体可以具有归属在这些合成纳米载体的平均直径或平均尺寸的5%、10%或20%之内的最小尺寸或最大尺寸。在一些实施例中,一个群体的合成纳米载体可以在大小、形状、和/或构成方面是不均匀的。
合成纳米载体可以是实心的或空心的,并且可以包含一个或多个层。在一些实施例中,每一层相对于其他一层或多层具有独特的构成和独特的特性。为了作为一个实例给出,合成纳米载体可以具有一个核/壳结构,其中该核是一个层(例如一个聚合物核)并且该壳是一个第二层(例如一个脂质双层或单层)。合成纳米载体可以包括多个不同的层。
在一些实施例中,合成纳米载体可以任选地包含一种或多种脂质。在一些实施例中,合成纳米载体可以包含一种脂质体。在一些实施例中,合成纳米载体可以包含一个脂质双层。在一些实施例中,合成纳米载体可以包含一个脂质单层。在一些实施例中,合成纳米载体可以包含一种微胶粒。在一些实施例中,合成纳米载体可以包含一个核,该核包含被一个脂质层(例如,脂质双层、脂质单层等等)围绕的一种聚合物基质。在一些实施例中,合成纳米载体可以包含被一个脂质层(例如,脂质双层、脂质单层等等)围绕的一个非聚合物核(例如,金属颗粒、量子点、陶瓷颗粒、骨颗粒、病毒颗粒、蛋白质、核酸、碳水化合物等等)。
在其他实施例中,合成纳米载体可以包含金属颗粒、量子点、陶瓷颗粒等等。在一些实施例中,非聚合物合成纳米载体是非聚合组分的一个聚集体,如金属原子(例如金原子)的一个聚集体。
在一些实施例中,合成纳米载体可以任选地包含一种或多种两亲实体。在一些实施例中,两亲实体可以促进具有增加的稳定性、改进的均匀性、或增加的粘度的合成纳米载体的产生。在一些实施例中,两亲实体可以与一个脂质膜(例如,脂质双层、脂质单层等等)的内表面结合。在本领域中已知的许多两亲实体可以适用于制造根据本发明的合成纳米载体。此类两亲实体包括但不限于:磷酸甘油酯类;磷脂酰胆碱类;二棕榈酰磷脂酰胆碱(DPPC);二油烯基磷脂酰基乙醇胺(DOPE);二油烯基氧丙基三乙基铵(DOTMA);二油酰基磷脂酰胆碱;胆固醇;胆固醇酯;二酰基甘油;二酰基甘油琥珀酸酯;二磷脂酰基甘油(DPPG);十六烷醇;脂肪醇类,如聚乙二醇(PEG);聚氧乙烯-9-月桂基醚;一种表面活性脂肪酸,如棕榈酸或油酸;脂肪酸类;脂肪酸甘油单酯类;脂肪酸甘油二酯类;脂肪酸酰胺类;脱水山梨糖醇三油酸酯(85)甘氨胆酸酯;脱水山梨糖醇单月桂酸酯(20);聚山梨醇酯20(20);聚山梨醇酯60(60);聚山梨醇酯65(65);聚山梨醇酯80(80);聚山梨醇酯85(85);聚氧乙烯单硬脂酸酯;表面活性素;泊洛沙姆;一种脱水山梨糖醇脂肪酸酯,如脱水山梨糖醇三油酸酯;卵磷脂;溶血卵磷脂;磷脂酰丝氨酸;磷脂酰肌醇;鞘磷脂;磷脂酰乙醇胺(脑磷脂);心磷脂;磷脂酸;脑苷脂;双十六烷基磷酸酯;二棕榈酰磷脂酰甘油;硬脂酰胺;十二烷胺;十六烷胺;乙酰基棕榈酸酯;蓖麻油酸甘油酯;十八酸十六烷基酯;肉豆蔻酸异丙酯;四丁酚醛(tyloxapol);聚(乙二醇)5000-磷脂酰乙醇胺;聚(乙二醇)400-单硬脂酸酯;磷脂;具有高表面活性剂特性的合成的和/或天然的洗涤剂;脱氧胆酸酯;环糊精;离液序列高的盐;离子对试剂;以及它们的组合。两亲实体组分可以是不同两亲实体的混合物。本领域普通技术人员将认识到,这是具有表面活性剂活性的物质的示例性的、而不是全面的清单。任何两亲实体可以用于有待根据本发明使用的合成纳米载体的生产中。
在一些实施例中,合成纳米载体可以任选地包含一种或多种碳水化合物。碳水化合物可以是天然的或合成的。碳水化合物可以是衍生的天然碳水化合物。在某些实施例中,碳水化合物包含单糖或二糖,包括但不限于:葡萄糖、果糖、半乳糖、核糖、乳糖、蔗糖、麦芽糖、海藻糖、纤维二糖(cellbiose)、甘露糖、木糖、阿拉伯糖、葡糖醛酸、半乳糖醛酸、甘露糖醛酸、葡糖胺、半乳糖胺、以及神经氨酸。在某些实施例中,碳水化合物是一种多糖,包括但不限于:支链淀粉、纤维素、微晶纤维素、羟丙基甲基纤维素(HPMC)、羟基纤维素(HC)、甲基纤维素(MC)、葡聚糖、环葡聚糖、糖原、羟乙基淀粉、卡拉胶、多聚糖(glycon)、直链淀粉、壳聚糖、N,O-羧甲基壳聚糖、藻胶和海藻酸、淀粉、甲壳质、菊糖、魔芋、葡萄甘露聚糖(glucommannan)、石耳素、肝素、透明质酸、凝胶多糖、以及黄原胶。在实施例中,这些发明的合成纳米载体并不包含(或特别排除)碳水化合物,如多糖。在某些实施例中,该碳水化合物可以包含一种碳水化合物衍生物,如一种糖醇,包括但不限于:甘露醇、山梨醇、木糖醇、赤藓糖醇、麦芽糖醇、以及乳糖醇。
在一些实施例中,合成纳米载体可以包含一种或多种聚合物。在一些实施例中,这些合成纳米载体包含一种或多种聚合物,该聚合物是非甲氧基封端的普朗尼克聚合物。在一些实施例中,构成这些合成纳米载体的至少1%、2%、3%、4%、5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、97%、或99%(重量/重量)的这些聚合物是非甲氧基封端的普朗尼克聚合物。在一些实施例中,构成这些合成纳米载体的所有这些聚合物是非甲氧基封端的普朗尼克聚合物。在一些实施例中,这些合成纳米载体包含一种或多种聚合物,该聚合物是非甲氧基封端的聚合物。在一些实施例中,构成这些合成纳米载体的至少1%、2%、3%、4%、5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、97%、或99%(重量/重量)的这些聚合物是非甲氧基封端的聚合物。在一些实施例中,构成这些合成纳米载体的所有这些聚合物是非甲氧基封端的聚合物。在一些实施例中,这些合成纳米载体包含一种或多种聚合物,这些聚合物不包含普朗尼克聚合物。在一些实施例中,构成这些合成纳米载体的至少1%、2%、3%、4%、5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、97%、或99%(重量/重量)的这些聚合物不包含普朗尼克聚合物。在一些实施例中,构成这些合成纳米载体的所有这些聚合物不包含普朗尼克聚合物。在一些实施例中,可以由包被层(例如脂质体、脂质单层、微胶粒等)环绕这样一种聚合物。在一些实施例中,合成纳米载体的不同成分可以与该聚合物偶联。
可以通过多种方法中的任一种使这些免疫抑制剂和/或抗原与这些合成纳米载体偶联。通常,该偶联可以是这些免疫抑制剂和/或抗原与这些合成纳米载体之间键合的结果。这种键合可以导致这些免疫抑制剂和/或抗原附着至合成纳米载体的表面上和/或被包含(封装)在合成纳米载体之内。然而,在一些实施例中,这些免疫抑制剂和/或抗原由于这些合成纳米载体的结构而被合成纳米载体封装,而不是键合至合成纳米载体上。在多个优选的实施例中,合成纳米载体包含如在此所提供的一种聚合物,并且这些免疫抑制剂和/或抗原与聚合物偶联。
当由于这些免疫抑制剂和/或抗原与合成纳米载体之间的键合而发生偶联时,该偶联可以经由一个偶联部分而发生。一个偶联部分可以是通过其使免疫抑制剂和/或抗原键合至合成纳米载体上的任何部分。此类部分包括共价键(如一个酰胺键或酯键)、以及使免疫抑制剂和/或抗原键合(共价地或非共价地)至该合成纳米载体上的单独的分子。此类分子包括连接物或聚合物或其单元。例如,该偶联部分可以包含免疫抑制剂和/或抗原静电结合至其上的一种带电荷的聚合物。作为另一个实例,该偶联部分可以包含它共价结合至其上的一种聚合物或其单元。
在多个优选的实施例中,这些合成纳米载体包含如在此所提供的一种聚合物。这些合成纳米载体可以是完全聚合的或它们可以是聚合物与其他材料的混合物。
在一些实施例中,具有合成纳米载体的这些聚合物结合以形成一种聚合物基质。在这些实施例中的一些中,一种组分(如一种免疫抑制剂或抗原)可以与该聚合物基质中的一种或多种聚合物共价结合。在一些实施例中,共价结合是由一个连接物介导的。在一些实施例中,一种组分可以与该聚合物基质中的一种或多种聚合物非共价结合。例如,在一些实施例中,一种组分可以被封装在一种聚合物基质之内、被聚合物基质围绕、和/或分散在整个聚合物基质中。可替代地或另外地,一种组分可以通过疏水相互作用、电荷相互作用、范德华力等等与一种聚合物基质中的一种或多种聚合物结合。用于从其形成聚合物基质的各种各样的聚合物和方法是常规已知的。
聚合物可以是天然的或非天然的(合成的)聚合物。聚合物可以是均聚物或包含两种或更多种单体的共聚物。在序列方面,共聚物可以是随机的、嵌段的,或包含随机序列与嵌段序列的组合。典型地,根据本发明的聚合物是有机聚合物。
在一些实施例中,聚合物包含一种聚酯、聚碳酸酯、聚酰胺、或聚醚、或其单元。在其他实施例中,聚合物包含聚(乙二醇)(PEG)、聚丙二醇、聚(乳酸)、聚(乙醇酸)、聚(乳酸-乙醇酸)共聚物、或一种聚己酸内酯、或其单元。在一些实施例中,优选的是该聚合物是可生物降解的。因此,在这些实施例中,优选的是如果该聚合物包含一种聚醚(如聚(乙二醇)或聚丙二醇或其单元),则该聚合物包含一种聚醚和一种可生物降解的聚合物的嵌段共聚物,使得该聚合物是可生物降解的。在其他实施例中,该聚合物不仅仅包含一种聚醚或其单元,如聚(乙二醇)或聚丙二醇或其单元。
适合用于本发明的聚合物的其他实例包括但不限于:聚乙烯、聚碳酸酯(例如聚(1,3-二噁烷-2酮))、聚酐(例如聚(癸二酸酐))、聚丙基延胡索酸酯(polypropylfumerate)、聚酰胺(例如聚己内酰胺)、聚缩醛、聚醚、聚酯(例如聚丙交酯、聚乙交酯、丙交酯-乙交酯共聚物、聚己酸内酯、多羟基酸(例如聚(β-羟基烷酸酯)、聚(原酸酯)、聚氰基丙烯酸酯、聚乙烯醇、聚氨酯、聚磷腈、聚丙烯酸酯、聚甲基丙烯酸酯、聚脲、聚苯乙烯、以及聚胺、聚赖氨酸、聚赖氨酸-PEG共聚物、以及聚(乙烯亚胺)、聚(乙烯亚胺)-PEG共聚物。
在一些实施例中,根据本发明的聚合物包括在21C.F.R.§177.2600下已经由美国食品与药品管理局(FDA)批准用于人的聚合物,包括但并不局限于聚酯(例如聚乳酸、聚(乳酸乙醇酸)共聚物、聚己内酯、聚戊内酯、聚(1,3-二噁烷-2酮));聚酐(例如聚(癸二酸酐));聚醚(例如聚乙二醇);聚氨酯;聚甲基丙烯酸酯;聚丙烯酸酯;以及聚氰基丙烯酸酯。
在一些实施例中,聚合物可以是亲水性的。例如,聚合物可以包含阴离子基团(例如磷酸根、硫酸根、羧酸根);阳离子基团(例如,季胺基团);或极性基团(例如,羟基基团、硫醇基团、胺基团)。在一些实施例中,包含一种亲水性聚合物基质的合成纳米载体在该合成纳米载体内产生亲水环境。在一些实施例中,聚合物可以是疏水性的。在一些实施例中,包含疏水性聚合物基质的合成纳米载体在该合成纳米载体内产生疏水环境。聚合物亲水性或疏水性的选择可以影响被结合(例如偶联)在合成纳米载体之内的材料的性质。
在一些实施例中,聚合物可以用一个或多个部分和/或官能团修饰。根据本发明,可以使用各种各样的部分或官能团。在一些实施例中,可以用聚乙二醇(PEG)、用碳水化合物、和/或用衍生自多糖类的非环状聚缩醛来修饰聚合物(Papisov(巴比索夫),2001,ACSSymposium Series,786:301)。可以使用Gref(格里夫)等人的美国专利号5543158、或VonAndrian(冯安德里安)等人的WO公开WO2009/051837中的全部传授内容进行某些实施例。
在一些实施例中,可以用脂质或脂肪酸基团修饰聚合物。在一些实施例中,脂肪酸基团可以是丁酸、己酸、辛酸、癸酸、月桂酸、肉豆蔻酸、棕榈酸、硬脂酸、花生酸、山嵛酸、或廿四烷酸中的一种或多种。在一些实施例中,脂肪酸基团可以是棕榈烯酸、油酸、异油酸、亚麻酸、α-亚麻酸、γ-亚麻酸、花生四烯酸、二十碳烯酸、花生四烯酸、二十碳五烯酸、二十二碳六烯酸、或芥酸中的一种或多种。
在一些实施例中,聚合物可以是聚酯,包括共聚物,这些共聚物包括乳酸和乙醇酸单元(例如聚(乳酸乙醇酸共聚物)和聚(丙交酯乙交酯共聚物)),在此统称为“PLGA”;以及包括乙醇酸单元的均聚物,在此称为“PGA”,以及乳酸单元(例如聚-L-乳酸、聚-D-乳酸、聚-D,L-乳酸、聚-L-丙交酯、聚-D-丙交酯、以及聚-D,L-丙交酯),在此统称为“PLA”。在一些实施例中,示例性的聚酯包括,例如多羟基酸;PEG共聚物和丙交酯与乙交酯的共聚物(例如PLA-PEG共聚物、PGA-PEG共聚物、PLGA-PEG共聚物),以及它们的衍生物)。在一些实施例中,聚酯包括例如聚(己内酯)、聚(己内酯)-PEG共聚物、聚(L-丙交酯--L-赖氨酸共聚物)、聚(丝氨酸酯)、聚(4-羟基-L-脯氨酸酯)、聚[α-(4-氨基丁基)-L-乙醇酸]、以及它们的衍生物。
在一些实施例中,聚合物可以是PLGA。PLGA是一种生物相容的并且生物可降解的乳酸和乙醇酸的共聚物,并且多种形式的PLGA特征在于乳酸:乙醇酸的比率。乳酸可以是L-乳酸、D-乳酸、或D,L-乳酸。可以通过改变乳酸∶乙醇酸的比率调整PLGA的降解速率。在一些实施例中,根据本发明的将使用的PLGA特征在于大约85∶15、大约75∶25、大约60∶40、大约50∶50、大约40∶60、大约25∶75、或者大约15∶85的乳酸∶乙醇酸比率。
在一些实施例中,聚合物可以是一种或多种丙烯酸聚合物。在某些实施例中,丙烯酸聚合物包括,例如丙烯酸和甲基丙烯酸的共聚物、甲基丙烯酸甲酯共聚物、甲基丙烯酸乙氧基乙酯、甲基丙烯酸氰基乙基酯、甲基丙烯酸氨基烷基酯共聚物、聚(丙烯酸)、聚(甲基丙烯酸)、甲基丙烯酸烷基酰胺共聚物、聚(甲基丙烯酸甲酯)、聚(甲基丙烯酸酸酐)、甲基丙烯酸甲酯、聚甲基丙烯酸酯、聚(甲基丙烯酸甲酯)共聚物、聚丙烯酰胺、甲基丙烯酸氨基烷基酯共聚物、甲基丙烯酸缩水甘油酯共聚物、聚腈基丙烯酸酯、以及包括一种或多种以上聚合物的组合。该丙烯酸聚合物可以包含具有低含量的季铵基团的丙烯酸酯和甲基丙烯酸酯的完全聚合的共聚物。
在一些实施例中,聚合物可以是阳离子型聚合物。通常,阳离子型聚合物能够缩合和/或保护核酸(例如DNA、或它的衍生物)的带负电的链。含有胺的聚合物(例如聚(赖氨酸)(Zauner(泽纳)等人,1998,先进药物递送综述,30:97;以及Kabanov(卡巴诺夫)等人,1995,生物共轭化学,6:7)、聚(亚乙基亚胺)(PEI;Boussif(波希夫)等人,1995,美国科学院院刊,1995,92:7297)、以及聚(酰胺胺)树枝状聚合物(Kukowska(库科斯卡)-Latallo(拉塔罗)等人,1996,美国科学院院刊,93:4897;Tang(唐)等人,1996,生物共轭化学,7:703;以及Haensler(亨斯勒)等人,1993,生物共轭化学,4:372)在生理pH下是带正电的,在多种细胞系中与核酸形成离子对,并且介导转染。在多个实施例中,这些发明的合成纳米载体可以不包含(或可以排除)阳离子型聚合物。
在一些实施例中,聚合物可以是带有阳离子侧链的可降解聚酯(Putnam(普特南)等人,1999,大分子,32:3658;Barrera(巴雷拉)等人,1993,美国化学会志,115:11010;Kwon(权)等人,1989,大分子,22:3250;Lim(林)等人,1999,美国化学会志,121:5633;以及Zhou(周)等人,1990,大分子,23:3399)。这些聚酯的实例包括聚(L-丙交酯L-赖氨酸共聚物)(Barrera(巴雷拉)等人,1993,美国化学会志,115:11010)、聚(丝氨酸酯)(Zhou(周)等人,1990,大分子,23:3399)、聚(4-羟基-L-脯氨酸酯)(Putnam(普特南)等人,1999,大分子,32:3658;以及Lim(林)等人,1999,美国化学会志,121:5633)、以及聚(4-羟基-L-脯氨酸酯)(Putnam(普特南)等人,1999,大分子,32:3658;以及Lim(林)等人,1999,美国化学会志,121:5633)。
这些和其他聚合物的特性以及用于制备它们的方法在本领域中是熟知的(参见,例如美国专利6,123,727;5,804,178;5,770,417;5,736,372;5,716,404;6,095,148;5,837,752;5,902,599;5,696,175;5,514,378;5,512,600;5,399,665;5,019,379;5,010,167;4,806,621;4,638,045;以及4,946,929;Wang(王)等人,2001,美国化学会志,123:9480;Lim(林)等人,2001,美国化学会志,123:2460;Langer(朗格尔),2000,化学研究评述,33:94;Langer(朗格尔),1999,控释杂志,62:7;以及Uhrich(乌利希)等人,1999,化学评论,99:3181)。更一般地,在Concise Encyclopedia of Polymer Science and PolymericAmines and Ammonium Salts,Goethals(戈萨尔斯)编辑,培格曼出版社,1980中;在Principles of Polymerization by Odian,约翰·威利父子出版公司,第四版,2004中;在Allcock(阿尔库克)等人的Contemporary Polymer Chemistry,Prentice-Hall,1981中;在Deming(德明)等人,1997,自然,390:386中;以及在美国专利6,506,577、6,632,922、6,686,446、以及6,818,732中说明了用于合成某些适合的聚合物的多种方法。
在一些实施例中,聚合物可以是线型聚合物或分支聚合物。在一些实施例中,聚合物可以是树枝状化合物。在一些实施例中,聚合物可以是基本上彼此交联的。在一些实施例中,聚合物可以基本上不交联。在一些实施例中,聚合物可以根据本发明进行使用而不经历交联步骤。进一步理解的是,本发明的合成纳米载体可以包含嵌段共聚物、接枝共聚物、共混物、混合物、和/或任何上述及其他聚合物的加合物。本领域的那些技术人员将认识到,在此列出的这些聚合物代表根据本发明可以使用的聚合物的示例性的、而不是全面的清单。
在一些实施例中,合成纳米载体不包含聚合物组分。在一些实施例中,合成纳米载体可以包含金属颗粒、量子点、陶瓷颗粒等等。在一些实施例中,非聚合物合成纳米载体是非聚合组分的一个聚集体,如金属原子(例如金原子)的一个聚集体。
根据本发明的多种组合物包含与药学上可接受的赋形剂(如防腐剂、缓冲剂、盐水或磷酸盐缓冲盐水)组合的合成纳米载体。可以使用常规药物制造和配制技术制造这些组合物,以实现有用的剂型。在一个实施例中,将发明的合成纳米载体与防腐剂一起悬浮在注射用无菌盐水溶液中。
在多个实施例中,当制备合成纳米载体作为载体时,用于将组分与合成纳米载体偶联的方法可以是有用的。如果该组分是小分子,那么在组装这些合成纳米载体之前将该组分附接至聚合物上可能是有利的。在多个实施例中,制备具有用于将该组分与合成纳米载体偶联的表面基团的合成纳米载体也可能是有利的,该偶联是通过使用这些表面基团而不是将该组分附接至聚合物上且随后在合成纳米载体的构建中使用这种聚合物共轭物来进行。
在某些实施例中,该偶联可以是共价连接物。在多个实施例中,根据本发明的多肽可以经由1,2,3-三唑连接物共价偶联至外表面上,该连接物通过纳米载体表面上的叠氮基团与含有炔基的抗原或免疫抑制剂进行1,3-偶极环加成反应、或通过纳米载体表面上的炔与含有叠氮基团的抗原或免疫抑制剂进行1,3-偶极环加成反应而形成。此类环加成反应优选地是在铜(I)催化剂以及适合的Cu(I)-配体和将Cu(II)化合物还原成催化活性的Cu(I)化合物的还原剂存在下进行的。此类Cu(I)催化的叠氮-炔环加成反应(CuAAC)也可以称为点击反应。
另外,共价偶联可以包含共价连接物,该共价连接物包含酰胺连接物、二硫化物连接物、硫醚连接物、腙连接物、酰肼连接物、亚胺或肟连接物、脲或硫脲连接物、脒连接物、胺连接物、以及磺酰胺连接物。
酰胺连接物经由一种组分(如抗原或免疫抑制剂)上的胺与第二组分(如纳米载体)的羧酸基团之间的酰胺键形成。该连接物中的酰胺键可以用被适当保护的氨基酸与被活化的羧酸(如被N-羟基丁二酰亚胺活化的酯)、使用任何常规酰胺键形成反应制成。
二硫化物连接物经由在例如R1-S-S-R2的形式的两个硫原子之间形成二硫(S-S)键制成。二硫键可以通过含有硫醇基/巯基(-SH)的组分与聚合物或纳米载体上另一个被活化的硫醇基或含有硫醇基/巯基的纳米载体与含有被活化的硫醇基的组分进行硫醇交换形成。
三唑连接物(特别是其中R1和R2可以是任何化学实体的形式的1,2,3-三唑)是通过附接至第一组分(如纳米载体)上的叠氮基与附接至第二组分(如免疫抑制剂或抗原)上的末端炔的1,3-偶极环加成反应制成。该1,3-偶极环加成反应在有或无催化剂的情况下、优选地在有经由1,2,3-三唑官能团连接两个组分的Cu(I)催化剂的情况下进行。夏普里斯(Sharpless)等人,在德国应用化学(Angew.Chem.Int.Ed.),41(14),2596,(2002)中以及梅尔达尔(Meldal)等人,在化学评述(Chem.Rev.),2008,108(8),2952-3015中详细描述了此化学作用,并且该化学作用常常被称为“点击”反应或CuAAC。
在多个实施例中,制备了一种在聚合物链末端含有一个叠氮基或炔基的聚合物。然后使用此聚合物来制备合成纳米载体,以此方式使得多个炔或叠氮基放置在该纳米载体的表面上。可替代地,可以通过另一种途径制备该合成纳米载体,并且随后用炔或叠氮基功能化。该组分是在或者炔(如果该聚合物含有叠氮基)或者叠氮基(如果该聚合物含有炔)存在下制备。然后在具有或不具有催化剂的情况下允许该组分与该纳米载体经由1,3-偶极环加成反应进行反应,该催化剂将该组分经由1,4-二取代的1,2,3-三唑连接物共价偶联至颗粒上。
硫醚连接物通过以例如R1-S-R2的形式形成硫-碳(硫醚)键制成。硫醚可以通过用第二组分上的烷基化基团(如卤基或环氧基)烷基化一种组分上的硫醇基/巯基(-SH)制成。硫醚连接物还可以通过将一种组分上的硫醇基/巯基与作为迈克尔受体的含有马来酰亚胺基团或乙烯砜基团的第二组分上的缺电子烯基进行迈克尔加成来形成。以另一种方式,硫醚连接物可以通过一种组分上的硫醇基/巯基与第二组分上的烯基进行自由基硫醇-烯反应来制备。
腙连接物通过一种组分上的酰肼基与第二组分上的醛基/酮基进行反应制成。
酰肼连接物通过一种组分上的肼基与第二组分上的羧酸基团进行反应来形成。此类反应通常使用类似于形成酰胺键的化学方法(其中羧酸用活化试剂活化)来进行。
亚胺或肟连接物通过一种组分上的胺或N-烷氧基胺基(或氨氧基)与第二组分上的醛或酮基进行反应来形成。
脲或硫脲连接物通过一种组分上的胺基与第二组分上的异氰酸酯或异硫氰酸酯基进行反应来制备。
脒连接物通过一种组分上的胺基与第二组分上的亚氨酸酯基团进行反应来制备。
胺连接物通过一种组分上的胺基与第二组分上的烷基化基团(如卤基、环氧基、或磺酸酯基)进行烷基化反应制成。可替代地,胺连接物还可以用适合的还原试剂(如氰基硼氢化钠或三乙酰氧基硼氢化钠)、通过一种组分上的胺基与第二组分上的醛基或酮基进行还原胺化反应制成。
磺酰胺连接物通过一种组分上的胺基与第二组分上的磺酰基卤化物(如磺酰氯)基团进行反应制成。
砜连接物通过亲核试剂与乙烯砜进行迈克尔加成制成。或者该乙烯砜或者该亲核试剂可以位于纳米载体的表面上或附接至一种组分上。
该组分还可以经由非共价共轭方法与纳米载体共轭。例如,带负电荷的抗原或免疫抑制剂可以通过静电吸附与带正电荷的纳米载体共轭。含有金属配体的组分还可以经由金属-配体络合物与含有金属络合物的纳米载体共轭。
在多个实施例中,该组分可以在组装该合成纳米载体之前附接至聚合物(例如聚乳酸-嵌段-聚乙二醇)上,或可以形成该合成纳米载体而使得反应性或可活化基团在它的表面上。在后一种情况下,可以制备该组分以使其具有与由这些合成纳米载体的表面呈现的附接化学性质相容的基团。在其他实施例中,可以使用一种适合的连接物将肽组分附接至VLP或脂质体上。连接物是能够将两个分子连接在一起的化合物或试剂。在一个实施例中,该连接物可以是在赫曼森(Hermanson)2008中所描述的同双功能或异双功能试剂。例如,可以在EDC存在下用同双功能连接物(己二酸二酰肼(ADH))处理表面上含有羧基的VLP或脂质体合成纳米载体,以形成具有ADH连接物的相应合成纳米载体。然后使所得被ADH连接的合成纳米载体经由NC上的该ADH连接物的另一端与含有酸基团的肽组分共轭,以产生相应的VLP或脂质体肽共轭物。
针对可获得的共轭方法的详细描述,参见2008年由学术出版公司(AcademicPress,Inc.)出版的第2版,赫曼森·G T(Hermanson G T)“生物共轭技术(BioconjugateTechniques)”。除了共价附接之外,该组分可以通过吸附至预先形成的合成纳米载体上来偶联、或它可以通过在该合成纳米载体形成过程中进行封装来偶联。
在此所提供的任何免疫抑制剂可以与该合成纳米载体偶联。免疫抑制剂包括但不限于:抑制素;mTOR抑制剂,如雷帕霉素或一种雷帕霉素类似物;TGF-β信号剂;TGF-β受体激动剂;组蛋白去乙酰化酶(HDAC)抑制剂;皮质类固醇类;线粒体功能抑制剂,如鱼藤酮;P38抑制剂;NF-κβ抑制剂;腺苷受体激动剂;前列腺素E2激动剂;磷酸二酯酶抑制剂,如磷酸二酯酶4抑制剂;蛋白酶体抑制剂;激酶抑制剂;G-蛋白偶联受体激动剂;G-蛋白偶联受体拮抗剂;糖皮质激素类;类视黄醇类;细胞因子抑制剂;细胞因子受体抑制剂;细胞因子受体活化剂;过氧化物酶体增殖物激活受体拮抗剂;过氧化物酶体增殖物激活受体激动剂;组蛋白去乙酰化酶抑制剂;钙调磷酸酶抑制剂;磷酸酶抑制剂,以及氧化的ATP。免疫抑制剂还包括IDO、维生素D3、环孢霉素A、芳香烃受体抑制剂、白藜芦醇、硫唑嘌呤、6-巯基嘌呤、阿司匹林、尼氟酸、雌三醇、雷公藤甲素、白细胞介素(例如,IL-1、IL-10)、环孢霉素A、siRNA靶向细胞因子或细胞因子受体等。
抑制素的实例包括:阿托伐他汀(atorvastatin)( )、西立伐他汀(cerivastatin)、氟伐他汀(fluvastatin)(XL)、洛伐他汀(lovastatin)( )、美伐他汀(mevastatin)匹伐他汀(pitavastatin)罗苏伐他汀(rosuvastatin)罗苏伐他汀以及辛伐他汀(simvastatin)
mTOR抑制剂的实例包括:雷帕霉素和其类似物(例如,CCL-779、RAD001、AP23573、C20-甲代烯丙基雷帕霉素(C20-Marap)、C16-(S)-丁基磺酰氨基雷帕霉素(C16-BSrap)、C16-(S)-3-甲基吲哚雷帕霉素(C16-iRap)(贝尔(Bayle)等人,化学与生物学(Chemistry&Biology)2006,13:99-107))、AZD8055、BEZ235(NVP-BEZ235)、大黄根酸(大黄酚)、德福罗莫司(deforolimus)(MK-8669)、依维莫司(everolimus)(RAD0001)、KU-0063794、PI-103、PP242、替西罗莫司(temsirolimus)以及WYE-354(可获自赛立克公司(Selleck),休斯顿(Houston),德克萨斯州(TX),美国(USA))。
TGF-β信号剂的实例包括:TGF-β配体(例如,活化素A、GDF1、GDF11、骨形态发生蛋白、nodal、TGF-β)和它们的受体(例如,ACVR1B、ACVR1C、ACVR2A、ACVR2B、BMPR2、BMPR1A、BMPR1B、TGFβRI、TGFβRII)、R-SMADS/co-SMADS(例如,SMAD1、SMAD2、SMAD3、SMAD4、SMAD5、SMAD8)、以及配体抑制剂(例如,卵泡抑素、头蛋白、腱蛋白、DAN、lefty、LTBP1、THBS1、核心蛋白聚糖)。
线粒体功能抑制剂的实例包括:苍术苷(二钾盐)、米酵菌酸(三铵盐)、羰基氰化间氯苯腙、羧基苍术苷(例如,来自苍术属植物(Atractylis gummifera))、CGP-37157、(-)-鱼藤素(例如,来自栓皮豆(Mundulea sericea))、F16、己糖激酶II VDAC结合域肽、寡霉素、鱼藤酮、Ru360、SFK1、以及缬氨霉素(例如,来自极暗黄链霉菌(Streptomyces fulvissimus))(EMD4生物科学(EMD4Biosciences),美国(USA))。
P38抑制剂的实例包括:SB-203580(4-(4-氟苯基)-2-(4-甲基亚硫酰基苯基)-5-(4-吡啶基)1H-咪唑)、SB-239063(反式-1-(4-羟基环己基)-4-(氟苯基)-5-(2-甲氧基-嘧啶-4-基)咪唑)、SB-220025(5-(2-氨基-4-嘧啶基)-4-(4-氟苯基)-1-(4-哌啶基)咪唑))、以及ARRY-797。
NF(例如,NK-κβ)抑制剂的实例包括:IFRD1、2-(1,8-萘啶-2-基)-苯酚、5-氨基水杨酸、BAY 11-7082、BAY 11-7085、CAPE(咖啡酸苯乙酯)、马来酸二乙酯、IKK-2抑制剂IV、IMD 0354、乳胞素(lactacystin)、MG-132[Z-Leu-Leu-Leu-CHO]、NFκB活化抑制剂III、NF-κB活化抑制剂II、JSH-23、小白菊内酯(parthenolide)、氧化苯胂(PAO)、PPM-18、吡咯烷二硫代氨基甲酸铵盐、QNZ、RO 106-9920、楝酰胺(rocaglamide)、楝酰胺AL、楝酰胺C、楝酰胺I、楝酰胺J、洛克米兰醇(rocaglaol)、(R)-MG-132、水杨酸钠、雷公藤甲素(PG490)、蟛蜞菊内酯(wedelolactone)。
腺苷受体激动剂的实例包括CGS-21680和ATL-146e。
前列腺素E2激动剂的实例包括E-前列腺素类激素2(E-Prostanoid 2)和E-前列腺素类激素4。
磷酸二酯酶抑制剂(非选择性和选择性抑制剂)的实例包括:咖啡因、氨茶碱、IBMX(3-异丁基-1-甲基黄嘌呤)、副黄嘌呤、己酮可可碱、可可碱、茶碱、甲基化的黄嘌呤类、长春西汀(vinpocetine)、EHNA(赤-9-(2-羟基-3-壬基)腺嘌呤)、阿那格雷(anagrelide)、伊诺昔酮(enoximone)(PERFANTM)、米利酮(milrinone)、左昔孟坦(levosimendon)、松叶菊碱(mesembrine)、异丁司特(ibudilast)、吡拉米司特(piclamilast)、木犀草素(luteolin)、屈他维林(drotaverine)、罗氟司特(roflumilast)(DAXASTM、DALIRESPTM)、西地那非(sildenafil)( )、他达拉非(tadalafil)伐地那非(vardenafil)乌地那非(udenafil)、阿伐那非(avanafil)、淫羊藿苷(icariin)、4-甲基哌嗪、以及吡唑并嘧啶-7-1。
蛋白酶体抑制剂的实例包括硼替佐米(bortezomib)、双硫仑(disulfiram)、表儿茶素-3-没食子酸盐、以及盐孢菌酰胺A(salinosporamide A)。
激酶抑制剂的实例包括:贝伐单抗(bevacizumab)、BIBW 2992、西妥昔单抗(cetuxima)伊马替尼(imatinib)曲妥单抗(trastuzumab)吉非替尼(gefitinib)兰尼单抗(ranibizumab)哌加他尼(pegaptanib)、索拉非尼(sorafenib)、达沙替尼(dasatinib)、舒尼替尼(sunitinib)、埃罗替尼(erlotinib)、尼罗替尼(nilotinib)、拉帕替尼(lapatinib)、帕尼单抗(panitumumab)、凡德他尼(vandetanib)、E7080、帕唑帕尼(pazopanib)、木利替尼(mubritinib)。
糖皮质激素类的实例包括:氢化可的松(皮质醇)、醋酸可的松、强的松(prednisone)、泼尼松龙(prednisolone)、甲泼尼龙(methylprednisolone)、地塞米松(dexamethasone)、倍他米松(betamethasone)、曲安西龙(triamcinolone)、倍氯米松(beclometasone)、醋酸氟氢可的松、醋酸脱氧皮质酮(DOCA)、以及醛固酮。
类视黄醇类的实例包括:视黄醇、视黄醛、维甲酸(视黄酸,RETIN-)、异维甲酸阿利维甲酸(alitretinoin)依曲替酯(etretinate)(TEGISONTM)和它的代谢物阿维A(acitretin)他扎罗汀(tazarotene)贝沙罗汀(bexarotene)以及阿达帕林(adapalene)
细胞因子抑制剂的实例包括IL1ra、IL1受体拮抗剂、IGFBP、TNF-BF、尿调节素(uromodulin)、α-2-巨球蛋白、环孢霉素A、戊烷脒、以及己酮可可碱
过氧化物酶体增殖物活化的受体拮抗剂的实例包括GW9662、PPARγ拮抗剂III、G335、T0070907(EMD4生物科学(EMD4Biosciences),美国(USA))。
过氧化物酶体增殖物活化的受体激动剂的实例包括:吡格列酮(pioglitazone)、环格列酮(ciglitazone)、氯贝特(clofibrate)、GW1929、GW7647、L-165,041、LY 171883、PPARγ活化剂、Fmoc-Leu、曲格列酮(troglitazone)、以及WY-14643(EMD4生物科学(EMD4Biosciences),美国(USA))。
组蛋白去乙酰化酶抑制剂的实例包括:异氢肟酸类(或异氢肟酸酯类),如曲古抑菌素A(trichostatin A);环状四肽类(如曲破辛B(trapoxin B))和缩肽类;苯甲酰胺类;亲电酮类;脂肪族酸化合物,如苯基丁酸酯和丙戊酸;异羟肟酸类,如伏立诺他(vorinostat)(SAHA)、贝林司他(belinostat)(PXD101)、LAQ824、以及帕比司他(panobinostat)(LBH589);苯甲酰胺类,如恩替诺特(entinostat)(MS-275)、CI994、以及莫替司他(mocetinostat)(MGCD0103)、烟酰胺;NAD的衍生物、二氢香豆素、萘并吡喃酮(naphthopyranonc)、以及2-羟基萘醛类。
钙调磷酸酶抑制剂的实例包括环孢霉素、吡美莫司(pimecrolimus)、伏环孢素(voclosporin)、以及他克莫司(tacrolimus)。
磷酸酶抑制剂的实例包括:BN82002盐酸盐、CP-91149、花萼海绵诱癌素A(calyculin A)、斑蝥酸(cantharidic acid)、斑蝥素(cantharidin)、氯氰菊酯(cypermethrin)、乙基-3,4-迪磷他汀(ethyl-3,4-dephostatin)、福司曲星(fostriecin)钠盐、MAZ51、甲基-3,4-迪磷他汀(methyl-3,4-dephostatin)、NSC 95397、去甲斑蝥素(norcantharidin)、来自凹形原甲藻(prorocentrum concavum)的冈田酸铵盐、冈田酸、冈田酸钾盐、冈田酸钠盐、氧化苯胂、各种磷酸酶抑制剂混合、蛋白质磷酸酶1C、蛋白质磷酸酶2A抑制蛋白、蛋白质磷酸酶2A1、蛋白质磷酸酶2A2、原钒酸钠。
在一些实施例中,在此所描述的这些治疗性蛋白APC可呈递抗原也与合成纳米载体偶联。在一些实施例中,这些治疗性蛋白APC可呈递抗原与这些免疫抑制剂偶联至其上的相同或不同的合成纳米载体偶联。在其他实施例中,这些治疗性蛋白APC可呈递抗原不与任何合成纳米载体偶联。治疗性蛋白APC可呈递抗原包括在此提供的任何治疗性蛋白、或其片段或衍生物。
治疗性蛋白包括但不限于:可输注的治疗性蛋白、酶、酶辅助因子、激素、凝血因子、细胞因子和干扰素、生长因子、单克隆抗体、及多克隆抗体(例如,作为替代疗法向受试者给予的多克隆抗体)、以及与庞贝氏病相关的蛋白质(例如,阿葡糖苷酶α、rhGAA(例如,Myozyme和Lumizyme(健赞公司(Genzyme)))。治疗性蛋白还包括涉及在凝血级联系统中的蛋白质。治疗性蛋白包括但不限于:因子VIII、因子VII、因子IX、因子V、血管性血友病因子、von Heldebrant因子、组织型纤溶酶原激活物、胰岛素、生长激素、α促红细胞生成素、VEGF、促血小板生成素、溶菌酶、抗凝血酶等等。治疗性蛋白还包括脂肪因子类,如瘦素和脂联素。如下和在此其他地方描述了治疗性蛋白的其他实例。还包括作为抗原而提供的任何治疗性蛋白的片段或衍生物。
在具有溶酶体贮积症的受试者的酶替代疗法中使用的治疗性蛋白的实例包括但不限于:用于治疗高雪病的伊米苷酶(例如,CEREZYMETM)、用于治疗法布里病的a-半乳糖苷酶A(a-gal A)(例如,阿加糖酶β、FABRYZYMETM)、用于治疗庞贝氏病的酸性a-葡糖苷酶(GAA)(例如,阿葡糖苷酶α、LUMIZYMETM、MYOZYMETM)、用于治疗粘多糖病的芳基硫酸酯酶B(例如,拉罗尼酶(laronidase)、ALDURAZYMETM、艾度硫酸酯酶、ELAPRASETM、芳基硫酸酯酶B、NAGLAZYMETM)。
酶的实例包括氧化还原酶、转移酶、水解酶、裂解酶、异构酶、以及连接酶。
激素的实例包括:褪黑素(N-乙酰基-5-甲氧基色胺)、血清素、甲状腺素(或四碘甲状腺原氨酸)(一种甲状腺激素)、三碘甲状腺原氨酸(一种甲状腺激素)、肾上腺素(Epinephrine)(或肾上腺素(adrenaline))、去甲肾上腺素(Norepinephrine)(或去甲肾上腺素(noradrenaline))、多巴胺(或催乳素抑制激素)、抗苗勒氏管激素(或苗勒氏管抑制因子或激素)、脂联素、促肾上腺皮质激素(Adrenocorticotropic hormone)(或促肾上腺皮质激素(corticotropin))、血管紧张素原和血管紧张素、抗利尿激素(Antidiuretichormone)(或加压素(vasopressin)、精氨酸加压素(arginine vasopressin))、心房利钠肽(或心房肽)、降钙素、缩胆囊素(Cholecystokinin)、促肾上腺皮质激素释放激素、红细胞生成素、促卵泡激素、胃泌素、胃饥饿素(Ghrelin)、胰高血糖素(Glucagon)、胰高血糖素样肽(GLP-1)、GIP、促性腺激素释放激素、生长激素释放激素、人绒毛膜促性腺激素、人胎盘催乳素、生长激素、抑制素(Inhibin)、胰岛素、胰岛素样生长因子(或生长调节素)、瘦素、促黄体激素、促黑素细胞激素、阿立新(Orexin)、催产素、甲状旁腺激素、催乳素、松弛素、分泌素、促生长素抑制素、促血小板生成素、促甲状腺激素(或促甲状腺素)、促甲状腺素释放激素、皮质醇、醛固酮、睾酮、脱氢表雄酮、雄烯二酮、二氢睾酮、雌二醇、雌酮、雌三醇、黄体酮、骨化三醇(1,25-二羟基维生素D3)、骨化二醇(25-羟基维生素D3)、前列腺素类、白三烯类、前列腺环素、凝血噁烷、催乳素释放激素、促脂解素、脑利钠肽、神经肽Y、组胺、内皮素、胰多肽、肾素、以及脑啡肽。
血液和凝血因子的实例包括:因子I(纤维蛋白原)、因子II(凝血酶原)、组织因子、因子V(促凝血球蛋白原、易变因子)、因子VII(稳定因子、前转变素)、因子VIII(抗血友病球蛋白)、因子IX(克雷司马斯因子(Christmas factor)或血浆促凝血酶原激酶组分)、因子X(斯图亚特因子(Stuart-Prower factor))、因子Xa、因子XI、因子XII(哈格曼因子(Hagemanfactor))、因子XIII(纤维蛋白稳定因子)、血管性血友病因子、前激肽释放酶(费莱彻因子(Fletcher factor))、高分子量激肽原(HMWK)(菲茨杰拉德因子)、纤连蛋白、纤维蛋白、凝血酶、抗凝血酶III、肝素辅助因子II、蛋白C、蛋白S、蛋白Z、蛋白Z相关蛋白酶抑制剂(ZPI)、纤溶酶原、α2-抗纤维蛋白溶酶、组织型纤溶酶原激活物(tPA)、尿激酶、纤溶酶原激活物抑制剂-1(PAI1)、纤溶酶原激活物抑制剂-2(PAI2)、癌性促凝物质、以及阿法依泊汀(益比奥(Epogen)、普罗克里特(Procrit))。
细胞因子的实例包括:淋巴因子、白细胞介素、及趋化因子、1型细胞因子(如IFN-γ、TGF-β)、以及2型细胞因子(如IL-4、IL-10、以及IL-13)。
生长因子的实例包括:肾上腺髓质素(AM)、血管生成素(Ang)、自分泌运动因子、骨形态发生蛋白(BMP)、脑源性神经营养因子(BDNF)、表皮生长因子(EGF)、红细胞生成素(EPO)、成纤维细胞生长因子(FGF)、胶质细胞系源性神经营养因子(GDNF)、粒细胞集落刺激因子(G-CSF)、粒细胞巨噬细胞集落刺激因子(GM-CSF)、生长分化因子-9(GDF9)、肝细胞生长因子(HGF)、肝细胞瘤源性生长因子(HDGF)、胰岛素样生长因子(IGF)、促移行因子、肌生长抑制素(GDF-8)、神经生长因子(NGF)和其他神经营养蛋白、血小板源性生长因子(PDGF)、促血小板生成素(TPO)、α-转化生长因子(TGF-α)、β-转化生长因子(TGF-β)、α-肿瘤坏死因子(TNF-α)、血管内皮生长因子(VEGF)、Wnt信号通路、胎盘生长因子(PlGF)、[(胎牛生长激素)](FBS)、IL-1、IL-2、IL-3、IL-4、IL-5、IL-6、以及IL-7。
单克隆抗体的实例包括:阿巴伏单抗(Abagovomab)、阿昔单抗(Abciximab)、阿达木单抗(Adalimumab)、阿德木单抗(Adecatumumab)、阿非莫单抗(Afelimomab)、阿夫土珠(Afutuzumab)、培化阿珠单抗(Alacizumab pegol)、ALD、阿仑单抗(Alemtuzumab)、喷替酸阿妥莫单抗(Altumomab pentetate)、麻安莫单抗(Anatumomab mafenatox)、安芦珠单抗(Anrukinzumab)、抗胸腺细胞球蛋白、阿泊珠单抗(Apolizumab)、阿西莫单抗(Arcitumomab)、阿塞珠单抗(Aselizumab)、那他珠单抗(Atlizumab)(托珠单抗(tocilizumab))、阿托木单抗(Atorolimumab)、巴品珠单抗(Bapineuzumab)、巴利昔单抗(Basiliximab)、巴维昔单抗(Bavituximab)、贝妥莫单抗(Bectumomab)、贝利木单抗(Belimumab)、贝那利珠单抗(Benralizumab)、柏替木单抗(Bertilimumab)、贝索单抗(Besilesomab)、贝伐单抗(Bevacizumab)、比西单抗(Biciromab)、比伐珠单抗-美登素(Bivatuzumab mertansine)、兰妥莫单抗(Blinatumomab)、贝伦妥单抗-维多汀(Brentuximab vedotin)、布雷奴单抗(Briakinumab)、卡那单抗(Canakinumab)、莫坎妥珠单抗(Cantuzumab mertansine)、卡罗单抗喷地肽(Capromab pendetide)、卡妥索单抗(Catumaxomab)、西利珠单抗(Cedelizumab)、赛妥珠单抗(Certolizumab pegol)、西妥昔单抗(Cetuximab)、泊西他珠单抗(Citatuzumab bogatox)、西妥木单抗(Cixutumumab)、克立昔单抗(Clenoliximab)、克伐珠单抗(Clivatuzumab tetraxetan)、可那木单抗(Conatumumab)、达西珠单抗(Dacetuzumab)、达利珠单抗(Daclizumab)、达雷木单抗(Daratumumab)、地诺单抗(Denosumab)、地莫单抗(Detumomab)、阿托度单抗(Dorlimomabaritox)、达利珠单抗(Dorlixizumab)、依美昔单抗(Ecromeximab)、依库珠单抗(Eculizumab)、埃巴单抗(Edobacomab)、依决洛单抗(Edrecolomab)、依法利珠单抗(Efalizumab)、依芬古单抗(Efungumab)、依洛珠单抗(Elotuzumab)、艾西莫单抗(Elsilimomab)、培化恩莫单抗(Enlimomab pegol)、西艾匹莫单抗(Epitumomabcituxetan)、依帕珠单抗(Epratuzumab)、厄利珠单抗(Erlizumab)、厄妥索单抗(Ertumaxomab)、埃达珠单抗(Etaracizumab)、艾维单抗(Exbivirumab)、法索单抗(Fanolesomab)、法拉莫单抗(Faralimomab)、法利珠单抗(Farletuzumab)、泛维珠单抗(Felvizumab)、非扎奴单抗(Fezakinumab)、芬妥木单抗(Figitumumab)、芳妥珠单抗(Fontolizumab)、福拉韦单抗(Foravirumab)、夫苏木单抗(Fresolimumab)、加利昔单抗(Galiximab)、罗氏单抗(Gantenerumab)、加维莫单抗(Gavilimomab)、吉妥珠单抗-奥唑米星(Gemtuzumab ozogamicin)、GC1008、吉瑞昔单抗(Girentuximab)、格雷帕珠单抗-维德汀(Glembatumumab vedotin)、戈利木单抗(Golimumab)、戈利昔单抗(Gomiliximab)、伊巴珠单抗(Ibalizumab)、替伊莫单抗(Ibritumomab tiuxetan)、伊戈伏单抗(Igovomab)、英西单抗(Imciromab)、英夫利昔单抗(Infliximab)、英妥木单抗(Intetumumab)、伊诺莫单抗(Inolimomab)、伊珠单抗-奥加米星(Inotuzumab ozogamicin)、伊匹单抗(Ipilimumab)、伊妥木单抗(Iratumumab)、凯利昔单抗(Keliximab)、拉贝珠单抗(Labetuzumab)、来金珠单抗(Lebrikizumab)、来马索单抗(Lemalesomab)、乐德木单抗(Lerdelimumab)、来沙木单抗(Lexatumumab)、利韦单抗(Libivirumab)、林妥珠单抗(Lintuzumab)、罗佛珠单抗-美登素(Lorvotuzumab mertansine)、鲁卡木单抗(Lucatumumab)、鲁昔单抗(Lumiliximab)、马帕木单抗(Mapatumumab)、马司莫单抗(Maslimomab)、马妥珠单抗(Matuzumab)、美泊利单抗(Mepolizumab)、美替木单抗(Metelimumab)、米拉珠单抗(Milatuzumab)、明瑞莫单抗(Minretumomab)、米妥莫单抗(Mitumomab)、莫罗木单抗(Morolimumab)、莫维珠单抗(Motavizumab)、莫罗单抗-CD3(Muromonab-CD3)、他那可洛单抗(Nacolomab tafenatox)、他那莫单抗(Naptumomab estafenatox)、那他珠单抗(Natalizumab)、奈巴库单抗(Nebacumab)、奈昔木单抗(Necitumumab)、奈瑞莫单抗(Nerelimomab)、尼妥珠单抗(Nimotuzumab)、莫诺非莫单抗(Nofetumomab merpentan)、奥瑞珠单抗(Ocrelizumab)、奥度莫单抗(Odulimomab)、奥法木单抗(Ofatumumab)、奥拉雷单抗(Olaratumab)、奥马珠单抗(Omalizumab)、莫奥珠单抗(Oportuzumab monatox)、奥戈伏单抗(Oregovomab)、奥昔珠单抗(Otelixizumab)、帕吉昔单抗(Pagibaximab)、帕利珠单抗(Palivizumab)、帕尼单抗(Panitumumab)、帕诺库单抗(Panobacumab)、帕考珠单抗(Pascolizumab)、帕尼单抗(Pemtumomab)、帕妥珠单抗(Pertuzumab)、培克珠单抗(Pexelizumab)、平妥单抗(Pintumomab)、普立昔单抗(Priliximab)、普托木单抗(Pritumumab)、瑞非韦鲁(Rafivirumab)、礼来单抗(Ramucirumab)、来尼珠单抗(Ranibizumab)、瑞希巴库(Raxibacumab)、瑞加韦单抗(Regavirumab)、瑞利珠单抗(Reslizumab)、利妥木单抗(Rilotumumab)、利妥珠单抗(Rituximab)、罗妥木单抗(Robatumumab)、罗利珠单抗(Rontalizumab)、罗韦来单抗(Rovelizumab)、芦利珠单抗(Ruplizumab)、喷地肽沙妥莫单抗(Satumomab pendetide)、司韦单抗(Sevirumab)、西罗珠单抗(Sibrotuzumab)、西法木单抗(Sifalimumab)、司妥昔单抗(Siltuximab)、希普利珠单抗(Siplizumab)、苏兰珠单抗(solanezumab)、索尼普单抗(Sonepcizumab)、索土珠单抗(Sontuzumab)、司他芦单抗(Stamulumab)、硫索单抗(Sulesomab)、他珠单抗(Tacatuzumab tetraxetan)、他度珠单抗(Tadocizumab)、他利珠单抗(Talizumab)、他尼珠单抗(Tanezumab)、帕他莫单抗(Taplitumomab paptox)、特非珠单抗(Tefibazumab)、阿替莫单抗(Telimomab aritox)、替妥莫单抗(Tenatumomab)、替奈昔单抗(Teneliximab)、替利珠单抗(Teplizumab)、替西莫单抗(Ticilimumab)(替西木单抗(tremelimumab))、替加珠单抗(Tigatuzumab)、托珠单抗(Tocilizumab)(阿替珠单抗(atlizumab))、托利珠单抗(Toralizumab)、托西莫单抗(Tositumomab)、曲妥珠单抗(Trastuzumab)、曲美木单抗(Tremelimumab)、西莫白细胞介素单抗(Tucotuzumab celmoleukin)、妥韦单抗(Tuvirumab)、乌珠单抗(Urtoxazumab)、优特克单抗(Ustekinumab)、伐利昔单抗(Vapaliximab)、维多珠单抗(Vedolizumab)、维妥珠单抗(Veltuzumab)、维帕莫单抗(Vepalimomab)、维西珠单抗(Visilizumab)、伏洛昔单抗(Volociximab)、伏妥莫单抗(Votumumab)、扎鲁木单抗(Zalutumumab)、扎木单抗(Zanolimumab)、齐拉木单抗(Ziralimumab)、以及阿佐莫单抗(Zolimomab aritox)。
输注疗法或可注射的治疗性蛋白的实例包括:例如,塔西单抗(Tocilizumab)(罗氏公司(Roche)/)、α-1抗胰蛋白酶(卡美达公司(Kamada)/AAT)、(Affymax和Takeda,合成肽)、白蛋白干扰素α-2b(诺华公司(Novartis)/ZalbinTM)、(嫁接集团(Pharming Group),C1抑制剂替代疗法)、替莫瑞林(tesamorelin)(治疗技术公司(Theratechnologies)/Egrifta,合成生长激素释放因子)、奥瑞珠单抗(ocrelizumab)(遗传技术公司(Genentech)、罗氏公司(Roche)以及生物遗传公司(Biogen))、杯利单抗(belimumab)(葛兰素史克公司(GlaxoSmithKline)/)、聚乙二醇重组尿酸酶(Savient制药公司/KrystexxaTM)、α-他利苷酶(Protalix公司/Uplyso)、阿加糖酶α(夏尔公司(Shire)/)、葡糖脑苷脂酶α(夏尔公司(Shire))。
对根据本发明的方面有用的另外的治疗性蛋白对于本领域普通技术人员而言将是显而易见的,并且本发明在此方面是不受限的。
在一些实施例中,可以对一种组分(如抗原或免疫抑制剂)进行分离。分离是指该成分与它的天然环境分离并且以容许对它进行鉴定或使用的足够量存在。这意味着,例如,该成分可以(i)通过表达克隆选择性地产生或(ii)如通过色谱法或电泳进行纯化。分离的成分可以是基本上纯的,但是不需要如此。由于在药物制剂中分离的成分可以与药学上可接受的赋形剂相混合,按该制剂的重量计该成分可以仅包含小的百分比。虽然如此,该成分是分离的原因在于,它已经从在活系统中可能与其结合的物质中分离出来,即从其他脂质或蛋白质中分离出来。可以对在此提供的任何成分进行分离并且以分离的形式包含在这些组合物中。
D.制造和使用本发明的组合物和相关方法的方法
可以使用本领域中已知的各种各样的方法制备合成纳米载体。例如,可以通过如纳米沉淀、使用流体通道的流动聚焦、喷雾干燥、单和双乳液溶剂蒸发、溶剂萃取、相分离、研磨、微乳液步骤、微制造、纳米制造、牺牲层、简单和复杂凝聚法的方法、以及本领域的那些普通技术人员熟知的其他方法形成合成纳米载体。可替代地或另外地,已经说明了用于单分散半导体,传导性的、磁性的、有机的、以及其他纳米材料的水性和有机溶剂合成(Pellegrino(佩莱格里诺)等人,2005,小物质,1:48;Murray(莫雷)等人,2000,材料科学年度评论,30:545;以及Trindade(特林达德)等人,2001,材料化学,13:3843)。在文献中已经描述了另外的方法(参见,例如,多布罗夫(Doubrow)编著,“医药中的微胶囊和纳米颗粒(Microcapsules and Nanoparticles in Medicine and Pharmacy)”,CRC出版社,博卡拉顿(Boca Raton),1992;马西威兹(Mathiowitz)等人,1987,控释期刊(J.Control.Release),5:13;马西威兹(Mathiowitz)等人,1987,反应性聚合物(ReactivePolymers),6:275;以及马西威兹(Mathiowitz)等人,1988,应用聚合物科学期刊(J.Appl.Polymer Sci.),35:755;美国专利5578325和6007845;P·保利赛利(P.Paolicelli)等人,“可以有效结合并递送病毒样颗粒的表面修饰的基于PLGA的纳米颗粒(Surface-modified PLGA-based Nanoparticles that can Efficiently Associateand Deliver Virus-like Particles)”,纳米医学(Nanomedicine),5(6):843-853(2010))。
可以使用各种方法将各种材料封装在所令人希望的合成纳米载体中,这些方法包括但不限于:C·阿斯泰特(C.Astete)等人,“PLGA纳米颗粒的合成和表征(Synthesis andcharacterization of PLGA nanoparticles)”生物材料科学期刊(J.Biomater.Sci.)聚合物版,第17卷,第3期,第247-289页(2006);K·阿芙古斯塔基斯(K.Avgoustakis)“PEG化的聚(丙交酯)和聚(丙交酯-共-乙交酯)纳米颗粒:制备、特性以及在药物递送中的可能应用(Pegylated Poly(Lactide)and Poly(Lactide-Co-Glycolide)Nanoparticles:Preparation,Properties and Possible Applications in Drug Delivery)”当前药物递送(Current Drug Delivery)1:321-333(2004);里斯·C(C.Reis)等人,“纳米封装I.用于制备载药聚合物纳米颗粒的方法(Nanoencapsulation I.Methods for preparation ofdrug-loaded polymeric nanoparticles)”纳米医学(Nanomedicine)2:8-21(2006);P·保利赛利(P.Paolicelli)等人,“可以有效结合和递送病毒样颗粒的表面修饰的基于PLGA的纳米颗粒(Surface-modified PLGA-based Nanoparticles that can EfficientlyAssociate and Deliver Virus-like Particles)”纳米医学(Nanomedicine),5(6):843-853(2010)。可以使用其他适合于将材料封装至合成纳米载体中的方法,这些方法包括但不限于披露在昂格尔(Unger)的美国专利6,632,671(2003年10月14日)中的方法。
在某些实施例中,通过纳米沉淀工艺或喷雾干燥来制备合成纳米载体。可以改变在制备合成纳米载体中使用的条件以产生具有所希望的大小和特性(例如,疏水性、亲水性、外部形态学、“粘性”、形状等等)的颗粒。制备这些合成纳米载体的方法和使用的条件(例如,溶剂、温度、浓度、空气流速等等)可以取决于有待偶联至这些合成纳米载体上的材料和/或该聚合物基质的组成。
如果通过任何以上方法制备的颗粒具有在希望的范围外的大小范围,那么可以按大小分类这些颗粒,例如使用一个筛。
本发明的合成纳米载体的成分(即,组分)(如构成一个免疫特征表面的部分、靶向部分、聚合物基质、抗原、免疫抑制剂等)可以例如通过一个或多个共价键偶联至整体的合成纳米载体上或可以借助一个或多个连接物来偶联。使合成纳米载体功能化的另外方法可以由以下文献改编而来:萨尔茨曼(Saltzman)等人的公布的美国专利申请2006/0002852、戴斯蒙(DeSimone)等人的公布的美国专利申请2009/0028910、或默西(Murthy)等人的公布的国际专利申请WO/2008/127532 A1。
可替代地或另外地,可以经由非共价相互作用使合成纳米载体直接地或间接地偶联至组分上。在非共价的实施例中,通过非共价相互作用介导非共价偶联,这些非共价相互作用包括但不限于:电荷相互作用、亲和相互作用、金属配位、物理吸附、主-客体相互作用、疏水相互作用、TT堆积相互作用、氢键相互作用、范德华相互作用、磁相互作用、静电相互作用、偶极-偶极相互作用、和/或其组合。此类偶联可以安排在本发明合成纳米载体的一个外表面或一个内表面上。在多个实施例中,封装和/或吸附是偶联的形式。在多个实施例中,本发明的这些合成纳米载体可以通过在相同媒介物或递送系统中混合而与抗原相组合。
可以使用传统的药物混合方法组合多个群体的合成纳米载体以形成根据本发明的药物剂型。这些方法包括液体-液体混合,其中两种或更多种各自含有一个或多个纳米载体子集的悬浮液被直接组合或经由一个或多个含有稀释剂的容器被集合在一起。因为合成纳米载体还可以以粉末形式生产或贮存,所以可以进行干燥的粉末-粉末混合,因为可以将两种或更多种粉末再悬浮于共同的介质中。取决于纳米载体的特性和它们的相互作用潜力,一种或另一种混合途径可能也有优势。
包含合成纳米载体的典型的发明组合物可以包含无机或有机缓冲剂(例如,磷酸、碳酸、乙酸、或柠檬酸的钠盐或钾盐)和pH调节剂(例如,盐酸、氢氧化钠或氢氧化钾、柠檬酸或乙酸的盐、氨基酸和它们的盐)、抗氧化剂(例如,抗坏血酸、α-生育酚)、表面活性剂(例如,聚山梨酯20、聚山梨酯80、聚氧乙烯9-10壬基酚、去氧胆酸钠)、溶液和/或低温/冻干稳定剂(例如,蔗糖、乳糖、甘露醇、海藻糖)、渗透调节剂(例如,盐类或糖类)、抗细菌剂(例如,苯甲酸、苯酚、庆大霉素)、消泡剂(例如,聚二甲基硅酮(polydimethylsilozone))、防腐剂(例如,硫柳汞、2-苯氧乙醇、EDTA)、聚合物稳定剂和粘度调节剂(例如,聚乙烯吡咯酮、泊洛沙姆488、羧甲基纤维素)、以及共溶剂(例如,甘油、聚乙二醇、乙醇)。
根据本发明的组合物包含与药学上可接受的赋形剂组合的本发明的合成纳米载体。可以使用常规药物制造和配制技术制造这些组合物,以实现有用的剂型。适合用于实践本发明的技术可以在以下文献中找到:爱德华·L保罗(Edward L.Paul),维克多·A.Atiemo-Obeng(Victor A.Atiemo-Obeng)以及苏珊娜·M.Kresta(Suzanne M.Kresta)编著的工业混合手册:科学与实践(Handbook of Industrial Mixing:Science andPractice),2004约翰威利国际出版公司(John Wiley&Sons,Inc.);和奥斯丁·M.E.(M.E.Auten)编著的制药学:剂型设计科学(Pharmaceutics:The Science of Dosage FormDesign),第2版,2001,丘吉尔利文斯通出版社(Churchill Livingstone)。在一个实施例中,将本发明的合成纳米载体与防腐剂一起悬浮在注射用无菌盐水溶液中。
应当理解可以按任何适合的方式制造本发明的这些组合物,并且本发明绝不局限于可以使用在此描述的方法所产生的组合物。适当方法的选择可能需要注意被结合的特定部分的特性。
在一些实施例中,本发明的合成纳米载体是在无菌条件下制造或最后进行灭菌。这可以确保所得的组合物是无菌的并且是非感染性的,因此当与非无菌的组合物相比时提高了安全性。这提供了有价值的安全措施,尤其是当接受合成纳米载体的受试者具有免疫缺陷、正在遭受感染、和/或易受感染时。在一些实施例中,取决于配制策略,可以将本发明的合成纳米载体冻干并且储存在悬浮液中或呈冻干粉末形式,持续延长的时间而无活性损失。
可以通过各种途径给予本发明的这些组合物,这些途径包括但不限于皮下、鼻内、静脉内、腹膜内、肌肉内、透粘膜、透粘膜、舌下、直肠、眼睛、肺部、皮肤内、经皮肤、经皮或真皮内或这些途径的组合。给予途径还包括通过吸入或肺气溶胶来进行的给予。用于制备气溶胶递送系统的技术是本领域技术人员众所周知的(参见,例如夏拉(Sciarra)和库替(Cutie),“气溶胶(Aerosols),”雷明顿的药物科学(Remington’s PharmaceuticalSciences),第18版,1990,第1694-1712页;该文献通过引用的方式结合在此)。
本发明的作为基于细胞的治疗而提供的治疗性蛋白可以通过肠胃外、动脉内注射、鼻内或静脉内给予或通过注射至淋巴结或眼前房或通过局部给予至感兴趣的器官或组织而进行给予。可以通过皮下、鞘内、心室内、肌肉内、腹膜内、冠状动脉内、胰腺内、肝内或支气管注射来进行给予。
本发明的这些组合物可以按有效的量给予,如在此其他地方描述的有效的量。根据本发明,剂型的剂量含有不同量的多个群体的合成纳米载体和/或不同量的免疫抑制剂和/或抗原。本发明的剂型中存在的合成纳米载体和/或免疫抑制剂和/或抗原的量可以根据这些抗原和/或免疫抑制剂的性质、有待完成的治疗益处、以及其他此类参数而改变。在多个实施例中,可以进行剂量范围研究,以建立有待存在于该剂型中的合成纳米载体群体的最佳治疗量以及免疫抑制剂和/或抗原的量。在多个实施例中,这些合成纳米载体和/或这些免疫抑制剂和/或抗原是以一定的量存在于该剂型中,当向受试者给予时,该量是有效于产生针对这些抗原的致耐受性免疫应答。在受试者中使用常规剂量范围研究和技术,也许有可能确定对产生致耐受性免疫应答有效的免疫抑制剂和/或抗原的量。可以在多种频率下给予本发明的剂型。在一个优选的实施例中,至少一次给予该剂型足以产生药理学上相关的应答。在多个更优选的实施例中,利用至少两次给予、至少三次给予、或至少四次给予该剂型来确保药理学上相关的应答。
可以在疾病、紊乱或病症发作之前启动这些发明组合物的预防性给予,或可以在紊乱、紊乱或病症建立之后启动治疗性给予。
在一些实施例中,例如在给予一种治疗性蛋白之前进行合成纳米载体的给予。在多个示例性的实施例中,在给予一种治疗性蛋白之前包括但不限于30天、25天、20天、15天、14天、13天、12天、11天、10天、9天、8天、7天、6天、5天、4天、3天、2天、1天、或0天给予合成纳米载体一次或多次。另外或可替代地,可以在治疗性蛋白给予之后向受试者给予合成纳米载体。在多个示例性的实施例中,在给予一种治疗性蛋白之后包括但不限于1天、2天、3天、4天、5天、6天、7天、8天、9天、10天、11天、12天、13天、14天、15天、20天、25天、30天等等而给予合成纳米载体一次或多次。
在一些实施例中,在初始给予已经在受试者中产生一种致耐受性应答之后向该受试者给予维持剂量(例如,在此提供的合成纳米载体组合物的维持剂量),例如以便维持在初始剂量之后所达到的致耐受性作用、以便防止该受试者中的所不希望的免疫应答、或以便防止该受试者变为处于经历所不希望的免疫应答或所不希望的水平的免疫应答风险中的受试者。在一些实施例中,该维持剂量是与该受试者接受的初始剂量相同的剂量。在一些实施例中,该维持剂量是比初始剂量更低的剂量。例如,在一些实施例中,该维持剂量是约3/4、约2/3、约1/2、约1/3、约1/4、约1/8、约1/10、约1/20、约1/25、约1/50、约1/100、约1/1,000、约1/10,000、约1/100,000、或约1/1,000,000(重量/重量)的初始剂量。
出于免疫抑制的目的,在此描述的这些组合物和方法可以用来诱导或增强一种致耐受性免疫应答和/或抑制、调节、引导或重定向所不希望的免疫应答。在此描述的这些组合物和方法可以用来在已经被给予、正在被给予或将要被给予一种治疗性蛋白的受试者中产生一种致耐受性免疫应答。
实例
实例1:具有或不具有卵白蛋白肽(323-339)的带有偶联的雷帕霉素的合成纳米载
体的免疫应答
材料
从巴亨美洲公司(Bachem Americas Inc.,柏市街(Kashiwa Street)3132号,托伦斯(Torrance)加利福尼亚州(CA)90505;区号#4065609)购买卵白蛋白肽323-339,即一种已知为卵白蛋白的T和B细胞表位的17氨基酸肽。从TSZ化学品公司(TSZ CHEM,威尔逊街(Wilson Street)185号,弗雷明汉(Framingham),马萨诸塞州(MA)01702;产品目录#R1017)购买雷帕霉素。从SurModics制药公司(SurModics Pharmaceuticals,汤姆马丁路(TomMartin Drive)756号,伯明翰(Birmingham),亚拉巴马州(AL)35211;产品代码7525DLG 7A)购买丙交酯∶乙交酯比为3∶1并且特性粘度为0.75dL/g的PLGA。从EMD化学品公司(EMDChemicals,产品编号1.41350.1001)购买聚乙烯醇(85%-89%水解的)。
溶液1:在稀释的盐酸水溶液中的20mg/mL的卵白蛋白肽323-339@20mg/mL。通过在室温下将卵白蛋白肽溶解在0.13M盐酸溶液中而制备该溶液。
溶液2:在二氯甲烷中的雷帕霉素@50mg/mL。通过将雷帕霉素溶解在纯二氯甲烷中而制备该溶液。
溶液3:在二氯甲烷中的PLGA@100mg/mL。通过将PLGA溶解在纯二氯甲烷中而制备该溶液。
溶液4:在100mM的pH 8的磷酸盐缓冲液中的聚乙烯醇@50mg/mL。
用于制备含有雷帕霉素和卵白蛋白(323-339)的合成纳米载体的方法
首先制备第一油包水乳液。通过将溶液1(0.2mL)、溶液2(0.2mL)、以及溶液3(1.0mL)合并在一个小的压力管中并且使用布兰森数字超声波仪(Branson DigitalSonifier)250在50%振幅下进行声处理40秒来制备W1/O1。然后通过将溶液4(3.0mL)与第一W1/O1乳液合并、涡旋10秒、并且使用布兰森数字超声波仪250在30%振幅下进行声处理60秒来制备第二乳液(W1/O1/W2)。
将该W1/O1/W2乳液添加到含有70mM的pH 8磷酸盐缓冲溶液(30mL)的烧杯中并且在室温下搅拌2小时以允许二氯甲烷蒸发并且允许合成纳米载体形成。通过以下方式来洗涤一部分合成纳米载体:将合成纳米载体悬浮液转移至一个离心管中,并且在21,000×g和4℃下离心一小时、去除上清液、并且将沉淀再悬浮于磷酸盐缓冲盐水中。重复该洗涤程序,并且将沉淀再悬浮于磷酸盐缓冲盐水中以用于约10mg/mL的最终的合成纳米载体分散液。
通过HPLC分析来确定在合成纳米载体中的肽和雷帕霉素的量。通过重量法来确定每mL悬浮液的总的干燥合成纳米载体质量。
用于含有雷帕霉素的合成纳米载体的方法
首先制备第一油包水乳液。通过将0.13M盐酸溶液(0.2mL)、溶液2(0.2mL)、以及溶液3(1.0mL)合并在一个小的压力管中并且使用布兰森数字超声波仪250在50%振幅下进行声处理40秒来制备W1/O1。然后通过将溶液4(3.0mL)与第一W1/O1乳液合并、涡旋10秒、并且使用布兰森数字超声波仪250在30%振幅下进行声处理60秒来制备第二乳液(W1/O1/W2)。
将该W1/O1/W2乳液添加到含有70mM的pH 8磷酸盐缓冲溶液(30mL)的烧杯中并且在室温下搅拌2小时以允许二氯甲烷蒸发并且允许合成纳米载体形成。通过以下方式来洗涤一部分合成纳米载体:将合成纳米载体悬浮液转移至一个离心管中,并且在21,000×g和4℃下离心一小时、去除上清液、并且将沉淀再悬浮于磷酸盐缓冲盐水中。重复该洗涤程序,并且将沉淀再悬浮于磷酸盐缓冲盐水中以用于约10mg/mL的最终的合成纳米载体分散液。
通过HPLC分析来确定在合成纳米载体中的雷帕霉素的量。通过重量法来确定每mL悬浮液的总的干燥合成纳米载体质量。
用于测量雷帕霉素负载量的方法
收集近似3mg的合成纳米载体,并且离心以使上清液与合成纳米载体沉淀分离。向该沉淀添加乙腈,并且对样品进行声处理并且离心以去除任何不溶的材料。将该上清液和沉淀注射在RP-HPLC上,并且在278nm处读取吸光度。该沉淀中发现的μg用来计算%包载(负载),在上清液和沉淀中的μg用来计算回收的总μg。
用于测量卵白蛋白(323-339)负载量的方法
收集近似3mg的合成纳米载体,并且离心以使上清液与合成纳米载体沉淀分离。向该沉淀添加三氟乙醇并且对样品进行声处理以溶解该聚合物,添加0.2%三氟乙酸并且对样品进行声处理并且然后离心以去除任何不溶的材料。将该上清液和沉淀注射在RP-HPLC上,并且在215nm处读取吸光度。该沉淀中发现的μg用来计算%包载(负载),在上清液和沉淀中的μg用来计算回收的总μg。
在Treg细胞发育上的抗原特异性致耐受性树突状细胞(Tdc)活性
该测定包括使用具有对免疫显性卵白蛋白(323-339)特异的转基因T细胞受体的OTII小鼠。为了产生抗原特异性tDC,将CD11c+脾脏细胞分离,并且在1μg/ml或无抗原下在体外添加卵白蛋白(323-339)肽。然后将可溶的或纳米载体封装的雷帕霉素添加到DC中保持2小时,然后将这些DC充分洗涤以从培养物中去除游离雷帕霉素。将纯化的应答CD4+CD25-细胞从OTH小鼠分离并且以10∶1的T与DC比添加到tDC中。然后将tDC与OTII T-细胞的混合物培养4-5天,并且通过如图1所示的流式细胞术来分析Treg细胞(CD4+CD25highFoxP3+)的频率。基于同种型对照选择区域。
实例2:具有偶联的布洛芬的介孔二氧化硅纳米颗粒(预示的)
介孔SiO2纳米颗粒核心通过溶胶-凝胶法产生。将十六烷基三甲基溴化铵(CTAB)(0.5g)溶解在去离子水(500mL)中,并且然后将2M的NaOH水溶液(3.5mL)添加到CTAB溶液中。将该溶液搅拌30分钟,并且然后向该溶液中添加四乙氧基硅烷(TEOS)(2.5mL)。在80℃的温度下将生成的凝胶搅拌3小时。通过过滤捕获形成的白色沉淀,随后用去离子水洗涤并且在室温下干燥。然后通过悬浮于HCl的乙醇溶液中过夜而从颗粒中提取出残留的表面活性剂。将这些颗粒用乙醇洗涤、离心、并且在超声处理下再分散。这个洗涤程序另外再重复两次。
然后使用(3-氨基丙基)-三乙氧基硅烷(APTMS)用氨基对SiO2纳米颗粒进行功能化。为此,将颗粒悬浮在乙醇(30mL)中,并且将APTMS(50μL)添加到悬浮液中。允许该悬浮液在室温下静置2小时,并且然后煮沸4小时,通过周期性地添加乙醇使体积保持恒定。残留的反应物通过五个离心洗涤和再分散于纯乙醇中的循环来去除。
在一个单独的反应中,产生1-4nm直径的金种子。在此反应中使用的所有的水首先被去离子并且然后从玻璃蒸馏。将水(45.5mL)添加到100mL圆底烧瓶中。在搅拌下,添加0.2M水性NaOH(1.5mL),随后添加氯化四(羟甲基)鏻(THPC)的1%水溶液(1.0mL)。在添加THPC溶液之后两分钟,添加已经老化至少15分钟的氯金酸的10mg/mL水溶液(2mL)。通过用水透析来纯化这些金种子。
为了形成核-壳纳米载体,将以上形成的氨基功能化的SiO2纳米颗粒首先在室温下与这些金种子混合2小时。将金修饰的SiO2颗粒通过离心来收集,并且与氯金酸和碳酸氢钾的水溶液混合来形成金外壳。然后将这些颗粒离心洗涤、并且再分散于水中。通过将这些颗粒悬浮于布洛芬钠的溶液(1mg/L)中72小时来负载布洛芬。然后将游离的布洛芬通过离心从颗粒中洗涤出并且再分散于水中。
实例3:含有环孢霉素A的脂质体(预示的)
这些脂质体使用薄膜水合来形成。将1,2-二棕榈酰-sn-甘油基-3-磷酸胆碱(DPPC)(32μmol)、胆固醇(32μmol)、以及环孢霉素A(6.4μmol)溶解在纯氯仿(3mL)中。将此脂质溶液添加到50mL的圆底烧瓶中,并且在60℃的温度下在旋转蒸发器上蒸发溶剂。烧瓶然后用氮气冲洗以去除残留溶剂。将磷酸盐缓冲盐水(2mL)和五个玻璃珠添加到烧瓶中,并且通过在60℃下摇晃1小时来使脂质膜水合以形成悬浮液。将该悬浮液转移到一个小的压力管中并且在60℃下进行声处理,持续四个30秒脉冲循环,其中在每个脉冲之间有30秒的延迟。然后使悬浮液在室温下静置2小时,以允许完全水合。离心洗涤脂质体,随后再悬浮于新鲜磷酸盐缓冲盐水中。
实例4:含有聚合物-雷帕霉素共轭物的聚合纳米载体(预示的)
PLGA-雷帕霉素共轭物的制备:
将具有酸端基的PLGA聚合物(7525DLG1A,酸值0.46mmol/g,Lakeshore生物材料公司(Lakeshore Biomaterials);5g,2.3mmol,1.0当量)溶解在30mL的二氯甲烷(DCM)中。添加N,N-二环己基碳二亚胺(1.2当量,2.8mmol,0.57g),随后添加雷帕霉素(1.0当量,2.3mmol,2.1g)和4-二甲氨基吡啶(DMAP)(2.0当量,4.6mmol,0.56g)。将混合物在室温下搅拌2天。然后过滤混合物以去除不溶的二环己脲。将滤液浓缩至体积大约为10mL并且添加到100mL的异丙醇(IPA)中以沉淀出PLGA-雷帕霉素共轭物。将IPA层去除并且聚合物然后用50mL的IPA和50mL的甲基叔丁醚(MTBE)洗涤。然后将聚合物在35℃下真空干燥2天,给出呈白色固体的PLGA-雷帕霉素(大约6.5g)。
含有PLGA-雷帕霉素共轭物和卵白蛋白肽(323-339)的纳米载体的制备:
根据实例1中所述的程序如下制备含有PLGA-雷帕霉素的纳米载体:
如下制备用于纳米载体形成的溶液:
溶液1:在稀释的盐酸水溶液中的卵白蛋白肽323-339@20mg/mL。通过在室温下将卵白蛋白肽溶解在0.13M盐酸溶液中而制备该溶液。溶液2:在二氯甲烷中的PLGA-雷帕霉素@100mg/mL。通过将PLGA-雷帕霉素溶解在纯二氯甲烷中而制备该溶液。溶液3:在二氯甲烷中的PLA-PEG@100mg/mL。通过将PLA-PEG溶解在纯二氯甲烷中而制备该溶液。溶液4:在100mM的pH 8的磷酸盐缓冲液中的聚乙烯醇@50mg/mL。
首先制备第一油包水乳液。通过将溶液1(0.2mL)、溶液2(0.75mL)、以及溶液3(0.25mL)合并在一个小的压力管中并且使用布兰森数字超声波仪250在50%振幅下进行声处理40秒来制备W1/O1。然后通过将溶液4(3.0mL)与第一W1/O1乳液合并、涡旋10秒、并且使用布兰森数字超声波仪250在30%振幅下进行声处理60秒来制备第二乳液(W1/O1/W2)。将该W1/O1/W2乳液添加到含有70mM的pH 8磷酸盐缓冲溶液(30mL)的烧杯中并且在室温下搅拌2小时以允许二氯甲烷蒸发并且允许纳米载体形成。通过以下方式来洗涤一部分纳米载体:将纳米载体悬浮液转移至一个离心管中,并且在75,600×g和4℃下离心35分钟、去除上清液、并且将沉淀再悬浮于磷酸盐缓冲盐水中。重复该洗涤程序,并且将沉淀再悬浮于磷酸盐缓冲盐水中以用于约10mg/mL的最终的纳米载体分散液。
实例5:含有雷帕霉素的金纳米载体(AuNCs)的制备(预示的)
HS-PEG-雷帕霉素的制备:
将PEG酸二硫化物(1.0当量)、雷帕霉素(2.0-2.5当量)、DCC(2.5当量)以及DMAP(3.0当量)在无水DMF中的溶液在室温下搅拌过夜。通过过滤去除不溶的二环己脲并且将滤液添加到异丙醇(IPA)中以沉淀出PEG-二硫化物-二-雷帕霉素酯并用IPA洗涤并干燥。聚合物然后用在DMF中的三(2-羧乙基)膦盐酸盐处理,以便将PEG二硫化物还原成硫醇基PEG雷帕霉素酯(HS-PEG-雷帕霉素)。通过沉淀从IPA回收生成的聚合物并且如先前所述进行干燥并且通过H NMR和GPC来分析。
金NCs(AuNCs)的形成:
在一个装备有冷凝器的1L圆底烧瓶中,在剧烈搅拌下加热回流500mL的1mMHAuCl4的水溶液10分钟。然后向搅拌的溶液迅速添加50mL的40mM的柠檬酸三钠溶液。将生成的深酒红色溶液保持回流25-30分钟,然后停止加热,并且冷却该溶液至室温。然后通过一个0.8μm薄膜过滤器过滤该溶液,以给出AuNCs溶液。使用可见光谱学和透射电子显微术表征AuNCs。这些AuNCs直径大约20nm,被柠檬酸盐封盖,并且吸收峰在520nm处。
具有HS-PEG-雷帕霉素的AuNCs共轭物:
将150μl的HS-PEG-雷帕霉素的溶液(在10mM pH 9.0碳酸盐缓冲液中的10μM)添加到1mL的20nm直径的柠檬酸盐包裹的金纳米载体(1.16nM)中,以产生2500∶1的硫醇基与金的摩尔比。在室温在氩下搅拌混合物1小时以允许金纳米载体上的硫醇与柠檬酸盐完全交换。然后通过在12,000g下离心30分钟将表面上的具有PEG-雷帕霉素的AuNCs纯化。将上清液倾析出来并且然后将含有AuNC-S-PEG-雷帕霉素的沉淀用1x PBS缓冲液沉淀洗涤。然后将纯化的金-PEG-雷帕霉素纳米载体再悬浮于合适的缓冲液中以便进行进一步分析和生物测定。
实例6:含有卵白蛋白的介孔二氧化硅-金核-壳纳米载体(预示的)
介孔SiO2纳米颗粒核心通过溶胶-凝胶法来产生。将十六烷基三甲基溴化铵(CTAB)(0.5g)溶解在去离子水(500mL)中,并且然后将2M的NaOH水溶液(3.5mL)添加到CTAB溶液中。将该溶液搅拌30分钟,并且然后向该溶液中添加四乙氧基硅烷(TEOS)(2.5mL)。在80℃的温度下将生成的凝胶搅拌3小时。通过过滤捕获形成的白色沉淀,随后用去离子水洗涤并且在室温下干燥。然后通过悬浮于HCl的乙醇溶液中过夜而从颗粒中提取出残留的表面活性剂。将这些颗粒用乙醇洗涤、离心、并且在超声处理下再分散。这个洗涤程序另外再重复两次。
然后使用(3-氨基丙基)-三乙氧基硅烷(APTMS)用氨基对SiO2纳米颗粒进行功能化。为此,将颗粒悬浮在乙醇(30mL)中,并且将APTMS(50μL)添加到悬浮液中。允许该悬浮液在室温下静置2小时,并且然后煮沸4小时,通过周期性地添加乙醇使体积保持恒定。残留的反应物通过五个离心洗涤和再分散于纯乙醇中的循环来去除。
在一个单独的反应中,产生1-4nm直径的金种子。在此反应中使用的所有的水首先被去离子并且然后从玻璃蒸馏。将水(45.5mL)添加到100mL圆底烧瓶中。在搅拌下,添加0.2M水性NaOH(1.5mL),随后添加氯化四(羟甲基)鏻(THPC)的1%水溶液(1.0mL)。在添加THPC溶液之后两分钟,添加已经老化至少15分钟的氯金酸的10mg/mL水溶液(2mL)。通过用水透析来纯化这些金种子。
为了形成核-壳纳米载体,将以上形成的氨基功能化的SiO2纳米颗粒首先在室温下与这些金种子混合2小时。将金修饰的SiO2颗粒通过离心来收集,并且与氯金酸和碳酸氢钾的水溶液混合来形成金外壳。然后将这些颗粒离心洗涤、并且再分散于水中。通过将这些颗粒悬浮于硫醇化的卵白蛋白溶液(1mg/L)中72小时来负载硫醇化的卵白蛋白(通过用2-亚氨基硫烷盐酸盐处理卵白蛋白而制成)。颗粒然后用1 x PBS(pH 7.4)沉淀洗涤以去除游离蛋白。然后将生成的含有卵白蛋白的二氧化硅-金核-壳纳米载体再悬浮于1 x PBS中以便进行进一步分析和测定。
实例7:含有雷帕霉素和卵白蛋白的脂质体(预示的)
这些脂质体通过薄膜水合来形成。将1,2-二棕榈酰-sn-甘油基-3-磷酸胆碱(DPPC)(32μmol)、胆固醇(32μmol)、以及雷帕霉素(6.4μmol)溶解在纯氯仿(3mL)中。将此脂质溶液添加到10mL玻璃管中,并且在氮气流下去除溶剂并且真空干燥6小时。通过用2.0ml的25mM MOPS缓冲液pH 8.5使该膜水合来获得多层囊泡,其含有过量的卵白蛋白。使管涡旋,直到脂质膜从管表面上剥落。为了将多层囊泡打破成单层的,应用十个冷冻(液氮)和融化(30℃水浴)循环。然后将样品在25mM MOPS缓冲液pH 8.5中稀释到1ml。通过使样品10倍穿过200nm孔聚碳酸酯过滤器而挤出而将生成的脂质体的大小均匀化。然后使用生成的脂质体用于进一步分析和生物测定。
实例8:由具有表面共轭的卵白蛋白的修饰聚氨基酸组成的聚合纳米载体(预示
的)
步骤1.用L-苯丙氨酸乙酯(L-PAE)修饰的聚(γ-谷氨酸)(γ-PGA)的制备:将4.7单位毫摩尔的γ-PGA(Mn=300kD)溶解在0.3N-NaHCO3水溶液(50mL)中。将L-PAE(4.7mmol)和EDC.HCl(4.7mmol)添加到该溶液中并且在4C下搅拌30分钟。然后在搅拌下将该溶液保持在室温24小时。使用具有MWCO 50kD的透析薄膜通过渗析去除低分子量化学物质。通过冻干获得生成的γ-PGA-接枝-L-PAE。
步骤2.由γ-PGA-接枝-L-PAE聚合物制备纳米颗粒:通过沉淀和透析方法来制备由γ-PGA-接枝-L-PAE组成的纳米颗粒。将γ-PGA-接枝-L-PAE(20mg)溶解在2ml的DMSO中,随后添加2mL的水以形成半透明溶液。然后在室温下用蒸馏水使用纤维素薄膜配管(50,000MWCO)透析该溶液72小时,以形成纳米颗粒并且去除有机溶剂。蒸馏水以12小时的间隔进行更换。然后使用生成的纳米颗粒溶液(在水中的10mg/mL)以用于抗原共轭。
步骤3.卵白蛋白与γ-PGA纳米颗粒的共轭:γ-PGA纳米颗粒(10mg/ml)的表面羧酸基团首先在环境温度下通过EDC和NHS(各自在磷酸盐缓冲液中的10mg/mL,pH 5.8)活化2小时。在沉淀洗涤以去除过量的EDC/NHS之后,将活化的纳米颗粒与1mL的卵白蛋白(10mg/ml)混合在磷酸盐缓冲盐水(PBS,pH 7.4)中,并且将混合物在4℃-8℃下孵育24小时。将生成的卵白蛋白共轭的γ-PGA纳米颗粒用PBS洗涤两次并且以5mg/mL再悬浮于PBS中以便进行进一步分析和生物测定。
实例9:红细胞生成素(EPO)封装的γ-PGA纳米颗粒(预示的)
为了制备EPO封装的γ-PGA纳米颗粒,将0.25-4mg的EPO溶解在1mL的PBS(pH 7.4)中,并且将1mL的γ-PGA-接枝-L-PAE(DMSO中的10mg/mL)添加到EPO溶液中。将生成的溶液在14,000x g下离心15分钟并且用PBS重复清洗。然后将生成的EPO封装的γ-PGA纳米颗粒再悬浮于PBS(5mg/mL)中以便进行进一步分析和生物测定。
实例10:含有卵白蛋白的金纳米载体(AuNCs)的制备(预示的)
步骤1.金NCs(AuNCs)的形成:在一个装备有冷凝器的1L圆底烧瓶中,在剧烈搅拌下加热回流500mL的1mM HAuCl4的水溶液10分钟。然后向搅拌的溶液迅速添加50mL的40mM的柠檬酸三钠溶液。将生成的深酒红色溶液保持回流25-30分钟,然后停止加热,并且冷却该溶液至室温。然后通过一个0.8μm薄膜过滤器过滤该溶液,以给出AuNCs溶液。使用可见光谱学和透射电子显微术表征AuNCs。这些AuNCs直径大约20nm,被柠檬酸盐包裹,并且吸收峰在520nm处。
步骤2.卵白蛋白与AuNCs的共轭:将150μl的硫醇化的卵白蛋白溶液(在10mM pH9.0碳酸盐缓冲液中的10μM)添加到1mL的20nm直径的柠檬酸盐封盖的金纳米载体(1.16nM)中,以产生2500∶1的硫醇基与金的摩尔比。在室温在氩下搅拌混合物1小时以允许金纳米载体上的硫醇与柠檬酸盐完全交换。然后通过在12,000g下离心30分钟将表面上的具有卵白蛋白的AuNCs纯化。将上清液倾析出来并且然后将含有AuNC-卵白蛋白的沉淀用1 x PBS缓冲液沉淀洗涤。然后将纯化的金-卵白蛋白纳米载体再悬浮于合适的缓冲液中以便进行进一步分析和生物测定。
实例11:在体内评估对红细胞生成素α的致耐受性免疫应答(预示的)
Balb/c小鼠用不完全弗氏佐剂中的阿法依伯汀免疫以便诱导CD4+ T-细胞增殖,评定增殖水平。随后,将本发明的包含阿法依伯汀的MHC II类限制性表位和免疫抑制剂的组合物以剂量依赖性方式进行皮下给予。然后将相同小鼠再次暴露于阿法依伯汀,并且再次评定CD4+ T细胞增殖的水平。然后监测CD4+ T细胞群的变化,其中在随后用阿法依伯汀激发时CD4+ T细胞增殖降低,表明了致耐受性免疫应答。
实例12:在体内评估使用包含免疫抑制剂和APC可呈递抗原的合成纳米载体的致
耐受性免疫应答
合成纳米载体生产的材料和方法
纳米载体1
从TSZ化学品公司(威尔逊街185号,弗雷明汉,马萨诸塞州01702;产品目录#R1017)购买雷帕霉素。从SurModics制药公司(汤姆马丁路756号,伯明翰,亚拉巴马州35211;产品代码7525 DLG 7A)购买丙交酯∶乙交酯比为3∶1并且特性粘度为0.75dL/g的PLGA。合成了PEG嵌段大约为5,000Da并且PLA嵌段大约为20,000Da的PLA-PEG嵌段共聚物。从EMD化学品公司(产品编号1.41350.1001)购买聚乙烯醇(85%-89%水解的)。
如下制备溶液:
溶液1:在二氯甲烷中的雷帕霉素@50mg/mL。通过将雷帕霉素溶解在纯二氯甲烷中而制备该溶液。
溶液2:在二氯甲烷中的PLGA@100mg/mL。通过将PLGA溶解在纯二氯甲烷中而制备该溶液。
溶液3:在二氯甲烷中的PLA-PEG@100mg/mL。通过将PLA-PEG溶解在纯二氯甲烷中而制备该溶液。
溶液4:在100mM的pH 8的磷酸盐缓冲液中的聚乙烯醇@50mg/mL。
使用水包油乳液来制备纳米载体。通过将溶液1(0.2mL)、溶液2(0.75mL)、溶液3(0.25mL)、以及溶液4(3mL)合并在一个小的压力管中并且使用布兰森数字超声波仪250在30%振幅下进行声处理60秒来制备O/W乳液。将该O/W乳液添加到含有70mM的pH 8磷酸盐缓冲溶液(30mL)的烧杯中并且在室温下搅拌2小时以允许二氯甲烷蒸发并且允许纳米载体形成。通过以下方式来洗涤一部分纳米载体:将纳米载体悬浮液转移至一个离心管中,并且在21,000×g和4℃下离心45分钟、去除上清液、并且将沉淀再悬浮于磷酸盐缓冲盐水中。重复该洗涤程序,并且将沉淀再悬浮于磷酸盐缓冲盐水中以用于约10mg/mL的最终的纳米载体分散液。
通过动态光散射来确定纳米载体大小。通过HPLC分析来确定在纳米载体中的雷帕霉素的量。通过重量法来确定每mL悬浮液的总的干燥纳米载体质量。
纳米载体2
从巴亨美洲公司(柏市街3132号,托伦斯,加利福尼亚州90505;区号#4065609)购买卵白蛋白肽323-339,即一种已知为卵白蛋白的T和B细胞表位的17氨基酸肽。从SurModics制药公司(汤姆马丁路756号,伯明翰,亚拉巴马州35211;产品代码7525 DLG 7A)购买丙交酯∶乙交酯比为3∶1并且特性粘度为0.75dL/g的PLGA。合成了PEG嵌段大约为5,000Da并且PLA嵌段大约为20,000Da的PLA-PEG嵌段共聚物。从EMD化学品公司(产品编号1.41350.1001)购买聚乙烯醇(85%-89%水解的)。
如下制备溶液:
溶液1:在稀释的盐酸水溶液中的卵白蛋白肽323-339@20mg/mL。通过在室温下将卵白蛋白肽溶解在0.13M盐酸溶液中而制备该溶液。
溶液2:在二氯甲烷中的PLGA@100mg/mL。通过将PLGA溶解在纯二氯甲烷中而制备该溶液。
溶液3:在二氯甲烷中的PLA-PEG@100mg/mL。通过将PLA-PEG溶解在纯二氯甲烷中而制备该溶液。
溶液4:在100mM的pH 8的磷酸盐缓冲液中的聚乙烯醇@50mg/mL。
首先制备第一油包水乳液。通过将溶液1(0.2mL)、溶液2(0.75mL)、以及溶液3(0.25mL)合并在一个小的压力管中并且使用布兰森数字超声波仪250在50%振幅下进行声处理40秒来制备W1/O1。然后通过将溶液4(3.0mL)与第一W1/O1乳液合并、涡旋10秒、并且使用布兰森数字超声波仪250在30%振幅下进行声处理60秒来制备第二乳液(W1/O1/W2)。
将该W1/O1/W2乳液添加到含有70mM的pH 8磷酸盐缓冲溶液(30mL)的烧杯中并且在室温下搅拌2小时以允许二氯甲烷蒸发并且允许纳米载体形成。通过以下方式来洗涤一部分纳米载体:将纳米载体悬浮液转移至一个离心管中,并且在75,600×g和4℃下离心35分钟、去除上清液、并且将沉淀再悬浮于磷酸盐缓冲盐水中。重复该洗涤程序,并且将沉淀再悬浮于磷酸盐缓冲盐水中以用于约10mg/mL的最终的纳米载体分散液。
通过动态光散射来确定纳米载体大小。通过HPLC分析来确定在纳米载体中的肽的量。通过重量法来确定每mL悬浮液的总的干燥纳米载体质量。
纳米载体3
从LKT实验设备公司(LKT Laboratories,Inc.,大学路西(University AvenueWest)2233号,圣保罗(St.Paul),明尼苏达州(MN)55114;产品目录#S3449)购买辛伐他汀。从SurModics制药公司(汤姆马丁路756号,伯明翰,亚拉巴马州35211;产品代码7525 DLG7A)购买丙交酯∶乙交酯比为3∶1并且特性粘度为0.75dL/g的PLGA。合成了PEG嵌段大约为5,000Da并且PLA嵌段大约为20,000Da的PLA-PEG嵌段共聚物。从EMD化学品公司(产品编号1.41350.1001)购买聚乙烯醇(85%-89%水解的)。
如下制备溶液:
溶液1:在二氯甲烷中的辛伐他汀@50mg/mL。通过将辛伐他汀溶解在纯二氯甲烷中而制备该溶液。
溶液2:在二氯甲烷中的PLGA@100mg/mL。通过将PLGA溶解在纯二氯甲烷中而制备该溶液。
溶液3:在二氯甲烷中的PLA-PEG@100mg/mL。通过将PLA-PEG溶解在纯二氯甲烷中而制备该溶液。
溶液4:在100mM的pH 8的磷酸盐缓冲液中的聚乙烯醇@50mg/mL。
使用水包油乳液来制备纳米载体。通过将溶液1(0.15mL)、溶液2(0.75mL)、溶液3(0.25mL)、以及溶液4(3mL)合并在一个小的压力管中并且使用布兰森数字超声波仪250在30%振幅下进行声处理60秒来制备O/W乳液。将该O/W乳液添加到含有70mM的pH 8磷酸盐缓冲溶液(30mL)的烧杯中并且在室温下搅拌2小时以允许二氯甲烷蒸发并且允许纳米载体形成。通过以下方式来洗涤一部分纳米载体:将纳米载体悬浮液转移至一个离心管中,并且在75,600×g和4℃下离心35分钟、去除上清液、并且将沉淀再悬浮于磷酸盐缓冲盐水中。重复该洗涤程序,并且将沉淀再悬浮于磷酸盐缓冲盐水中以用于约10mg/mL的最终的纳米载体分散液。
通过动态光散射来确定纳米载体大小。通过HPLC分析来确定在纳米载体中的辛伐他汀的量。通过重量法来确定每mL悬浮液的总的干燥纳米载体质量。
纳米载体4
从巴亨美洲公司(柏市街3132号,托伦斯,加利福尼亚州90505;区号#4065609)购买卵白蛋白肽323-339,即一种已知为卵白蛋白的T和B细胞表位的17氨基酸肽。从TSZ化学品公司(威尔逊街185号,弗雷明汉,马萨诸塞州01702;产品目录#R1017)购买雷帕霉素。从SurModics制药公司(汤姆马丁路756号,伯明翰,亚拉巴马州35211;产品代码7525 DLG 7A)购买丙交酯∶乙交酯比为3∶1并且特性粘度为0.75dL/g的PLGA。合成了PEG嵌段大约为5,000Da并且PLA嵌段大约为20,000Da的PLA-PEG嵌段共聚物。从EMD化学品公司(产品编号1.41350.1001)购买聚乙烯醇(85%-89%水解的)。
如下制备溶液:
溶液1:在稀释的盐酸水溶液中的卵白蛋白肽323-339@20mg/mL。通过在室温下将卵白蛋白肽溶解在0.13M盐酸溶液中而制备该溶液。
溶液2:在二氯甲烷中的雷帕霉素@50mg/mL。通过将雷帕霉素溶解在纯二氯甲烷中而制备该溶液。
溶液3:在二氯甲烷中的PLGA@100mg/mL。通过将PLGA溶解在纯二氯甲烷中而制备该溶液。
溶液4:在二氯甲烷中的PLA-PEG@100mg/mL。通过将PLA-PEG溶解在纯二氯甲烷中而制备该溶液。
溶液5:在100mM的pH 8的磷酸盐缓冲液中的聚乙烯醇@50mg/mL。
首先制备第一油包水乳液。通过将溶液1(0.2mL)、溶液2(0.2mL)、溶液3(0.75mL)、以及溶液4(0.25mL)合并在一个小的压力管中并且使用布兰森数字超声波仪250在50%振幅下进行声处理40秒来制备W1/O1。然后通过将溶液5(3.0mL)与第一W1/O1乳液合并、涡旋10秒、并且使用布兰森数字超声波仪250在30%振幅下进行声处理60秒来制备第二乳液(W1/O1/W2)。
将该W1/O1/W2乳液添加到含有70mM的pH 8磷酸盐缓冲溶液(30mL)的烧杯中并且在室温下搅拌2小时以允许二氯甲烷蒸发并且允许纳米载体形成。通过以下方式来洗涤一部分纳米载体:将纳米载体悬浮液转移至一个离心管中,并且在21,000×g和4℃下离心45分钟、去除上清液、并且将沉淀再悬浮于磷酸盐缓冲盐水中。重复该洗涤程序,并且将沉淀再悬浮于磷酸盐缓冲盐水中以用于约10mg/mL的最终的纳米载体分散液。
通过动态光散射来确定纳米载体大小。通过HPLC分析来确定在纳米载体中的肽和雷帕霉素的量。通过重量法来确定每mL悬浮液的总的干燥纳米载体质量。
纳米载体5
从巴亨美洲公司(柏市街3132号,托伦斯,加利福尼亚州90505;区号#4065609)购买卵白蛋白肽323-339,即一种已知为卵白蛋白的T和B细胞表位的17氨基酸肽。从LKT实验设备公司(大学路西2233号,圣保罗,明尼苏达州55114;产品目录#S3449)购买辛伐他汀。从SurModics制药公司(汤姆马丁路756号,伯明翰,亚拉巴马州35211;产品代码7525 DLG 7A)购买丙交酯∶乙交酯比为3∶1并且特性粘度为0.75dL/g的PLGA。合成了PEG嵌段大约为5,000Da并且PLA嵌段大约为20,000Da的PLA-PEG嵌段共聚物。从EMD化学品公司(产品编号1.41350.1001)购买聚乙烯醇(85%-89%水解的)。
如下制备溶液:
溶液1:在稀释的盐酸水溶液中的卵白蛋白肽323-339@20mg/mL。通过在室温下将卵白蛋白肽溶解在0.13M盐酸溶液中而制备该溶液。
溶液2:在二氯甲烷中的辛伐他汀@50mg/mL。通过将辛伐他汀溶解在纯二氯甲烷中而制备该溶液。
溶液3:在二氯甲烷中的PLGA@100mg/mL。通过将PLGA溶解在纯二氯甲烷中而制备该溶液。
溶液4:在二氯甲烷中的PLA-PEG@100mg/mL。通过将PLA-PEG溶解在纯二氯甲烷中而制备该溶液。
溶液5:在100mM的pH 8的磷酸盐缓冲液中的聚乙烯醇@50mg/mL。
首先制备第一油包水乳液。通过将溶液1(0.2mL)、溶液2(0.15mL)、溶液3(0.75mL)、以及溶液4(0.25mL)合并在一个小的压力管中并且使用布兰森数字超声波仪250在50%振幅下进行声处理40秒来制备W1/O1。然后通过将溶液5(3.0mL)与第一W1/O1乳液合并、涡旋10秒、并且使用布兰森数字超声波仪250在30%振幅下进行声处理60秒来制备第二乳液(W1/O1/W2)。
将该W1/O1/W2乳液添加到含有70mM的pH 8磷酸盐缓冲溶液(30mL)的烧杯中并且在室温下搅拌2小时以允许二氯甲烷蒸发并且允许纳米载体形成。通过以下方式来洗涤一部分纳米载体:将纳米载体悬浮液转移至一个离心管中,并且在75,600×g和4℃下离心35分钟、去除上清液、并且将沉淀再悬浮于磷酸盐缓冲盐水中。重复该洗涤程序,并且将沉淀再悬浮于磷酸盐缓冲盐水中以用于约10mg/mL的最终的纳米载体分散液。
通过动态光散射来确定纳米载体大小。通过HPLC分析来确定在纳米载体中的肽和辛伐他汀的量。通过重量法来确定每mL悬浮液的总的干燥纳米载体质量。
体内给予1
收获来自B6.Cg-Tg(TcraTcrb)425Cbn/J(OTII)和C57BL/6(B6)小鼠的脾脏、机械解离并且单独过滤通过70μM筛以产生单细胞悬浮液。然后以2步骤的方法提取纯化的CD4+CD25-细胞。使用美天旎生物技术公司(Miltenyi Biotec)的AutoMACS磁性细胞分选仪将脾脏细胞首先用CD4+ T-细胞分离试剂盒II进行标记,并且未标记的部分用CD25耗尽试剂盒耗尽CD25+细胞。纯化的B6细胞在与纯化的OTII细胞以等浓度混合之前用细胞内染料羧基荧光素琥珀酰亚胺酯(CFSE)进行染色。然后将它们静脉(i.v.)注射到B6.SJL-Ptprca/BoyAi(CD45.1)受体小鼠中。
第二天,用靶向的致耐受性合成疫苗颗粒(t2SVP)处理受体CD45.1小鼠。它们负载有卵白蛋白肽(323-339)(OVA 323-339)、雷帕霉素(Rapa)和/或辛伐他汀(Simva)的组合并且皮下地(s.c.)给予。
注射构成一个致耐受性处理,并且随后进行另外4次注射,每次注射之间间隔2周。在治疗计划完成之后,将受体CD45.1动物杀死并且收获它们的脾脏和腘淋巴结、机械解离并且单独过滤通过70μM筛以产生单细胞悬浮液。通过用RBC裂解缓冲液孵育来使脾脏细胞耗尽红血细胞(RBC)(干细胞技术(Stem Cell Technologies))并且对脾脏和淋巴结二者都进行细胞计数。
将脾脏或淋巴结细胞在增补有10U/ml IL-2的CM(完全培养基)中培养、在96孔圆底(RB)培养板中以0.3×106细胞/孔乙用OPII再刺激、并且在37℃、5%CO2下孵育。细胞在第2天分裂并且在第5天被收获。收集上清液并且冷冻,同时对细胞进行染色以便通过流式细胞术进行表型分析。将这些细胞在碧迪公司(Becton Dickinson)的FacsCanto流式细胞仪上进行分析。
体内给予2
收获来自B6.Cg-Tg(TcraTcrb)425Cbn/J(OTII)和C57BL/6(B6)小鼠的脾脏、机械解离并且单独过滤通过70μM筛以产生单细胞悬浮液。然后使用美天旎生物技术公司AutoMACS磁性细胞分选仪以2步骤的方法提取纯化的CD4+CD25-细胞。脾脏细胞使用美天旎的CD4+ T-细胞分离试剂盒II来标记。未标记的CD4+ T-细胞部分然后用CD25耗尽试剂盒耗尽CD25+细胞。然后,来自B6小鼠的纯化的CD4细胞在与纯化的OTII细胞以等浓度混合之前用细胞内染料羧基荧光素琥珀酰亚胺酯(CFSE)进行染色。然后将它们静脉(i.v.)注射到B6.SJL-Ptprca/BoyAi(CD45.1)受体小鼠中。
第二天,用靶向的致耐受性合成疫苗颗粒处理受体CD45.1小鼠。它们包含卵白蛋白肽(323-339)(OVA323-339)、雷帕霉素(Rapa)以及辛伐他汀(Simva)的组合并且皮下地(s.c.)或静脉内地(i.v.)给予。
在治疗计划完成之后,将受体CD45.1动物杀死并且收获它们的脾脏和腘淋巴结、机械解离并且单独过滤通过70μM筛以产生单细胞悬浮液。通过与RBC裂解缓冲液结合来使脾脏细胞耗尽红血细胞(RBC)(干细胞技术)并且对脾脏和淋巴结二者都进行细胞计数。
将脾脏或淋巴结细胞在增补有10U/ml IL-2的CM中培养、在96孔圆底(RB)培养板中以0.3×106细胞/孔用1μM OPII再刺激、并且在37℃、5%CO2下孵育。细胞在第2天分裂并且在第5天被收获。收集上清液并且冷冻,同时对细胞进行染色以便通过流式细胞术进行表型分析。这些细胞在碧迪公司的FacsCanto流式细胞仪上进行分析。
结果
结果显示在图2和图3(免疫调节剂1:雷帕霉素;免疫调节剂2:辛伐他汀)中。这些图显示了体内效应并且证实,与单独使用抗原或包含抗原而有和没有免疫刺激分子的合成纳米载体相比,使用包含抗原和免疫抑制剂的合成纳米载体降低了效应免疫细胞的抗原特异性扩增。
实例13:使用合成纳米载体的致耐受性免疫应答
材料和方法
纳米载体1
从沃辛顿生物化学公司(Worthington Biochemical Corporation,瓦萨路(VassarAvenue)730号,莱克伍德(Lakewood),新泽西州(NJ)08701;产品代码3048)购买卵白蛋白。从SurModics制药公司(汤姆马丁路756号,伯明翰,亚拉巴马州35211;产品代码7525 DLG 7A)购买丙交酯∶乙交酯比为3∶1并且特性粘度为0.75dL/g的PLGA。从EMD化学品公司(产品编号1.41350.1001)购买聚乙烯醇(85%-89%水解的)。合成了PEG嵌段大约为5,000Da并且PLA嵌段大约为20,000Da的PLA-PEG嵌段共聚物。从西格玛奥德里奇公司(云杉街(Spruce Street)3050号,圣路易斯(St.Louis),密苏里州(MO)63103;产品代码C6445)购买胆酸钠水合物。
如下制备溶液:
溶液1:在磷酸盐缓冲盐水溶液中的卵白蛋白@50mg/mL。通过在室温下将卵白蛋白溶解在磷酸盐缓冲盐水溶液中而制备该溶液。溶液2:在二氯甲烷中的PLGA@100mg/mL。通过将PLGA溶解在纯二氯甲烷中而制备该溶液。溶液3:在二氯甲烷中的PLA-PEG@100mg/mL。通过将PLA-PEG溶解在纯二氯甲烷中而制备该溶液。溶液4:在100mM的pH 8的磷酸盐缓冲液中的聚乙烯醇@50mg/mL和胆酸钠水合物@10mg/mL。
首先制备第一油包水乳液。通过将溶液1(0.2mL)、溶液2(0.75mL)、以及溶液3(0.25mL)合并在一个小的压力管中并且使用布兰森数字超声波仪250在50%振幅下进行声处理40秒来制备W1/O1。然后通过将溶液4(3.0mL)与第一WI/O1乳液合并、涡旋10秒、并且使用布兰森数字超声波仪250在30%振幅下进行声处理60秒来制备第二乳液(W1/O1/W2)。将该W1/O1/W2乳液添加到含有70mM的pH 8磷酸盐缓冲溶液(30mL)的烧杯中并且在室温下搅拌2小时以允许二氯甲烷蒸发并且允许纳米载体形成。通过以下方式来洗涤一部分纳米载体:将纳米载体悬浮液转移至一个离心管中,并且在75,600×g和4℃下离心35分钟、去除上清液、并且将沉淀再悬浮于磷酸盐缓冲盐水中。重复该洗涤程序,并且将沉淀再悬浮于磷酸盐缓冲盐水中以用于约10mg/mL的最终的纳米载体分散液。
通过动态光散射来确定纳米载体大小。通过邻苯二醛荧光测定来确定在纳米载体中的蛋白质的量。通过重量法来确定每mL悬浮液的总的干燥纳米载体质量。
纳米载体2
从沃辛顿生物化学公司(瓦萨路730号,莱克伍德,新泽西州08701;产品代码3048)购买卵白蛋白。从TSZ化学品公司(威尔逊街185号,弗雷明汉,马萨诸塞州01702;产品目录#R1017)购买雷帕霉素。从SurModics制药公司(汤姆马丁路756号,伯明翰,亚拉巴马州35211;产品代码7525 DLG 7A)购买丙交酯∶乙交酯比为3∶1并且特性粘度为0.75dL/g的PLGA。合成了PEG嵌段大约为5,000Da并且PLA嵌段大约为20,000Da的PLA-PEG嵌段共聚物。从EMD化学品公司(产品编号1.41350.1001)购买聚乙烯醇(85%-89%水解的)。从西格玛奥德里奇公司(云杉街(Spruce Street)3050号,圣路易斯(St.Louis),密苏里州(MO)63103;产品代码C6445)购买胆酸钠水合物。
如下制备溶液:
溶液1:在磷酸盐缓冲盐水溶液中的卵白蛋白@50mg/mL。通过在室温下将卵白蛋白溶解在磷酸盐缓冲盐水溶液中而制备该溶液。溶液2:在二氯甲烷中的雷帕霉素@50mg/mL。通过将雷帕霉素溶解在纯二氯甲烷中而制备该溶液。溶液3:在二氯甲烷中的PLGA@100mg/mL。通过将PLGA溶解在纯二氯甲烷中而制备该溶液。溶液4:在二氯甲烷中的PLA-PEG@100mg/mL。通过将PLA-PEG溶解在纯二氯甲烷中而制备该溶液。溶液5:在100mM的pH 8的磷酸盐缓冲液中的聚乙烯醇@50mg/mL和胆酸钠水合物@10mg/mL。
首先制备第一油包水乳液。通过将溶液1(0.2mL)、溶液2(0.2mL)、溶液3(0.75mL)、以及溶液4(0.25mL)合并在一个小的压力管中并且使用布兰森数字超声波仪250在50%振幅下进行声处理40秒来制备W1/O1。然后通过将溶液5(3.0mL)与第一W1/O1乳液合并、涡旋10秒、并且使用布兰森数字超声波仪250在30%振幅下进行声处理60秒来制备第二乳液(W1/O1/W2)。将该W1/O1/W2乳液添加到含有70mM的pH 8磷酸盐缓冲溶液(30mL)的烧杯中并且在室温下搅拌2小时以允许二氯甲烷蒸发并且允许纳米载体形成。通过以下方式来洗涤一部分纳米载体:将纳米载体悬浮液转移至一个离心管中,并且在75,600×g和4℃下离心35分钟、去除上清液、并且将沉淀再悬浮于磷酸盐缓冲盐水中。重复该洗涤程序,并且将沉淀再悬浮于磷酸盐缓冲盐水中以用于约10mg/mL的最终的纳米载体分散液。
通过动态光散射来确定纳米载体大小。通过HPLC分析来确定在纳米载体中的雷帕霉素的量。通过邻苯二醛荧光测定来确定在纳米载体中的蛋白质的量。通过重量法来确定每mL悬浮液的总的干燥纳米载体质量。
免疫
这个实验的目的是通过测量抗原特异性免疫球蛋白来评定封装的(t2SVP)免疫抑制剂对进行中的抗体应答的作用。一组动物保持未免疫以作为对照。两组动物使用卵白蛋白的“被动给予”或用3次注射(第0天、第14天以及第28天)OVA和CpG的主动免疫进行免疫,随后进行抗体滴度评定并且休息一周或两周。另两组接受相同的免疫、但是在接受该处理的同时每2周接受加强剂量(boost)。将这些组各自分成三个亚组以测试不同处理改变所诱导的Ig滴度的能力。一个对照亚组不接受致耐受性处理。向其他亚组施用另两个处理,包括只携带OVA蛋白或与免疫抑制剂组合的NP。
对于免疫,动物接受20μl/肢的OVA+CpG(12.5μg OVA+10μg CpG),两个后肢皮下给予,或在100μl中25μg的OVA静脉内给予。致耐受性处理包括使用10μg的OVA静脉内给予200μl的t2SVP。纳米颗粒以500μg/ml的OVA含量提供。以在所有组中注射相同量的OVA的这种方式将t2SVP稀释。
IgG的测量
测量IgG抗体的水平。使用在PBS中的封闭剂酪蛋白(赛默飞世尔科技公司(ThermoFisher),目录#37528)作为稀释剂。使用含0.05%Tween-20的PBS作为洗涤缓冲液,该洗涤缓冲液是通过将10ml的Tween-20(西格玛公司(Sigma),目录#P9416-100mL)添加至2升10xPBS储备液(PBS:10 X PBS液体浓缩物,4L,EMD化学品公司,目录#6505)和18升去离子水中而制备的。
使用处于5mg/ml储备液浓度的OVA蛋白作为包被材料。使用1∶1000稀释度达到5μg/ml作为工作浓度。以每孔100μl稀释的OVA来包被测定板的每个孔,并且将板用密封薄膜(VWR目录#60941-120)密封,并在4℃孵育过夜。使用Costar901796孔平底板作为测定板Costar9017。
使用低结合的聚丙烯96孔板或管作为准备板(set-up plate),样品在转移至测定板中之前在这些准备板中进行制备。这些准备板不合有任何抗原并且因此,在样品的准备过程中血清抗体不会结合至板上。准备板是用于样品制备以便在使用抗原包被板来制备样品的情况下,使样品制备或吸移过程中可能发生的结合降至最低。在准备板中制备样品之前,将孔用稀释剂覆盖以阻断任何非特异性结合,并且将板密封并在4℃孵育过夜。
测定板用洗涤缓冲液洗涤三次,并且在最后一次洗涤之后将洗涤缓冲液从各孔中完全吸出。洗涤之后,将300μl稀释剂添加至一个或多个测定板的各孔中以阻断非特异性结合,并且将板在室温孵育至少2小时。在准备板中将血清样品制备成适当的起始稀释液。有时也在1.5ml管中使用稀释剂制备起始稀释液。基于先前数据(当可利用时)确定适当的起始稀释度。在没有先前数据可利用时,最低起始稀释度是1∶40。一旦被稀释,就将200μl起始稀释度的血清样品转移到准备板的适当孔中。
一个示例性准备板布置描述如下:2列和11列含有被稀释到1μg/mL(1∶4000稀释度)的抗卵白蛋白单克隆IgG2b同种型(艾碧康公司(AbCam),ab17291)标准品。3列-10列含有血清样品(处于适当稀释度)。1列和12列未用于样品或标准品以便避免由边缘效应引起的任何测量偏差。而是,1列和12列含有200μl稀释剂。使用1∶40稀释的正常小鼠血清作为阴性对照。使用从0.5mg/mL储备液(BD生物科学公司(BD Bioscience))进行1∶500稀释的抗小鼠IgG2a作为同种型对照。
一旦在准备板中制备了所有样品,就将该板密封并在4℃储存,直到测定板的阻断是完全的为止。测定板用洗涤缓冲液洗涤三次,并且在最后一次洗涤之后将洗涤缓冲液完全吸出。洗涤之后,将100μL稀释剂添加至测定板的B-H行的所有孔中。使用12通道的移液管将样品从准备板转移到测定板中。转移之前通过来回3次吸移150μl稀释的血清将样品混合。混合之后,将150μl每种样品从准备板转移并添加至对应测定板的A行中。
一旦每种样品的起始稀释液被从准备板转移至测定板的A行,就如下述将连续稀释液在测定板上吸移:使用12通道的移液管从A行移除50μl的每种血清样品并且与先前添加至B行的各孔中的100μl稀释剂混合。此步骤沿着整个板重复。在吸移了最后一行的稀释液之后,从最后一行的孔中移除50μl流体并丢弃,从而在测定板的每孔中产生100μl的最终体积。一旦在这些测定板中制备了样品稀释液,就将这些板在室温孵育至少2小时。
孵育之后,用洗涤缓冲液将板洗涤三次。将检测抗体(HRP共轭的山羊抗小鼠抗IgG,艾碧康公司,ab98717)在稀释剂中进行1:1500稀释(0.33μg/mL),并且向各孔中添加100μl的稀释抗体。将板在室温孵育1小时并且然后用洗涤缓冲液洗涤三次,其中每个洗涤步骤包括至少30秒的浸泡时间。
洗涤之后,向各孔中添加检测底物。在即将要添加至测定板中之前将等份的底物A和底物B(BD生物科学公司,TMB底物试剂组,目录#555214)组合,并向各孔中添加100μl的混合底物溶液并在黑暗中孵育10分钟。在10分钟时间后通过向各孔中添加50μl终止溶液(2NH2SO4)来终止反应。添加了该终止溶液之后立即在板阅读器上评定各孔的光密度(OD):450nm减去570nm处的读数。使用分子装置公司(Molecular Device)的软件SoftMax Prov5.4进行数据分析。在一些情况下,用x轴上的稀释度(对数标度)和y轴上的OD值(线性标度)制备一个四参数对数拟合曲线,并且确定每种样品的半数最大值(EC50)。将该布置的顶部处的板模板调节成反映每种样品(每列1种)的稀释度。
结果
图4显示了与单独包含肽的纳米载体相比,使用包含肽抗原和免疫抑制剂的纳米载体使抗原特异性抗体的产生减少。右图3显示了强免疫刺激剂CpG的使用抵消了在一些情况下包含雷帕霉素的合成纳米载体的致耐受性作用。
实例14:使用合成纳米载体的致耐受性免疫应答
材料和方法
如以上实例(实例13)中所述制备纳米载体。
免疫
这个实验的目的在于通过测量同时接受免疫原和NP-处理的动物中的抗原特异性免疫球蛋白来评定封装的(t2SVP)免疫抑制剂对出现的抗体应答的作用。一组动物保持未免疫以作为对照(但是接受该处理)。第二组动物使用卵白蛋白的“被动给予”进行免疫,并且第三组在肩胛下区域中使用OVA和CpG进行免疫。这些组各自两周一次注射给予纳米颗粒(NP)并且在加强剂量前一天监测抗OVA Ig水平。对于免疫,动物接受皮下注射(肩胛下)的100μl的OVA+CpG或在100μl中静脉内注射的25μg的OVA。致耐受性处理包括静脉内给予100μl的t2SVP。纳米载体以5mg/ml提供。t2SVP是以在所有组中注射相同量的OVA的这种方式进行稀释。在第0天、第14天、第28天、第42天、第56天进行注射。
IgG的测量
测量IgG抗体的水平。使用含封闭剂酪蛋白的PBS(赛默飞世尔科技公司,目录#37528)作为稀释剂。使用含0.05%Tween-20的PBS作为洗涤缓冲液,该洗涤缓冲液是通过将10ml的Tween-20(西格玛公司,目录#P9416-100mL)添加至2升10 x PBS储备液(PBS:10XPBS液体浓缩物,4L,EMD化学品公司,目录#6505)和18升去离子水中而制备的。
使用处于5mg/ml储备液浓度的OVA蛋白作为包被材料。使用1∶1000稀释度达到5μg/ml作为工作浓度。以每孔100μl稀释的OVA来包被测定板的每个孔,并且将板用密封薄膜(VWR目录#60941-120)密封,并在4℃孵育过夜。使用Costar901796孔平底板作为测定板Costar9017。
使用低结合的聚丙烯96孔板或管作为准备板,样品在转移至测定板中之前在这些准备板中进行制备。这些准备板不含有任何抗原并且因此,在样品的准备过程中血清抗体不会结合至板上。准备板是用于样品制备以便在使用抗原包被板来制备样品的情况下,使样品制备或吸移过程中可能发生的结合降至最低。在准备板中制备样品之前,将孔用稀释剂覆盖以阻断任何非特异性结合,并且将板密封并在4℃孵育过夜。
测定板用洗涤缓冲液洗涤三次,并且在最后一次洗涤之后将洗涤缓冲液从各孔中完全吸出。洗涤之后,将300μl稀释剂添加至一个或多个测定板的各孔中以阻断非特异性结合,并且将板在室温孵育至少2小时。在准备板中将血清样品制备成适当的起始稀释液。有时也在1.5ml管中使用稀释剂制备起始稀释液。基于先前数据(当可获得时)确定适当的起始稀释度。在没有先前数据可利用时,最低起始稀释度是1∶40。一旦被稀释,就将200μl起始稀释度的血清样品转移到准备板的适当孔中。
一个示例性准备板布局描述如下:2列和11列含有被稀释到1μg/mL(1∶4000稀释度)的抗卵白蛋白单克隆IgG2b同种型(艾碧康公司,ab17291)标准品。3列-10列含有血清样品(处于适当稀释度)。1列和12列未用于样品或标准品以便避免由边缘效应引起的任何测量偏差。而是,1列和12列含有200μl稀释剂。使用1∶40稀释的正常小鼠血清作为阴性对照。使用从0.5mg/mL储备液(BD生物科学公司)进行1∶500稀释的抗小鼠IgG2a作为同种型对照。
一旦在准备板中制备了所有样品,就将该板密封并在4℃储存,直到测定板的阻断是完全的为止。测定板用洗涤缓冲液洗涤三次,并且在最后一次洗涤之后将洗涤缓冲液完全吸出。洗涤之后,将100μL稀释剂添加至测定板的B-H行的所有孔中。使用12通道的移液管将样品从准备板转移到测定板中。转移之前通过来回3次吸移150μl稀释的血清将样品混合。混合之后,将150μl每种样品从准备板转移并添加至对应测定板的A行中。
一旦每种样品的起始稀释液被从准备板转移至测定板的A行,就如下述将连续稀释液在测定板上吸移:使用12通道的移液管从A行移除50μl的每种血清样品并且与先前添加至B行的各孔中的100μl稀释剂混合。此步骤沿着整个板重复。在吸移了最后一行的稀释液之后,从最后一行的孔中移除50μl流体并丢弃,从而在测定板的每孔中产生100μl的最终体积。一旦在这些测定板中制备了样品稀释液,就将这些板在室温孵育至少2小时。
孵育之后,用洗涤缓冲液将板洗涤三次。将检测抗体(HRP共轭的山羊抗小鼠抗IgG,艾碧康公司,ab98717)在稀释剂中进行1:1500稀释(0.33μg/mL),并且向各孔中添加100μl的稀释抗体。将板在室温孵育1小时并且然后用洗涤缓冲液洗涤三次,其中每个洗涤步骤包括至少30秒的浸泡时间。
洗涤之后,向各孔中添加检测底物。在即将要添加至测定板中之前将等份的底物A和底物B(BD生物科学公司,TMB底物试剂组,目录#555214)组合,并向各孔中添加100μl的混合底物溶液并在黑暗中孵育10分钟。在10分钟时间后通过向各孔中添加50μl终止溶液(2NH2SO4)来终止反应。添加了该终止溶液之后立即在板阅读器上评定各孔的光密度(OD):450nm减去570nm处的读数。使用分子装置公司(Molecular Device)的软件SoftMax Prov5.4进行数据分析。在一些情况下,用x轴上的稀释度(对数标度)和y轴上的OD值(线性标度)制备一个四参数对数拟合曲线,并且确定每个样品的半数最大值(EC50)。将该布置的顶部处的板模板调节成反映每种样品(每列1种)的稀释度。
结果
图5显示了与单独包含抗原的纳米载体相比,使用包含抗原和免疫抑制剂的纳米载体使抗原特异性抗体的产生减少。再次,数据还显示强免疫刺激剂CpG的使用抵消了在一些情况下包含雷帕霉素的合成纳米载体的致耐受性作用。
实例15:评定具有抗原和免疫抑制剂的纳米载体对免疫应答的作用
材料和方法
纳米载体1
从巴亨美洲公司(柏市街3132号,托伦斯,加利福尼亚州90505,区号#4065609)购买卵白蛋白肽323-339,即一种已知为卵白蛋白的T和B细胞表位的17氨基酸肽。从SurModics制药公司(汤姆马丁路756号,伯明翰,亚拉巴马州35211;产品代码7525DLG 7A)购买丙交酯∶乙交酯比为3∶1并且特性粘度为0.75dL/g的PLGA。合成了PEG嵌段大约为5,000Da并且PLA嵌段大约为20,000Da的PLA-PEG嵌段共聚物。从EMD化学品公司(产品编号1.41350.1001)购买聚乙烯醇(85%-89%水解的)。
如下制备溶液:
溶液1:在稀释的盐酸水溶液中的卵白蛋白肽323-339@20mg/mL。通过在室温下将卵白蛋白肽溶解在0.13M盐酸溶液中而制备该溶液。溶液2:在二氯甲烷中的PLGA@100mg/mL。通过将PLGA溶解在纯二氯甲烷中而制备该溶液。溶液3:在二氯甲烷中的PLA-PEG@100mg/mL。通过将PLA-PEG溶解在纯二氯甲烷中而制备该溶液。溶液4:在100mM的pH 8的磷酸盐缓冲液中的聚乙烯醇@50mg/mL。
首先制备第一油包水乳液。通过将溶液1(0.2mL)、溶液2(0.75mL)、以及溶液3(0.25mL)合并在一个小的压力管中并且使用布兰森数字超声波仪250在50%振幅下进行声处理40秒来制备W1/O1。然后通过将溶液4(3.0mL)与第一W1/O1乳液合并、涡旋10秒、并且使用布兰森数字超声波仪250在30%振幅下进行声处理60秒来制备第二乳液(W1/O1/W2)。将该WI/O1/W2乳液添加到含有70mM的pH 8磷酸盐缓冲溶液(30mL)的烧杯中并且在室温下搅拌2小时以允许二氯甲烷蒸发并且允许纳米载体形成。通过以下方式来洗涤一部分纳米载体:将纳米载体悬浮液转移至一个离心管中,并且以75,600×g和4℃离心45分钟、去除上清液、并且将沉淀再悬浮于磷酸盐缓冲盐水中。重复该洗涤程序,并且将沉淀再悬浮于磷酸盐缓冲盐水中以用于约10mg/mL的最终的纳米载体分散液。
通过动态光散射来确定纳米载体大小。通过HPLC分析来确定在纳米载体中的肽的量。通过重量法来确定每mL悬浮液的总的干燥纳米载体质量。
纳米载体2
从巴亨美洲公司(柏市街3132号,托伦斯,加利福尼亚州90505,区号#4065609)购买卵白蛋白肽323-339,即一种已知为卵白蛋白的T和B细胞表位的17氨基酸肽。从TSZ化学品公司(威尔逊街185号,弗雷明汉,马萨诸塞州01702;产品目录#R1017)购买雷帕霉素。从SurModics制药公司(汤姆马丁路756号,伯明翰,亚拉巴马州35211;产品代码7525DLG 7A)购买丙交酯∶乙交酯比为3∶1并且特性粘度为0.75dL/g的PLGA。合成了PEG嵌段大约为5,000Da并且PLA嵌段大约为20,000Da的PLA-PEG嵌段共聚物。从EMD化学品公司(产品编号1.41350.1001)购买聚乙烯醇(85%-89%水解的)。
如下制备溶液:
溶液1:在稀释的盐酸水溶液中的卵白蛋白肽323-339@20mg/mL。通过在室温下将卵白蛋白肽溶解在0.13M盐酸溶液中而制备该溶液。溶液2:在二氯甲烷中的雷帕霉素@50mg/mL。通过将雷帕霉素溶解在纯二氯甲烷中而制备该溶液。溶液3:在二氯甲烷中的PLGA@100mg/mL。通过将PLGA溶解在纯二氯甲烷中而制备该溶液。溶液4:在二氯甲烷中的PLA-PEG@100mg/mL通过将PLA-PEG溶解在纯二氯甲烷中而制备该溶液。溶液5:在100mM的pH8的磷酸盐缓冲液中的聚乙烯醇@50mg/mL。
首先制备第一油包水乳液。通过将溶液1(0.2mL)、溶液2(0.2mL)、溶液3(0.75mL)、以及溶液4(0.25mL)合并在一个小的压力管中并且使用布兰森数字超声波仪250在50%振幅下进行声处理40秒来制备W1/O1。然后通过将溶液5(3.0mL)与第一W1/O1乳液合并、涡旋10秒、并且使用布兰森数字超声波仪250在30%振幅下进行声处理60秒来制备第二乳液(W1/O1/W2)。将该W1/O1/W2乳液添加到含有70mM的pH 8磷酸盐缓冲溶液(30mL)的烧杯中并且在室温下搅拌2小时以允许二氯甲烷蒸发并且允许纳米载体形成。通过以下方式来洗涤一部分纳米载体:将纳米载体悬浮液转移至一个离心管中,并且以21,000×g和4℃离心45分钟、去除上清液、并且将沉淀再悬浮于磷酸盐缓冲盐水中。重复该洗涤程序,并且将沉淀再悬浮于磷酸盐缓冲盐水中以用于约10mg/mL的最终的纳米载体分散液。
通过动态光散射来确定纳米载体大小。通过HPLC分析来确定在纳米载体中的肽和雷帕霉素的量。通过重量法来确定每mL悬浮液的总的干燥纳米载体质量。
免疫
动物每2周在它们接受处理的同时接受免疫。将这些组各自分成三个亚组以测试不同处理改变所诱导的Ig滴度的能力。一个对照亚组不接受致耐受性处理。两个亚组接受仅带有OVA323-339肽或与雷帕霉素组合的纳米载体。
经由以下途径给予免疫(每个动物的值):20μl/肢的OVA+CpG(12.5μgOVA+10μgCpG),两个后肢都是皮下注射。经由以下途径给予致耐受性处理(每个动物的值):以100μg/ml的OVA323-339含量提供200μl纳米载体。
IgG的测量
测量IgG抗体的水平。使用含封闭剂酪蛋白的PBS(赛默飞世尔科技公司,目录#37528)作为稀释剂。使用含0.05%Tween-20的PBS作为洗涤缓冲液,该洗涤缓冲液是通过将10ml的Tween-20(西格玛公司,目录#P9416-100mL)添加至2升10 x PBS储备液(PBS:10XPBS液体浓缩物,4L,EMD化学品公司,目录#6505)和18升去离子水中而制备的。
使用处于5mg/ml储备液浓度的OVA蛋白作为包被材料。使用1∶1000稀释度达到5μg/ml作为工作浓度。以每孔100μl稀释的OVA来包被测定板的每个孔,并且将板用密封薄膜(VWR目录#60941-120)密封,并在4℃孵育过夜。使用Costar901796孔平底板作为测定板Costar9017。
使用低结合的聚丙烯96孔板或管作为准备板,样品在转移至测定板中之前在这些准备板中进行制备。这些准备板不含有任何抗原并且因此,在样品的准备过程中血清抗体不会结合至板上。准备板是用于样品制备以便在使用抗原包被板来制备样品的情况下,使样品制备或吸液过程中可能发生的结合降至最低。在准备板中制备样品之前,将孔用稀释剂覆盖以阻断任何非特异性结合,并且将板密封并在4℃孵育过夜。
测定板用洗涤缓冲液洗涤三次,并且在最后一次洗涤之后将洗涤缓冲液从各孔中完全吸出。洗涤之后,将300μl稀释剂添加至一个或多个测定板的各孔中以阻断非特异性结合,并且将板在室温孵育至少2小时。在准备板中将血清样品制备成适当的起始稀释液。有时也在1.5ml管中使用稀释剂制备起始稀释液。基于先前数据(当可获得时)确定适当的起始稀释度。在没有先前数据可利用时,最低起始稀释度是1∶40。一旦被稀释,就将200μl起始稀释度的血清样品转移到准备板的适当孔中。
一个示例性准备板布局描述如下:2列和11列含有被稀释到1μg/mL(1∶4000稀释度)的抗卵白蛋白单克隆IgG2b同种型(艾碧康公司,ab17291)标准品。3-10列含有血清样品(处于适当的稀释度)。1列和12列未用于样品或标准品以便避免由边缘效应引起的任何测量偏差。而是,1列和12列含有200μl稀释剂。使用1∶40稀释的正常小鼠血清作为阴性对照。使用从0.5mg/mL储备液(BD生物科学公司)进行1∶500稀释的抗小鼠IgG2a作为同种型对照。
一旦在准备板中制备了所有样品,就将该板密封并在4℃储存,直到测定板的阻断是完全的为止。测定板用洗涤缓冲液洗涤三次,并且在最后一次洗涤之后将洗涤缓冲液完全吸出。洗涤之后,将100μL稀释剂添加至测定板的B-H行的所有孔中。使用12通道的移液管将样品从准备板转移到测定板中。转移之前通过来回3次吸移150μl稀释的血清将样品混合。混合之后,将150μl每种样品从准备板转移并添加至对应测定板的A行中。
一旦每种样品的起始稀释液被从准备板转移至测定板的A行,就如下述将连续稀释液在测定板上吸移:使用12通道的移液管从A行移除50μl的每种血清样品并且与先前添加至B行的各孔中的100μl稀释剂混合。此步骤沿着整个板重复。在吸移了最后一行的稀释液之后,从最后一行的孔中移除50μl流体并丢弃,从而在测定板的每孔中产生100μl的最终体积。一旦在这些测定板中制备了样品稀释液,就将这些板在室温孵育至少2小时。
孵育之后,用洗涤缓冲液将板洗涤三次。将检测抗体(HRP共轭的山羊抗小鼠抗IgG,艾碧康公司,ab98717)在稀释剂中进行1∶1500稀释(0.33μg/mL),并且向各孔中添加100μl的稀释抗体。将板在室温孵育1小时并且然后用洗涤缓冲液洗涤三次,其中每个洗涤步骤包括至少30秒的浸泡时间。
洗涤之后,向各孔中添加检测底物。在即将要添加至测定板中之前将等份的底物A和底物B(BD生物科学公司,TMB底物试剂组,目录#555214)组合,并向各孔中添加100μl的混合底物溶液并在黑暗中孵育10分钟。在10分钟时间后通过向各孔中添加50μl终止溶液(2NH2SO4)来终止反应。添加了该终止溶液之后立即在板阅读器上评定各孔的光密度(OD):450nm减去570nm处的读数。使用分子装置公司(Molecular Device)的软件SoftMax Prov5.4进行数据分析。在一些情况下,用x轴上的稀释度(对数标度)和y轴上的OD值(线性标度)制备一个四参数对数拟合曲线,并且确定每个样品的半数最大值(EC50)。将该布置的顶部处的板模板调节成反映每种样品(每列1种)的稀释度。
%OVA+分裂B细胞的测定
通过流式细胞术评定卵白蛋白+B细胞分裂。将来自实验动物的脾细胞用一种适用于长期细胞标记的硫醇反应性荧光探针Cell Tracker Orange (CTO)染色,并且在完全培养基中在37C、5%CO2下用卵白蛋白或肽培养3天。在第3天,将细胞洗涤、用抗CD16/32抗体阻断并接着用对B220和CD19特异的共轭抗体染色。还将Alexa 647共轭的卵白蛋白与这些细胞一起孵育以标记卵白蛋白特异性BCR。通过比较差异性CTO染色评定CD19+B220+OVA-Alexa647+的那些脾细胞的增殖。将CTO低的那些标记为增殖性卵白蛋白+B细胞并且与CTO高的卵白蛋白+B细胞进行比较,以便定量出百分数。
结果
图6显示了使用包含ova肽和免疫抑制剂雷帕霉素的合成纳米载体的给予使抗原特异性的IgG水平降低。图7也证明使用这些合成纳米载体的降低,但是为抗原特异性B细胞数目的降低。这些结果证明了使用与ova肽(包含MHC II类限制性表位)和免疫抑制剂偶联的合成纳米载体使所不希望的免疫应答降低。这些结果在抗原特异性B细胞的减少将会提供益处的任何情境下是有关的。
实例16:评定具有抗原和免疫抑制剂的纳米载体的作用
纳米载体
根据以上提供的方法(实例15)制备纳米载体。
免疫
将纳米载体融化并平衡。初始稀释液构成一个10x储备溶液,并且进一步在OVA323-339中稀释到100μg/ml的浓度或1x溶液。将这个1x溶液用于以每静脉内注射按200μl进行注射。将动物用OVA蛋白(OVA)免疫并且用OVA323-339肽处理以便评定纳米载体控制在B细胞抗原不存在下的免疫应答的能力。免疫途径如下:10μg的OVA+4mg明矾(Alum),腹膜内,每只Balb/C初次接受试验的雌性小鼠400μl。实验组各自由5只动物组成。脾细胞用抗原使用CFSE或CTO重新刺激,以便测定抗原特异性增殖的量。
具体免疫细胞类型的水平
使用FlowJo软件分析FCS文件。排除7AAD阳性细胞(一种标记死细胞的核染色)并且将依赖于CD4、CD8、Gr-1、F4/80、B220、TCRb以及CD11b表达的细胞形态定量。
用于T细胞子集的门控策略→7AAD-F4/80-GR-1-TCRb+CD4+/-CD8+/-
用于B细胞子集的门控策略→7AAD-B220+TCRb-
用于嗜酸性粒细胞的门控策略→7AAD-F4/80-Gr-1+TCRb-CD11b+Gr-1+
分裂CD4+ T细胞%的测定
借助流式细胞术计算卵白蛋白反应性CD4+ T细胞的频率。将来自实验动物的脾细胞用一种适用于长期细胞标记的硫醇反应性荧光探针CFSE染色,并且在完全培养基中在37C、5%CO2下用卵白蛋白培养3天。在第3天,将细胞洗涤、用抗CD16/32抗体阻断并接着用对TCR CD4和CD8a特异的共轭抗体染色。通过比较差异性CFSE染色评定TCR+CD4或TCR+CD8a+脾细胞的增殖。
结果
图8和图9证明了这些纳米载体在动物模型中的有效性。具体来说,图8证明来自用包含OVA323-339(MHC II类限制性表位)和免疫抑制剂的合成纳米载体处理的动物受试者的灌洗样品中CD4+ T细胞的数目减少。图9证明由同样的处理引起的分裂CD4+ T细胞的百分数降低。
本申请还涉及以下实施方案:
1.一种组合物,包含:
(i)第一群体的合成纳米载体,这些第一群体的合成纳米载体与免疫抑制剂偶联,和
(ii)第二群体的合成纳米载体,这些第二群体的合成纳米载体与治疗性蛋白APC可呈递抗原偶联。
2.如实施方案1所述的组合物,其中该第一群体和第二群体是相同的。
3.如实施方案1或2所述的组合物,其中这些免疫抑制剂包括一种抑制素、一种mTOR抑制剂、一种TGF-β信号剂、一种皮质类固醇、一种线粒体功能抑制剂、一种P38抑制剂、一种NF-κβ抑制剂、一种腺苷受体激动剂、一种前列腺素E2激动剂、一种磷酸二酯酶4抑制剂、一种HDAC抑制剂、或一种蛋白酶体抑制剂。
4.如实施方案4所述的组合物,其中该mTOR抑制剂是雷帕霉素。
5.如实施方案1-4中任一项所述的组合物,其中这些治疗性蛋白APC可呈递抗原包含一种治疗性蛋白的MHC I类限制性和/或MHC II类限制性表位。
6.如实施方案5所述的组合物,其中这些治疗性蛋白APC可呈递抗原包含一种治疗性蛋白的MHC II类限制性表位。
7.如实施方案1-6中任一项所述的组合物,其中这些治疗性蛋白APC可呈递抗原包含一种治疗性蛋白的B细胞表位。
8.如实施方案1-6中任一项所述的组合物,其中这些治疗性蛋白APC可呈递抗原基本上不包含治疗性蛋白的B细胞表位。
9.如实施方案1-8中任一项所述的组合物,其中这些治疗性蛋白APC可呈递抗原包括一种用于蛋白质替代或蛋白质补充疗法的治疗性蛋白、或其片段。
10.如实施方案1-9中任一项所述的组合物,其中这些治疗性蛋白APC可呈递抗原包括一种可输注或可注射的治疗性蛋白、酶、酶辅助因子、激素、血液或凝血因子、细胞因子、干扰素、生长因子、单克隆抗体、多克隆抗体、或与庞贝氏病相关的蛋白质、或其片段。
11.如实施方案10所述的组合物,其中该可输注或可注射的治疗性蛋白包括托珠单抗(Tocilizumab)、α-1抗胰蛋白酶、Hematide、白蛋白干扰素α-2b、Rhucin、替莫瑞林(tesamorelin)、奥瑞珠单抗(ocrelizumab)、贝利木单抗(belimumab)、聚乙二醇重组尿酸酶(pegloticase)、α-他利苷酶(taliglucerase alfa)、阿加糖酶α(agalsidase alfa)、或葡糖脑苷脂酶α(velaglucerase alfa)。
12.如实施方案10所述的组合物,其中该酶包括氧化还原酶、转移酶、水解酶、裂解酶、异构酶或连接酶。
13.如实施方案10所述的组合物,其中酶包括用于针对溶酶体贮积症的酶替代疗法的酶。
14.如实施方案13所述的组合物,其中用于针对溶酶体贮积症的酶替代疗法的酶包括伊米苷酶(imiglucerase)、a-半乳糖苷酶A(a-gal A)、阿加糖酶β、酸性a-葡萄糖苷酶(GAA)、阿葡糖苷酶α、LUMIZYME、MYOZYME、芳基硫酸酯酶B、拉罗尼酶(laronidase)、ALDURAZYME、艾度硫酸酯酶(idursulfase)、ELAPRASE、芳基硫酸酯酶B或NAGLAZYME。
15.如实施方案10所述的组合物,其中该细胞因子包括一种淋巴因子、白细胞介素、趋化因子、1型细胞因子、或一种2型细胞因子。
16.如实施方案10所述的组合物,其中该血液和凝血因子包括因子I、因子II、组织因子、因子V、因子VII、因子VIII、因子IX、因子X、因子Xa、因子XII、因子XIII、血管性血友病因子、前激肽释放酶、高分子量激肽原、纤连蛋白、抗凝血酶III、肝素辅助因子II、蛋白C、蛋白S、蛋白Z、蛋白Z相关蛋白酶抑制剂(ZPI)、血纤溶酶原、α2-抗纤维蛋白溶酶、组织型纤溶酶原激活物(tPA)、尿激酶、纤溶酶原激活物抑制剂-1(PAI1)、纤溶酶原激活物抑制剂-2(PAI2)、癌性促凝物质、或阿法依伯汀。
17.如实施方案1-16中任一项所述的组合物,其中该组合物处于有效产生针对该治疗性蛋白APC可呈递抗原的一种致耐受性免疫应答的量。
18.如实施方案1-17中任一项所述的组合物,其中当向受试者给予时,该组合物处于有效降低治疗性蛋白特异性抗体的产生和/或CD4+ T细胞增殖和/或活性和/或B细胞增殖和/或活性的量。
19.如实施方案1-18中任一项所述的组合物,其中平均在这些第一和/或第二群体的合成纳米载体上的该免疫抑制剂和/或治疗性蛋白APC可呈递抗原的负载是在0.0001%与50%之间。
20.如实施方案19所述的组合物,其中平均在这些第一和/或第二群体的合成纳米载体上的该免疫抑制剂和/或治疗性蛋白APC可呈递抗原的负载是在0.1%与10%之间。
21.如实施方案1-20中任一项所述的组合物,其中该第一群体和/或第二群体的这些合成纳米载体包括脂质纳米颗粒、聚合物纳米颗粒、金属纳米颗粒、基于表面活性剂的乳液、树枝状化合物、巴基球、纳米线、病毒样颗粒、或肽或蛋白质颗粒。
22.如实施方案21所述的组合物,其中该第一和/或第二群体的这些合成纳米载体包括脂质纳米颗粒。
23.如实施方案22所述的组合物,其中该第一和/或第二群体的这些合成纳米载体包括脂质体。
24.如实施方案21所述的组合物,其中该第一和/或第二群体的这些合成纳米载体包括金属纳米颗粒。
25.如实施方案24所述的组合物,其中这些金属纳米颗粒包括金纳米颗粒。
26.如实施方案21所述的组合物,其中该第一和/或第二群体的这些合成纳米载体包括聚合物纳米颗粒。
27.如实施方案26所述的组合物,其中该聚合物纳米颗粒包括聚合物,该聚合物是一种非甲氧基封端的普朗尼克聚合物。
28.如实施方案26或27所述的组合物,其中这些聚合物纳米颗粒包括聚酯、与聚醚偶联的聚酯、聚氨基酸、聚碳酸酯、聚缩醛、聚缩酮、多糖、聚乙基噁唑啉、或聚乙烯亚胺。
29.如实施方案28所述的组合物,其中该聚酯包含一种聚(乳酸)、聚(乙醇酸)、聚(乳酸-乙醇酸)共聚物、或聚己酸内酯。
30.如实施方案28或29所述的组合物,其中这些聚合物纳米颗粒包括聚酯以及与聚醚偶联的聚酯。
31.如实施方案28-30中任一项所述的组合物,其中该聚醚包括聚乙二醇或聚丙二醇。
32.如实施方案1-31中任一项所述的组合物,其中使用对该第一和/或第二群体的这些合成纳米载体进行的动态光散射而获得的粒度分布的平均值是大于100nm的直径。
33.如实施方案32所述的组合物,其中该直径大于150nm。
34.如实施方案33所述的组合物,其中该直径大于200nm。
35.如实施方案34所述的组合物,其中该直径大于250nm。
36.如实施方案35所述的组合物,其中该直径大于300nm。
37.如实施方案1-36中任一项所述的组合物,其中该第一群体和/或第二群体的这些合成纳米载体的长宽比大于1∶1、1∶1.2、1∶1.5、1∶2、1∶3、1∶5、1∶7或1∶10。
38.如实施方案1-37中任一项所述的组合物,其中该组合物进一步包含一种药学上可接受的赋形剂。
39.一种包含如实施方案1至38中任一项所述的组合物的剂型。
40.一种包括向受试者给予如实施方案1-38中任一项所述的组合物或如实施方案39所述的剂型的方法,该受试者正被给予或将被给予一种治疗性蛋白。
41.如实施方案40所述的方法,其中该方法进一步包括向该受试者给予该治疗性蛋白。
42.如实施方案40或41所述的方法,其中在给予该组合物或剂型之前、与此同时或在此之后给予该治疗性蛋白。
43.如实施方案40-42中任一项所述的方法,其中向该受试者给予一个或多个维持剂量的该组合物或剂型。
44.如实施方案40-43中任一项所述的方法,其中该方法进一步包括在给予该组合物或剂型和/或该治疗性蛋白之前和/或之后评定该受试者中所不希望的免疫应答的产生。
45.如实施方案44所述的方法,其中该所不希望的免疫应答是产生治疗性蛋白特异性抗体和/或CD4+ T细胞增殖和/或活性和/或B细胞增殖和/或活性。
46.如实施方案40-45中任一项所述的方法,其中该治疗性蛋白包括一种用于蛋白质替代或蛋白质补充疗法的治疗性蛋白。
47.如实施方案40-45中任一项所述的方法,其中该治疗性蛋白包括一种可输注或可注射的治疗性蛋白、酶、酶辅助因子、激素、血液或凝血因子、细胞因子、干扰素、生长因子、单克隆抗体、多克隆抗体、或与庞贝氏病相关的蛋白质。
48.如实施方案47所述的方法,其中该可输注或可注射的治疗性蛋白包含托珠单抗(Tocilizumab)、α-1抗胰蛋白酶、Hematide、白蛋白干扰素α-2b、Rhucin、替莫瑞林(tesamorelin)、奥瑞珠单抗(ocrelizumab)、贝利木单抗(belimumab)、聚乙二醇重组尿酸酶(pegloticase)、α-他利苷酶(taliglucerase alfa)、阿加糖酶α(agalsidase alfa)、或葡糖脑苷脂酶α(velaglucerase alfa)。
49.如实施方案47所述的方法,其中该酶包括氧化还原酶、转移酶、水解酶、裂解酶、异构酶、或连接酶。
50.如实施方案47所述的方法,其中酶包括用于针对溶酶体贮积症的酶替代疗法的酶。
51.如实施方案50所述的方法,其中用于针对溶酶体贮积症的酶替代疗法的酶包括伊米苷酶(imiglucerase)、a-半乳糖苷酶A(a-gal A)、阿加糖酶β、酸性a-葡萄糖苷酶(GAA)、阿葡糖苷酶α、LUMIZYME、MYOZYME、芳基硫酸酯酶B、拉罗尼酶(laronidase)、ALDURAZYME、艾度硫酸酯酶(idursulfase)、ELAPRASE、芳基硫酸酯酶B、或NAGLAZYME。
52.如实施方案47所述的方法,其中该细胞因子包括一种淋巴因子、白细胞介素、趋化因子、1型细胞因子、或一种2型细胞因子。
53.如实施方案47所述的方法,其中该血液和凝血因子包括因子I、因子II、组织因子、因子V、因子VII、因子VIII、因子IX、因子X、因子Xa、因子XII、因子XIII、血管性血友病因子、前激肽释放酶、高分子量激肽原、纤连蛋白、抗凝血酶III、肝素辅助因子II、蛋白C、蛋白S、蛋白Z、蛋白Z相关蛋白酶抑制剂(ZPI)、纤溶酶原、α2-抗纤维蛋白溶酶、组织型纤溶酶原激活物(tPA)、尿激酶、纤溶酶原激活物抑制剂-1(PAI1)、纤溶酶原激活物抑制剂-2(PAI2)、癌性促凝物质、或阿法依伯汀。
54.如实施方案40-53中任一项所述的方法,其中通过静脉内、腹膜内、透粘膜、经口、皮下、肺部、鼻内、皮内或肌肉内给予来进行这些第一和/或第二群体的合成纳米载体和/或治疗性蛋白的给予。
55.如实施方案54所述的方法,其中通过吸入或静脉内、皮下或透粘膜给予来进行这些第一和/或第二群体的合成纳米载体和/或治疗性蛋白的给予。
56.一种方法,包括:
向受试者给予一种组合物,该组合物包含:
(i)第一群体的合成纳米载体,这些第一群体的合成纳米载体与免疫抑制剂偶联,和
(ii)第二群体的合成纳米载体,这些第二群体的合成纳米载体与治疗性蛋白APC可呈递抗原偶联,
其中,该组合物的量是有效于减少对抗这些治疗性蛋白APC可呈递抗原的一种所不希望的免疫应答的产生。
57.一种方法,包括:
通过给予一种组合物来降低受试者中一种所不希望的免疫应答的产生,该组合物包含:
(i)第一群体的合成纳米载体,这些第一群体的合成纳米载体与免疫抑制剂偶联,和
(ii)第二群体的合成纳米载体,这些第二群体的合成纳米载体与治疗性蛋白APC可呈递抗原偶联。
58.一种方法,包括:
根据一种治疗方案向受试者给予一种组合物,该治疗方案先前已显示在一个或多个测试受试者中降低针对治疗性蛋白APC可呈递抗原的一种所不希望的免疫应答的产生;
其中,该组合物包含:
(i)第一群体的合成纳米载体,这些第一群体的合成纳米载体与免疫抑制剂偶联,和
(ii)第二群体的合成纳米载体,这些第二群体的合成纳米载体与治疗性蛋白APC可呈递抗原偶联。
59.如实施方案56-58中任一项所述的方法,其中该第一群体和第二群体是相同的。
60.如实施方案56-59中任一项所述的方法,其中该方法进一步包括提供或鉴定该受试者。
61.如实施方案56-60中任一项所述的方法,其中该方法进一步包括在给予该组合物之前和/或之后评定该受试者中该所不希望的免疫应答的产生。
62.如实施方案61所述的方法,其中该所不希望的免疫应答是产生治疗性蛋白特异性抗体和/或CD4+ T细胞增殖和/或活性和/或B细胞增殖和/或活性。
63.如实施方案56-62中任一项所述的方法,其中这些免疫抑制剂包含一种抑制素、一种mTOR抑制剂、一种TGF-β信号剂、一种皮质类固醇、一种线粒体功能抑制剂、一种P38抑制剂、一种NF-κβ抑制剂、一种腺苷受体激动剂、一种前列腺素E2激动剂、一种磷酸二酯酶4抑制剂、一种HDAC抑制剂、或一种蛋白酶体抑制剂。
64.如实施方案63所述的方法,其中该mTOR抑制剂是雷帕霉素。
65.如实施方案56-64中任一项所述的方法,其中这些治疗性蛋白APC可呈递抗原包含一种治疗性蛋白的MHC I类限制性和/或MHC II类限制性表位。
66.如实施方案65所述的方法,其中这些治疗性蛋白APC可呈递抗原包含一种治疗性蛋白的MHC II类限制性表位。
67.如实施方案56-66中任一项所述的方法,其中这些治疗性蛋白APC可呈递抗原包含一种治疗性蛋白的B细胞表位。
68.如实施方案56-67中任一项所述的方法,其中该治疗性蛋白包括用于蛋白质替代或蛋白质补充疗法的治疗性蛋白。
69.如实施方案56-68中任一项所述的方法,其中该治疗性蛋白包括一种可输注或可注射的治疗性蛋白、酶、酶辅助因子、激素、血液或凝血因子、细胞因子、干扰素、生长因子、单克隆抗体、多克隆抗体、或与庞贝氏病相关的蛋白质。
70.如实施方案69所述的方法,其中该可输注或可注射的治疗性蛋白包括托珠单抗(Tocilizumab)、α-1抗胰蛋白酶、Hematide、白蛋白干扰素α-2b、Rhucin、替莫瑞林(tesamorelin)、奥瑞珠单抗(ocrelizumab)、贝利木单抗(belimumab)、聚乙二醇重组尿酸酶(pegloticase)、α-他利苷酶(taliglucerase alfa)、阿加糖酶α(agalsidase alfa)、或葡糖脑苷脂酶α(velaglucerase alfa)。
71.如实施方案69所述的方法,其中该酶包括氧化还原酶、转移酶、水解酶、裂解酶、异构酶、或连接酶。
72.如实施方案69所述的方法,其中酶包括用于针对溶酶体贮积症的酶替代疗法的酶。
73.如实施方案72所述的方法,其中用于针对溶酶体贮积症的酶替代疗法的酶包括伊米苷酶(imiglucerase)、a-半乳糖苷酶A(a-gal A)、阿加糖酶β、酸性a-葡萄糖苷酶(GAA)、阿葡糖苷酶α、LUMIZYME、MYOZYME、芳基硫酸酯酶B、拉罗尼酶(laronidase)、ALDURAZYME、艾度硫酸酯酶(idursulfase)、ELAPRASE、芳基硫酸酯酶B、或NAGLAZYME。
74.如实施方案69所述的方法,其中该细胞因子包括一种淋巴因子、白细胞介素、趋化因子、1型细胞因子、或一种2型细胞因子。
75.如实施方案69所述的方法,其中该血液和凝血因子包括因子I、因子II、组织因子、因子V、因子VII、因子VIII、因子IX、因子X、因子Xa、因子XII、因子XIII、血管性血友病因子、前激肽释放酶、高分子量激肽原、纤连蛋白、抗凝血酶III、肝素辅助因子II、蛋白C、蛋白S、蛋白Z、蛋白Z相关蛋白酶抑制剂(ZPI)、纤溶酶原、α2-抗纤维蛋白溶酶、组织型纤溶酶原激活物(tPA)、尿激酶、纤溶酶原激活物抑制剂-1(PAI1)、纤溶酶原激活物抑制剂-2(PAI2)、癌性促凝物质、或阿法依伯汀。
76.如实施方案56-75中任一项所述的方法,其中该组合物处于有效降低治疗性蛋白特异性抗体的产生和/或CD4+ T细胞增殖和/或活性和/或B细胞增殖和/或活性的量。
77.如实施方案56-76中任一项所述的方法,其中平均在这些第一群体和/或第二群体的合成纳米载体上的该免疫抑制剂和/或治疗性蛋白APC可呈递抗原的负载是在0.0001%与50%之间。
78.如实施方案56-76中任一项所述的方法,其中平均在这些第一群体和/或第二群体的合成纳米载体上的该免疫抑制剂和/或治疗性蛋白APC可呈递抗原的负载是在0.1%与10%之间。
79.如实施方案56-78中任一项所述的方法,其中该第一群体和/或第二群体的这些合成纳米载体包括脂质纳米颗粒、聚合物纳米颗粒、金属纳米颗粒、基于表面活性剂的乳液、树枝状化合物、巴基球、纳米线、病毒样颗粒、或肽或蛋白质颗粒。
80.如实施方案79所述的方法,其中该第一和/或第二群体的这些合成纳米载体包括脂质纳米颗粒。
81.如实施方案80所述的方法,其中该第一和/或第二群体的这些合成纳米载体包括脂质体。
82.如实施方案79所述的方法,其中该第一和/或第二群体的这些合成纳米载体包括金属纳米颗粒。
83.如实施方案82所述的方法,其中这些金属纳米颗粒包括金纳米颗粒。
84.如实施方案79所述的方法,其中该第一和/或第二群体的这些合成纳米载体包括聚合物纳米颗粒。
85.如实施方案84所述的方法,其中该聚合物纳米颗粒包括聚合物,该聚合物是一种非甲氧基封端的普朗尼克聚合物。
86.如实施方案84或85所述的方法,其中这些聚合物纳米颗粒包括聚酯、与聚醚偶联的聚酯、聚氨基酸、聚碳酸酯、聚缩醛、聚缩酮、多糖、聚乙基噁唑啉或聚乙烯亚胺。
87.如实施方案86所述的方法,其中该聚酯包括一种聚(乳酸)、聚(乙醇酸)、聚(乳酸-乙醇酸)共聚物、或聚己酸内酯。
88.如实施方案86或87所述的方法,其中这些聚合物纳米颗粒包括聚酯以及与聚醚偶联的聚酯。
89.如实施方案86-88中任一项所述的方法,其中该聚醚包括聚乙二醇或聚丙二醇。
90.如实施方案56-89中任一项所述的方法,其中使用对该第一和/或第二群体的这些合成纳米载体进行的动态光散射而获得的粒度分布的平均值是大于100nm的直径。
91.如实施方案90所述的方法,其中该直径大于150nm。
92.如实施方案91所述的方法,其中该直径大于200nm。
93.如实施方案92所述的方法,其中该直径大于250nm。
94.如实施方案93所述的方法,其中该直径大于300nm。
95.如实施方案56-94中任一项所述的组合物,其中该第一群体和/或第二群体的这些合成纳米载体的长宽比大于1∶1、1∶1.2、1∶1.5、1∶2、1∶3、1∶5、1∶7或1∶10。
96.如实施方案56-95中任一项所述的方法,其中该组合物进一步包含一种药学上可接受的赋形剂。
97.如实施方案56-96中任一项所述的方法,其中该方法进一步包括向该受试者给予该治疗性蛋白。
98.如实施方案97所述的方法,其中在给予该组合物之前、与此同时或在此之后给予该治疗性蛋白。
99.如实施方案56-98中任一项所述的方法,其中向该受试者给予一个或多个维持剂量的该组合物。
100.如实施方案56-99中任一项所述的方法,其中该方法进一步包括在给予该组合物和/或治疗性蛋白之前和/或之后评定该受试者中一种所不希望的免疫应答的产生。
101.如实施方案100所述的方法,其中该所不希望的免疫应答是产生治疗性蛋白特异性抗体和/或CD4+ T细胞增殖和/或活性和/或B细胞增殖和/或活性。
102.如实施方案56-101中任一项所述的方法,其中该给予是通过静脉内、腹膜内、透粘膜、经口、皮下、肺部、鼻内、皮内或肌肉内给予进行的。
103.如实施方案102所述的方法,其中该给予是通过吸入或静脉内、皮下或透粘膜给予进行的。
104.一种方法,包括:
(i)产生第一群体的合成纳米载体,这些第一群体的合成纳米载体与免疫抑制剂偶联,并且
(ii)产生第二群体的合成纳米载体,这些第二群体的合成纳米载体与治疗性蛋白APC可呈递抗原偶联。
105.如实施方案104所述的方法,其中该第一群体和第二群体是相同的。
106.如实施方案104或105所述的方法,其中产生的这些第一和第二群体的合成纳米载体是如在实施方案1-38中任一项所定义的。
107.如实施方案104-106中任一项所述的方法,其中该方法进一步包括产生一种组合物的一种剂型,该组合物包含产生的这些第一和第二群体的合成纳米载体。
108.如实施方案104-107中任一项所述的方法,其中该方法进一步包括制造一种包含这些第一群体和第二群体的合成纳米载体的组合物、或可供受试者给予的剂型。
109.如实施方案104-108中任一项所述的方法,其中该方法进一步包括评定使用一种包含这些第一群体和第二群体的合成纳米载体的组合物的一种所不希望的免疫应答的降低。
110.如实施方案109所述的方法,其中该所不希望的免疫应答是产生治疗性蛋白特异性抗体和/或CD4+ T细胞增殖和/或活性和/或B细胞增殖和/或活性。
111.一种用于生产一种组合物或剂型的工艺,该组合物或剂型包含:
(i)第一群体的合成纳米载体,这些第一群体的合成纳米载体与免疫抑制剂偶联,和
(ii)第二群体的合成纳米载体,这些第二群体的合成纳米载体与治疗性蛋白APC可呈递抗原偶联,
该工艺包括如在实施方案104-110中任一项所述的方法中所定义的步骤。
112.一种通过如实施方案104-111中任一项所述的方法或工艺可获得的组合物或剂型。
113.一种供在治疗或预防中使用的如实施方案1-38和112中任一项所述的组合物或如实施方案39所述的剂型。
114.一种如实施方案1-38和112中任一项所述的组合物或如实施方案39所述的剂型,用于在一种诱导针对治疗性蛋白抗原的一种致耐受性免疫应答的方法、基于细胞的疗法、蛋白质替代疗法、蛋白质补充疗法、或如在实施方案40-110中任一项所定义的方法中使用。
115.如实施方案1-38和112中任一项所述的组合物或如实施方案39所述的剂型用于制造一种药剂的用途,该药剂用于在一种诱导针对治疗性蛋白抗原的一种致耐受性免疫应答的方法、基于细胞的疗法、蛋白质替代疗法、蛋白质补充疗法、或如在实施方案40-110中任一项所定义的方法中使用。
116.一种包含如实施方案112-114中任一项所述的组合物的剂型。
Claims (10)
1.一种组合物,包含:
(i)第一群体的合成纳米载体,这些第一群体的合成纳米载体与免疫抑制剂偶联,和
(ii)第二群体的合成纳米载体,这些第二群体的合成纳米载体与治疗性蛋白APC可呈递抗原偶联。
2.如权利要求1所述的组合物,其中该第一群体和第二群体是相同的。
3.如权利要求1或2所述的组合物,其中这些免疫抑制剂包括一种抑制素、一种mTOR抑制剂、一种TGF-β信号剂、一种皮质类固醇、一种线粒体功能抑制剂、一种P38抑制剂、一种NF-κβ抑制剂、一种腺苷受体激动剂、一种前列腺素E2激动剂、一种磷酸二酯酶4抑制剂、一种HDAC抑制剂、或一种蛋白酶体抑制剂。
4.如权利要求4所述的组合物,其中该mTOR抑制剂是雷帕霉素。
5.如权利要求1-4中任一项所述的组合物,其中这些治疗性蛋白APC可呈递抗原包含一种治疗性蛋白的MHC I类限制性和/或MHC II类限制性表位。
6.如权利要求5所述的组合物,其中这些治疗性蛋白APC可呈递抗原包含一种治疗性蛋白的MHC II类限制性表位。
7.如权利要求1-6中任一项所述的组合物,其中这些治疗性蛋白APC可呈递抗原包含一种治疗性蛋白的B细胞表位。
8.如权利要求1-6中任一项所述的组合物,其中这些治疗性蛋白APC可呈递抗原基本上不包含治疗性蛋白的B细胞表位。
9.如权利要求1-8中任一项所述的组合物,其中这些治疗性蛋白APC可呈递抗原包括一种用于蛋白质替代或蛋白质补充疗法的治疗性蛋白、或其片段。
10.如权利要求1-9中任一项所述的组合物,其中这些治疗性蛋白APC可呈递抗原包括一种可输注或可注射的治疗性蛋白、酶、酶辅助因子、激素、血液或凝血因子、细胞因子、干扰素、生长因子、单克隆抗体、多克隆抗体、或与庞贝氏病相关的蛋白质、或其片段。
Applications Claiming Priority (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161480946P | 2011-04-29 | 2011-04-29 | |
US61/480,946 | 2011-04-29 | ||
US201161513514P | 2011-07-29 | 2011-07-29 | |
US61/513,514 | 2011-07-29 | ||
US201161531153P | 2011-09-06 | 2011-09-06 | |
US201161531209P | 2011-09-06 | 2011-09-06 | |
US201161531175P | 2011-09-06 | 2011-09-06 | |
US201161531204P | 2011-09-06 | 2011-09-06 | |
US201161531164P | 2011-09-06 | 2011-09-06 | |
US201161531147P | 2011-09-06 | 2011-09-06 | |
US201161531168P | 2011-09-06 | 2011-09-06 | |
US201161531180P | 2011-09-06 | 2011-09-06 | |
US201161531215P | 2011-09-06 | 2011-09-06 | |
US201161531194P | 2011-09-06 | 2011-09-06 | |
US61/531,209 | 2011-09-06 | ||
US61/531,168 | 2011-09-06 | ||
US61/531,147 | 2011-09-06 | ||
US61/531,180 | 2011-09-06 | ||
US61/531,164 | 2011-09-06 | ||
US61/531,204 | 2011-09-06 | ||
US61/531,175 | 2011-09-06 | ||
US61/531,215 | 2011-09-06 | ||
US61/531,194 | 2011-09-06 | ||
US61/531,153 | 2011-09-06 | ||
CN201280020302.4A CN103491957A (zh) | 2011-04-29 | 2012-04-27 | 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280020302.4A Division CN103491957A (zh) | 2011-04-29 | 2012-04-27 | 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107670054A true CN107670054A (zh) | 2018-02-09 |
Family
ID=47068065
Family Applications (34)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280020312.8A Pending CN103501813A (zh) | 2011-04-29 | 2012-04-27 | 用于降低抗体应答的致耐受性合成纳米载体 |
CN201280020407.XA Pending CN103517716A (zh) | 2011-04-29 | 2012-04-27 | 用于诱导调节性b细胞的致耐受性合成纳米载体 |
CN201710304258.4A Pending CN107261154A (zh) | 2011-04-29 | 2012-04-27 | 致耐受性合成纳米载体 |
CN201710304257.XA Pending CN107970440A (zh) | 2011-04-29 | 2012-04-27 | 致耐受性合成纳米载体 |
CN202311101154.5A Pending CN117205331A (zh) | 2011-04-29 | 2012-04-27 | 用于降低抗体应答的致耐受性合成纳米载体 |
CN201710194493.0A Pending CN107837402A (zh) | 2011-04-29 | 2012-04-27 | 从合成纳米载体中控制释放免疫抑制剂 |
CN202311101952.8A Pending CN117065050A (zh) | 2011-04-29 | 2012-04-27 | 用于降低细胞毒性t淋巴细胞应答的致耐受性合成纳米载体 |
CN202410142938.0A Pending CN118078979A (zh) | 2011-04-29 | 2012-04-27 | 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体 |
CN201280020311.3A Active CN103501820B (zh) | 2011-04-29 | 2012-04-27 | 用于效应性t细胞的抗原特异性缺失的致耐受性合成纳米载体 |
CN201280020293.9A Pending CN103501786A (zh) | 2011-04-29 | 2012-04-27 | 致耐受性合成纳米载体 |
CN201710800310.5A Pending CN107670054A (zh) | 2011-04-29 | 2012-04-27 | 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体 |
CN201710247154.4A Pending CN107252481A (zh) | 2011-04-29 | 2012-04-27 | 用于过敏症治疗的致耐受性合成纳米载体 |
CN201410795620.9A Pending CN104623666A (zh) | 2011-04-29 | 2012-04-27 | 用于诱导调节性b细胞的致耐受性合成纳米载体 |
CN201280020302.4A Pending CN103491957A (zh) | 2011-04-29 | 2012-04-27 | 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体 |
CN201611214876.1A Pending CN107126552A (zh) | 2011-04-29 | 2012-04-27 | 用于产生cd8+调节性t细胞的致耐受性合成纳米载体 |
CN201611213970.5A Pending CN107029213A (zh) | 2011-04-29 | 2012-04-27 | 用于产生cd8+调节性t细胞的致耐受性合成纳米载体 |
CN201710194492.6A Pending CN107320734A (zh) | 2011-04-29 | 2012-04-27 | 从合成纳米载体中控制释放免疫抑制剂 |
CN201280020380.4A Pending CN103501812A (zh) | 2011-04-29 | 2012-04-27 | 用于过敏症治疗的致耐受性合成纳米载体 |
CN202111502784.4A Pending CN114306638A (zh) | 2011-04-29 | 2012-04-27 | 从合成纳米载体中控制释放免疫抑制剂 |
CN201710247155.9A Pending CN107252487A (zh) | 2011-04-29 | 2012-04-27 | 用于过敏症治疗的致耐受性合成纳米载体 |
CN201710800423.5A Pending CN107670030A (zh) | 2011-04-29 | 2012-04-27 | 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体 |
CN201710755435.0A Pending CN107693798A (zh) | 2011-04-29 | 2012-04-27 | 用于降低细胞毒性t淋巴细胞应答的致耐受性合成纳米载体 |
CN202110202213.2A Pending CN113018452A (zh) | 2011-04-29 | 2012-04-27 | 用于效应性t细胞的抗原特异性缺失的致耐受性合成纳米载体 |
CN201710234341.9A Pending CN107261151A (zh) | 2011-04-29 | 2012-04-27 | 用于降低抗体应答的致耐受性合成纳米载体 |
CN201710759432.4A Pending CN107693799A (zh) | 2011-04-29 | 2012-04-27 | 用于降低细胞毒性t淋巴细胞应答的致耐受性合成纳米载体 |
CN201280020361.1A Pending CN103533935A (zh) | 2011-04-29 | 2012-04-27 | 用于降低细胞毒性t淋巴细胞应答的致耐受性合成纳米载体 |
CN201710420561.0A Pending CN107261123A (zh) | 2011-04-29 | 2012-04-27 | 用于诱导调节性b细胞的致耐受性合成纳米载体 |
CN202311202032.5A Pending CN117298266A (zh) | 2011-04-29 | 2012-04-27 | 致耐受性合成纳米载体 |
CN202410143139.5A Pending CN118078980A (zh) | 2011-04-29 | 2012-04-27 | 致耐受性合成纳米载体 |
CN201280020398.4A Pending CN103517707A (zh) | 2011-04-29 | 2012-04-27 | 从合成纳米载体中控制释放免疫抑制剂 |
CN201710230780.2A Pending CN107343959A (zh) | 2011-04-29 | 2012-04-27 | 用于降低抗体应答的致耐受性合成纳米载体 |
CN201610345030.5A Pending CN105999295A (zh) | 2011-04-29 | 2012-04-27 | 用于效应性t细胞的抗原特异性缺失的致耐受性合成纳米载体 |
CN201280020294.3A Pending CN103501787A (zh) | 2011-04-29 | 2012-04-27 | 用于产生cd8+调节性t细胞的致耐受性合成纳米载体 |
CN202311101967.4A Pending CN117018224A (zh) | 2011-04-29 | 2012-04-27 | 用于降低细胞毒性t淋巴细胞应答的致耐受性合成纳米载体 |
Family Applications Before (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280020312.8A Pending CN103501813A (zh) | 2011-04-29 | 2012-04-27 | 用于降低抗体应答的致耐受性合成纳米载体 |
CN201280020407.XA Pending CN103517716A (zh) | 2011-04-29 | 2012-04-27 | 用于诱导调节性b细胞的致耐受性合成纳米载体 |
CN201710304258.4A Pending CN107261154A (zh) | 2011-04-29 | 2012-04-27 | 致耐受性合成纳米载体 |
CN201710304257.XA Pending CN107970440A (zh) | 2011-04-29 | 2012-04-27 | 致耐受性合成纳米载体 |
CN202311101154.5A Pending CN117205331A (zh) | 2011-04-29 | 2012-04-27 | 用于降低抗体应答的致耐受性合成纳米载体 |
CN201710194493.0A Pending CN107837402A (zh) | 2011-04-29 | 2012-04-27 | 从合成纳米载体中控制释放免疫抑制剂 |
CN202311101952.8A Pending CN117065050A (zh) | 2011-04-29 | 2012-04-27 | 用于降低细胞毒性t淋巴细胞应答的致耐受性合成纳米载体 |
CN202410142938.0A Pending CN118078979A (zh) | 2011-04-29 | 2012-04-27 | 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体 |
CN201280020311.3A Active CN103501820B (zh) | 2011-04-29 | 2012-04-27 | 用于效应性t细胞的抗原特异性缺失的致耐受性合成纳米载体 |
CN201280020293.9A Pending CN103501786A (zh) | 2011-04-29 | 2012-04-27 | 致耐受性合成纳米载体 |
Family Applications After (23)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710247154.4A Pending CN107252481A (zh) | 2011-04-29 | 2012-04-27 | 用于过敏症治疗的致耐受性合成纳米载体 |
CN201410795620.9A Pending CN104623666A (zh) | 2011-04-29 | 2012-04-27 | 用于诱导调节性b细胞的致耐受性合成纳米载体 |
CN201280020302.4A Pending CN103491957A (zh) | 2011-04-29 | 2012-04-27 | 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体 |
CN201611214876.1A Pending CN107126552A (zh) | 2011-04-29 | 2012-04-27 | 用于产生cd8+调节性t细胞的致耐受性合成纳米载体 |
CN201611213970.5A Pending CN107029213A (zh) | 2011-04-29 | 2012-04-27 | 用于产生cd8+调节性t细胞的致耐受性合成纳米载体 |
CN201710194492.6A Pending CN107320734A (zh) | 2011-04-29 | 2012-04-27 | 从合成纳米载体中控制释放免疫抑制剂 |
CN201280020380.4A Pending CN103501812A (zh) | 2011-04-29 | 2012-04-27 | 用于过敏症治疗的致耐受性合成纳米载体 |
CN202111502784.4A Pending CN114306638A (zh) | 2011-04-29 | 2012-04-27 | 从合成纳米载体中控制释放免疫抑制剂 |
CN201710247155.9A Pending CN107252487A (zh) | 2011-04-29 | 2012-04-27 | 用于过敏症治疗的致耐受性合成纳米载体 |
CN201710800423.5A Pending CN107670030A (zh) | 2011-04-29 | 2012-04-27 | 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体 |
CN201710755435.0A Pending CN107693798A (zh) | 2011-04-29 | 2012-04-27 | 用于降低细胞毒性t淋巴细胞应答的致耐受性合成纳米载体 |
CN202110202213.2A Pending CN113018452A (zh) | 2011-04-29 | 2012-04-27 | 用于效应性t细胞的抗原特异性缺失的致耐受性合成纳米载体 |
CN201710234341.9A Pending CN107261151A (zh) | 2011-04-29 | 2012-04-27 | 用于降低抗体应答的致耐受性合成纳米载体 |
CN201710759432.4A Pending CN107693799A (zh) | 2011-04-29 | 2012-04-27 | 用于降低细胞毒性t淋巴细胞应答的致耐受性合成纳米载体 |
CN201280020361.1A Pending CN103533935A (zh) | 2011-04-29 | 2012-04-27 | 用于降低细胞毒性t淋巴细胞应答的致耐受性合成纳米载体 |
CN201710420561.0A Pending CN107261123A (zh) | 2011-04-29 | 2012-04-27 | 用于诱导调节性b细胞的致耐受性合成纳米载体 |
CN202311202032.5A Pending CN117298266A (zh) | 2011-04-29 | 2012-04-27 | 致耐受性合成纳米载体 |
CN202410143139.5A Pending CN118078980A (zh) | 2011-04-29 | 2012-04-27 | 致耐受性合成纳米载体 |
CN201280020398.4A Pending CN103517707A (zh) | 2011-04-29 | 2012-04-27 | 从合成纳米载体中控制释放免疫抑制剂 |
CN201710230780.2A Pending CN107343959A (zh) | 2011-04-29 | 2012-04-27 | 用于降低抗体应答的致耐受性合成纳米载体 |
CN201610345030.5A Pending CN105999295A (zh) | 2011-04-29 | 2012-04-27 | 用于效应性t细胞的抗原特异性缺失的致耐受性合成纳米载体 |
CN201280020294.3A Pending CN103501787A (zh) | 2011-04-29 | 2012-04-27 | 用于产生cd8+调节性t细胞的致耐受性合成纳米载体 |
CN202311101967.4A Pending CN117018224A (zh) | 2011-04-29 | 2012-04-27 | 用于降低细胞毒性t淋巴细胞应答的致耐受性合成纳米载体 |
Country Status (15)
Country | Link |
---|---|
US (34) | US20120276156A1 (zh) |
EP (15) | EP3679933A1 (zh) |
JP (32) | JP6491879B2 (zh) |
KR (25) | KR20190123796A (zh) |
CN (34) | CN103501813A (zh) |
AU (34) | AU2012249401A1 (zh) |
BR (5) | BR112013027508A2 (zh) |
CA (11) | CA3192054A1 (zh) |
DK (1) | DK2701739T3 (zh) |
EA (16) | EA028807B1 (zh) |
ES (1) | ES2806268T3 (zh) |
HU (1) | HUE050142T2 (zh) |
IL (15) | IL297146A (zh) |
MX (13) | MX2013012599A (zh) |
WO (12) | WO2012149301A2 (zh) |
Families Citing this family (516)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6993506B2 (en) | 2000-12-05 | 2006-01-31 | Jgr Acquisition, Inc. | Method and device utilizing polymorphic data in e-commerce |
US9060770B2 (en) | 2003-05-20 | 2015-06-23 | Ethicon Endo-Surgery, Inc. | Robotically-driven surgical instrument with E-beam driver |
US20070084897A1 (en) | 2003-05-20 | 2007-04-19 | Shelton Frederick E Iv | Articulating surgical stapling instrument incorporating a two-piece e-beam firing mechanism |
US9072535B2 (en) | 2011-05-27 | 2015-07-07 | Ethicon Endo-Surgery, Inc. | Surgical stapling instruments with rotatable staple deployment arrangements |
US11998198B2 (en) | 2004-07-28 | 2024-06-04 | Cilag Gmbh International | Surgical stapling instrument incorporating a two-piece E-beam firing mechanism |
US8215531B2 (en) | 2004-07-28 | 2012-07-10 | Ethicon Endo-Surgery, Inc. | Surgical stapling instrument having a medical substance dispenser |
US11896225B2 (en) | 2004-07-28 | 2024-02-13 | Cilag Gmbh International | Staple cartridge comprising a pan |
US7669746B2 (en) | 2005-08-31 | 2010-03-02 | Ethicon Endo-Surgery, Inc. | Staple cartridges for forming staples having differing formed staple heights |
US11484312B2 (en) | 2005-08-31 | 2022-11-01 | Cilag Gmbh International | Staple cartridge comprising a staple driver arrangement |
US10159482B2 (en) | 2005-08-31 | 2018-12-25 | Ethicon Llc | Fastener cartridge assembly comprising a fixed anvil and different staple heights |
US9237891B2 (en) | 2005-08-31 | 2016-01-19 | Ethicon Endo-Surgery, Inc. | Robotically-controlled surgical stapling devices that produce formed staples having different lengths |
US11246590B2 (en) | 2005-08-31 | 2022-02-15 | Cilag Gmbh International | Staple cartridge including staple drivers having different unfired heights |
US7934630B2 (en) | 2005-08-31 | 2011-05-03 | Ethicon Endo-Surgery, Inc. | Staple cartridges for forming staples having differing formed staple heights |
US20070106317A1 (en) | 2005-11-09 | 2007-05-10 | Shelton Frederick E Iv | Hydraulically and electrically actuated articulation joints for surgical instruments |
US8067237B2 (en) | 2005-12-13 | 2011-11-29 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
US11793518B2 (en) | 2006-01-31 | 2023-10-24 | Cilag Gmbh International | Powered surgical instruments with firing system lockout arrangements |
US20120292367A1 (en) | 2006-01-31 | 2012-11-22 | Ethicon Endo-Surgery, Inc. | Robotically-controlled end effector |
US8186555B2 (en) | 2006-01-31 | 2012-05-29 | Ethicon Endo-Surgery, Inc. | Motor-driven surgical cutting and fastening instrument with mechanical closure system |
US7845537B2 (en) | 2006-01-31 | 2010-12-07 | Ethicon Endo-Surgery, Inc. | Surgical instrument having recording capabilities |
US11224427B2 (en) | 2006-01-31 | 2022-01-18 | Cilag Gmbh International | Surgical stapling system including a console and retraction assembly |
US20110295295A1 (en) | 2006-01-31 | 2011-12-01 | Ethicon Endo-Surgery, Inc. | Robotically-controlled surgical instrument having recording capabilities |
US11278279B2 (en) | 2006-01-31 | 2022-03-22 | Cilag Gmbh International | Surgical instrument assembly |
US20110024477A1 (en) | 2009-02-06 | 2011-02-03 | Hall Steven G | Driven Surgical Stapler Improvements |
US8820603B2 (en) | 2006-01-31 | 2014-09-02 | Ethicon Endo-Surgery, Inc. | Accessing data stored in a memory of a surgical instrument |
US7753904B2 (en) | 2006-01-31 | 2010-07-13 | Ethicon Endo-Surgery, Inc. | Endoscopic surgical instrument with a handle that can articulate with respect to the shaft |
US8708213B2 (en) | 2006-01-31 | 2014-04-29 | Ethicon Endo-Surgery, Inc. | Surgical instrument having a feedback system |
US8992422B2 (en) | 2006-03-23 | 2015-03-31 | Ethicon Endo-Surgery, Inc. | Robotically-controlled endoscopic accessory channel |
US8322455B2 (en) | 2006-06-27 | 2012-12-04 | Ethicon Endo-Surgery, Inc. | Manually driven surgical cutting and fastening instrument |
US10568652B2 (en) | 2006-09-29 | 2020-02-25 | Ethicon Llc | Surgical staples having attached drivers of different heights and stapling instruments for deploying the same |
US11980366B2 (en) | 2006-10-03 | 2024-05-14 | Cilag Gmbh International | Surgical instrument |
US8632535B2 (en) | 2007-01-10 | 2014-01-21 | Ethicon Endo-Surgery, Inc. | Interlock and surgical instrument including same |
US8684253B2 (en) | 2007-01-10 | 2014-04-01 | Ethicon Endo-Surgery, Inc. | Surgical instrument with wireless communication between a control unit of a robotic system and remote sensor |
US11291441B2 (en) | 2007-01-10 | 2022-04-05 | Cilag Gmbh International | Surgical instrument with wireless communication between control unit and remote sensor |
US8827133B2 (en) | 2007-01-11 | 2014-09-09 | Ethicon Endo-Surgery, Inc. | Surgical stapling device having supports for a flexible drive mechanism |
US11039836B2 (en) | 2007-01-11 | 2021-06-22 | Cilag Gmbh International | Staple cartridge for use with a surgical stapling instrument |
US7604151B2 (en) | 2007-03-15 | 2009-10-20 | Ethicon Endo-Surgery, Inc. | Surgical stapling systems and staple cartridges for deploying surgical staples with tissue compression features |
US8931682B2 (en) | 2007-06-04 | 2015-01-13 | Ethicon Endo-Surgery, Inc. | Robotically-controlled shaft based rotary drive systems for surgical instruments |
US11857181B2 (en) | 2007-06-04 | 2024-01-02 | Cilag Gmbh International | Robotically-controlled shaft based rotary drive systems for surgical instruments |
US7753245B2 (en) | 2007-06-22 | 2010-07-13 | Ethicon Endo-Surgery, Inc. | Surgical stapling instruments |
US11849941B2 (en) | 2007-06-29 | 2023-12-26 | Cilag Gmbh International | Staple cartridge having staple cavities extending at a transverse angle relative to a longitudinal cartridge axis |
US10328133B2 (en) | 2008-02-13 | 2019-06-25 | President And Fellows Of Harvard College | Continuous cell programming devices |
US9179912B2 (en) | 2008-02-14 | 2015-11-10 | Ethicon Endo-Surgery, Inc. | Robotically-controlled motorized surgical cutting and fastening instrument |
US8573465B2 (en) | 2008-02-14 | 2013-11-05 | Ethicon Endo-Surgery, Inc. | Robotically-controlled surgical end effector system with rotary actuated closure systems |
US11986183B2 (en) | 2008-02-14 | 2024-05-21 | Cilag Gmbh International | Surgical cutting and fastening instrument comprising a plurality of sensors to measure an electrical parameter |
US8636736B2 (en) | 2008-02-14 | 2014-01-28 | Ethicon Endo-Surgery, Inc. | Motorized surgical cutting and fastening instrument |
BRPI0901282A2 (pt) | 2008-02-14 | 2009-11-17 | Ethicon Endo Surgery Inc | instrumento cirúrgico de corte e fixação dotado de eletrodos de rf |
US7819298B2 (en) | 2008-02-14 | 2010-10-26 | Ethicon Endo-Surgery, Inc. | Surgical stapling apparatus with control features operable with one hand |
US7866527B2 (en) | 2008-02-14 | 2011-01-11 | Ethicon Endo-Surgery, Inc. | Surgical stapling apparatus with interlockable firing system |
US9585657B2 (en) | 2008-02-15 | 2017-03-07 | Ethicon Endo-Surgery, Llc | Actuator for releasing a layer of material from a surgical end effector |
US11648005B2 (en) | 2008-09-23 | 2023-05-16 | Cilag Gmbh International | Robotically-controlled motorized surgical instrument with an end effector |
US9005230B2 (en) | 2008-09-23 | 2015-04-14 | Ethicon Endo-Surgery, Inc. | Motorized surgical instrument |
US8210411B2 (en) | 2008-09-23 | 2012-07-03 | Ethicon Endo-Surgery, Inc. | Motor-driven surgical cutting instrument |
US9386983B2 (en) | 2008-09-23 | 2016-07-12 | Ethicon Endo-Surgery, Llc | Robotically-controlled motorized surgical instrument |
US8608045B2 (en) | 2008-10-10 | 2013-12-17 | Ethicon Endo-Sugery, Inc. | Powered surgical cutting and stapling apparatus with manually retractable firing system |
US8517239B2 (en) | 2009-02-05 | 2013-08-27 | Ethicon Endo-Surgery, Inc. | Surgical stapling instrument comprising a magnetic element driver |
CA2751664A1 (en) | 2009-02-06 | 2010-08-12 | Ethicon Endo-Surgery, Inc. | Driven surgical stapler improvements |
US20110223201A1 (en) * | 2009-04-21 | 2011-09-15 | Selecta Biosciences, Inc. | Immunonanotherapeutics Providing a Th1-Biased Response |
MX2011012598A (es) | 2009-05-27 | 2012-04-19 | Selecta Biosciences Inc | Nanoportadores sinteticos objetivos con liberacion sensible al ph de agentes inmunomoduladores. |
AU2010293059B2 (en) * | 2009-08-26 | 2017-03-16 | Selecta Biosciences, Inc. | Compositions that induce T cell help |
US8851354B2 (en) | 2009-12-24 | 2014-10-07 | Ethicon Endo-Surgery, Inc. | Surgical cutting instrument that analyzes tissue thickness |
EA201500857A1 (ru) | 2010-05-26 | 2016-06-30 | Селекта Байосайенсиз, Инк. | Комбинированные вакцины с синтетическими наноносителями |
KR20130102534A (ko) | 2010-07-12 | 2013-09-17 | 에이티와이알 파마, 인코포레이티드 | 히스티딜trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견 |
US8783543B2 (en) | 2010-07-30 | 2014-07-22 | Ethicon Endo-Surgery, Inc. | Tissue acquisition arrangements and methods for surgical stapling devices |
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
US11298125B2 (en) | 2010-09-30 | 2022-04-12 | Cilag Gmbh International | Tissue stapler having a thickness compensator |
US11812965B2 (en) | 2010-09-30 | 2023-11-14 | Cilag Gmbh International | Layer of material for a surgical end effector |
US11925354B2 (en) | 2010-09-30 | 2024-03-12 | Cilag Gmbh International | Staple cartridge comprising staples positioned within a compressible portion thereof |
US9700317B2 (en) | 2010-09-30 | 2017-07-11 | Ethicon Endo-Surgery, Llc | Fastener cartridge comprising a releasable tissue thickness compensator |
US9320523B2 (en) | 2012-03-28 | 2016-04-26 | Ethicon Endo-Surgery, Llc | Tissue thickness compensator comprising tissue ingrowth features |
US8857694B2 (en) | 2010-09-30 | 2014-10-14 | Ethicon Endo-Surgery, Inc. | Staple cartridge loading assembly |
US9241714B2 (en) | 2011-04-29 | 2016-01-26 | Ethicon Endo-Surgery, Inc. | Tissue thickness compensator and method for making the same |
US9629814B2 (en) | 2010-09-30 | 2017-04-25 | Ethicon Endo-Surgery, Llc | Tissue thickness compensator configured to redistribute compressive forces |
US10945731B2 (en) | 2010-09-30 | 2021-03-16 | Ethicon Llc | Tissue thickness compensator comprising controlled release and expansion |
US8695866B2 (en) | 2010-10-01 | 2014-04-15 | Ethicon Endo-Surgery, Inc. | Surgical instrument having a power control circuit |
DE19177059T1 (de) | 2010-10-01 | 2021-10-07 | Modernatx, Inc. | N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen |
DK2624873T3 (da) | 2010-10-06 | 2020-03-02 | Harvard College | Injicerbare, pore-dannende hydrogeler til materiale-baserede celleterapier |
EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
US20130323319A1 (en) | 2010-11-12 | 2013-12-05 | Getts Consulting And Project Management | Modified immune-modulating particles |
WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
BR112013027794B1 (pt) | 2011-04-29 | 2020-12-15 | Ethicon Endo-Surgery, Inc | Conjunto de cartucho de grampos |
BR112013027508A2 (pt) | 2011-04-29 | 2017-03-14 | Selecta Biosciences Inc | nanotransportadores sintéticos tolerogênicos para reduzir respostas de anticorpos |
US11207064B2 (en) | 2011-05-27 | 2021-12-28 | Cilag Gmbh International | Automated end effector component reloading system for use with a robotic system |
EA201490381A1 (ru) | 2011-07-29 | 2014-06-30 | Селекта Байосайенсиз, Инк. | Синтетические наноносители, которые стимулируют формирование гуморального иммунного ответа и иммунного ответа, опосредованного цитотоксическими т-лимфоцитами (ctl) |
US9901616B2 (en) | 2011-08-31 | 2018-02-27 | University Of Georgia Research Foundation, Inc. | Apoptosis-targeting nanoparticles |
AU2012305931B2 (en) | 2011-09-08 | 2017-09-07 | Yeda Research And Development Co. Ltd | Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
LT3682905T (lt) | 2011-10-03 | 2022-02-25 | Modernatx, Inc. | Modifikuoti nukleozidai, nukleotidai ir nukleorūgštys bei jų naudojimas |
EP2591801A1 (en) * | 2011-11-14 | 2013-05-15 | Universitätsklinikum Hamburg-Eppendorf | Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions |
PL2791160T3 (pl) | 2011-12-16 | 2022-06-20 | Modernatx, Inc. | Kompozycje zmodyfikowanego mrna |
EP2812028A4 (en) | 2012-02-07 | 2016-01-06 | Jolla Inst Allergy Immunolog | EPITOPES OF ALLERGENIC PROTEINS AND METHOD AND USE TO IMMUNE REACTION MODULATION |
EP2814514B1 (en) | 2012-02-16 | 2017-09-13 | Atyr Pharma, Inc. | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
WO2013123298A1 (en) | 2012-02-17 | 2013-08-22 | University Of Georgia Research Foundation, Inc. | Nanoparticles for mitochondrial trafficking of agents |
IN2014DN08394A (zh) * | 2012-03-23 | 2015-05-08 | Esteve Labor Dr | |
JP6105041B2 (ja) | 2012-03-28 | 2017-03-29 | エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. | 低圧環境を画定するカプセルを含む組織厚コンペンセーター |
BR112014024102B1 (pt) | 2012-03-28 | 2022-03-03 | Ethicon Endo-Surgery, Inc | Conjunto de cartucho de prendedores para um instrumento cirúrgico, e conjunto de atuador de extremidade para um instrumento cirúrgico |
RU2644272C2 (ru) | 2012-03-28 | 2018-02-08 | Этикон Эндо-Серджери, Инк. | Узел ограничения, включающий компенсатор толщины ткани |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
CN104411338A (zh) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
CA2870309C (en) | 2012-04-16 | 2024-02-20 | President And Fellows Of Harvard College | Mesoporous silica compositions for modulating immune responses |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9597385B2 (en) | 2012-04-23 | 2017-03-21 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
US9101358B2 (en) | 2012-06-15 | 2015-08-11 | Ethicon Endo-Surgery, Inc. | Articulatable surgical instrument comprising a firing drive |
BR112014032207B1 (pt) | 2012-06-21 | 2021-07-27 | Northwestern University | Composição compreendendo um antígeno acoplado a uma partícula transportadora e uso de um antígeno acoplado a uma partícula transportadora |
US11278284B2 (en) | 2012-06-28 | 2022-03-22 | Cilag Gmbh International | Rotary drive arrangements for surgical instruments |
US9282974B2 (en) | 2012-06-28 | 2016-03-15 | Ethicon Endo-Surgery, Llc | Empty clip cartridge lockout |
US9226751B2 (en) | 2012-06-28 | 2016-01-05 | Ethicon Endo-Surgery, Inc. | Surgical instrument system including replaceable end effectors |
BR112014032776B1 (pt) | 2012-06-28 | 2021-09-08 | Ethicon Endo-Surgery, Inc | Sistema de instrumento cirúrgico e kit cirúrgico para uso com um sistema de instrumento cirúrgico |
US20140001231A1 (en) | 2012-06-28 | 2014-01-02 | Ethicon Endo-Surgery, Inc. | Firing system lockout arrangements for surgical instruments |
US9289256B2 (en) | 2012-06-28 | 2016-03-22 | Ethicon Endo-Surgery, Llc | Surgical end effectors having angled tissue-contacting surfaces |
RU2636861C2 (ru) | 2012-06-28 | 2017-11-28 | Этикон Эндо-Серджери, Инк. | Блокировка пустой кассеты с клипсами |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
BR112015009883A2 (pt) | 2012-10-30 | 2017-08-22 | Univ Monash | Novas moléculas imunoterapêuticas e os usos das mesmas |
CN105120877A (zh) * | 2012-11-05 | 2015-12-02 | 株式会社雷吉姆恩 | 免疫耐受诱导物 |
RS63237B1 (sr) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminalno modifikovana rnk |
MX368026B (es) | 2013-03-01 | 2019-09-12 | Ethicon Endo Surgery Inc | Instrumento quirúrgico articulable con vías conductoras para la comunicación de la señal. |
BR112015021082B1 (pt) | 2013-03-01 | 2022-05-10 | Ethicon Endo-Surgery, Inc | Instrumento cirúrgico |
SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
CN114099461A (zh) | 2013-03-13 | 2022-03-01 | onCOUR制药股份有限公司 | 用于治疗炎症的免疫修饰性颗粒 |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US9883860B2 (en) | 2013-03-14 | 2018-02-06 | Ethicon Llc | Interchangeable shaft assemblies for use with a surgical instrument |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
US9629629B2 (en) | 2013-03-14 | 2017-04-25 | Ethicon Endo-Surgey, LLC | Control systems for surgical instruments |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
DK3460054T3 (da) | 2013-03-15 | 2021-01-18 | Atyr Pharma Inc | Histidyl-tRNA-syntetase-Fc-konjugater |
WO2014154907A1 (de) | 2013-03-28 | 2014-10-02 | Protagen Ag | Verfahren zur diagnose von neuromyelitis optica |
KR102233251B1 (ko) | 2013-04-03 | 2021-03-26 | 엔-폴드 엘엘씨 | 신규 나노입자 조성물 |
US10136887B2 (en) | 2013-04-16 | 2018-11-27 | Ethicon Llc | Drive system decoupling arrangement for a surgical instrument |
BR112015026109B1 (pt) | 2013-04-16 | 2022-02-22 | Ethicon Endo-Surgery, Inc | Instrumento cirúrgico |
CA2910579C (en) * | 2013-05-03 | 2023-09-26 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
CN111068061A (zh) * | 2013-05-03 | 2020-04-28 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
CN112933234A (zh) * | 2013-06-04 | 2021-06-11 | 西莱克塔生物科技公司 | 非免疫抑制性抗原特异性免疫治疗剂的重复施用 |
EP2813242A1 (en) * | 2013-06-13 | 2014-12-17 | PLS-Design GmbH | Low molecular weight immune-modulators as adjuvants for specific immunotherapy |
HUE047329T2 (hu) * | 2013-08-13 | 2020-04-28 | Univ Northwestern | Peptiddel konjugált részecskék |
JP6416260B2 (ja) | 2013-08-23 | 2018-10-31 | エシコン エルエルシー | 動力付き外科用器具のための発射部材後退装置 |
US10624634B2 (en) | 2013-08-23 | 2020-04-21 | Ethicon Llc | Firing trigger lockout arrangements for surgical instruments |
CA2923029A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US20160228521A1 (en) * | 2013-09-16 | 2016-08-11 | Allertein Therapeutics, Llc | Managing immune responses in transplantation |
WO2015042664A1 (en) | 2013-09-25 | 2015-04-02 | Monash University | Novel immunotherapeutic composition and uses thereof |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
DK3071696T3 (da) | 2013-11-22 | 2019-10-07 | Mina Therapeutics Ltd | C/ebp alfa kort aktiverings-rna-sammensætninger og fremgangsmåder til anvendelse |
KR101483378B1 (ko) * | 2013-12-24 | 2015-01-15 | 이영환 | 금 나노 입자를 함유하는 물을 이용한 금 나노 입자를 포함하는 달걀 제조방법 |
MX2016009217A (es) * | 2014-01-17 | 2017-05-12 | Fundació Inst D'investigació En Ciències De La Salut Germans Trias I Pujol | Inmunoterapia basada en liposomas. |
US9962161B2 (en) | 2014-02-12 | 2018-05-08 | Ethicon Llc | Deliverable surgical instrument |
EP2918262B1 (en) * | 2014-03-10 | 2023-08-09 | PLS-Design GmbH | Induction of antigen-specific tolerance by peripheral phagocytosis |
WO2015138992A1 (en) | 2014-03-14 | 2015-09-17 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
US9826977B2 (en) | 2014-03-26 | 2017-11-28 | Ethicon Llc | Sterilization verification circuit |
US10004497B2 (en) | 2014-03-26 | 2018-06-26 | Ethicon Llc | Interface systems for use with surgical instruments |
BR112016021943B1 (pt) | 2014-03-26 | 2022-06-14 | Ethicon Endo-Surgery, Llc | Instrumento cirúrgico para uso por um operador em um procedimento cirúrgico |
US9801628B2 (en) | 2014-09-26 | 2017-10-31 | Ethicon Llc | Surgical staple and driver arrangements for staple cartridges |
JP6612256B2 (ja) | 2014-04-16 | 2019-11-27 | エシコン エルエルシー | 不均一な締結具を備える締結具カートリッジ |
US20150297225A1 (en) | 2014-04-16 | 2015-10-22 | Ethicon Endo-Surgery, Inc. | Fastener cartridges including extensions having different configurations |
CN106456176B (zh) | 2014-04-16 | 2019-06-28 | 伊西康内外科有限责任公司 | 包括具有不同构型的延伸部的紧固件仓 |
BR112016023807B1 (pt) | 2014-04-16 | 2022-07-12 | Ethicon Endo-Surgery, Llc | Conjunto de cartucho de prendedores para uso com um instrumento cirúrgico |
US10561422B2 (en) | 2014-04-16 | 2020-02-18 | Ethicon Llc | Fastener cartridge comprising deployable tissue engaging members |
CN107073090A (zh) | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | 结合的疫苗装置和杀死癌细胞的方法 |
CN104028745A (zh) * | 2014-06-11 | 2014-09-10 | 浙江大学 | 一种利用丝素蛋白调控金纳米颗粒自组装的方法 |
US20150359865A1 (en) * | 2014-06-17 | 2015-12-17 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease |
US20170210788A1 (en) | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
US10016199B2 (en) | 2014-09-05 | 2018-07-10 | Ethicon Llc | Polarity of hall magnet to identify cartridge type |
US11311294B2 (en) | 2014-09-05 | 2022-04-26 | Cilag Gmbh International | Powered medical device including measurement of closure state of jaws |
BR112017004361B1 (pt) | 2014-09-05 | 2023-04-11 | Ethicon Llc | Sistema eletrônico para um instrumento cirúrgico |
AU2015311706A1 (en) * | 2014-09-07 | 2017-02-02 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
CN113620978A (zh) | 2014-09-11 | 2021-11-09 | 加利福尼亚大学董事会 | mTORC1抑制剂 |
US10105142B2 (en) | 2014-09-18 | 2018-10-23 | Ethicon Llc | Surgical stapler with plurality of cutting elements |
MX2017003960A (es) | 2014-09-26 | 2017-12-04 | Ethicon Llc | Refuerzos de grapas quirúrgicas y materiales auxiliares. |
US11523821B2 (en) | 2014-09-26 | 2022-12-13 | Cilag Gmbh International | Method for creating a flexible staple line |
CA2962214A1 (en) | 2014-09-26 | 2016-03-31 | Seqirus UK Limited | Vaccination of immunocompromised subjects |
US9924944B2 (en) | 2014-10-16 | 2018-03-27 | Ethicon Llc | Staple cartridge comprising an adjunct material |
US20180015101A1 (en) | 2014-10-28 | 2018-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for antigen-specific tolerance |
US10517594B2 (en) | 2014-10-29 | 2019-12-31 | Ethicon Llc | Cartridge assemblies for surgical staplers |
US11141153B2 (en) | 2014-10-29 | 2021-10-12 | Cilag Gmbh International | Staple cartridges comprising driver arrangements |
CN113244191A (zh) * | 2014-11-05 | 2021-08-13 | 西莱克塔生物科技公司 | 与具有处于稳定的超饱和状态之雷帕霉素的合成纳米颗粒相关的方法和组合物 |
US9844376B2 (en) | 2014-11-06 | 2017-12-19 | Ethicon Llc | Staple cartridge comprising a releasable adjunct material |
US10736636B2 (en) | 2014-12-10 | 2020-08-11 | Ethicon Llc | Articulatable surgical instrument system |
US10085748B2 (en) | 2014-12-18 | 2018-10-02 | Ethicon Llc | Locking arrangements for detachable shaft assemblies with articulatable surgical end effectors |
US9844375B2 (en) | 2014-12-18 | 2017-12-19 | Ethicon Llc | Drive arrangements for articulatable surgical instruments |
US9844374B2 (en) | 2014-12-18 | 2017-12-19 | Ethicon Llc | Surgical instrument systems comprising an articulatable end effector and means for adjusting the firing stroke of a firing member |
US10245027B2 (en) | 2014-12-18 | 2019-04-02 | Ethicon Llc | Surgical instrument with an anvil that is selectively movable about a discrete non-movable axis relative to a staple cartridge |
US9987000B2 (en) | 2014-12-18 | 2018-06-05 | Ethicon Llc | Surgical instrument assembly comprising a flexible articulation system |
RU2703684C2 (ru) | 2014-12-18 | 2019-10-21 | ЭТИКОН ЭНДО-СЕРДЖЕРИ, ЭлЭлСи | Хирургический инструмент с упором, который выполнен с возможностью избирательного перемещения относительно кассеты со скобами вокруг дискретной неподвижной оси |
CA3012602A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
US11154301B2 (en) | 2015-02-27 | 2021-10-26 | Cilag Gmbh International | Modular stapling assembly |
US10245033B2 (en) | 2015-03-06 | 2019-04-02 | Ethicon Llc | Surgical instrument comprising a lockable battery housing |
US10441279B2 (en) | 2015-03-06 | 2019-10-15 | Ethicon Llc | Multiple level thresholds to modify operation of powered surgical instruments |
JP2020121162A (ja) | 2015-03-06 | 2020-08-13 | エシコン エルエルシーEthicon LLC | 測定の安定性要素、クリープ要素、及び粘弾性要素を決定するためのセンサデータの時間依存性評価 |
US9993248B2 (en) | 2015-03-06 | 2018-06-12 | Ethicon Endo-Surgery, Llc | Smart sensors with local signal processing |
US10052044B2 (en) | 2015-03-06 | 2018-08-21 | Ethicon Llc | Time dependent evaluation of sensor data to determine stability, creep, and viscoelastic elements of measures |
US10433844B2 (en) | 2015-03-31 | 2019-10-08 | Ethicon Llc | Surgical instrument with selectively disengageable threaded drive systems |
EP3280464A4 (en) | 2015-04-10 | 2018-09-26 | President and Fellows of Harvard College | Immune cell trapping devices and methods for making and using the same |
CN104758261A (zh) * | 2015-04-30 | 2015-07-08 | 中国医学科学院生物医学工程研究所 | 淫羊藿苷plga纳米粒子及制备方法及用途 |
EP3303635B1 (en) | 2015-06-01 | 2021-09-01 | California Institute of Technology | Compositions and methods for screening t cells with antigens for specific populations |
EP3310342A4 (en) * | 2015-06-16 | 2019-03-06 | The Trustees of the University of Pennsylvania | INORGANIC PARTICLES WITH QUICK-LOAD PROLONGED RELEASE IN DRUG SUBSTANCE |
BR112018000217A2 (pt) * | 2015-07-15 | 2018-09-04 | Celator Pharmaceuticals Inc | sistemas de distribuição de nanopartículas aperfeiçoados |
DK3322425T3 (da) | 2015-07-16 | 2023-06-12 | Yeda Res & Dev | Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi |
WO2017019214A1 (en) | 2015-07-29 | 2017-02-02 | Musc Foundation For Research Development | Donor organ pre-treatment formulation |
US10617418B2 (en) | 2015-08-17 | 2020-04-14 | Ethicon Llc | Implantable layers for a surgical instrument |
EP3347053B1 (en) | 2015-09-13 | 2022-05-25 | The Research Foundation For State University Of New York | Functional, segregated, charged telodendrimers and nanocarriers and methods of making and using same |
HUE057613T2 (hu) | 2015-09-17 | 2022-05-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
US10238386B2 (en) | 2015-09-23 | 2019-03-26 | Ethicon Llc | Surgical stapler having motor control based on an electrical parameter related to a motor current |
US10105139B2 (en) | 2015-09-23 | 2018-10-23 | Ethicon Llc | Surgical stapler having downstream current-based motor control |
KR102514116B1 (ko) | 2015-09-24 | 2023-03-23 | 삼성전자주식회사 | 반도체 나노결정 입자 및 이를 포함하는 소자 |
US10299878B2 (en) | 2015-09-25 | 2019-05-28 | Ethicon Llc | Implantable adjunct systems for determining adjunct skew |
US10524788B2 (en) * | 2015-09-30 | 2020-01-07 | Ethicon Llc | Compressible adjunct with attachment regions |
US11890015B2 (en) | 2015-09-30 | 2024-02-06 | Cilag Gmbh International | Compressible adjunct with crossing spacer fibers |
US10736633B2 (en) | 2015-09-30 | 2020-08-11 | Ethicon Llc | Compressible adjunct with looping members |
US10980539B2 (en) | 2015-09-30 | 2021-04-20 | Ethicon Llc | Implantable adjunct comprising bonded layers |
US20170157215A1 (en) * | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
EP3964200A1 (en) | 2015-12-10 | 2022-03-09 | ModernaTX, Inc. | Compositions and methods for delivery of therapeutic agents |
US11433136B2 (en) | 2015-12-18 | 2022-09-06 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
US10799463B2 (en) | 2015-12-22 | 2020-10-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
DK3394093T3 (da) | 2015-12-23 | 2022-04-19 | Modernatx Inc | Fremgangsmåder til anvendelse af ox40-ligand-kodende polynukleotider |
US10368865B2 (en) | 2015-12-30 | 2019-08-06 | Ethicon Llc | Mechanisms for compensating for drivetrain failure in powered surgical instruments |
US10292704B2 (en) | 2015-12-30 | 2019-05-21 | Ethicon Llc | Mechanisms for compensating for battery pack failure in powered surgical instruments |
US10265068B2 (en) | 2015-12-30 | 2019-04-23 | Ethicon Llc | Surgical instruments with separable motors and motor control circuits |
WO2017120612A1 (en) | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
WO2017136837A1 (en) | 2016-02-06 | 2017-08-10 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
US11213293B2 (en) | 2016-02-09 | 2022-01-04 | Cilag Gmbh International | Articulatable surgical instruments with single articulation link arrangements |
CN108882932B (zh) | 2016-02-09 | 2021-07-23 | 伊西康有限责任公司 | 具有非对称关节运动构造的外科器械 |
US10448948B2 (en) | 2016-02-12 | 2019-10-22 | Ethicon Llc | Mechanisms for compensating for drivetrain failure in powered surgical instruments |
US11224426B2 (en) | 2016-02-12 | 2022-01-18 | Cilag Gmbh International | Mechanisms for compensating for drivetrain failure in powered surgical instruments |
EP3426285B1 (en) * | 2016-03-11 | 2024-05-29 | Cartesian Therapeutics, Inc. | Formulations and doses of pegylated uricase |
US10426467B2 (en) | 2016-04-15 | 2019-10-01 | Ethicon Llc | Surgical instrument with detection sensors |
US10335145B2 (en) | 2016-04-15 | 2019-07-02 | Ethicon Llc | Modular surgical instrument with configurable operating mode |
US11179150B2 (en) | 2016-04-15 | 2021-11-23 | Cilag Gmbh International | Systems and methods for controlling a surgical stapling and cutting instrument |
US10357247B2 (en) | 2016-04-15 | 2019-07-23 | Ethicon Llc | Surgical instrument with multiple program responses during a firing motion |
US11607239B2 (en) | 2016-04-15 | 2023-03-21 | Cilag Gmbh International | Systems and methods for controlling a surgical stapling and cutting instrument |
US10492783B2 (en) | 2016-04-15 | 2019-12-03 | Ethicon, Llc | Surgical instrument with improved stop/start control during a firing motion |
US10828028B2 (en) | 2016-04-15 | 2020-11-10 | Ethicon Llc | Surgical instrument with multiple program responses during a firing motion |
US10456137B2 (en) | 2016-04-15 | 2019-10-29 | Ethicon Llc | Staple formation detection mechanisms |
US10433840B2 (en) | 2016-04-18 | 2019-10-08 | Ethicon Llc | Surgical instrument comprising a replaceable cartridge jaw |
US20170296173A1 (en) | 2016-04-18 | 2017-10-19 | Ethicon Endo-Surgery, Llc | Method for operating a surgical instrument |
US11317917B2 (en) | 2016-04-18 | 2022-05-03 | Cilag Gmbh International | Surgical stapling system comprising a lockable firing assembly |
EP3251662A1 (en) * | 2016-06-07 | 2017-12-06 | Tolerogenics S.à.r.l. | Matrix-embedded tolerance-promotion adjuvants for subcutaneous immunotherapy |
NL2017204B1 (en) | 2016-06-08 | 2017-12-18 | Kei International Ltd | Solid substrate comprising antigens immobilised thereto, biosensor comprising said solid substrate and method for detecting the presence of mycobacterial material in a sample |
CA3029813A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
JP2018012694A (ja) * | 2016-07-12 | 2018-01-25 | 日本化薬株式会社 | ラパマイシン類結合ブロック共重合体 |
CN115305229A (zh) | 2016-07-13 | 2022-11-08 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
WO2018067477A1 (en) * | 2016-10-05 | 2018-04-12 | Wang tian xin | Methods and reagents to treat autoimmune diseases and allergy |
US20210363220A1 (en) * | 2016-10-05 | 2021-11-25 | Tianxin Wang | Methods and reagents to treat autoimmune diseases and allergy |
US20190008900A1 (en) * | 2017-07-07 | 2019-01-10 | Tian Xin Wang | Methods and reagents to treat autoimmune diseases and allergy |
US10398732B2 (en) | 2016-10-13 | 2019-09-03 | Marshall University Research Corporation | Compositions and methods for treating striated muscle injury, treating striated muscle atrophy and/or for promoting striated muscle growth |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
US11464836B2 (en) | 2016-12-08 | 2022-10-11 | Curevac Ag | RNA for treatment or prophylaxis of a liver disease |
US11542490B2 (en) | 2016-12-08 | 2023-01-03 | CureVac SE | RNAs for wound healing |
JP7010956B2 (ja) | 2016-12-21 | 2022-01-26 | エシコン エルエルシー | 組織をステープル留めする方法 |
US10675026B2 (en) | 2016-12-21 | 2020-06-09 | Ethicon Llc | Methods of stapling tissue |
US11134942B2 (en) | 2016-12-21 | 2021-10-05 | Cilag Gmbh International | Surgical stapling instruments and staple-forming anvils |
JP7086963B2 (ja) | 2016-12-21 | 2022-06-20 | エシコン エルエルシー | エンドエフェクタロックアウト及び発射アセンブリロックアウトを備える外科用器具システム |
US11191539B2 (en) | 2016-12-21 | 2021-12-07 | Cilag Gmbh International | Shaft assembly comprising a manually-operable retraction system for use with a motorized surgical instrument system |
US20180168615A1 (en) | 2016-12-21 | 2018-06-21 | Ethicon Endo-Surgery, Llc | Method of deforming staples from two different types of staple cartridges with the same surgical stapling instrument |
US10610224B2 (en) | 2016-12-21 | 2020-04-07 | Ethicon Llc | Lockout arrangements for surgical end effectors and replaceable tool assemblies |
US10448950B2 (en) | 2016-12-21 | 2019-10-22 | Ethicon Llc | Surgical staplers with independently actuatable closing and firing systems |
US10898186B2 (en) | 2016-12-21 | 2021-01-26 | Ethicon Llc | Staple forming pocket arrangements comprising primary sidewalls and pocket sidewalls |
US10485543B2 (en) | 2016-12-21 | 2019-11-26 | Ethicon Llc | Anvil having a knife slot width |
JP6983893B2 (ja) | 2016-12-21 | 2021-12-17 | エシコン エルエルシーEthicon LLC | 外科用エンドエフェクタ及び交換式ツールアセンブリのためのロックアウト構成 |
US20180168625A1 (en) | 2016-12-21 | 2018-06-21 | Ethicon Endo-Surgery, Llc | Surgical stapling instruments with smart staple cartridges |
US10893864B2 (en) | 2016-12-21 | 2021-01-19 | Ethicon | Staple cartridges and arrangements of staples and staple cavities therein |
US10588631B2 (en) | 2016-12-21 | 2020-03-17 | Ethicon Llc | Surgical instruments with positive jaw opening features |
CN110087565A (zh) | 2016-12-21 | 2019-08-02 | 爱惜康有限责任公司 | 外科缝合系统 |
US10582928B2 (en) | 2016-12-21 | 2020-03-10 | Ethicon Llc | Articulation lock arrangements for locking an end effector in an articulated position in response to actuation of a jaw closure system |
US11419606B2 (en) | 2016-12-21 | 2022-08-23 | Cilag Gmbh International | Shaft assembly comprising a clutch configured to adapt the output of a rotary firing member to two different systems |
ES2981555T3 (es) * | 2017-01-04 | 2024-10-09 | Worg Pharmaceuticals Zhejiang Co Ltd | Péptidos de S-arrestina y usos terapéuticos de los mismos |
WO2018129268A1 (en) * | 2017-01-07 | 2018-07-12 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
US11555178B2 (en) | 2017-01-18 | 2023-01-17 | Yeda Research And Development Co. Ltd. | Genetically modified veto cells and use of same in immunotherapy |
US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
AU2018236123B2 (en) | 2017-03-11 | 2024-04-18 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
WO2018170336A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
DK3596042T3 (da) | 2017-03-15 | 2022-04-11 | Modernatx Inc | Krystalformer af aminolipider |
HRP20230063T1 (hr) | 2017-03-15 | 2023-03-17 | Modernatx, Inc. | Spoj i pripravci za intracelularnu isporuku terapijskih sredstava |
US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
JP2020517638A (ja) | 2017-04-20 | 2020-06-18 | エータイアー ファーマ, インコーポレイテッド | 肺の炎症を治療するための組成物および方法 |
WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
US10888321B2 (en) | 2017-06-20 | 2021-01-12 | Ethicon Llc | Systems and methods for controlling velocity of a displacement member of a surgical stapling and cutting instrument |
US10307170B2 (en) | 2017-06-20 | 2019-06-04 | Ethicon Llc | Method for closed loop control of motor velocity of a surgical stapling and cutting instrument |
US10881399B2 (en) | 2017-06-20 | 2021-01-05 | Ethicon Llc | Techniques for adaptive control of motor velocity of a surgical stapling and cutting instrument |
US11382638B2 (en) | 2017-06-20 | 2022-07-12 | Cilag Gmbh International | Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured time over a specified displacement distance |
US11071554B2 (en) | 2017-06-20 | 2021-07-27 | Cilag Gmbh International | Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on magnitude of velocity error measurements |
US10980537B2 (en) | 2017-06-20 | 2021-04-20 | Ethicon Llc | Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured time over a specified number of shaft rotations |
USD879809S1 (en) | 2017-06-20 | 2020-03-31 | Ethicon Llc | Display panel with changeable graphical user interface |
US11653914B2 (en) | 2017-06-20 | 2023-05-23 | Cilag Gmbh International | Systems and methods for controlling motor velocity of a surgical stapling and cutting instrument according to articulation angle of end effector |
US11517325B2 (en) | 2017-06-20 | 2022-12-06 | Cilag Gmbh International | Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured displacement distance traveled over a specified time interval |
US11090046B2 (en) | 2017-06-20 | 2021-08-17 | Cilag Gmbh International | Systems and methods for controlling displacement member motion of a surgical stapling and cutting instrument |
US10779820B2 (en) | 2017-06-20 | 2020-09-22 | Ethicon Llc | Systems and methods for controlling motor speed according to user input for a surgical instrument |
US11324503B2 (en) | 2017-06-27 | 2022-05-10 | Cilag Gmbh International | Surgical firing member arrangements |
US11266405B2 (en) | 2017-06-27 | 2022-03-08 | Cilag Gmbh International | Surgical anvil manufacturing methods |
US20180368844A1 (en) | 2017-06-27 | 2018-12-27 | Ethicon Llc | Staple forming pocket arrangements |
US10993716B2 (en) | 2017-06-27 | 2021-05-04 | Ethicon Llc | Surgical anvil arrangements |
US10903685B2 (en) | 2017-06-28 | 2021-01-26 | Ethicon Llc | Surgical shaft assemblies with slip ring assemblies forming capacitive channels |
USD906355S1 (en) | 2017-06-28 | 2020-12-29 | Ethicon Llc | Display screen or portion thereof with a graphical user interface for a surgical instrument |
US10639037B2 (en) | 2017-06-28 | 2020-05-05 | Ethicon Llc | Surgical instrument with axially movable closure member |
US11246592B2 (en) | 2017-06-28 | 2022-02-15 | Cilag Gmbh International | Surgical instrument comprising an articulation system lockable to a frame |
EP4070740A1 (en) | 2017-06-28 | 2022-10-12 | Cilag GmbH International | Surgical instrument comprising selectively actuatable rotatable couplers |
US11564686B2 (en) | 2017-06-28 | 2023-01-31 | Cilag Gmbh International | Surgical shaft assemblies with flexible interfaces |
US11058424B2 (en) | 2017-06-28 | 2021-07-13 | Cilag Gmbh International | Surgical instrument comprising an offset articulation joint |
US10765427B2 (en) | 2017-06-28 | 2020-09-08 | Ethicon Llc | Method for articulating a surgical instrument |
US11259805B2 (en) | 2017-06-28 | 2022-03-01 | Cilag Gmbh International | Surgical instrument comprising firing member supports |
US10932772B2 (en) | 2017-06-29 | 2021-03-02 | Ethicon Llc | Methods for closed loop velocity control for robotic surgical instrument |
WO2019010471A1 (en) * | 2017-07-07 | 2019-01-10 | Wang tian xin | METHODS AND REAGENTS FOR TREATING AUTOIMMUNE DISEASES AND ALLERGY |
US11471155B2 (en) | 2017-08-03 | 2022-10-18 | Cilag Gmbh International | Surgical system bailout |
US11944300B2 (en) | 2017-08-03 | 2024-04-02 | Cilag Gmbh International | Method for operating a surgical system bailout |
US11974742B2 (en) | 2017-08-03 | 2024-05-07 | Cilag Gmbh International | Surgical system comprising an articulation bailout |
US11304695B2 (en) | 2017-08-03 | 2022-04-19 | Cilag Gmbh International | Surgical system shaft interconnection |
MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
JP7285828B2 (ja) | 2017-09-05 | 2023-06-02 | トルク セラピューティクス, インコーポレイテッド | 治療用タンパク質組成物ならびにその作製および使用方法 |
US11447773B2 (en) | 2017-09-08 | 2022-09-20 | Mina Therapeutics Limited | Stabilized HNF4A saRNA compositions and methods of use |
US20200208152A1 (en) | 2017-09-08 | 2020-07-02 | Mina Therapeutics Limited | Stabilized sarna compositions and methods of use |
USD907648S1 (en) | 2017-09-29 | 2021-01-12 | Ethicon Llc | Display screen or portion thereof with animated graphical user interface |
US10743872B2 (en) | 2017-09-29 | 2020-08-18 | Ethicon Llc | System and methods for controlling a display of a surgical instrument |
USD907647S1 (en) | 2017-09-29 | 2021-01-12 | Ethicon Llc | Display screen or portion thereof with animated graphical user interface |
US11399829B2 (en) | 2017-09-29 | 2022-08-02 | Cilag Gmbh International | Systems and methods of initiating a power shutdown mode for a surgical instrument |
US20220025015A1 (en) * | 2017-10-03 | 2022-01-27 | Tianxin Wang | Methods, compositions and therapeutical vaccine for autoimmune diseases and allergy treatment |
EP3691673A4 (en) * | 2017-10-05 | 2021-06-09 | Epivax, Inc. | REGULATORY T-CELL EPITOPES |
US11134944B2 (en) | 2017-10-30 | 2021-10-05 | Cilag Gmbh International | Surgical stapler knife motion controls |
US11090075B2 (en) | 2017-10-30 | 2021-08-17 | Cilag Gmbh International | Articulation features for surgical end effector |
US10842490B2 (en) | 2017-10-31 | 2020-11-24 | Ethicon Llc | Cartridge body design with force reduction based on firing completion |
US10966718B2 (en) | 2017-12-15 | 2021-04-06 | Ethicon Llc | Dynamic clamping assemblies with improved wear characteristics for use in connection with electromechanical surgical instruments |
US10828033B2 (en) | 2017-12-15 | 2020-11-10 | Ethicon Llc | Handheld electromechanical surgical instruments with improved motor control arrangements for positioning components of an adapter coupled thereto |
US11071543B2 (en) | 2017-12-15 | 2021-07-27 | Cilag Gmbh International | Surgical end effectors with clamping assemblies configured to increase jaw aperture ranges |
US11197670B2 (en) | 2017-12-15 | 2021-12-14 | Cilag Gmbh International | Surgical end effectors with pivotal jaws configured to touch at their respective distal ends when fully closed |
US11033267B2 (en) | 2017-12-15 | 2021-06-15 | Ethicon Llc | Systems and methods of controlling a clamping member firing rate of a surgical instrument |
US10779826B2 (en) | 2017-12-15 | 2020-09-22 | Ethicon Llc | Methods of operating surgical end effectors |
US10779825B2 (en) | 2017-12-15 | 2020-09-22 | Ethicon Llc | Adapters with end effector position sensing and control arrangements for use in connection with electromechanical surgical instruments |
US10869666B2 (en) | 2017-12-15 | 2020-12-22 | Ethicon Llc | Adapters with control systems for controlling multiple motors of an electromechanical surgical instrument |
US10835330B2 (en) | 2017-12-19 | 2020-11-17 | Ethicon Llc | Method for determining the position of a rotatable jaw of a surgical instrument attachment assembly |
USD910847S1 (en) | 2017-12-19 | 2021-02-16 | Ethicon Llc | Surgical instrument assembly |
US11020112B2 (en) | 2017-12-19 | 2021-06-01 | Ethicon Llc | Surgical tools configured for interchangeable use with different controller interfaces |
US11311290B2 (en) | 2017-12-21 | 2022-04-26 | Cilag Gmbh International | Surgical instrument comprising an end effector dampener |
US11364027B2 (en) | 2017-12-21 | 2022-06-21 | Cilag Gmbh International | Surgical instrument comprising speed control |
US11129680B2 (en) | 2017-12-21 | 2021-09-28 | Cilag Gmbh International | Surgical instrument comprising a projector |
US11076853B2 (en) | 2017-12-21 | 2021-08-03 | Cilag Gmbh International | Systems and methods of displaying a knife position during transection for a surgical instrument |
JP2021515037A (ja) | 2018-02-26 | 2021-06-17 | アントルクス,インコーポレーテッド | 寛容原性リポソーム及びその使用方法 |
WO2019197845A1 (en) | 2018-04-12 | 2019-10-17 | Mina Therapeutics Limited | Sirt1-sarna compositions and methods of use |
CN108841774B (zh) * | 2018-05-02 | 2021-11-26 | 南开大学 | 一种双响应型纳米仿生界面的制备及其在细胞捕获与应需无损释放中的应用 |
CN108753716A (zh) * | 2018-06-14 | 2018-11-06 | 杭州启澜生物医学技术有限公司 | 一种体外扩增人外周血cd3+t细胞的方法 |
NL2021443B1 (en) | 2018-08-08 | 2020-02-20 | Kei International Ltd | Synthetic antigens for tuberculosis detection |
EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND THEIR USES |
CN110836966A (zh) * | 2018-08-15 | 2020-02-25 | 王镕 | 用于抗原特异性t细胞含量检测的检测纳米颗粒、检测方法及试剂盒等 |
US11253256B2 (en) | 2018-08-20 | 2022-02-22 | Cilag Gmbh International | Articulatable motor powered surgical instruments with dedicated articulation motor arrangements |
US11039834B2 (en) | 2018-08-20 | 2021-06-22 | Cilag Gmbh International | Surgical stapler anvils with staple directing protrusions and tissue stability features |
US11324501B2 (en) | 2018-08-20 | 2022-05-10 | Cilag Gmbh International | Surgical stapling devices with improved closure members |
US10912559B2 (en) | 2018-08-20 | 2021-02-09 | Ethicon Llc | Reinforced deformable anvil tip for surgical stapler anvil |
US11045192B2 (en) | 2018-08-20 | 2021-06-29 | Cilag Gmbh International | Fabricating techniques for surgical stapler anvils |
US11083458B2 (en) | 2018-08-20 | 2021-08-10 | Cilag Gmbh International | Powered surgical instruments with clutching arrangements to convert linear drive motions to rotary drive motions |
US10856870B2 (en) | 2018-08-20 | 2020-12-08 | Ethicon Llc | Switching arrangements for motor powered articulatable surgical instruments |
USD914878S1 (en) | 2018-08-20 | 2021-03-30 | Ethicon Llc | Surgical instrument anvil |
US11291440B2 (en) | 2018-08-20 | 2022-04-05 | Cilag Gmbh International | Method for operating a powered articulatable surgical instrument |
US11207065B2 (en) | 2018-08-20 | 2021-12-28 | Cilag Gmbh International | Method for fabricating surgical stapler anvils |
CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
CN109439626B (zh) * | 2018-11-09 | 2022-10-14 | 复旦大学附属中山医院 | 一种有助于体外获得Th22细胞的组合物及其用途 |
DE102018220631A1 (de) * | 2018-11-29 | 2020-06-04 | B. Braun Melsungen Ag | Wässrige Zusammensetzung, insbesondere zur Behandlung von Schleimhaut und/oder Wunden |
CN111388679A (zh) * | 2019-01-03 | 2020-07-10 | 北京大学 | 蛋白质-螺旋聚氨基酸偶联物、其制备方法及用途 |
CN111574590B (zh) * | 2019-02-18 | 2022-04-22 | 常州市第一人民医院 | 一种具有抗肿瘤功能的多肽及其应用 |
US11147551B2 (en) | 2019-03-25 | 2021-10-19 | Cilag Gmbh International | Firing drive arrangements for surgical systems |
US11696761B2 (en) | 2019-03-25 | 2023-07-11 | Cilag Gmbh International | Firing drive arrangements for surgical systems |
US11147553B2 (en) | 2019-03-25 | 2021-10-19 | Cilag Gmbh International | Firing drive arrangements for surgical systems |
US11172929B2 (en) | 2019-03-25 | 2021-11-16 | Cilag Gmbh International | Articulation drive arrangements for surgical systems |
EP3953473A1 (en) | 2019-04-12 | 2022-02-16 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
US11648009B2 (en) | 2019-04-30 | 2023-05-16 | Cilag Gmbh International | Rotatable jaw tip for a surgical instrument |
US11452528B2 (en) | 2019-04-30 | 2022-09-27 | Cilag Gmbh International | Articulation actuators for a surgical instrument |
US11432816B2 (en) | 2019-04-30 | 2022-09-06 | Cilag Gmbh International | Articulation pin for a surgical instrument |
US11903581B2 (en) | 2019-04-30 | 2024-02-20 | Cilag Gmbh International | Methods for stapling tissue using a surgical instrument |
US11253254B2 (en) | 2019-04-30 | 2022-02-22 | Cilag Gmbh International | Shaft rotation actuator on a surgical instrument |
US11426251B2 (en) | 2019-04-30 | 2022-08-30 | Cilag Gmbh International | Articulation directional lights on a surgical instrument |
US11471157B2 (en) | 2019-04-30 | 2022-10-18 | Cilag Gmbh International | Articulation control mapping for a surgical instrument |
CA3141636A1 (en) * | 2019-05-23 | 2020-11-26 | Uti Limited Partnership | Nanoparticles comprising non-classical mhc and uses thereof |
US11291451B2 (en) | 2019-06-28 | 2022-04-05 | Cilag Gmbh International | Surgical instrument with battery compatibility verification functionality |
US11464601B2 (en) | 2019-06-28 | 2022-10-11 | Cilag Gmbh International | Surgical instrument comprising an RFID system for tracking a movable component |
US11298132B2 (en) | 2019-06-28 | 2022-04-12 | Cilag GmbH Inlernational | Staple cartridge including a honeycomb extension |
US11553971B2 (en) | 2019-06-28 | 2023-01-17 | Cilag Gmbh International | Surgical RFID assemblies for display and communication |
US11478241B2 (en) | 2019-06-28 | 2022-10-25 | Cilag Gmbh International | Staple cartridge including projections |
US11376098B2 (en) | 2019-06-28 | 2022-07-05 | Cilag Gmbh International | Surgical instrument system comprising an RFID system |
US11660163B2 (en) | 2019-06-28 | 2023-05-30 | Cilag Gmbh International | Surgical system with RFID tags for updating motor assembly parameters |
US11497492B2 (en) | 2019-06-28 | 2022-11-15 | Cilag Gmbh International | Surgical instrument including an articulation lock |
US11224497B2 (en) | 2019-06-28 | 2022-01-18 | Cilag Gmbh International | Surgical systems with multiple RFID tags |
US11051807B2 (en) | 2019-06-28 | 2021-07-06 | Cilag Gmbh International | Packaging assembly including a particulate trap |
US11350938B2 (en) | 2019-06-28 | 2022-06-07 | Cilag Gmbh International | Surgical instrument comprising an aligned rfid sensor |
US11638587B2 (en) | 2019-06-28 | 2023-05-02 | Cilag Gmbh International | RFID identification systems for surgical instruments |
US11259803B2 (en) | 2019-06-28 | 2022-03-01 | Cilag Gmbh International | Surgical stapling system having an information encryption protocol |
US12004740B2 (en) | 2019-06-28 | 2024-06-11 | Cilag Gmbh International | Surgical stapling system having an information decryption protocol |
US11399837B2 (en) | 2019-06-28 | 2022-08-02 | Cilag Gmbh International | Mechanisms for motor control adjustments of a motorized surgical instrument |
US11426167B2 (en) | 2019-06-28 | 2022-08-30 | Cilag Gmbh International | Mechanisms for proper anvil attachment surgical stapling head assembly |
US11246678B2 (en) | 2019-06-28 | 2022-02-15 | Cilag Gmbh International | Surgical stapling system having a frangible RFID tag |
US11627959B2 (en) | 2019-06-28 | 2023-04-18 | Cilag Gmbh International | Surgical instruments including manual and powered system lockouts |
US11684434B2 (en) | 2019-06-28 | 2023-06-27 | Cilag Gmbh International | Surgical RFID assemblies for instrument operational setting control |
US11298127B2 (en) | 2019-06-28 | 2022-04-12 | Cilag GmbH Interational | Surgical stapling system having a lockout mechanism for an incompatible cartridge |
US11523822B2 (en) | 2019-06-28 | 2022-12-13 | Cilag Gmbh International | Battery pack including a circuit interrupter |
US11219455B2 (en) | 2019-06-28 | 2022-01-11 | Cilag Gmbh International | Surgical instrument including a lockout key |
US11771419B2 (en) | 2019-06-28 | 2023-10-03 | Cilag Gmbh International | Packaging for a replaceable component of a surgical stapling system |
WO2021041991A1 (en) * | 2019-08-29 | 2021-03-04 | Diomics Corporation | Hydrophilic biopolymer medicament delivery mechanism |
TW202124360A (zh) | 2019-09-19 | 2021-07-01 | 美商現代公司 | 用於治療劑之細胞內遞送之支鏈尾端脂質化合物及組合物 |
WO2021061707A1 (en) | 2019-09-23 | 2021-04-01 | Omega Therapeutics, Inc. | Compositions and methods for modulating apolipoprotein b (apob) gene expression |
AU2020352552A1 (en) | 2019-09-23 | 2022-03-17 | Omega Therapeutics, Inc. | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression |
EP4048269A1 (en) * | 2019-10-21 | 2022-08-31 | Selecta Biosciences, Inc. | Methods and compositions for treating liver diseases and disorders |
US20210206879A1 (en) * | 2019-12-06 | 2021-07-08 | Yale University | Enhanced targeting platform |
US11529137B2 (en) | 2019-12-19 | 2022-12-20 | Cilag Gmbh International | Staple cartridge comprising driver retention members |
US12035913B2 (en) | 2019-12-19 | 2024-07-16 | Cilag Gmbh International | Staple cartridge comprising a deployable knife |
US11931033B2 (en) | 2019-12-19 | 2024-03-19 | Cilag Gmbh International | Staple cartridge comprising a latch lockout |
US11446029B2 (en) | 2019-12-19 | 2022-09-20 | Cilag Gmbh International | Staple cartridge comprising projections extending from a curved deck surface |
US11529139B2 (en) | 2019-12-19 | 2022-12-20 | Cilag Gmbh International | Motor driven surgical instrument |
US11701111B2 (en) | 2019-12-19 | 2023-07-18 | Cilag Gmbh International | Method for operating a surgical stapling instrument |
US11559304B2 (en) | 2019-12-19 | 2023-01-24 | Cilag Gmbh International | Surgical instrument comprising a rapid closure mechanism |
US11504122B2 (en) | 2019-12-19 | 2022-11-22 | Cilag Gmbh International | Surgical instrument comprising a nested firing member |
US11576672B2 (en) | 2019-12-19 | 2023-02-14 | Cilag Gmbh International | Surgical instrument comprising a closure system including a closure member and an opening member driven by a drive screw |
US11844520B2 (en) | 2019-12-19 | 2023-12-19 | Cilag Gmbh International | Staple cartridge comprising driver retention members |
US11304696B2 (en) | 2019-12-19 | 2022-04-19 | Cilag Gmbh International | Surgical instrument comprising a powered articulation system |
US11464512B2 (en) | 2019-12-19 | 2022-10-11 | Cilag Gmbh International | Staple cartridge comprising a curved deck surface |
US11291447B2 (en) | 2019-12-19 | 2022-04-05 | Cilag Gmbh International | Stapling instrument comprising independent jaw closing and staple firing systems |
US11234698B2 (en) | 2019-12-19 | 2022-02-01 | Cilag Gmbh International | Stapling system comprising a clamp lockout and a firing lockout |
US11911032B2 (en) | 2019-12-19 | 2024-02-27 | Cilag Gmbh International | Staple cartridge comprising a seating cam |
US11607219B2 (en) | 2019-12-19 | 2023-03-21 | Cilag Gmbh International | Staple cartridge comprising a detachable tissue cutting knife |
KR20220146559A (ko) * | 2020-02-26 | 2022-11-01 | 셀렉타 바이오사이언시즈, 인크. | 면역억제제를 포함하는 합성 나노담체를 사용하는 방법 및 조성물 |
EP4118207A1 (en) | 2020-03-11 | 2023-01-18 | Omega Therapeutics, Inc. | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression |
IL297274A (en) * | 2020-04-14 | 2022-12-01 | Selecta Biosciences Inc | Methods and compositions for inducing autophagy |
USD975850S1 (en) | 2020-06-02 | 2023-01-17 | Cilag Gmbh International | Staple cartridge |
USD975851S1 (en) | 2020-06-02 | 2023-01-17 | Cilag Gmbh International | Staple cartridge |
USD974560S1 (en) | 2020-06-02 | 2023-01-03 | Cilag Gmbh International | Staple cartridge |
USD975278S1 (en) | 2020-06-02 | 2023-01-10 | Cilag Gmbh International | Staple cartridge |
USD967421S1 (en) | 2020-06-02 | 2022-10-18 | Cilag Gmbh International | Staple cartridge |
USD976401S1 (en) | 2020-06-02 | 2023-01-24 | Cilag Gmbh International | Staple cartridge |
USD966512S1 (en) | 2020-06-02 | 2022-10-11 | Cilag Gmbh International | Staple cartridge |
US11857182B2 (en) | 2020-07-28 | 2024-01-02 | Cilag Gmbh International | Surgical instruments with combination function articulation joint arrangements |
US11617577B2 (en) | 2020-10-29 | 2023-04-04 | Cilag Gmbh International | Surgical instrument comprising a sensor configured to sense whether an articulation drive of the surgical instrument is actuatable |
US11931025B2 (en) | 2020-10-29 | 2024-03-19 | Cilag Gmbh International | Surgical instrument comprising a releasable closure drive lock |
US11452526B2 (en) | 2020-10-29 | 2022-09-27 | Cilag Gmbh International | Surgical instrument comprising a staged voltage regulation start-up system |
US11517390B2 (en) | 2020-10-29 | 2022-12-06 | Cilag Gmbh International | Surgical instrument comprising a limited travel switch |
US11896217B2 (en) | 2020-10-29 | 2024-02-13 | Cilag Gmbh International | Surgical instrument comprising an articulation lock |
USD980425S1 (en) | 2020-10-29 | 2023-03-07 | Cilag Gmbh International | Surgical instrument assembly |
US12053175B2 (en) | 2020-10-29 | 2024-08-06 | Cilag Gmbh International | Surgical instrument comprising a stowed closure actuator stop |
US11779330B2 (en) | 2020-10-29 | 2023-10-10 | Cilag Gmbh International | Surgical instrument comprising a jaw alignment system |
US11534259B2 (en) | 2020-10-29 | 2022-12-27 | Cilag Gmbh International | Surgical instrument comprising an articulation indicator |
US11717289B2 (en) | 2020-10-29 | 2023-08-08 | Cilag Gmbh International | Surgical instrument comprising an indicator which indicates that an articulation drive is actuatable |
US11844518B2 (en) | 2020-10-29 | 2023-12-19 | Cilag Gmbh International | Method for operating a surgical instrument |
USD1013170S1 (en) | 2020-10-29 | 2024-01-30 | Cilag Gmbh International | Surgical instrument assembly |
JP2023548965A (ja) * | 2020-11-09 | 2023-11-21 | スカイ・セラピューティクス・カンパニー・リミテッド | 固相の物質及びこれを含む分散組成物 |
EP4241761A4 (en) * | 2020-11-09 | 2024-09-25 | Scai Therapeutics Co Ltd | CYCLOSPORINE A SOLID AND DISPERSION COMPOSITION COMPRISING SAME |
CN112480244A (zh) * | 2020-11-24 | 2021-03-12 | 华科同济干细胞基因工程有限公司 | 一种抗过敏性纳米抗体组合物、抗体测定方法及喷雾剂 |
US11849943B2 (en) | 2020-12-02 | 2023-12-26 | Cilag Gmbh International | Surgical instrument with cartridge release mechanisms |
US11627960B2 (en) | 2020-12-02 | 2023-04-18 | Cilag Gmbh International | Powered surgical instruments with smart reload with separately attachable exteriorly mounted wiring connections |
US11653915B2 (en) | 2020-12-02 | 2023-05-23 | Cilag Gmbh International | Surgical instruments with sled location detection and adjustment features |
US11678882B2 (en) | 2020-12-02 | 2023-06-20 | Cilag Gmbh International | Surgical instruments with interactive features to remedy incidental sled movements |
US11890010B2 (en) | 2020-12-02 | 2024-02-06 | Cllag GmbH International | Dual-sided reinforced reload for surgical instruments |
US11653920B2 (en) | 2020-12-02 | 2023-05-23 | Cilag Gmbh International | Powered surgical instruments with communication interfaces through sterile barrier |
US11944296B2 (en) | 2020-12-02 | 2024-04-02 | Cilag Gmbh International | Powered surgical instruments with external connectors |
US11744581B2 (en) | 2020-12-02 | 2023-09-05 | Cilag Gmbh International | Powered surgical instruments with multi-phase tissue treatment |
US11737751B2 (en) | 2020-12-02 | 2023-08-29 | Cilag Gmbh International | Devices and methods of managing energy dissipated within sterile barriers of surgical instrument housings |
GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
CN112807425A (zh) * | 2021-01-14 | 2021-05-18 | 南方医科大学深圳医院 | 一种tTIM融合蛋白疫苗、制备方法及应用 |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
US11744583B2 (en) | 2021-02-26 | 2023-09-05 | Cilag Gmbh International | Distal communication array to tune frequency of RF systems |
US11925349B2 (en) | 2021-02-26 | 2024-03-12 | Cilag Gmbh International | Adjustment to transfer parameters to improve available power |
US11980362B2 (en) | 2021-02-26 | 2024-05-14 | Cilag Gmbh International | Surgical instrument system comprising a power transfer coil |
US11723657B2 (en) | 2021-02-26 | 2023-08-15 | Cilag Gmbh International | Adjustable communication based on available bandwidth and power capacity |
US11950779B2 (en) | 2021-02-26 | 2024-04-09 | Cilag Gmbh International | Method of powering and communicating with a staple cartridge |
US11730473B2 (en) | 2021-02-26 | 2023-08-22 | Cilag Gmbh International | Monitoring of manufacturing life-cycle |
US11950777B2 (en) | 2021-02-26 | 2024-04-09 | Cilag Gmbh International | Staple cartridge comprising an information access control system |
US11793514B2 (en) | 2021-02-26 | 2023-10-24 | Cilag Gmbh International | Staple cartridge comprising sensor array which may be embedded in cartridge body |
US12108951B2 (en) | 2021-02-26 | 2024-10-08 | Cilag Gmbh International | Staple cartridge comprising a sensing array and a temperature control system |
US11749877B2 (en) | 2021-02-26 | 2023-09-05 | Cilag Gmbh International | Stapling instrument comprising a signal antenna |
US11701113B2 (en) | 2021-02-26 | 2023-07-18 | Cilag Gmbh International | Stapling instrument comprising a separate power antenna and a data transfer antenna |
US11696757B2 (en) | 2021-02-26 | 2023-07-11 | Cilag Gmbh International | Monitoring of internal systems to detect and track cartridge motion status |
US11751869B2 (en) | 2021-02-26 | 2023-09-12 | Cilag Gmbh International | Monitoring of multiple sensors over time to detect moving characteristics of tissue |
US11812964B2 (en) | 2021-02-26 | 2023-11-14 | Cilag Gmbh International | Staple cartridge comprising a power management circuit |
US11759202B2 (en) | 2021-03-22 | 2023-09-19 | Cilag Gmbh International | Staple cartridge comprising an implantable layer |
US11806011B2 (en) | 2021-03-22 | 2023-11-07 | Cilag Gmbh International | Stapling instrument comprising tissue compression systems |
US11723658B2 (en) | 2021-03-22 | 2023-08-15 | Cilag Gmbh International | Staple cartridge comprising a firing lockout |
US11826012B2 (en) | 2021-03-22 | 2023-11-28 | Cilag Gmbh International | Stapling instrument comprising a pulsed motor-driven firing rack |
US11826042B2 (en) | 2021-03-22 | 2023-11-28 | Cilag Gmbh International | Surgical instrument comprising a firing drive including a selectable leverage mechanism |
US11737749B2 (en) | 2021-03-22 | 2023-08-29 | Cilag Gmbh International | Surgical stapling instrument comprising a retraction system |
US11717291B2 (en) | 2021-03-22 | 2023-08-08 | Cilag Gmbh International | Staple cartridge comprising staples configured to apply different tissue compression |
US11793516B2 (en) | 2021-03-24 | 2023-10-24 | Cilag Gmbh International | Surgical staple cartridge comprising longitudinal support beam |
US11896219B2 (en) | 2021-03-24 | 2024-02-13 | Cilag Gmbh International | Mating features between drivers and underside of a cartridge deck |
US11832816B2 (en) | 2021-03-24 | 2023-12-05 | Cilag Gmbh International | Surgical stapling assembly comprising nonplanar staples and planar staples |
US11744603B2 (en) | 2021-03-24 | 2023-09-05 | Cilag Gmbh International | Multi-axis pivot joints for surgical instruments and methods for manufacturing same |
US11896218B2 (en) | 2021-03-24 | 2024-02-13 | Cilag Gmbh International | Method of using a powered stapling device |
US11944336B2 (en) | 2021-03-24 | 2024-04-02 | Cilag Gmbh International | Joint arrangements for multi-planar alignment and support of operational drive shafts in articulatable surgical instruments |
US11786243B2 (en) | 2021-03-24 | 2023-10-17 | Cilag Gmbh International | Firing members having flexible portions for adapting to a load during a surgical firing stroke |
US11903582B2 (en) | 2021-03-24 | 2024-02-20 | Cilag Gmbh International | Leveraging surfaces for cartridge installation |
US11849944B2 (en) | 2021-03-24 | 2023-12-26 | Cilag Gmbh International | Drivers for fastener cartridge assemblies having rotary drive screws |
US11857183B2 (en) | 2021-03-24 | 2024-01-02 | Cilag Gmbh International | Stapling assembly components having metal substrates and plastic bodies |
US12102323B2 (en) | 2021-03-24 | 2024-10-01 | Cilag Gmbh International | Rotary-driven surgical stapling assembly comprising a floatable component |
US11786239B2 (en) | 2021-03-24 | 2023-10-17 | Cilag Gmbh International | Surgical instrument articulation joint arrangements comprising multiple moving linkage features |
US11849945B2 (en) | 2021-03-24 | 2023-12-26 | Cilag Gmbh International | Rotary-driven surgical stapling assembly comprising eccentrically driven firing member |
EP4314292A1 (en) | 2021-03-26 | 2024-02-07 | MiNA Therapeutics Limited | Tmem173 sarna compositions and methods of use |
CA3216491A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
US11826047B2 (en) | 2021-05-28 | 2023-11-28 | Cilag Gmbh International | Stapling instrument comprising jaw mounts |
CN113425702B (zh) * | 2021-06-25 | 2022-08-26 | 中国药科大学 | 应用微流控技术制备纳米颗粒、制备方法及装置和用途 |
EP4367242A2 (en) | 2021-07-07 | 2024-05-15 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
US20240342206A1 (en) | 2021-07-30 | 2024-10-17 | CureVac SE | mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES |
US11957337B2 (en) | 2021-10-18 | 2024-04-16 | Cilag Gmbh International | Surgical stapling assembly with offset ramped drive surfaces |
US11980363B2 (en) | 2021-10-18 | 2024-05-14 | Cilag Gmbh International | Row-to-row staple array variations |
US11877745B2 (en) | 2021-10-18 | 2024-01-23 | Cilag Gmbh International | Surgical stapling assembly having longitudinally-repeating staple leg clusters |
US11937816B2 (en) | 2021-10-28 | 2024-03-26 | Cilag Gmbh International | Electrical lead arrangements for surgical instruments |
US12089841B2 (en) | 2021-10-28 | 2024-09-17 | Cilag CmbH International | Staple cartridge identification systems |
WO2023099884A1 (en) | 2021-12-01 | 2023-06-08 | Mina Therapeutics Limited | Pax6 sarna compositions and methods of use |
GB202117758D0 (en) | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
WO2023144193A1 (en) | 2022-01-25 | 2023-08-03 | CureVac SE | Mrnas for treatment of hereditary tyrosinemia type i |
WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
WO2023170435A1 (en) | 2022-03-07 | 2023-09-14 | Mina Therapeutics Limited | Il10 sarna compositions and methods of use |
CN115475255A (zh) * | 2022-06-14 | 2022-12-16 | 澳门科技大学 | 一种酶响应型二氧化硅释纳米制剂、制备方法及应用 |
WO2024110516A1 (en) * | 2022-11-23 | 2024-05-30 | Ahead Therapeutics, S.L. | Tolerogenic composition |
WO2024134199A1 (en) | 2022-12-22 | 2024-06-27 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
KR102714037B1 (ko) * | 2023-11-30 | 2024-10-07 | 주식회사 지엔티파마 | 자가면역 질환 치료용 조성물 및 방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101437491A (zh) * | 2006-02-21 | 2009-05-20 | 洛桑聚合联合学院 | 用于免疫疗法的纳米颗粒 |
CN101646418A (zh) * | 2006-10-12 | 2010-02-10 | 昆士兰大学 | 调节免疫应答的组合物和方法 |
CN101861165A (zh) * | 2007-10-12 | 2010-10-13 | 麻省理工学院 | 疫苗纳米技术 |
Family Cites Families (307)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1995A (en) | 1841-03-03 | Latch of door and other locks | ||
US934897A (en) | 1907-08-08 | 1909-09-21 | Frank Dutcher | Fusee-cap. |
US927297A (en) | 1908-02-24 | 1909-07-06 | Charles Tuckfield | Engine. |
US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
DE3875306T2 (de) | 1987-02-24 | 1993-04-01 | Xoma Corp | Immunosuppression bei der auf immunotoxin basierten behandlung von menschen. |
US5912017A (en) | 1987-05-01 | 1999-06-15 | Massachusetts Institute Of Technology | Multiwall polymeric microspheres |
US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
US5268455A (en) * | 1989-05-25 | 1993-12-07 | Genentech, Inc. | Process for making biologically active polypeptides based on transforming growth factor-βsequences |
US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
US5679347A (en) | 1992-12-10 | 1997-10-21 | Brigham And Women's Hospital | Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods |
JPH08505625A (ja) | 1993-01-11 | 1996-06-18 | ダナ−ファーバー キャンサー インスティチュート | 細胞毒性tリンパ球応答の誘導 |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
WO1995003035A1 (en) | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Polymerized liposomes with enhanced stability for oral delivery |
US5468729A (en) | 1993-10-26 | 1995-11-21 | Alpha 1 Biomedicals | Method for treatment of autoimmune hepatitis |
CA2184242C (en) | 1994-02-28 | 2000-05-02 | Jorg Kreuter | Drug targeting system, method for preparing same and its use |
AU708472B2 (en) * | 1994-05-18 | 1999-08-05 | S.P.I. Synthetic Peptides Incorporated | Heterodimer polypeptide immunogen carrier composition and method |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
CA2200869A1 (en) | 1994-10-19 | 1996-05-02 | Bruce C. Trapnell | Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents |
US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
JPH10511957A (ja) | 1995-01-05 | 1998-11-17 | ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン | 表面改質ナノ微粒子並びにその製造及び使用方法 |
US6251957B1 (en) | 1995-02-24 | 2001-06-26 | Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
JP3462313B2 (ja) | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体dna及び変異型ウリカーゼの製造法 |
AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
WO1998010056A1 (en) | 1996-09-03 | 1998-03-12 | Health Research Inc. | Treatment of antigen presenting cells to modulate antigen presenting cell function |
US6368598B1 (en) | 1996-09-16 | 2002-04-09 | Jcrt Radiation Oncology Support Services, Inc. | Drug complex for treatment of metastatic prostate cancer |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
CA2302779C (en) | 1997-09-16 | 2010-02-02 | Oregon Health Sciences University | Recombinant mhc molecules useful for manipulation of antigen-specific t-cells |
CZ302352B6 (cs) | 1997-10-30 | 2011-03-30 | C. B. F. Leti, S. A. | Zpusob prípravy extraktu poskytujících toleranci proti alergenu a jejich použití |
US6018817A (en) | 1997-12-03 | 2000-01-25 | International Business Machines Corporation | Error correcting code retrofit method and apparatus for multiple memory configurations |
US6197229B1 (en) | 1997-12-12 | 2001-03-06 | Massachusetts Institute Of Technology | Method for high supercoiled DNA content microspheres |
US6254890B1 (en) | 1997-12-12 | 2001-07-03 | Massachusetts Institute Of Technology | Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids |
CA2316414A1 (en) | 1997-12-23 | 1999-07-01 | Introgene B.V. | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
CA2317724A1 (en) * | 1998-01-09 | 1999-07-15 | Circassia Limited | Methods and compositions for desensitisation |
FR2775435B1 (fr) | 1998-02-27 | 2000-05-26 | Bioalliance Pharma | Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs |
US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
SE9801288D0 (sv) | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
DE19827164A1 (de) | 1998-06-18 | 1999-12-23 | Merck Patent Gmbh | Katalytisch Titan(IV)-oxid vermittelte geminale symmetrische Dialkylierung von Carbonsäureamiden |
US6306640B1 (en) | 1998-10-05 | 2001-10-23 | Genzyme Corporation | Melanoma antigenic peptides |
NZ511055A (en) | 1998-10-05 | 2003-10-31 | Pharmexa As | Novel methods for therapeutic vaccination |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
WO2000032626A1 (en) | 1998-11-25 | 2000-06-08 | Regents Of The University Of Minnesota | Methods of using epitope peptides of human pathogens |
US6153217A (en) | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
US6558951B1 (en) | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
US7238368B2 (en) | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
AU769425B2 (en) | 1999-04-23 | 2004-01-29 | Alza Corporation | Conjugate having a cleavable linkage for use in a liposome |
US6800296B1 (en) | 1999-05-19 | 2004-10-05 | Massachusetts Institute Of Technology | Modification of surfaces using biological recognition events |
DE19951970A1 (de) * | 1999-10-28 | 2001-05-03 | Bionetworks Gmbh | Arzneimittel für die Toleranzinduktion |
WO2001064164A2 (en) | 2000-02-28 | 2001-09-07 | Genesegues, Inc. | Nanocapsule encapsulation system and method |
AU2001249182A1 (en) | 2000-03-14 | 2001-09-24 | Genetics Institute Inc. | Use of rapamycin and agents that inhibit b7 activity in immunomodulation |
CA2407897A1 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
US20060057553A1 (en) | 2000-05-30 | 2006-03-16 | Estuardo Aguilar-Cordova | Chimeric viral vectors for gene therapy |
JP4860886B2 (ja) | 2000-06-01 | 2012-01-25 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 二本鎖パルボウイルスベクター |
US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20020014242A1 (en) | 2000-07-31 | 2002-02-07 | Abraham Scaria | Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products |
CA2319928A1 (en) | 2000-09-18 | 2002-03-18 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
US7097837B2 (en) | 2001-02-19 | 2006-08-29 | Pharmexa A/S | Synthetic vaccine agents |
AU2002338571A1 (en) | 2001-04-11 | 2002-11-11 | Trustees Of The University Of Pennsylvania | Compositions and methods for suppressing immune responses |
US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
CN1294268C (zh) | 2001-09-03 | 2007-01-10 | 上海三维生物技术有限公司 | 可在肿瘤细胞内特异性复制并扩散的重组腺病毒载体 |
ES2266564T3 (es) * | 2001-10-19 | 2007-03-01 | Isotechnika Inc. | Sintesis de analogos de cicloporinas. |
ES2975413T3 (es) | 2001-12-17 | 2024-07-05 | Univ Pennsylvania | Secuencias de serotipo 8 de virus adenoasociado (AAV), vectores que las contienen y usos de las mismas |
GB0207440D0 (en) | 2002-03-28 | 2002-05-08 | Ppl Therapeutics Scotland Ltd | Tolerogenic antigen-presenting cells |
US20040038303A1 (en) | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
EP1549277A4 (en) | 2002-05-22 | 2007-09-05 | Cleveland Clinic Foundation | INDUCING AND MAINTAINING COMPLEX TISSUE ALLOGRAFT TOLERANCE |
CN1671673B (zh) | 2002-05-30 | 2010-05-26 | 斯克里普斯研究学院 | 铜催化的叠氮化物和乙炔的连接 |
BR0305018A (pt) | 2002-06-04 | 2004-09-21 | Univ Pittsburgh | Células dendrìticas tolerogênicas e usos terapêuticos para as mesmas |
AU2003247880B2 (en) * | 2002-07-03 | 2010-09-02 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20060121029A1 (en) * | 2002-08-30 | 2006-06-08 | Hiroshi Shiku | Method and composition for regulating the activity of regulatory t cells |
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
US20060127357A1 (en) | 2002-11-29 | 2006-06-15 | Roncarolo Maria G | Rapamycin and il-10 for the treatment of immune diseases |
DE602004008582T2 (de) | 2003-02-17 | 2008-05-21 | Peter Burkhard | Peptidische nanoteilchen als arzneimittelabgabe- und antigen-display-systeme |
WO2004075861A2 (en) | 2003-02-26 | 2004-09-10 | Children's Hospital, Inc. | Recombinant adeno-associated virus production |
MXPA05009556A (es) * | 2003-03-14 | 2005-11-16 | Wyeth Corp | Anticuerpos contra receptor de il-21 humano y sus usos. |
RU2351362C2 (ru) | 2003-03-26 | 2009-04-10 | Цитос Байотекнолоджи Аг | КОНЪЮГАТЫ ПЕПТИДА Melan-A, АНАЛОГА ВИРУСОПОДОБНОЙ ЧАСТИЦЫ |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
US7727969B2 (en) | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
US20060251711A1 (en) | 2003-08-28 | 2006-11-09 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating diseases of the respiratory tract of a mammal |
US7943179B2 (en) | 2003-09-23 | 2011-05-17 | Massachusetts Institute Of Technology | pH triggerable polymeric particles |
US20080160089A1 (en) | 2003-10-14 | 2008-07-03 | Medivas, Llc | Vaccine delivery compositions and methods of use |
DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
JP2007512355A (ja) | 2003-11-21 | 2007-05-17 | アルザ コーポレイション | 開裂性のpegで表面修飾されたリポソーム−dna複合体で媒介される遺伝子送達 |
AU2004311630A1 (en) * | 2003-12-02 | 2005-07-21 | Cytimmune Sciences, Inc. | Methods and compositions for the production of monoclonal antibodies |
WO2005055949A2 (en) | 2003-12-09 | 2005-06-23 | The Children's Hospital Of Philadelphia | Sustained release preparations composed of biocompatible complex microparticles |
PT1704585T (pt) | 2003-12-19 | 2017-05-05 | Univ North Carolina Chapel Hill | Métodos para fabricar microestruturas e nanoestruturas isoladas usando litografia suave ou impressão litográfica |
CN1960726A (zh) * | 2004-04-08 | 2007-05-09 | 应用研究系统Ars股份公司 | 包含jnk抑制剂和环孢菌素的组合物 |
EP1756147A2 (en) | 2004-06-01 | 2007-02-28 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
US7713550B2 (en) | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
WO2006080951A2 (en) | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
WO2006014579A2 (en) | 2004-07-08 | 2006-02-09 | The Regents Of California | Enhancing class i antigen presentation with synthetic sequences |
FR2874384B1 (fr) | 2004-08-17 | 2010-07-30 | Genethon | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
GB0421296D0 (en) | 2004-09-24 | 2004-10-27 | Angiogene Pharm Ltd | Bioreductively-activated prodrugs |
US20090017016A1 (en) | 2004-10-05 | 2009-01-15 | Tanox Inc. | Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-ige antibodies in patients receiving replacement therapy |
WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
EP1835889A1 (en) | 2004-12-15 | 2007-09-26 | Elan Pharma International Limited | Nanoparticulate tacrolimus formulations |
CN104083342A (zh) | 2004-12-31 | 2014-10-08 | 伊休蒂卡有限公司 | 纳米微粒组合物及其合成方法 |
GB0504206D0 (en) | 2005-03-01 | 2005-04-06 | Glaxo Group Ltd | Combination therapy |
JP2008532953A (ja) * | 2005-03-08 | 2008-08-21 | ライフサイクル ファーマ エー/エス | シロリムスおよび/またはその類縁物質を含む医薬組成物 |
EA200701998A1 (ru) | 2005-03-17 | 2008-02-28 | Элан Фарма Интернэшнл Лтд. | Композиции для инъекций наночастиц иммунодепрессивных соединений |
US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
US8173167B2 (en) * | 2005-04-12 | 2012-05-08 | Wisconsin Alumni Research Foundation | Micelle composition of polymer and passenger drug |
US20080305161A1 (en) | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
AU2006243960A1 (en) | 2005-05-10 | 2006-11-16 | Emory University | Strategies for delivery of active agents using micelles and particles |
AU2006282042B2 (en) * | 2005-06-17 | 2011-12-22 | The University Of North Carolina At Chapel Hill | Nanoparticle fabrication methods, systems, and materials |
TW200711649A (en) | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
CA2614049C (en) | 2005-07-06 | 2014-12-02 | Molly S. Shoichet | Method of biomolecule immobilization on polymers using click-type chemistry |
CN101247826A (zh) | 2005-08-25 | 2008-08-20 | 大鹏药品工业株式会社 | 固定或内包t细胞识别抗原表位肽的生物降解性纳米粒子 |
CN1979166A (zh) | 2005-11-30 | 2007-06-13 | 北京有色金属研究总院 | 一种制备免疫检测用纳米胶体金的工艺方法及其反应装置 |
EP2345412A1 (en) | 2005-12-02 | 2011-07-20 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
US20070128289A1 (en) | 2005-12-07 | 2007-06-07 | Zhao Jonathon Z | Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases |
US7745215B2 (en) | 2005-12-08 | 2010-06-29 | University Of Louisville Research Foundation, Inc. | Methods and compositions for expanding T regulatory cells |
EP1973608A1 (en) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
WO2007087341A2 (en) | 2006-01-25 | 2007-08-02 | The Board Of Trustees Of The University Of Illinois | Tolerogenic biodegradable artificial antigen presenting system |
WO2007093036A1 (en) | 2006-02-13 | 2007-08-23 | Oncolytics Biotech Inc. | Use of local immune suppression to enhance oncolytic viral therapy |
CA2643322C (en) | 2006-02-24 | 2015-07-21 | Novartis Ag | Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions |
US8568487B2 (en) | 2006-02-27 | 2013-10-29 | Biomet Manufacturing, Llc | Patient-specific hip joint devices |
EP2004666B1 (en) | 2006-03-27 | 2014-09-03 | Globeimmune, Inc. | Ras mutation and compositions and methods related thereto |
ES2776100T3 (es) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | Sistema para el suministro dirigido de agentes terapéuticos |
EP2012828A2 (en) | 2006-04-28 | 2009-01-14 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of cardiovascular disease |
CA2652280C (en) | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymers for functional particles |
WO2007137117A2 (en) | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
WO2007144150A1 (en) | 2006-06-12 | 2007-12-21 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
EP1880729A1 (en) | 2006-07-20 | 2008-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of soluble CD160 to suppress immunity |
WO2008019142A2 (en) | 2006-08-04 | 2008-02-14 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
WO2008019366A2 (en) | 2006-08-07 | 2008-02-14 | Ludwig Institute For Cancer Research | Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens |
US20100172993A1 (en) | 2006-08-11 | 2010-07-08 | Amarjit Singh | Particles for delivery of active ingredients, process of making and compositions thereof |
US20140010821A1 (en) | 2006-08-18 | 2014-01-09 | Aili Lao | Use of CD83 in combination therapies |
WO2008036374A2 (en) | 2006-09-21 | 2008-03-27 | Medistem Laboratories, Inc. | Allogeneic stem cell transplants in non-conditioned recipients |
BRPI0715299A2 (pt) | 2006-10-05 | 2013-07-23 | The Johns Hopkins University | mÉtodo para preparar nanoparticulas polimÉricas, mÉtodod para preparar uma coposiÇço micelar, micelas polimÉricas reconstituÍveis, composiÇço polimÉrica bioativa de nanopartÍculas, mÉtodo para proporcionar um medicamento a um paciente e processo para preparar composiÇÕes de nanoparticulas polimÉricas |
EP3590503A1 (en) * | 2006-10-12 | 2020-01-08 | The University of Queensland | Compositions and methods for modulating immune responses |
US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
WO2008147456A2 (en) | 2006-11-20 | 2008-12-04 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
US20100172994A1 (en) | 2006-11-22 | 2010-07-08 | University Of Florida Research Foundation, Inc. | Nanoparticles for Protection of Cells from Oxidative Stress |
WO2008069942A2 (en) | 2006-12-05 | 2008-06-12 | Biogen Idec Ma Inc. | Novel methods of enhancing delivery of a gene therapy vector using steroids |
WO2008071774A1 (en) | 2006-12-14 | 2008-06-19 | Cytos Biotechnology Ag | Purification process for coat protein of rna bacteriophages |
US9023984B2 (en) | 2006-12-29 | 2015-05-05 | The Regents Of The University Of Colorado, A Body Corporate | Diagnostic and therapeutic target for autoimmune diseases and uses thereof |
EP2112930B1 (en) * | 2007-02-21 | 2017-01-11 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cdid molecules |
KR20080078204A (ko) | 2007-02-22 | 2008-08-27 | 크레아젠 주식회사 | 면역억제능이 증가된 간엽줄기세포-매개 자가유래수지상세포 |
NZ621972A (en) | 2007-03-07 | 2015-09-25 | Abraxis Bioscience Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
CN101730526A (zh) | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
WO2008109852A2 (en) | 2007-03-07 | 2008-09-12 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of autoimmune conditions |
WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
JP2010523554A (ja) * | 2007-04-04 | 2010-07-15 | シグモイド・ファーマ・リミテッド | タクロリムスの医薬組成物 |
US20090074828A1 (en) | 2007-04-04 | 2009-03-19 | Massachusetts Institute Of Technology | Poly(amino acid) targeting moieties |
WO2008124165A2 (en) | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
EP2146747A1 (en) | 2007-04-12 | 2010-01-27 | Emory University | Novel strategies for delivery of active agents using micelles and particles |
EP1982729A1 (en) | 2007-04-20 | 2008-10-22 | Cytos Biotechnology AG | Vaccination Regimen for B-Cell Vaccines |
WO2008150868A1 (en) | 2007-05-29 | 2008-12-11 | The Board Of Trustees Of The University Of Illinois | Methods for inducing therapeutic t cells for immune diseases |
US20080311140A1 (en) | 2007-05-29 | 2008-12-18 | Baylor College Of Medicine | Antigen specific immunosuppression by dendritic cell therapy |
ES2496916T3 (es) | 2007-05-31 | 2014-09-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Epítopo de HPV al que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas |
KR20100035643A (ko) | 2007-06-05 | 2010-04-05 | 노파르티스 아게 | 성숙 수지상 세포에서의 허용유발 표현형의 유도 |
US20090004259A1 (en) | 2007-06-14 | 2009-01-01 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) | Methods of preparing a therapeutic formulation comprising galectin-induced tolerogenic dendritic cells |
JP5508260B2 (ja) * | 2007-07-09 | 2014-05-28 | アストラゼネカ アクチボラグ | mTORキナーゼおよび/またはP13Kに関連する病気に用いられるモルホリノピリミジン誘導体 |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
AU2008288283B2 (en) | 2007-08-15 | 2013-01-31 | Circassia Limited | Peptides for desensibilization against allergens |
WO2009038685A1 (en) | 2007-09-18 | 2009-03-26 | The Scripps Research Institute | Ligands for copper-catalyzed azide-alkyne cycloaddition reactions |
AU2008302035A1 (en) | 2007-09-21 | 2009-03-26 | Cytimmune Sciences, Inc. | Nanotherapeutic colloidal metal compositions and methods |
WO2009062502A1 (en) | 2007-11-13 | 2009-05-22 | Dandrit Biotech A/S | Method for generating tolerogenic dendritic cells employing decreased temperature |
US20090142318A1 (en) | 2007-11-30 | 2009-06-04 | Therakos, Inc. | METHOD TO EXPAND nTREG CELLS USING p70 S6 KINASE ANTAGONIST |
NZ587060A (en) | 2007-12-31 | 2012-09-28 | Nanocor Therapeutics Inc | Rna interference for the treatment of heart failure |
WO2009100394A2 (en) | 2008-02-08 | 2009-08-13 | Terumo Kabushiki Kaisha | Device for local intraluminal transport of a biologically and physiologically active agent |
EP2262489A2 (en) | 2008-02-28 | 2010-12-22 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Hollow nanoparticles and uses thereof |
WO2009111588A1 (en) | 2008-03-04 | 2009-09-11 | Liquidia Technologies, Inc. | Immunomodulator particles and methods of treating |
CA2722184A1 (en) * | 2008-04-25 | 2009-10-29 | Duke University | Regulatory b cells and their uses |
JP5727367B2 (ja) | 2008-05-15 | 2015-06-03 | ダイナバックス テクノロジーズ コーポレイション | 免疫賦活オリゴヌクレオチドを使用する長期疾患改良 |
JP5549014B2 (ja) * | 2008-05-27 | 2014-07-16 | 国立大学法人名古屋大学 | 免疫調節剤及びその利用 |
US20090297621A1 (en) | 2008-06-03 | 2009-12-03 | Abbott Cardiovascular Systems Inc. | Microparticles For The Treatment Of Disease |
PL2774608T3 (pl) | 2008-06-16 | 2020-05-18 | Pfizer Inc. | Polimerowe nanocząstki napełnione lekiem oraz sposoby ich wytwarzania i zastosowania |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
EP2324025A1 (en) | 2008-08-11 | 2011-05-25 | Smithkline Beecham Corporation | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
ES2433371T3 (es) | 2008-08-11 | 2013-12-10 | Glaxosmithkline Llc | Derivados de purina para uso en el tratamiento de enfermedades alérgicas, inflamatorias e infecciosas |
WO2010018132A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Compounds |
US20120034156A1 (en) | 2010-08-03 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Artificial cells |
EP2331124A1 (en) | 2008-08-15 | 2011-06-15 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of il-10 production |
US8323696B2 (en) | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
JP5702723B2 (ja) | 2008-09-04 | 2015-04-15 | ザ ジェネラル ホスピタル コーポレイション | 声帯および軟組織の増強および修復用ヒドロゲル |
CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
US8889124B2 (en) | 2008-09-25 | 2014-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Tolerogenic populations of dendritic cells |
WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US8277812B2 (en) * | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8343497B2 (en) * | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
JP5552630B2 (ja) | 2008-10-24 | 2014-07-16 | 学校法人 聖マリアンナ医科大学 | Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を試験する方法 |
WO2010047839A1 (en) | 2008-10-25 | 2010-04-29 | Aura Biosciences | Modified plant virus particles and uses therefor |
WO2010056143A1 (en) | 2008-11-13 | 2010-05-20 | Instituto De Medicina Molecular | The use of adjuvant to facilitate the induction of immune tolerance |
ES2776126T3 (es) | 2008-12-15 | 2020-07-29 | Pfizer | Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos |
US20100160089A1 (en) * | 2008-12-19 | 2010-06-24 | Tzu-Wei Lin | Appapatus and method for providing golfing information |
US20120076831A1 (en) | 2009-01-20 | 2012-03-29 | Stephen Miller | Compositions and methods for induction of antigen-specific tolerance |
EP2218784A1 (en) | 2009-02-04 | 2010-08-18 | Universität Leipzig | Vector(s) containing an inducible gene encoding a CDK4/CD6 inhibitor useful for treating neurodegenerative disorders |
PL2393830T3 (pl) * | 2009-02-05 | 2015-07-31 | Circassia Ltd | Peptydy traw dla szczepionki |
KR20100099849A (ko) | 2009-03-04 | 2010-09-15 | 동국대학교 산학협력단 | 면역억제제와 트랜스글루타미나제 2의 억제제를 함유한 아토피 피부염 치료용 조성물 |
WO2010114948A2 (en) | 2009-04-02 | 2010-10-07 | University Of Florida Research Foundation, Inc. | An inducible system for highly efficient production of recombinant adeno-associated virus (raav) vectors |
GB0906159D0 (en) | 2009-04-09 | 2009-05-20 | Summit Corp Plc | Drug combination for the treatment of proteostatic diseases |
US20110223201A1 (en) | 2009-04-21 | 2011-09-15 | Selecta Biosciences, Inc. | Immunonanotherapeutics Providing a Th1-Biased Response |
US20100273220A1 (en) | 2009-04-22 | 2010-10-28 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
KR101785120B1 (ko) | 2009-04-27 | 2017-10-12 | 이뮤론 리미티드 | 병적 장애의 치료 및/또는 예방에 이용되는 항-lps 풍부한 면역글로블린 조제물 |
MX2011012598A (es) | 2009-05-27 | 2012-04-19 | Selecta Biosciences Inc | Nanoportadores sinteticos objetivos con liberacion sensible al ph de agentes inmunomoduladores. |
CZ2011827A3 (cs) | 2009-06-25 | 2012-09-26 | Savient Pharmaceuticals, Inc. | Zpusoby a sady pro predpovídání rizika reakce na infuzi a ztráty odezvy zpusobené protilátkami, monitorováním kyseliny mocové v séru behem lécby pegylovanou urikázou |
US20120164189A1 (en) | 2009-07-07 | 2012-06-28 | Balu-Iyer Sathy V | Lipidic Compositions for Induction of Immune Tolerance |
AU2010293059B2 (en) | 2009-08-26 | 2017-03-16 | Selecta Biosciences, Inc. | Compositions that induce T cell help |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
EP2305277A1 (en) | 2009-09-18 | 2011-04-06 | Forskarpatent I Syd AB | Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis |
CN101703781A (zh) | 2009-10-28 | 2010-05-12 | 陕西北美基因股份有限公司 | 一种免疫抑制剂的磁性载药方法 |
KR101267813B1 (ko) | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
WO2011085231A2 (en) | 2010-01-08 | 2011-07-14 | Selecta Biosciences, Inc. | Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines |
WO2011097511A1 (en) | 2010-02-05 | 2011-08-11 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | REGULATORY B CELLS (tBREGS) AND THEIR USE |
CA2792258A1 (en) | 2010-03-05 | 2011-09-09 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
US20110272836A1 (en) | 2010-04-12 | 2011-11-10 | Selecta Biosciences, Inc. | Eccentric vessels |
US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
US8551487B2 (en) | 2010-05-07 | 2013-10-08 | Xoma Technology, Ltd. | Methods for the treatment of IL-1β related conditions |
EA201500857A1 (ru) | 2010-05-26 | 2016-06-30 | Селекта Байосайенсиз, Инк. | Комбинированные вакцины с синтетическими наноносителями |
MY166014A (en) | 2010-06-07 | 2018-05-21 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
US10131875B2 (en) | 2010-08-04 | 2018-11-20 | Duke University | Regulatory B cells and their uses |
US9518087B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
AU2011291519A1 (en) | 2010-08-20 | 2013-01-24 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza A virus hemagglutinin |
CN103079589A (zh) | 2010-08-23 | 2013-05-01 | 西莱克塔生物科技公司 | 用于诱导对抗原的免疫应答的靶向多表位剂型 |
WO2012034079A2 (en) | 2010-09-09 | 2012-03-15 | Micell Technologies, Inc. | Macrolide dosage forms |
EP2630493A4 (en) | 2010-10-22 | 2014-05-21 | Univ Florida | MICROPARTICLES TARGETING SPECIFIC ANTIGENS THAT INDUCE TOLERANCE AND USES THEREOF |
EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
WO2012092552A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
US9078911B2 (en) | 2011-02-08 | 2015-07-14 | The Charlotte-Mecklenburg Hospital Authority | Antisense oligonucleotides |
CA2827375C (en) | 2011-02-14 | 2022-07-19 | The Children's Hospital Of Philadelphia | Improved aav8 vector with enhanced functional activity and methods of use thereof |
US8654487B2 (en) | 2011-03-11 | 2014-02-18 | Siemens Industry, Inc. | Methods, systems, and apparatus and for detecting parallel electrical arc faults |
JP6320912B2 (ja) | 2011-03-25 | 2018-05-09 | セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. | 浸透圧媒介性放出合成ナノ担体 |
US20140155469A1 (en) | 2011-04-19 | 2014-06-05 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors and viruses |
EP2699688A1 (en) | 2011-04-20 | 2014-02-26 | The Trustees Of The University Of Pennsylvania | Regimens and compositions for aav-mediated passive immunization of airborne pathogens |
BR112013027508A2 (pt) | 2011-04-29 | 2017-03-14 | Selecta Biosciences Inc | nanotransportadores sintéticos tolerogênicos para reduzir respostas de anticorpos |
US20140135337A1 (en) | 2011-05-16 | 2014-05-15 | Genzyme Corporation | Induction of immune tolerance by using methotrexate |
EA201490381A1 (ru) | 2011-07-29 | 2014-06-30 | Селекта Байосайенсиз, Инк. | Синтетические наноносители, которые стимулируют формирование гуморального иммунного ответа и иммунного ответа, опосредованного цитотоксическими т-лимфоцитами (ctl) |
WO2013036294A1 (en) | 2011-09-06 | 2013-03-14 | Selecta Biosciences, Inc. | Antigen-specific induced tolerogenic dendritic cells to reduce cytotoxic t lymphocyte responses |
EP2753362A4 (en) | 2011-09-08 | 2015-04-15 | Univ Florida | MATERIALS AND METHODS FOR MODULATING THE IMMUNE RESPONSE |
US8865487B2 (en) | 2011-09-20 | 2014-10-21 | General Electric Company | Large area hermetic encapsulation of an optoelectronic device using vacuum lamination |
WO2013058812A1 (en) | 2011-10-19 | 2013-04-25 | President And Fellows Of Harvard College | Targeted delivery to pancreatic islet endothelial cells |
EP2591801A1 (en) | 2011-11-14 | 2013-05-15 | Universitätsklinikum Hamburg-Eppendorf | Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions |
JP6348064B2 (ja) | 2011-11-22 | 2018-06-27 | ザ チルドレンズ ホスピタル オブ フィラデルフィア | 効率の高いトランスジーン送達のためのウイルスベクター |
WO2013123503A1 (en) | 2012-02-17 | 2013-08-22 | The Children's Hospital Of Philadelphia | Aav vector compositions and methods for gene transfer to cells, organs and tissues |
US9909142B2 (en) | 2012-04-18 | 2018-03-06 | The Children's Hospital Of Philadelphia | Composition and methods for highly efficient gene transfer using AAV capsid variants |
EP2841097B1 (en) | 2012-04-24 | 2022-11-16 | Ohio State Innovation Foundation | Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome |
CN102871966B (zh) | 2012-10-19 | 2013-11-20 | 东南大学 | 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法 |
BR112015023793A2 (pt) | 2013-03-15 | 2017-07-18 | Us Dept Veterans Affairs | composições e métodos de terapias para indução de tolerância imune a substituição do fator vii em indivíduos com hemofilia a |
CN105431170B (zh) | 2013-04-08 | 2019-10-29 | 爱荷华大学研究基金会 | 嵌合腺相关病毒/博卡病毒细小病毒载体 |
CN111068061A (zh) | 2013-05-03 | 2020-04-28 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
CA2910579C (en) | 2013-05-03 | 2023-09-26 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
CN112933234A (zh) | 2013-06-04 | 2021-06-11 | 西莱克塔生物科技公司 | 非免疫抑制性抗原特异性免疫治疗剂的重复施用 |
CA2926215A1 (en) | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified pseudomonas exotoxin a |
US9276815B2 (en) | 2013-12-27 | 2016-03-01 | Dell Products L.P. | N-node virtual link trunking (VLT) systems management plane |
EP2916319A1 (en) | 2014-03-07 | 2015-09-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Concept for encoding of information |
PL3116900T3 (pl) | 2014-03-09 | 2021-03-08 | The Trustees Of The University Of Pennsylvania | Kompozycje użyteczne w leczeniu niedoboru transkarbamylazy ornitynowej (otc) |
GB201407322D0 (en) | 2014-04-25 | 2014-06-11 | Ospedale San Raffaele | Gene therapy |
US20150359865A1 (en) | 2014-06-17 | 2015-12-17 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease |
US20160220501A1 (en) | 2015-02-03 | 2016-08-04 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins |
AU2015279738A1 (en) | 2014-06-25 | 2016-12-22 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
AU2015311706A1 (en) | 2014-09-07 | 2017-02-02 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
CA2963168A1 (en) | 2014-10-06 | 2016-04-14 | Arthrogen B.V. | Aav-based gene therapy |
CN113244191A (zh) | 2014-11-05 | 2021-08-13 | 西莱克塔生物科技公司 | 与具有处于稳定的超饱和状态之雷帕霉素的合成纳米颗粒相关的方法和组合物 |
WO2017139212A1 (en) | 2016-02-08 | 2017-08-17 | Cyta Therapeutics, Inc. | Particle delivery of rapamycin to the liver |
EP3413917A4 (en) | 2016-02-10 | 2019-09-11 | Pfizer Inc | THERAPEUTIC NANOPARTICLES COMPRISING EGFR LIGANDS AND METHODS OF MAKING AND USING SAME |
EP3426285B1 (en) | 2016-03-11 | 2024-05-29 | Cartesian Therapeutics, Inc. | Formulations and doses of pegylated uricase |
US20180071394A1 (en) | 2016-08-25 | 2018-03-15 | Selecta Biosciences, Inc. | Polyester polymer matrices for the delivery of allergens |
US20180085319A1 (en) | 2016-09-27 | 2018-03-29 | Takashi Kei Kishimoto | Methods and compositions for treating cancer |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
WO2018127382A1 (en) | 2017-01-03 | 2018-07-12 | Ethris Gmbh | Ornithine transcarbamylase coding polyribonucleotides and formulations thereof |
WO2018129268A1 (en) | 2017-01-07 | 2018-07-12 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
AU2018236123B2 (en) | 2017-03-11 | 2024-04-18 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
EP3694543A1 (en) | 2017-10-13 | 2020-08-19 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
CA3092016A1 (en) | 2018-02-26 | 2020-08-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Drug delivery systems |
EP3790592A1 (en) | 2018-05-09 | 2021-03-17 | Yale University | Particles for spatiotemporal release of agents |
BR112021000763A2 (pt) | 2018-07-16 | 2021-04-13 | Selecta Biosciences, Inc. | Métodos e composições de construtos e vetores de otc |
CN112654370A (zh) | 2018-07-16 | 2021-04-13 | 西莱克塔生物科技公司 | Mma构建体和载体的方法和组合物 |
CA3138525A1 (en) | 2019-04-28 | 2020-11-05 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
EP3976802A1 (en) | 2019-05-28 | 2022-04-06 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
US20200399628A1 (en) | 2019-06-04 | 2020-12-24 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
EP4048269A1 (en) | 2019-10-21 | 2022-08-31 | Selecta Biosciences, Inc. | Methods and compositions for treating liver diseases and disorders |
CN118384281A (zh) | 2019-11-08 | 2024-07-26 | 西莱克塔生物科技公司 | 聚乙二醇化尿酸酶的制剂和剂量 |
KR20220146559A (ko) | 2020-02-26 | 2022-11-01 | 셀렉타 바이오사이언시즈, 인크. | 면역억제제를 포함하는 합성 나노담체를 사용하는 방법 및 조성물 |
AU2021236234A1 (en) | 2020-03-11 | 2022-10-06 | Selecta Biosciences, Inc. | Methods and compositions related to synthetic nanocarriers |
WO2022098901A1 (en) | 2020-11-04 | 2022-05-12 | Selecta Biosciences, Inc. | Compositions for reducing immune responses against immunoglobulin proteases |
JP2024514577A (ja) | 2021-04-09 | 2024-04-02 | セレクタ バイオサイエンシーズ インコーポレーテッド | 免疫寛容を増強するために高親和性il-2受容体アゴニストと組み合わせて免疫抑制剤を含む合成ナノキャリア |
-
2012
- 2012-04-27 BR BR112013027508A patent/BR112013027508A2/pt not_active Application Discontinuation
- 2012-04-27 CN CN201280020312.8A patent/CN103501813A/zh active Pending
- 2012-04-27 CA CA3192054A patent/CA3192054A1/en active Pending
- 2012-04-27 WO PCT/US2012/035431 patent/WO2012149301A2/en active Application Filing
- 2012-04-27 MX MX2013012599A patent/MX2013012599A/es unknown
- 2012-04-27 CN CN201280020407.XA patent/CN103517716A/zh active Pending
- 2012-04-27 KR KR1020197031091A patent/KR20190123796A/ko active Application Filing
- 2012-04-27 CN CN201710304258.4A patent/CN107261154A/zh active Pending
- 2012-04-27 CN CN201710304257.XA patent/CN107970440A/zh active Pending
- 2012-04-27 ES ES12777688T patent/ES2806268T3/es active Active
- 2012-04-27 MX MX2013012595A patent/MX2013012595A/es active IP Right Grant
- 2012-04-27 BR BR112013027500A patent/BR112013027500A2/pt not_active Application Discontinuation
- 2012-04-27 KR KR1020207027170A patent/KR20200115655A/ko not_active IP Right Cessation
- 2012-04-27 EP EP19203548.3A patent/EP3679933A1/en active Pending
- 2012-04-27 JP JP2014508594A patent/JP6491879B2/ja not_active Expired - Fee Related
- 2012-04-27 EA EA201391599A patent/EA028807B1/ru not_active IP Right Cessation
- 2012-04-27 CN CN202311101154.5A patent/CN117205331A/zh active Pending
- 2012-04-27 EP EP20167350.6A patent/EP3760201A1/en active Pending
- 2012-04-27 WO PCT/US2012/035555 patent/WO2012149393A2/en active Application Filing
- 2012-04-27 CN CN201710194493.0A patent/CN107837402A/zh active Pending
- 2012-04-27 JP JP2014508582A patent/JP6401609B2/ja active Active
- 2012-04-27 CA CA2834514A patent/CA2834514C/en active Active
- 2012-04-27 AU AU2012249401A patent/AU2012249401A1/en not_active Abandoned
- 2012-04-27 EA EA201391611A patent/EA201391611A1/ru unknown
- 2012-04-27 CA CA2834527A patent/CA2834527A1/en active Pending
- 2012-04-27 WO PCT/US2012/035629 patent/WO2012149454A2/en active Application Filing
- 2012-04-27 JP JP2014508584A patent/JP6422773B2/ja active Active
- 2012-04-27 CA CA2834519A patent/CA2834519A1/en active Pending
- 2012-04-27 WO PCT/US2012/035383 patent/WO2012149268A1/en active Application Filing
- 2012-04-27 MX MX2013012594A patent/MX2013012594A/es unknown
- 2012-04-27 US US13/457,962 patent/US20120276156A1/en not_active Abandoned
- 2012-04-27 DK DK12777688.8T patent/DK2701739T3/da active
- 2012-04-27 CN CN202311101952.8A patent/CN117065050A/zh active Pending
- 2012-04-27 EA EA201391601A patent/EA027410B1/ru not_active IP Right Cessation
- 2012-04-27 KR KR1020227036124A patent/KR102674640B1/ko active IP Right Grant
- 2012-04-27 JP JP2014508581A patent/JP6490964B2/ja active Active
- 2012-04-27 EP EP12776474.4A patent/EP2704693A4/en not_active Withdrawn
- 2012-04-27 EA EA201391610A patent/EA027380B1/ru not_active IP Right Cessation
- 2012-04-27 CN CN202410142938.0A patent/CN118078979A/zh active Pending
- 2012-04-27 MX MX2013012592A patent/MX2013012592A/es active IP Right Grant
- 2012-04-27 AU AU2012249537A patent/AU2012249537A1/en not_active Abandoned
- 2012-04-27 EP EP19203487.4A patent/EP3682877A1/en active Pending
- 2012-04-27 CA CA2834599A patent/CA2834599A1/en active Pending
- 2012-04-27 US US13/458,927 patent/US20120301510A1/en not_active Abandoned
- 2012-04-27 CN CN201280020311.3A patent/CN103501820B/zh active Active
- 2012-04-27 CN CN201280020293.9A patent/CN103501786A/zh active Pending
- 2012-04-27 WO PCT/US2012/035378 patent/WO2012149265A2/en active Application Filing
- 2012-04-27 KR KR1020137031627A patent/KR102283951B1/ko active IP Right Grant
- 2012-04-27 EA EA201391608A patent/EA027259B1/ru not_active IP Right Cessation
- 2012-04-27 CN CN201710800310.5A patent/CN107670054A/zh active Pending
- 2012-04-27 AU AU2012249567A patent/AU2012249567B2/en not_active Ceased
- 2012-04-27 MX MX2013012591A patent/MX2013012591A/es active IP Right Grant
- 2012-04-27 EP EP19203512.9A patent/EP3682878A1/en active Pending
- 2012-04-27 US US13/458,021 patent/US9265815B2/en active Active
- 2012-04-27 CN CN201710247154.4A patent/CN107252481A/zh active Pending
- 2012-04-27 CN CN201410795620.9A patent/CN104623666A/zh active Pending
- 2012-04-27 KR KR1020217042405A patent/KR20220002713A/ko not_active Application Discontinuation
- 2012-04-27 KR KR1020137031612A patent/KR102112002B1/ko active IP Right Grant
- 2012-04-27 CA CA2834532A patent/CA2834532A1/en active Pending
- 2012-04-27 IL IL297146A patent/IL297146A/en unknown
- 2012-04-27 EA EA201391597A patent/EA027103B1/ru not_active IP Right Cessation
- 2012-04-27 WO PCT/US2012/035581 patent/WO2012149411A1/en active Application Filing
- 2012-04-27 JP JP2014508579A patent/JP6336900B2/ja active Active
- 2012-04-27 CN CN201280020302.4A patent/CN103491957A/zh active Pending
- 2012-04-27 KR KR1020237021597A patent/KR20230104990A/ko not_active Application Discontinuation
- 2012-04-27 AU AU2012249550A patent/AU2012249550B2/en active Active
- 2012-04-27 IL IL283728A patent/IL283728B2/en unknown
- 2012-04-27 US US13/458,220 patent/US9987354B2/en active Active
- 2012-04-27 AU AU2012249540A patent/AU2012249540B2/en active Active
- 2012-04-27 US US13/458,980 patent/US20120301498A1/en not_active Abandoned
- 2012-04-27 US US13/457,977 patent/US9289476B2/en active Active
- 2012-04-27 EP EP12777486.7A patent/EP2701737B8/en active Active
- 2012-04-27 WO PCT/US2012/035366 patent/WO2012149255A2/en active Application Filing
- 2012-04-27 CN CN201611214876.1A patent/CN107126552A/zh active Pending
- 2012-04-27 KR KR1020137031639A patent/KR20140029469A/ko active Application Filing
- 2012-04-27 KR KR1020227004780A patent/KR20220026601A/ko active Application Filing
- 2012-04-27 KR KR1020247024639A patent/KR20240116583A/ko active Search and Examination
- 2012-04-27 CN CN201611213970.5A patent/CN107029213A/zh active Pending
- 2012-04-27 WO PCT/US2012/035371 patent/WO2012149259A1/en active Application Filing
- 2012-04-27 KR KR1020137031603A patent/KR20140029468A/ko active Application Filing
- 2012-04-27 MX MX2013012596A patent/MX2013012596A/es unknown
- 2012-04-27 CN CN201710194492.6A patent/CN107320734A/zh active Pending
- 2012-04-27 AU AU2012249419A patent/AU2012249419A1/en not_active Abandoned
- 2012-04-27 CN CN201280020380.4A patent/CN103501812A/zh active Pending
- 2012-04-27 EA EA201790030A patent/EA201790030A1/ru unknown
- 2012-04-27 CN CN202111502784.4A patent/CN114306638A/zh active Pending
- 2012-04-27 CN CN201710247155.9A patent/CN107252487A/zh active Pending
- 2012-04-27 KR KR1020237017278A patent/KR20230079465A/ko not_active Application Discontinuation
- 2012-04-27 EP EP12777688.8A patent/EP2701739B1/en active Active
- 2012-04-27 US US13/458,179 patent/US8652487B2/en not_active Expired - Fee Related
- 2012-04-27 US US13/458,284 patent/US20120276160A1/en not_active Abandoned
- 2012-04-27 JP JP2014508588A patent/JP6422775B2/ja not_active Expired - Fee Related
- 2012-04-27 JP JP2014508131A patent/JP2014513092A/ja active Pending
- 2012-04-27 EA EA201790109A patent/EA201790109A1/ru unknown
- 2012-04-27 IL IL228932A patent/IL228932B2/en unknown
- 2012-04-27 KR KR1020207013389A patent/KR102344744B1/ko active IP Right Grant
- 2012-04-27 CN CN201710800423.5A patent/CN107670030A/zh active Pending
- 2012-04-27 EA EA201790044A patent/EA201790044A1/ru unknown
- 2012-04-27 KR KR1020227045491A patent/KR20230006042A/ko not_active Application Discontinuation
- 2012-04-27 CA CA2834571A patent/CA2834571A1/en not_active Abandoned
- 2012-04-27 BR BR112013027517A patent/BR112013027517A2/pt not_active Application Discontinuation
- 2012-04-27 CN CN201710755435.0A patent/CN107693798A/zh active Pending
- 2012-04-27 KR KR1020217011489A patent/KR102457513B1/ko active IP Right Grant
- 2012-04-27 WO PCT/US2012/035574 patent/WO2012149405A2/en active Application Filing
- 2012-04-27 WO PCT/US2012/035405 patent/WO2012149282A2/en active Application Filing
- 2012-04-27 CN CN202110202213.2A patent/CN113018452A/zh active Pending
- 2012-04-27 EA EA201692374A patent/EA201692374A3/ru unknown
- 2012-04-27 IL IL305229A patent/IL305229A/en unknown
- 2012-04-27 KR KR1020137031613A patent/KR20140027361A/ko not_active Application Discontinuation
- 2012-04-27 CA CA2834533A patent/CA2834533A1/en active Pending
- 2012-04-27 KR KR1020137031602A patent/KR20140051171A/ko active Search and Examination
- 2012-04-27 EP EP12777664.9A patent/EP2704750B1/en active Active
- 2012-04-27 US US13/458,067 patent/US9295718B2/en active Active
- 2012-04-27 CN CN201710234341.9A patent/CN107261151A/zh active Pending
- 2012-04-27 EA EA201391600A patent/EA026880B1/ru not_active IP Right Cessation
- 2012-04-27 KR KR1020207013934A patent/KR20200057789A/ko not_active IP Right Cessation
- 2012-04-27 AU AU2012249493A patent/AU2012249493B2/en not_active Ceased
- 2012-04-27 KR KR1020217023501A patent/KR102536881B1/ko active IP Right Grant
- 2012-04-27 CN CN201710759432.4A patent/CN107693799A/zh active Pending
- 2012-04-27 CN CN201280020361.1A patent/CN103533935A/zh active Pending
- 2012-04-27 WO PCT/US2012/035360 patent/WO2012149252A2/en active Application Filing
- 2012-04-27 EP EP20207539.6A patent/EP3871691A1/en active Pending
- 2012-04-27 MX MX2013012593A patent/MX2013012593A/es active IP Right Grant
- 2012-04-27 WO PCT/US2012/035354 patent/WO2012149247A2/en active Application Filing
- 2012-04-27 BR BR112013027541-3A patent/BR112013027541B1/pt active IP Right Grant
- 2012-04-27 KR KR1020217021916A patent/KR20210090745A/ko not_active Application Discontinuation
- 2012-04-27 KR KR1020137031601A patent/KR20140034202A/ko active Application Filing
- 2012-04-27 EP EP12777473.5A patent/EP2701706A4/en not_active Withdrawn
- 2012-04-27 CN CN201710420561.0A patent/CN107261123A/zh active Pending
- 2012-04-27 MX MX2013012598A patent/MX2013012598A/es unknown
- 2012-04-27 KR KR1020237021526A patent/KR20230106708A9/ko not_active Application Discontinuation
- 2012-04-27 CN CN202311202032.5A patent/CN117298266A/zh active Pending
- 2012-04-27 MX MX2013012597A patent/MX2013012597A/es unknown
- 2012-04-27 US US13/457,936 patent/US10004802B2/en not_active Expired - Fee Related
- 2012-04-27 CN CN202410143139.5A patent/CN118078980A/zh active Pending
- 2012-04-27 EP EP20202438.6A patent/EP3848030A1/en active Pending
- 2012-04-27 JP JP2014508134A patent/JP6602536B2/ja active Active
- 2012-04-27 US US13/457,994 patent/US20120276157A1/en not_active Abandoned
- 2012-04-27 EA EA201790045A patent/EA201790045A1/ru unknown
- 2012-04-27 KR KR1020197028264A patent/KR20190112211A/ko active Application Filing
- 2012-04-27 EA EA201391602A patent/EA201391602A1/ru unknown
- 2012-04-27 CN CN201280020398.4A patent/CN103517707A/zh active Pending
- 2012-04-27 AU AU2012249553A patent/AU2012249553A1/en not_active Abandoned
- 2012-04-27 EA EA201790043A patent/EA201790043A1/ru unknown
- 2012-04-27 EP EP12777475.0A patent/EP2701738B1/en active Active
- 2012-04-27 CA CA2834619A patent/CA2834619A1/en active Pending
- 2012-04-27 EP EP12776063.5A patent/EP2701705A4/en not_active Withdrawn
- 2012-04-27 CN CN201710230780.2A patent/CN107343959A/zh active Pending
- 2012-04-27 CA CA2834534A patent/CA2834534A1/en not_active Abandoned
- 2012-04-27 CN CN201610345030.5A patent/CN105999295A/zh active Pending
- 2012-04-27 CA CA3182519A patent/CA3182519A1/en active Pending
- 2012-04-27 EA EA201791679A patent/EA201791679A1/ru unknown
- 2012-04-27 EA EA201391609A patent/EA027379B1/ru not_active IP Right Cessation
- 2012-04-27 EP EP12777648.2A patent/EP2704715B1/en active Active
- 2012-04-27 HU HUE12777688A patent/HUE050142T2/hu unknown
- 2012-04-27 JP JP2014508585A patent/JP6422774B2/ja active Active
- 2012-04-27 AU AU2012249544A patent/AU2012249544A1/en not_active Abandoned
- 2012-04-27 BR BR112013027514-6A patent/BR112013027514B1/pt active IP Right Grant
- 2012-04-27 US US13/457,999 patent/US9289477B2/en active Active
- 2012-04-27 EP EP12777148.3A patent/EP2704714A4/en not_active Withdrawn
- 2012-04-27 CN CN201280020294.3A patent/CN103501787A/zh active Pending
- 2012-04-27 KR KR1020137031614A patent/KR20140041505A/ko active Search and Examination
- 2012-04-27 CN CN202311101967.4A patent/CN117018224A/zh active Pending
- 2012-04-27 KR KR1020137031636A patent/KR20140033066A/ko not_active Application Discontinuation
-
2013
- 2013-10-17 IL IL228938A patent/IL228938A0/en unknown
- 2013-10-17 IL IL228936A patent/IL228936A0/en unknown
- 2013-10-17 IL IL228937A patent/IL228937A0/en unknown
- 2013-10-17 IL IL228935A patent/IL228935A0/en unknown
- 2013-10-17 IL IL228939A patent/IL228939A0/en unknown
- 2013-10-17 IL IL228934A patent/IL228934A0/en unknown
- 2013-10-28 MX MX2019013118A patent/MX2019013118A/es unknown
- 2013-10-28 MX MX2019011890A patent/MX2019011890A/es unknown
- 2013-10-28 MX MX2020004906A patent/MX2020004906A/es unknown
- 2013-10-28 MX MX2019013515A patent/MX2019013515A/es unknown
-
2014
- 2014-01-22 US US14/161,660 patent/US9993548B2/en not_active Expired - Fee Related
-
2015
- 2015-07-17 US US14/802,260 patent/US10039822B2/en active Active
- 2015-07-27 US US14/810,457 patent/US20160030554A1/en not_active Abandoned
- 2015-07-27 US US14/810,427 patent/US20150335762A1/en not_active Abandoned
- 2015-07-27 US US14/810,476 patent/US20150320870A1/en not_active Abandoned
- 2015-07-27 US US14/810,472 patent/US10420835B2/en active Active
- 2015-07-27 US US14/810,450 patent/US20160022650A1/en active Pending
- 2015-07-27 US US14/810,418 patent/US20150328333A1/en active Pending
- 2015-07-27 US US14/810,442 patent/US20150320728A1/en not_active Abandoned
- 2015-07-27 US US14/810,466 patent/US10441651B2/en not_active Expired - Fee Related
-
2016
- 2016-02-22 US US15/050,397 patent/US11717569B2/en active Active
- 2016-03-04 US US15/061,204 patent/US11779641B2/en active Active
- 2016-03-04 US US15/061,096 patent/US20160256401A1/en active Pending
-
2017
- 2017-03-01 JP JP2017038613A patent/JP6529531B2/ja active Active
- 2017-03-01 JP JP2017038592A patent/JP6737725B2/ja active Active
- 2017-03-01 JP JP2017037976A patent/JP2017122110A/ja active Pending
- 2017-03-01 JP JP2017038086A patent/JP2017122111A/ja active Pending
- 2017-03-01 JP JP2017038658A patent/JP2017122113A/ja active Pending
- 2017-05-29 AU AU2017203588A patent/AU2017203588B2/en active Active
- 2017-05-31 AU AU2017203655A patent/AU2017203655A1/en not_active Abandoned
- 2017-05-31 AU AU2017203656A patent/AU2017203656A1/en not_active Abandoned
- 2017-06-06 JP JP2017112098A patent/JP6833625B2/ja active Active
- 2017-06-26 AU AU2017204317A patent/AU2017204317A1/en not_active Abandoned
- 2017-06-30 JP JP2017129024A patent/JP7018689B2/ja active Active
- 2017-06-30 JP JP2017129071A patent/JP2017193568A/ja active Pending
- 2017-07-12 AU AU2017204814A patent/AU2017204814B2/en active Active
- 2017-09-11 AU AU2017225163A patent/AU2017225163B2/en not_active Ceased
- 2017-10-09 AU AU2017245278A patent/AU2017245278A1/en not_active Abandoned
- 2017-10-09 AU AU2017244514A patent/AU2017244514A1/en not_active Abandoned
- 2017-10-12 AU AU2017245402A patent/AU2017245402B2/en not_active Ceased
- 2017-12-26 JP JP2017249125A patent/JP6673893B2/ja active Active
-
2018
- 2018-08-06 US US16/056,204 patent/US11235057B2/en active Active
- 2018-09-07 JP JP2018167490A patent/JP7389544B2/ja active Active
- 2018-12-25 JP JP2018240886A patent/JP7303627B2/ja active Active
- 2018-12-25 JP JP2018241280A patent/JP7389549B2/ja active Active
-
2019
- 2019-05-08 JP JP2019088347A patent/JP7491669B2/ja active Active
- 2019-08-02 JP JP2019142675A patent/JP2020002140A/ja active Pending
- 2019-08-08 US US16/536,154 patent/US20200101154A1/en active Pending
- 2019-09-04 US US16/560,419 patent/US20200101155A1/en not_active Abandoned
- 2019-09-20 AU AU2019232935A patent/AU2019232935B2/en active Active
- 2019-09-20 AU AU2019232928A patent/AU2019232928B2/en active Active
- 2019-09-20 AU AU2019232931A patent/AU2019232931B2/en active Active
- 2019-09-20 AU AU2019232938A patent/AU2019232938B2/en active Active
- 2019-09-20 AU AU2019232934A patent/AU2019232934B2/en not_active Expired - Fee Related
- 2019-09-30 AU AU2019240565A patent/AU2019240565A1/en not_active Abandoned
- 2019-10-24 JP JP2019193206A patent/JP2020050658A/ja active Pending
- 2019-12-16 JP JP2019226735A patent/JP7242519B2/ja active Active
-
2020
- 2020-01-14 AU AU2020200252A patent/AU2020200252A1/en not_active Abandoned
- 2020-01-14 AU AU2020200254A patent/AU2020200254A1/en not_active Abandoned
- 2020-01-22 AU AU2020200446A patent/AU2020200446B2/en active Active
-
2021
- 2021-05-18 IL IL283252A patent/IL283252A/en unknown
- 2021-05-18 IL IL283253A patent/IL283253A/en unknown
- 2021-06-06 IL IL283730A patent/IL283730A/en unknown
- 2021-06-22 IL IL284303A patent/IL284303A/en unknown
- 2021-07-26 JP JP2021121676A patent/JP2021183613A/ja active Pending
- 2021-07-26 JP JP2021121785A patent/JP2021183616A/ja active Pending
- 2021-07-26 JP JP2021121468A patent/JP2021183612A/ja active Pending
- 2021-08-19 IL IL285736A patent/IL285736A/en unknown
- 2021-09-07 JP JP2021145736A patent/JP2022003032A/ja active Pending
- 2021-12-16 US US17/552,392 patent/US20220354947A1/en active Pending
-
2022
- 2022-04-11 AU AU2022202396A patent/AU2022202396A1/en active Pending
- 2022-06-22 AU AU2022204381A patent/AU2022204381A1/en active Pending
- 2022-06-22 AU AU2022204395A patent/AU2022204395A1/en active Pending
- 2022-06-22 AU AU2022204392A patent/AU2022204392A1/en active Pending
- 2022-06-23 AU AU2022204439A patent/AU2022204439A1/en active Pending
- 2022-07-05 AU AU2022204820A patent/AU2022204820A1/en active Pending
- 2022-08-03 AU AU2022211839A patent/AU2022211839A1/en active Pending
- 2022-09-26 JP JP2022152657A patent/JP2023002542A/ja active Pending
- 2022-12-08 US US18/063,610 patent/US20230321224A1/en active Pending
- 2022-12-09 US US18/064,211 patent/US20230310593A1/en active Pending
-
2023
- 2023-03-02 US US18/177,714 patent/US20230321225A1/en active Pending
- 2023-03-08 JP JP2023035719A patent/JP2023085278A/ja active Pending
- 2023-06-06 US US18/330,345 patent/US20240156955A1/en active Pending
- 2023-08-29 US US18/458,043 patent/US20240261396A1/en active Pending
- 2023-09-15 JP JP2023150330A patent/JP2024022587A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101437491A (zh) * | 2006-02-21 | 2009-05-20 | 洛桑聚合联合学院 | 用于免疫疗法的纳米颗粒 |
CN101646418A (zh) * | 2006-10-12 | 2010-02-10 | 昆士兰大学 | 调节免疫应答的组合物和方法 |
CN101861165A (zh) * | 2007-10-12 | 2010-10-13 | 麻省理工学院 | 疫苗纳米技术 |
Non-Patent Citations (1)
Title |
---|
郝平和: "《肾脏移植康复指南》", 30 June 2006, 天津:天津科技翻译出版公司 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220354947A1 (en) | Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180209 |